



SAPIENZA
UNIVERSITÀ DI ROMA

AI in Medicine and Education: Use, Misuse and Sustainability

April 9th - 10th, 2026

Aula Magna, Sapienza University of Rome

Organized by

Faculty of Medicine and Dentistry

Scientific Direction:

Department of Radiological Oncological and Pathological Sciences

Sapienza University of Rome

con il patrocinio di



Società Italiana di
Radiologia Medica
e Interventistica





April 9th

12:30 Registration and welcome coffee

13:30 - 13:50 Institutional greetings

Antonella Polimeni - Rettrice della Sapienza Università di Roma
Orazio Schillaci - Ministro della Salute

13:50 - 14:00 Opening Remarks

Domenico Alvaro – Valeria Panebianco

14:00 - 15:15 AI in Healthcare: Concepts, Context, and Collaboration

Moderator:

Domenico Alvaro, Maria Sabrina Sarto

14:00 - 14:15 Types of Artificial Intelligence: Classifications and Capabilities - Enrico Tronci

14:15 - 14:30 The Critical Need for AI Infrastructure - Leonardo Querzoni

14:30 - 14:45 Who Should Lead AI Development: the Engineering Perspective - Roberto Navigli

14:45 - 15:00 Who Should Lead AI Development: the Clinical Perspective - Andrea Laghi

15:00 - 15:15 Panel Discussion:

Guido Caldarelli, Evaristo Cisbani, Maurizio Mancini



15:15 - 17:15 AI Use Cases in different clinical settings and Research Between Innovation and Implementation

Moderator:

Giulia d'Amati, Andrea Isidori

Screening and Early detection

15:15 - 15:35 Breast - *Claudio Vernieri*

15:35 - 15:55 Prostate - *Francesco Giganti*

15:55 - 16:15 Cardiac - *Carlo De Cecco*

16:15 - 16:35 Dentistry - *Umberto Romeo*

16:35 - 16:55 Dermatology - *Giovanni Pellacani*

16:55 - 17:15 Panel Discussion:

Elisabetta Ferretti, Fabio Lucidi, Fabio Miraldi,
Pasquale Pignatelli



April 10th

9:00 - 11:00 **AI Use Cases in different clinical settings and Research Between Innovation and Implementation**

Moderator:

Carlo Catalano, Valentino Valentini

AI-guided therapeutical planning and Follow up:

09:00 - 09:20 **Thyroid – *Cosimo Durante***

09:20 - 09:40 **Lung – *Paolo Graziano***

09:40 - 10:00 **Liver – *Guido Carpino***

10:00 - 10:20 **Metabolism – *Alessio Molfino***

10:20 - 10:40 **The potential of AI to revolutionize surgery
*Alberto Breda***

10:40 - 11:00 **Panel Discussion:**

Antonio Angeloni, Giovanbattista Desideri,
Elisabetta Iannelli (Aimac), Alessandro Sciarra



11:00 - 11:30 Thematic Lecture - Digital Twin for Precision Medicine

Moderator:
Eugenio Gaudio

11:00 - 11:15 Where are we at and where we are going

Valeria Panebianco

11:15 - 11:30 Problem Solving or Problem Maker? - *Paolo Benanti*

11:30 - 12:45 Misuse and Risks of AI in Healthcare

Moderator:
Alessandro Mei, Paolo Villari

11:30 - 11:45 The AI Act and the Legal Landscape of Medical AI - *Paola Frati*

11:45 - 12:00 When AI Goes Wrong: Clinical Errors and Post-Market Surveillance - *Renato Cuocolo*

12:00 - 12:15 Explainability in AI-driven medicine
Pietro Liò

12:15 - 12:45 Panel Discussion:
Luisa Avitabile, Luigi Cinque, Paolo Falco

12:45 - 14:00 Lunch

14:00 - 14:15 Public-Interest AI: Commercial models vs public health initiatives - *Massimiliano Anziutti*
Lettura no ecm



**14:15- 15:45 AI in Medical Education –
Augmenting Human Learning**

Moderator:

Ersilia Barbato, Paolo Marchetti

14:15 - 14:30 How AI is Reshaping the Way Medical Students Learn
Andrea Botticelli

14:30 - 14:45 Virtual Patients, Scenario Training and the Role
of AI Tutors - *Arsela Prelaj*

14:45 - 15:00 LLM (Large Language Model) in the Classroom:
Hype or Help - *Manuel Mitola*

15:00 - 15:15 Virtual Reality: Advancing Clinic and Research - *Gaetano Tieri*

15:15 - 15:45 Panel Discussion:

Elena Judith Canettieri, Vito Cantisani,
Armando De Virgilio, Daniele Gianfrilli



**15:45 – 17:00 Building Sustainable, Equitable,
and Trustworthy AI for the Future**

Moderator:

Antonio Carcaterra, Alberto Nastasi

15:45 - 16:00 Who Pays, Who Profits? The economics
of medical AI - *Roberto Poscia*

16:00 - 16:15 Integrating AI into the Hospital Workflow
Niccolò Stefani

16:15 - 16:30 Trustworthy AI: Balancing Liability through
Ethics and Law - *Alberto Gambino*

16:30 - 17:00 Panel Discussion:
Mirzia Bianca, Annamaria Giannini, Alessio Jacona

Closing Remarks

RAZIONALE SCIENTIFICO

Il Razionale del congresso è basato su come l'intelligenza artificiale sta ridefinendo in modo profondo e trasversale la medicina, influenzando prevenzione, diagnosi, terapia, ricerca e formazione dei professionisti. Il congresso *"AI in Medicine and Education: Use, Misuse and Sustainability"* nasce con l'obiettivo di offrire una lettura critica e integrata di questa trasformazione, riunendo clinici, ingegneri, data scientist, giuristi, esperti di etica, **insieme a giornalisti, associazioni di pazienti e studenti**, per un confronto realmente multidisciplinare e aperto alla società.

La discussione prende avvio dai fondamenti dell'AI, dalle sue diverse declinazioni tecnologiche e dalle infrastrutture necessarie per un'adozione sicura ed efficace, per poi concentrarsi sui principali casi d'uso già maturi nella pratica clinica: dallo screening alla diagnostica avanzata fino allo sviluppo di digital twin per la medicina di precisione.

Verrà approfondito il ruolo dell'AI nella formazione universitaria, tra scenari simulati, tutor virtuali e nuovi paradigmi di apprendimento.

Un'attenzione particolare sarà dedicata ai rischi e alle criticità legati all'impiego dell'AI, incluse le vulnerabilità dei sistemi, le responsabilità medico-legali, il fenomeno dell'overtrust e le nuove sfide introdotte dal quadro normativo europeo. L'obiettivo finale del congresso è delineare le condizioni per uno sviluppo e un'implementazione di strumenti di AI superando le barriere oggi ancora esistenti, affinché l'utilizzo dell'AI possa essere equo e sostenibile, individuando modelli che sappiano armonizzare innovazione tecnologica, qualità dell'assistenza e tutela dei pazienti.

PERSONAL INFORMATION

Valeria Panebianco

 Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome



 Scopus Author's ID: <https://www.scopus.com/authid/detail.uri?authorId=7003270861>

Current Position: Director of the Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Full Professor of Radiology (MED36; MEDS22/A)

SCIENTIFIC PROFILE

Professor Valeria Panebianco is full professor of radiology and director of the department of radiological sciences, oncology and pathology at Sapienza University of Rome. She currently serves as the representative of macro-area C of the board of the college of directors at Sapienza University and coordinates the care unit for digital medicine. Her research activity is internationally recognized, with over 270 peer-reviewed publications and a consistent focus on precision diagnostics in genitourinary oncology, particularly prostate and bladder cancer. She has played a leading role in the development and dissemination of structured reporting systems such as VI-RADS, PI-RADS and PI-RR, and is currently chair of the ACR vi-rads steering committee and elected chair of the ESUR prostate MRI working group. She is a member of the eau guidelines panel on muscle-invasive and metastatic bladder cancer, of the ESR communication committee, and serves as president of the urogenital radiology section of the Italian Society of Radiology (SIRM). Her scientific efforts have recently focused on the integration of computational medicine, ai, and digital twin technologies to identify imaging biomarkers for early detection, therapy response assessment, and patient stratification. She has coordinated major eu-funded initiatives (e.g., HEAL ITALIA, D3 4 Health, EUCAIM) and clinical research randomized trials (e.g., PROSA-I for prostate cancer screening using MRI), with a leadership role in applying advanced imaging to real-world screening and treatment strategies. In recognition of her contributions, professor Panebianco was appointed by who to contribute to the blue book on urinary tumors and has been invited to lecture at all major radiological and urological congresses.

SCIENTIFIC ACHIEVEMENTS

Product type	Number	Data Base	Start	End
Papers	274	Scopus/Pubmed	1996	2025
Monographs	5	Google	1997	2025
Book Series	2	Scopus	2007	2025
Books Chapter	50	Google/Scopus	1995	2025

H-INDEX

Hirsch (H) index	50 (Scopus) – 58 (Google)
10-year Hirsch (H) index	40
5-years Hirsch (H) index	32

Conferences

Invited Lectures

Participation as a lecturer to many events organised by international and national societies:

- 2021-2022-2023-2024-2025: Several invited lectures in many national and international society congresses, courses and meetings.
- 2020: NIH ("ATour Around VI-RADS")
- 2016-Today: EAU
- 2014-Today: International Society of Magnetic Resonance in Medicine (ISMRM)
- 2014-Today: Radiological Society of North America (RSNA)
- 2010-Today: Italian Chapter dell' International Society of MR in Medicine (ISMRM)
- 2009-Today: European Society of Urogenital radiology (ESUR)
- 1995-Today: European Society of Radiology (ESR) - European Congress of Radiology (ECR)
- 1994-Today: Società Italiana di Radiologia Medica (SIRM)

Honours and awards

- 2023: Honorary Membership of Sociedad Española de Diagnostico Por Imagen del Abdomen (SEDIA)
- 2021: SoME Award: Most influential article "Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus-based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical prostatectomy" published in European Urology Oncology, Volume 4, Issue 6, 2021, according to PlumX metrics.
- 2019: Top 2% scientist of the world (Mendeley Data)
- 2017: Honorary Membership of the Accademia Medica di Roma

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV

Rome, 7th September 2025

Signature



Valeria Panebianco

Curriculum Vitae Europass

Enrico Tronci

Informazioni personali

Nome e Cognome: Enrico Tronci

Email: enrico.tronci@uniroma1.it

Affiliazione: Dipartimento di Informatica, Sapienza Università di Roma

Posizione attuale

Professore Ordinario di Informatica – Sapienza Università di Roma

Esperienza professionale

Professore Associato – Sapienza Università di Roma

Ricercatore – Università degli Studi dell'Aquila

Post-doc – ENS Lyon (Francia)

Istruzione e formazione

PhD in Matematica Applicata – Carnegie Mellon University (USA), 1991

Laurea in Ingegneria Elettronica – Sapienza Università di Roma, 1987

Competenze professionali

- Intelligenza Artificiale (AI)

- Digital Twins (DT)
- AI e DT for Systems Biology and Systems Medicine
- AI and DT for design and optimization of autonomous systems

Attività di ricerca e progetti

Responsabile scientifico di oltre 20 progetti di ricerca nazionali ed europei.

Pubblicazioni

- Oltre 100 pubblicazioni su riviste e conferenze internazionali peer-reviewed.
- H-index (Scopus): 24 – Citazioni: ~1755
- H-index (Google Scholar): 31 – Citazioni: ~2591

Pubblicazioni recenti e rilevanti

– M. Esposito, A. Leva, T. Mancini, L. Picchiami, E. Tronci. Simulation-Based Design of Industry-Size Control Systems With Formal Quality Guarantees, *IEEE Transactions on Industrial Informatics*, 2025.

- A. Marino, B. Sinimeri, E. Tronci, Enrico, T. Calamoneri. STARGATE-X: a Python package for statistical analysis on the REACTOME network. *Journal of Integrative Bioinformatics*, 2023.

- S Sinisi, V Alimguzhin, T Mancini, E Tronci, B Leeners, Complete populations of virtual patients for *in silico* clinical trials, *Bioinformatics*, 2020

- F Maggioli, T Mancini, E Tronci, SBML2Modelica: integrating biochemical models within open-standard simulation ecosystems, *Bioinformatics*, 2020.

Elenco completo disponibile su Google Scholar e sito personale.

LEONARDO QUERZONI

Curriculum Vitae

Roma, 30/12/2025

I – Informazioni generali

Nome	LEONARDO QUERZONI
Data di nascita	14/4/1975
Luogo di nascita	Roma
Cittadinanza	Italiana
Lingue conosciute	Italiano (madrelingua), Inglese (B2)

II – Istruzione e formazione

Tipo	Anno	Rilasciato da	Descrizione
Laurea	2003	Università degli Studi di Roma “La Sapienza”	Laurea in Ingegneria Informatica - 108/110 – Titolo della tesi: “Progetto e simulazione di un sistema di comunicazione content based publish/subscribe”
Dottorato di ricerca	2007	Università degli Studi di Roma “La Sapienza”	Dottorato di Ricerca in Ingegneria Informatica – Titolo della tesi: “Techniques for Efficient Event Routing” – Correlatori: Prof. Roberto Baldoni, Prof. Ricardo Jiménez-Peris – Revisori indipendenti: Prof. Bettina Kemme, Prof. Anne-Marie Kermarrec, Prof. Philip K. McKinley

III – Esperienza professionale

III.A – Incarichi accademici

Dal	Al	Istituzione	Posizione
2023	--	Università degli Studi di Roma “La Sapienza”	Professore ordinario presso il Dipartimento di Ingegneria Informatica Automatica e Gestionale “Antonio Ruberti” (SSD ING-INF/05)
2020	2023	Università degli Studi di Roma “La Sapienza”	Professore associato presso il Dipartimento di Ingegneria Informatica Automatica e Gestionale “Antonio Ruberti” (SSD ING-INF/05)
2008	2020	Università degli Studi di Roma “La Sapienza”	Ricercatore a tempo indeterminato presso il Dipartimento di Ingegneria Informatica Automatica e Gestionale “Antonio Ruberti” (SSD ING-INF/05)
2007	2008	Università degli Studi di Roma “La Sapienza”	Assegnista di ricerca presso il Dipartimento di Ingegneria Informatica Automatica e Gestionale “Antonio Ruberti” – Research topic: “Event-based middleware for dynamic distributed systems”
2016	2016	ENSAI - Rennes	Professore visitatore (1 mese)
2011	2011	INRIA Rhône-Alpes - Grenoble	Professore visitatore (3 mesi)
2005	2005	Universidad Politécnica de Madrid	Studente visitatore – Supervisore: Prof. Ricardo Jiménez-Péris (8 mesi)

III.B – Altri incarichi

- **Prorettore alle Tecnologie digitali e alla Cybersecurity** presso l'Università degli Studi di Roma "La Sapienza", da Novembre 2024.
- **Coordinatore** del Dottorato di Ricerca in Cybersecurity, gestito in collaborazione dall'Università degli Studi di Roma "La Sapienza" e l'Università LUISS Guido Carli, da Novembre 2022.
- **Presidente** dell'Innovation Board della Fondazione SERICS, da Luglio 2024
- **Presidente** del Centro di Competenza CYBER 4.0, da Febbraio 2022 ad Aprile 2025.
- **Membro** del Comitato Tecnico Scientifico della Fondazione SERICS, da Gennaio 2023.
- **Membro** del Comitato Scientifico dell'Accademia Cybersicurezza Lazio, da Ottobre 2022.
- **Delegato della Rettrice per la Cybersecurity** presso l'Università degli Studi di Roma "La Sapienza", da Giugno 2021 a Ottobre 2024.
- **Program Committee Track Co-Chair** (Big Data, Models, and Systems) per la 45th IEEE International Conference on Distributed Computing Systems (ICDCS), 2025.
- **General co-chair** per la 18th ACM EUROSYS Conference, Maggio 2023.
- **General co-chair** per la Conferenza ITASEC, Giugno 2022.
- **Publication co-chair** per il 7th European Symposium on Security and Privacy (EuroS&P), 2022.
- **Membro dello Steering Committee** della ACM International Conference on Distributed and Event-based Systems (DEBS), dal 2020.
- **Program Committee Co-Chair** per la 13th ACM International Conference on Distributed and Event-based Systems (DEBS), 2019.
- **General chair** per la 18th International Conference on Principles of Distributed Systems (OPODIS), 2014.

IV – Incarichi didattici

IV.A – Insegnamenti in Lauree e Laure Magistrali

A partire dall'anno accademico 2006/2007 tiene regolarmente i seguenti corsi:

- Cybersecurity
- Malware Analysis and Incident Forensics
- Sistemi di Calcolo
- Laboratorio di architetture software e sicurezza informatica
- Distributed Systems
- Fondamenti di Informatica
- Calcolatori Elettronici

IV.B – Esperienza didattica in programmi di Dottorato

Dal 2008 ha supervisionato le attività di ricerca dei seguenti studenti di dottorato:

- **Adriano Cerocchi**, "Valid Query Answers exploiting Node Virtualization", 2012 – Amministratore Delegato di Over Technologies S.p.A
- **Fabio Petroni**, "Mining at scale with latent factor models for matrix completion", 2015 – Group Leader at EMBL e Co-Founder di Samaya AI
- **Nicolò Rivetti di Val Cervo**, "Efficient stream analysis and its application to big data processing", 2016 – Agenzia per la Cybersicurezza Nazionale
- **Claudio Ciccotelli**, "Practical Fault Detection and Diagnosis in Data Centers", 2017 – Agenzia per la Cybersicurezza Nazionale

- F. Lombardi, L. Aniello, S. Bonomi, and L. Querzoni. Elastic symbiotic scaling of operators and resources in stream processing systems. *IEEE Transactions on Parallel and Distributed Systems*, 29(3):572–585, 2018.
- N. Rivetti, E. Anceaume, Y. Busnel, L. Querzoni, and B. Sericola. Online scheduling for shuffle grouping in distributed stream processing systems. In *Proceedings of the ACM/IFIP/USENIX Middleware Conference*, 2016.
- F. Petroni, L. Querzoni, K. Daudjee, S. Kamali, and G. Iacoboni. HDRF: Stream- Based Partitioning for Power-Law Graphs. In *Proceedings of the 24th ACM International Conference on Information and Knowledge Management (CIKM)*, 10 2015.
- N. Rivetti, L. Querzoni, E. Anceaume, Y. Busnel, and B. Sericola. Efficient key grouping for near-optimal load balancing in stream processing systems. In *Proceedings of the 9th ACM International Conference on Distributed Event-Based Systems (DEBS)*, June 2015.
- R. Baldoni, S. Bonomi, M. Platania, and L. Querzoni. Efficient notification ordering for geo-distributed pub/sub systems. *IEEE Transactions on Computers*, 64(10):2796–2808, 2015.
- L. Aniello, R. Baldoni, and L. Querzoni. Adaptive online scheduling in storm. In *Proceedings of the 7th ACM International Conference on Distributed Event-Based Systems (DEBS)*, July 2013.
- Y. Busnel, L. Querzoni, R. Baldoni, M. Bertier, and A.-M. Kermarrec. Analysis of deterministic tracking of multiple objects using a binary sensor network. *ACM Transactions on Sensor Networks*, 8(1):1–27, August 2011.
- R. Baldoni, A. Corsaro, L. Querzoni, S. Scipioni, and S. T. Piergiovanni. Coupling- based algorithm for internal clock synchronization of large scale dynamic systems. *IEEE Transactions on Parallel and Distributed Systems*, 21(5):607 – 619, 2010.
- R. Baldoni, R. Beraldi, V. Quéma, L. Querzoni, and S. T. Piergiovanni. Tera: Topic- based event routing for peer-to-peer architectures. In *Proceedings of the 1st International Conference on Distributed Event Based Systems (DEBS)*, Toronto, Canada, July 2007.

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae ai sensi dell’art. 13 del D. Lgs. 196/2003 e successive modificazioni

Leonardo Querzoni



Curriculum Vitae

Personal Information

Family Name, First Name: Navigli, Roberto
Researcher ID: orcid.org/0000-0003-3831-9706
Date of birth: February 12, 1978
Nationality: Italian
Home URL: <https://www.diag.uniroma1.it/navigli>

Education

Roberto Navigli obtained his Ph.D. in Computer Science in 2007 from the Sapienza University of Rome with a thesis on innovative techniques for knowledge-based Word Sense Disambiguation (WSD), supervised by Prof. Paola Velardi. He obtained his M.Sc. in Computer Science (summa cum laude) from Sapienza in 2001.

Current Position

2017-today **Full Professor**, Dept. of Computer, Control and Management Engineering (DIAG), since 2021; previously in the Dept. of Computer Science, Sapienza, Rome, Italy.

Previous Positions

2010-2017 Associate Professor, Department of Computer Science, Sapienza University of Rome.
2007-2010 Assistant Professor (ricercatore), Department of CS, Sapienza University of Rome.
2006-2007 Visiting Scholar, School of Informatics, University of Edinburgh, working with Mirella Lapata.

Fellowships and Awards

Fellow of AAAI, ACL, EurAI and ELLIS.

2021 The PI's MultiJEDI and MOUSSE ERC grants selected among "the 15 projects through which the ERC transformed science" [out of 10,000 grants]; selected among the three grantees invited to speak at the ceremony for the 10,000-th grantee. <https://erc.europa.eu/how-ERC-transformed-science/>
2021 Outstanding paper award at NAACL 2021, with S. Conia and A. Bacciu.
2018 Invited speaker at IJCAI-ECAI 2018, early career spotlight track.
2015 Winner of the META (Multilingual Europe Technology Alliance) prize as the creator of BabelNet, awarded "to outstanding products/services supporting the European Multilingual Information Society".
2007 AI*IA "Marco Cadoli" award for the best Ph.D. Thesis in AI.

Teaching Experience

At the Sapienza he has taught **courses for 4 Master's programmes** (AI & Robotics, Data Science, CS, Engineering in CS) on: Natural Language Processing (2010-today), Machine Learning (2007-2010), Object- Oriented Programming (2006-2021), Python Programming (2022-today). He has also taught at international summer schools and tutorial venues: ACL (2016), ESSLLI (2010, 2011), COLING (2014), RANLP (2017, 2009), EUROLAN (2015), SSSW (2015), and the 5th Lisbon Machine Learning School (LxMLS '15).

Organization of Scientific Meetings and Activities, and Community Service

- General Chair of ACL 2025.
- Program Co-Chair of ACL-IJCNLP 2021, the premier NLP conference, with 3000 + submissions.
- Associate Editor (2013-2020) of the Artificial Intelligence Journal (Elsevier).
- Action Editor (2020-2024) of the Transactions of the ACL (TACL).
- Panel Member for the ERC Starting Grant PE6 (2017, 2019, 2021).
- Editorial Board Member of Computational Linguistics (2011-2013, MIT Press).
- Editorial Board Member of Natural Language Engineering (2010-2018, Cambridge University Press).
- Senior Area Chair & Area/Track Chair of IJCAI (2017-2022), AAAI (2017-2022), ACL (2010, 2018-2019), WWW (2012), *SEM (2013, 2016), COLING (2016).
- Program Co-Chair of *SEM 2014; Senior PC member of IJCAI 2009 and IJCAI 2011.
- Member of the EACL board (European Chapter of Assoc. Comp. Linguistics) (2015-2016).
- Standing Elite Reviewer of Transactions of the Association for Computational Linguistics (TACL).



Curriculum Vitae

Personal information

First name / Surname

Andrea Laghi

Nationality

Italian

Date of birth

25.12.1967

Gender

Male

Occupational field

University; Healthcare and Research Organization

Work experience

ACADEMIC

01.06.2025 - present

Full Professor of Radiology, Department of Biomedical Sciences, Humanitas University, Rozzano (Milan)/IT

2025 - 2028

Director, Residency Programme in Radiology, Humanitas University, Rozzano (Milan)/IT

2022 - 2025

Director, Residency Programme in Radiology, Sapienza – University of Rome
Faculty of Medicine and Psychology

2018 - 2025

Course coordinator, Diagnostic Imaging Teaching Course, School of Medicine, Sapienza – University of Rome, Faculty of Medicine and Psychology, Rome/IT

2017 - 2025

Full Professor of Radiology, Sapienza University of Rome, Faculty of Medicine and Psychology, Rome/IT

2013 - 2015

Director, Residency Programme in Radiology, Sapienza – University of Rome, Faculty of Medicine and Dentistry, Rome/IT

2012 - 2014

Qualified for Full Professorship in Radiology (2014-20)
Ministry of Instruction, University and Research (MIUR), ASN –National Scientific Qualification, Bando 2012 (DD n. 222/2012)

2006 - 2017

Associate Professor of Radiology, Sapienza University of Rome, Faculty of Medicine and Dentistry, Rome/IT

2006 - 2018

Course coordinator, Diagnostic Imaging Teaching Course, School of Medicine, Sapienza – University of Rome, Faculty of Pharmacy and Medicine, Latina/IT

2006 - 2018

President, BSc Radiography programme, Sapienza – University of Rome, Faculty of Pharmacy and Medicine, Latina/IT

2003 - 2006

Vice-President, BSc Radiography programme, Sapienza – University of Rome, Faculty of Pharmacy and Medicine, Latina/IT

2001 - 2006

Researcher in Radiology, Sapienza University of Rome, Faculty of Medicine and Surgery, Rome/IT

HEALTHCARE

01.06.2025 - present

Director of the Department of Diagnostic Imaging, Humanitas Mirasole S.p.A., and Chairman of the Department of Diagnostic Imaging, IRCCS Humanitas Research Hospital, Rozzano, Milan/IT

2018 - 2025

Chairman of the Radiology Unit (UOC), AOU Sant'Andrea, Rome/IT

2012 - 2018	Chairman of the “Advanced Diagnostic Imaging” Unit (UOC) at ICOT Hospital, Latina/IT
2009 - 2012	“Acting” Chairman of the “Advanced Diagnostic Imaging” Unit (UOC) at ICOT Hospital, Latina/IT
2004 - 2009	Staff Radiologist, Responsible of the “Advanced Imaging Techniques” (UOS) at ICOT Hospital, Latina/IT
2001 - 2004	Staff Radiologist, Azienda Policlinico Umberto I – Rome, SS Diagnostic Radiology IV, (Dir. Prof. R. Passariello)
1999 - 2001	Staff Radiologist, Emergency Department, Azienda Policlinico Umberto I – Rome/IT,
1996 - 1999	Volunteer Assistant Radiologist, Azienda Policlinico Umberto I – Rome/IT, Institute of Radiology (II Chair, Director: Prof. R. Passariello)

INSTITUTIONAL - National

MINSAL / Ministry of Health

2025 - today	CTS (Technical Health Committee , D.M. 14 July 2025), Directorate-General for the Supervision of Public Bodies and Collegial Authorities, Member
2019 - 2025	CSS / Superior Health Council , Council Board LII and LIII – Section V, Member

CSS – Working groups

2016 - 2017	Member; “ <i>Appropriateness in Diagnostic Imaging and renewal of technology</i> ”, CSS - Section I. Coordinator: Prof. A.E. Cardinale
2019 - 2020	Coordinator; “ <i>Safety of conducted electrical weapons (CEW)</i> ”, CSS - Section V
2020	Member; “ <i>Orthopedic Diseases in Frail Patients</i> ”, CSS - Section I. Coordinator: Prof. A. Rota
2021	Member; “ <i>Revision of critical DRGs</i> ” CSS - Section I. Coordinator: Prof. B. Dallapiccola Coordinator; “ <i>Evaluation of AI systems as diagnostic support tools</i> ”. CSS - Section V Member; “ <i>Renewal of technology</i> ”, CSS - Section I. Coordinator: Prof. A.E. Cardinale
2022	Member; “ <i>Guidelines, diagnostic-therapeutic pathway, developments and perspectives of Robotic Surgery in NHS and considerations about knowledge transfer of Artificial Intelligence</i> ”, CSS - Section I. Coordinator: Prof. G. Scambia Member; “ <i>Reform of Health Information Systems: trials and privacy legislation</i> ”, CSS - Section I. Coordinators: Prof. P. Vineis, Prof. F. Locatelli Member; “ <i>Management of reports of donors with Creutzfeldt-Jakob disease (post donation information)</i> ”, CSS - Section II and V Coordinators: Prof. F. Locatelli, Prof. G. Curigliano
2024	Member; “ <i>Public health communication</i> ”, CSS – Section I. Coordinator: Prof. F. Locatelli Co-coordinator; “ <i>Minimum age for competitive sports participation</i> ”, CSS – Section I. Coordinator: Prof. G. Scambia
2024	Meeting of the G7 Ministers of Health , Ancona/IT, October 10-11. Session: “Artificial Intelligence and Health”, Keynote speaker G7 Health Technical Event , “Healthy and active ageing through Life-Long Prevention and Innovation”. Genoa/IT, July 11-12, Invited speaker

	G7 Policy brief on Artificial Intelligence: opportunities and challenges for the Health Sector , Member of the Working Group of the Italian Ministry of Health
2022	Working Group “ <i>Lung Cancer Screening</i> ”, Coordinator, Prof. G. Veronesi; Member and coordinator radiology sub-group
2021	Working Group of Experts in Magnetic Resonance (Law n. 160, August 7, 2016, Art. 21 bis); Member
2009 - 2010	Committee on “ <i>Diagnostic and therapeutic appropriateness criteria of oncologic diseases at higher incidence: breast, lung, prostate, colo-rectal, pancreatic cancers and lymphomas</i> ”, Coordinator, Prof. A. Del Maschio; Member
	CNEL (National Council of Economy and Labour)
2025 - today	Working Group, “ <i>Role of Digitization and Artificial Intelligence Applied to Healthcare Services</i> ”, Member and Co-coordinator
	MIUR / Ministry of Instruction, University and Research
2015 - today	“REPRISE” (Register of Expert Peer Reviewers for Italian Scientific Evaluation) Group; Member ANVUR - Agenzia Nazionale di Valutazione del Sistema Universitario e della Ricerca / National Agency of the University System Evaluation and Research 2013 - 2014 VQR 2004-2010; Reviewer 2015 - 2016 VQR 2011-2014, GEV 6 – Medical Sciences; Member
	AGENAS (National Agency for Regional Health Services)
2024 - 2025	Working Group on Teleradiology, Member
	Lazio Region
2011	“Rectal Cancer” Working Group, Oncologic Network of Lazio region. Coordinator, Prof. V. Valentini; Member
	OMCEO / Ordine Provinciale dei Medici-Chirurghi e degli Odontoiatri
2018 - 2020	Diagnostic Imaging Committee; Member
	AIRC / Italian Association for Cancer Research
2014 - 2020	Scientific Committee and Scholarship Committee, Board Member
	INSTITUTIONAL - International
	EU - European Union
2014 - 2017	Commission Expert Group on Cancer Control (CEGCC); Delegate on behalf of the European Society of Radiology (ESR)
2008 - today	UEG (United European Gastroenterology), Member of the General Assembly, Education Committee, Future Trends Committee, PAG – Patient Advisory Group
2004 - 2023	ESGAR (European Society of Gastrointestinal and Abdominal Radiology), Member of the Executive Committee, Chairman of the Education and Workshop Committees, Vice-President, President

2011 - 2021	ESOI (European Society of Oncologic Imaging), Member of the Executive Committee, Treasurer, President, Past-President
2019 - today	SIRM (Italian Society of Medical and Interventional Radiology), Executive Committee, Member
2019 - 2020	SIRM (Italian Society of Medical and Interventional Radiology), Subspecialty Group on Abdominal and Gastrointestinal Radiology, President
2015 - 2018	ESHI (European Society of Hybrid Imaging), Founder and Board Member
2015 - 2016	ANVUR (National Agency of the University System Evaluation and Research), VQR 2011-2014, GEV 6 – Medical Sciences, Member
2014 - 2020	AIRC (Italian Association for Cancer Research), Scientific Committee and Scholarship Committee, Board Member
2014 - 2017	EU (European Union), Commission Expert Group on Cancer Control (CEGCC), Delegate on behalf of the European Society of Radiology (ESR)

Education and training

2020-21	Advanced Training Course in Public Health and Healthcare Organization and Management, Sapienza, Certificate of Managerial Training for General Directors of Healthcare Organizations and Other Institutions of the National Health Service (NHS) (D.lgs 171/2016), Sapienza – University of Rome, Rome/IT
2004-07	Board certification in Nuclear Medicine, <i>cum laude</i> Thesis: “PET-CT in the evaluation of colo-rectal cancer”; Supervisor, Prof. R. Massa
1992-96	Board certification in Radiology, <i>cum laude</i> Thesis: “MR Cholangiography”; Supervisor, Prof. R. Passariello
1996	New York University (NYU), New York (USA), Internship Tutor: Dr. A.J. Megibow; Topics: spiral CT, clinical applications; advanced image post-processing
1995	AFIP (Armed Force Institute of Pathology) “Walter Reed” Hospital, Washington DC (USA) Six-weeks course on Radiologic-Pathologic correlation
1993 - 1994	Boston University, Boston (USA), Internship Tutor: Prof. J.T. Ferrucci; Topics: abdominal imaging and MR cholangiography
1986-92	Graduation in Medicine & Surgery, <i>cum laude</i> Thesis: “Hypermedia program for teaching anatomy in diagnostic imaging”; Supervisor, Prof. R. Passariello

Personal skills and competences

Mother tongue

Other language(s)

Self-assessment

European level ()*

English

Italian

Understanding		Speaking		Writing	
Listening	Reading	Spoken interaction	Spoken production		
C1	C1	C1	C1	C1	C1

(*) [Common European Framework of Reference for Languages](#)

cancer screening, imaging of inflammatory bowel diseases, and response assessment in oncologic therapies. His scientific leadership has been acknowledged through appointments as President of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) and the European Society of Oncologic Imaging (ESOI), and as President of the ESGAR Annual Congress in Rome in 2019.

Prof. Laghi's ability to combine scientific vision with clinical applicability has made him a prominent figure in shaping the future of radiology, particularly in the domains of precision medicine and imaging innovation.

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV

Pieve Emanuele, 23 October 2025

In faith,
Prof. Andrea Laghi

A handwritten signature in dark ink, appearing to read 'A. Laghi', is positioned below the typed name.

VERNIERI CLAUDIO

Address: Via Strambio 26, 20133, Milan, Italy
Telephone: +39 3889786077
E-mail: claudio.vernieri@unimi.it; claudio.vernieri@istitutotumori.mi.it; claudio.vernieri@ifom.eu
Date/place of birth: July 28, 1984, Naples, Italy
Fiscal code: VRNCLD84L28F839W

EDUCATION AND TRAINING

- December 2019: Board Certification in Medical Oncology (score: 70/70 cum laude) from the University of Milan. Title of the thesis: “Safety, feasibility and biological effects of cyclic fasting-mimicking diet (FMD) in cancer patients”.
- December 2014 – December 2019: Residency in Medical Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Milan, Italy).
- December 2014 – December 2019: Joint Post-Doc at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Milan, Italy) and IFOM ETS, the AIRC Institute of Molecular Oncology (Milan, Italy).
- April 2014 – November 2014: post-doc fellow at IFOM (Milan, Italy).
- January 2010 – March 2014: PhD in Molecular Medicine at the SEMM (European School of Molecular Oncology) in IFOM (Milan, Italy). Title of the thesis: “Cdk1 kinase counteracts PP2A^{Cdc55} phosphatase to induce APC/C phosphorylation and adaptation to the Spindle Assembly Checkpoint (SAC) in budding yeast”.
- July 2009 – December 2009: Resident in Clinical Radiotherapy at Policlinico Universitario “Federico II” (Naples, Italy).
- July 2008: M.D. degree in Medicine received from the University Federico II of Naples, Italy, with the final mark of 110/110 cum laude and honors by the Degree Committee (Naples, Italy). Title of the thesis: “Study of the effects induced by the association of a selective inhibitor of farnesyltransferase (tipifarnib) with ionizing radiations in cell lines from squamocellular neoplasms (Kb, Cal-27)”.
- September 2002 – July 2008: student of Medicine and Surgery at the University Federico II of Naples.

RESEARCH AND PROFESSIONAL EXPERIENCE

October 2024 – present

Associate Professor at the University of Milan, Milan, Italy

September 2024 – present

Member of the Scientific Committee of Psiconcologia.net platform

December 2023–September 2024

Assistant Professor at the University of Milan, Milan, Italy

April 2023– present

Elected Member of the Scientific Direction Advisory Committee of IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy

November 2022– present

Elected Member of the Scientific Committee (CTS) of Accademia “Umberto Veronesi”

January 2020 – present

Principal Investigator at IFOM ETS, the AIRC Institute of Molecular Oncology, as director of the “Metabolic Reprogramming in Solid Tumors” program

January 2020 – present

Medical Oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori, responsible for the design, coordination and conduction of clinical trials focused on breast cancer and cancer metabolism (NCT03340935, NCT03454282, NCT03709147), including studies in the role of Principal Investigator (NCT04248998 and NCT04001725).

January 2020 – present

Member of the Faculty board for the PhD program at the SEMM (European School of Molecular Medicine)

January 2019 – December 2022

Elected Member of the Scientific Directorate of Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.

February 2018 – present

Member of the Cancer Core Europe (CCE) Network and local responsible for CCE Clinical Trials and translational research activities (Basket-of-Basket Clinical Trial; DART project funded by H2020).

December 2014 – December 2019

Resident in Medical Oncology at the Medical Oncology Department of Fondazione IRCCS Istituto Nazionale Tumori di Milano under the supervision of Prof. Filippo de Braud. I was involved in: 1) designing and conducting independent clinical trials to target cancer metabolism, including prospective studies on calorie restriction and metformin (NCT03340935, NCT03454282, NCT03709147, NCT04248998, NCT04001725); 2) clinical management of patients with limited-stage and advanced breast cancer, including treatment with chemotherapy, endocrine therapy and molecular targeted treatments; 3) participation in sponsored clinical trials in breast cancer patients, including studies with immunotherapy, cyclin-dependent kinase 4/6 inhibitors, PI3K inhibitors and new immune conjugates; 4) supervision, with the role of mentor and thesis co-advisor, of students in Medicine in projects focused on the study of lipid metabolism in HER2+ BC and pancreatic neuroendocrine tumors (pNETs); 5) coordination of clinical and translational research activities of residents in Medical Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano; 6) collaboration or conduction of translational research project focused on breast cancer, lung cancer, renal cancer and pNETs.

December 2014 – December 2019

Joint IFOM-INT post-Doc, working on research projects focused on cancer metabolism and tumor resistance to taxanes, in collaboration with the groups directed by Prof. Marco Foiani, Prof. Valter Longo, Dr. Andrea Ciliberto and Dr. Stefano Casola.

April 2014 – November 2014

Post-doctoral fellowship in the “Quantitative Biology of Cell Division” Laboratory directed by Dr. Andrea Ciliberto.

January 2010 – March 2014

PhD student at the SEMM (European School of Molecular Medicine) at the F.I.R.C. Institute of Molecular Oncology (IFOM) in Milan, under the supervision of Dr. Andrea Ciliberto.

Main project: The balance between APC subunit phosphorylation by Cdk1/CycB, and dephosphorylation by PP2A^{Cdc55} in the adaptation to the spindle assembly checkpoint (SAC) in budding yeast cells. **Secondary projects:** collaborations with Prof. Andrea Musacchio's group (IEO, Milan) to study the role of Aurora B in the SAC of mammalian cells and with Prof. Ruggero Pardi in San Raffaele (Milan, Italy) on models of cellular migration in the Medaka fish model.

September 2006 – July 2008

SKILLS AND COMPETENCES

- Leadership experience: Group leader at IFOM (director of an independent research program currently involving 9 scientists: Dr. Giulia Salvadori, Dr. Mattia Rediti, Dr. Francesca Ligorio, Dr. Marzia Santamaria, Dr. Beatrice Cantarelli, Dr. Maria Elena Steidl, Dr. Keagile Bati, Dr. Giacomo Mazzoli, Dr. Leonardo Provenzano) and leader at INT (reponsible for clinical research programs involving 8 medical oncologists and nutritionists: Dr. Francesca Ligorio, Dr. Giovanna Armani, Dr. Leonardo Provenzano, Dr. Flavia Jacobs, Dr. Giuseppe Fotia, Dr. Giacomo Mazzoli, Dr. Lucrezia Zanenga, Dr. Silvia Paderno).
- Expertise in designing, conducting and coordinating clinical trials in patients with limited-stage and advanced cancers (Clinicaltrials.gov Identifiers: NCT03340935, NCT03454282, NCT03709147, NCT04248998, NCT04001725; NCT06805812).
- Statistics, biostatistics, survival analysis, multivariable analysis, propensity score analysis (R, MATLAB); image processing (Adobe Photoshop, ImageJ).
- Molecular Biology (DNA, RNA and protein techniques), Biochemistry (western blot analysis, immunoprecipitation assays), Yeast Genetics, Cell Biology (Cell culture, viability assays), Flow Cytometry, Microscopy (Bright field, IF/ICC, live cell microscopy on yeast and mammalian cells), Softwares (Programming in Python and MATLAB; automated image analysis (vHCS Scan, CellProfiler).
- Expertise in conducting bioinformatic analyses of transcriptomic, proteomic and metabolomic data from cell lines, mouse samples and human samples.
- Computational approaches to biological problems through mathematical modeling and analysis (ordinary differential equations; MATLAB and XPP/XPPAUT).
- Clinical independence in managing cancer patients in their global cure process (5-year clinical experience as a Resident in Medical Oncology).
- Clinical independence as a general medical doctor (2-year experience as a medical volunteer assisting patients with basic medical needs at Naga, Milan, Italy).
- Mentorship experience: Mentor of students in Biology (Dr. Valentina Francia) and Medicine (Dr. Pietro Indelicato, Dr. Marta Rossi, Dr. Luca Zambelli). Mentor of PhD students in Nutrition Sciences (Dr. Marzia Sucameli). Mentor of Residents in Medical Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori (Dr. Francesca Ligorio; Dr. Riccardo Lobefaro; Dr. Emma Zattarin; Dr. Giorgia Peverelli; Dr. Leonardo Provenzano; Dr. Caterina Sposetti; Dr. Giuseppe Fotia; Dr. Giacomo Mazzoli). Mentor of PhD students in Molecular Oncology at IFOM (Dr. Beatrice Cantarelli, UK PhD; Dr. Marzia Santamaria, UK PhD; Dr. Francesca Ligorio, UK PhD; Dr. Emanuele Frigo; Dr. Giacomo Mazzoli; Dr. Keagile Bati). Mentor of Post-Doc in Molecular Oncology (Dr. Giulia Salvadori; Dr. Mattia Pavani; Dr. Mattia Rediti; Dr. Maria Elena Steidl).
- Internal supervisor of PhD students: Riccardo Valzelli (mentor: Saverio Minucci at IEO, Istituto Europeo di Oncologia); Bianca Barzaghi (mentor: Giuseppe Testa at IEO, Istituto Europeo di Oncologia)
- Internal examiner of PhD students: Giulia Salvadori (2019) from Valter Longo's group (IFOM)

GRANTS AND FELLOWSHIPS

- **November 2024: AIRC IG (Investigator grant)** for a project entitled "Targeted amino acid supplementation plus fasting as a novel anticancer strategy against the "big

killers”: AMINOFAST”. PI: C. Vernieri: Project code: IG 2024 ID 30499. 1.784.000 euro for 5 years

- **September 2023: ERC Starting Grant** for a project entitled “METABALANCANCER – Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy”. PI: C. Vernieri. Project code: 101117893. 1.499.250 euro for 5 years
- **October 2022:** internal grant of the Scientific Directorate of Fondazione IRCCS Istituto Nazionale dei Tumori for a project entitled “Leucine supplementation plus fasting-mimicking diet to improve the efficacy of chemoimmunotherapy in triple-negative breast cancer”. PI: C. Vernieri; 530.000,00 euros for 3 years
- **June 2020: H2020 Grant (H2020-SC1-2020-Lump-Sum-RTD)** within the Cancer Core Europe Consortium for a project entitled “CCE_DART”. PI of Work Package 10: Claudio Vernieri. Budget allocated for WP10: 116.264,50 euros for 5 years.
- **November 2019: My First AIRC Grant (MFAG)** for a project entitled “Exploiting inducible metabolic vulnerabilities to improve chemotherapy efficacy in triple negative breast cancer”. PI: C. Vernieri. Project Code: 22977 (499.118,4 euros for 5 years).
- **June 2019:** internal grant of the Scientific Directorate of Fondazione IRCCS Istituto Nazionale dei Tumori for studies focused on triple-negative breast cancer metabolism (205.000,00 euros in 3 years). PI: C. Vernieri.
- **November 2014:** one-year AIRC post-doctoral fellowship. Title of the project: “*Uncovering the role of Cdc20 levels in the heterogeneity of times of adaptation to the Spindle Assembly Checkpoint*”.
- **December 2014:** five-year fellowship from the University of Milan as a resident in Medical Oncology.
- **January 2010:** full Doctorial Scholarship Awarded by the University of Milan through competitive admission to the research doctorate course denominated “PhD in Molecular Medicine”.
- **July 2009:** five-year fellowship from the University Federico II of Naples as a resident in Radiotherapy.

COLLABORATOR IN OTHER GRANTS

- AIRC IG: PI Maria Vittoria Dieci (2022-2027). Title of the project: “Immunometabolic profile to personalize immunotherapy for patients with triple negative breast cancer”. Collaborator in the conduction of translational immunometabolic evaluations in tumor specimens and plasma samples from patients enrolled in the A-BRAVE trial.
- AIRC IG: PI Giancarlo Pruneri (2022-2027). Title of the project: “UNDERSTAND – Untavelling tumor resistance mechanisms in HR+ aDvanced bReaST cANcer undergoing CDK4/6 inhibitors therapy”. Collaborator of the clinical part of the study, and responsible for preclinical experiments (Task 4) to identify metabolic mechanisms of HR+/HER2- BC cell resistance to CDK4/6 inhibitors.
- AIRC IG: PI Tiziana Triulzi (2021-2025). Title of the project: “New potential therapeutic targets for triple negative breast cancer patients from the study of tumor-adipocyte crosstalk”.
- AIRC IG: PI Paolo Maiuri (2021-2025). Title of the project: “Mechano-perturbation of the cell nucleus in tumor progression”.
- AIRC IG: PI Serenella M. Pupa (2010-2024). Title of the Project: “Targeting fatty acid uptake pathway to revert resistance to anti-HER2 agents in HER2-positive breast cancer”.

- AIRC IG: PI Andrea Ciliberto (2018-2023). Title of the Project: “Dissecting the role of Cdc20 in the resistance to antimetabolites: from evolution experiments to clinical testing”.
- AIRC IG: PI Marina C. Garassino (2017-2021). Title of the Project: “Exploiting LKB1 vulnerability by selective metabolic treatments in advanced Non-Small Cell Lung Cancer”
- AIRC IG: PI Licia Rivoltini (2017-2022). Title of the Project: “Dietary intervention and physical exercise as modulators of cancer immunity in clinical setting”.
- Bando per la valorizzazione della Ricerca Istituzionale 2017 della Fondazione IRCCS Istituto Nazionale dei Tumori. PI: Filippo de Braud (2018-2020). Title of the Project: “Metabolic and immunomodulatory effects of high-dose glucocorticoids plus/minus metformin in metastatic cancer patients”
- ERANET TRANSCAN-2 (Joint Translational Call for Proposals 2015). PI: Filippo de Braud (2018-2020). Title of the Project: “Impact of Dietary Intervention on tumour immunity”

AWARDS

- **October 2024:** University of Padua Award for Advances in Breast Cancer 2024 Awardee lecture entitled “Boosting Academic Research to Meet the Unmet Needs in Breast Cancer Therapy”.
- **March 2023:** MERIT AWARD 2023 for Medicine by the Association “Insieme con Merito” (Milan, Italy)
- **January 2022:** Award by the EACR (European Association for Cancer Research) for the manuscript entitled “Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients”, which was included in the list of “*The EACR’s Top 10 Cancer Research Publications*”.
- **May 2019:** 2018 Young Researcher Award of the Fondazione IRCCS Istituto Nazionale dei Tumori for results obtained in the field of Translational Cancer Research.
- **February 2018:** Conquer Cancer Foundation Merit Award for a work entitled: “*Prognostic and predictive role of Fumarate Hydratase in metastatic clear cell Renal Cell Carcinoma*” presented at the 2018 Genitourinary Cancers Symposium (ASCO GU 2018).

PATENTS

Co-inventor of “Preparazione alimentare a basso contenuto calorico per l'alimentazione di pazienti affetti da neoplasie”. Italian Patent released. First deposited Italian patent n. 102019000009954 (24th June 2019). Extension PCT WO 2020/261131 24th June 2020. European Patent n. 20740399 (pending). Canadian patent n. 2,144,217 (pending). USA (pending).

Co-inventor of “Preparazione alimentare per l'alimentazione di pazienti oncologici avente un ridotto apporto calorico”. International patent request n. PCT/IT2020/000083. Deposited on 17th Dec 2020 (pending)

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

- ASCO: American Society of Clinical Oncology
- ESMO: European Society of Medical Oncology
- AIOM: Associazione Italiana di Oncologia medica
- CCE: Cancer Core Europe

REVIEWER FOR THE FOLLOWING SCIENTIFIC JOURNALS:

- The Lancet Oncology
- Annals of Oncology
- Cell Reports Medicine
- Nature Communications
- Journal of Thoracic Oncology
- Journal for ImmunoTherapy of Cancer
- Cancer Communications
- Aging Cell
- Cancer Research
- European Journal of Cancer
- Oncogene
- International Journal of Cancer
- Trends in Endocrinology and Metabolism
- NPJ Breast Cancer
- Cancers (Basel)
- Cancer Treatment Reviews
- Scientific Reports
- The Breast
- Oncotarget
- Critical Reviews in Oncology/Hematology
- Therapeutic Advances in Medical Oncology
- Translational Cancer Research
- Annals of Translational Medicine
- Cancer Management and Research
- Tumori Journal

REVIEWER OF GRANT APPLICATIONS

- **March 2022:** Reviewer of a preclinical grant application for the Swiss Cancer Research and Swiss Cancer League
- **February 2022:** Reviewer of a clinical grant application for the Swiss Cancer Research and Swiss Cancer League
- **September 2021:** Reviewer of grant application for the KWF Kankerbestrijding (Dutch Cancer Society)
- **December 2020:** Reviewer of the “Bando per la valorizzazione della ricerca istituzionale in ambito oncologico 2020” for Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia

PUBLICATIONS

- 1 Blondeaux E, Delucchi V, Mariamidze E, Bernstein-Molho R, Frank S, Ferrari A, Linn S, Jeong Kim H, Agostinetto E, Paluch-Shimon S, Cortesi L, Di Meglio A, Balmana J, Yerushalmi R, Rodriguez-Wallberg KA, Renaud T, Cui W, Moore HCF, Wong SM, Pogoda K, Lustberg M, Phillips KA, Han S, Puglisi F, **Vernieri C**, Bajpai J, Sonnenblick A, Rousset-Jablonski C, De Marchis L, De Giorgi U, Bianchini G, Texeira L, Duhoux FP, Villarreal-Garza C, Sini V, Fruscio R, Del Mastro L, Demeestere I, Azim HA Jr, Peccatori FA, Partridge AH, Lambertini M. *J Natl Cancer Inst* 2025. PMID: 40623009
- 2 Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, Bernstein-Molho R, Linn S, Kwong A, Pogoda K, Balmana J, Smeets A, Bajpai J, Moore HCF,

- Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Mando P, Lee JE, Fruscio R, Cui W, Wong SM, **Vernieri C**, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Guven DC, Lee M, Villarreal-Garza C, Hwang SE, De Marchis L, Puglisi F, Kemp Z, Meireles PA, Parokonnaya A, Werutsky G, Okano M, Azim HA Jr, Mati K, Rosenberg S, Gelber R, Boni L, Lambertini M. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. *Lancet Oncol* 2025. PMID: 40347973.
- 3 Magaton IM, Blondeaux E, Hamy AS, Linn S, Bernstein-Molho R, Peccatori FA, Ferrari A, Carrasco E, Paluch-Shimon S, Agostinetti E, Venturelli M, Luis IMV, Rodriguez-Wallberg KA, Kim HJ, Sorouri K, Renaud T, Moore HCF, Cui W, Bajpa J, Rousset-Jablonski C, De Marchis L, Yerushalmi R, Wong SM, Han S, Phillips KA, Pogoda K, Puglisi F, Chirco A, Duhoux FP, Meattini I, Villarreal-Garza C, **Vernieri C**, Bruzzzone M, Demeestere I, Azim HA Jr, Partridge AH, Lambertini M. Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study. *Eur J Cancer* 2025. PMID: 40300260
 - 4 Nichetti F, Brambilla M, Duca M, Piccolo A, Miliziano D, Cavalli C, Marra F, Ambrosini P, Zanella C, **Vernieri C**, Lorenzini D, Colombo E, Damian S, Baili P, Proto C, Busico A, Conca E, Capone I, Manoukian S, Tamborini E, Perrone F, Niger M, Vingiani A, Agnelli L, de Braud F, Pruneri G. Real-World Outcomes of Molecular Tumor Board Treatment Recommendations. *JCO Precis Oncol* 2025. PMID: 40499091
 - 5 Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Riconzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri A, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, **Vernieri C**, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F. Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors. *Breast* 2025. PMID: 40424680
 - 6 De Micheli V, Agnelli L, Conca E, Rabsiun Aramburu VL, Baggi A, Vingiani A, Duca M, Perrone F, Tamborini E, Piccolo A, Lorenzini D, Busico A, Capone I, Niger M, Proto C, **Vernieri C**, Manoukian S, Gancitano G, Ferrario M, Franzini JM, De Braud F, Pruneri G, Jommi C. Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study. *BMJ Open* 2025. PMID: 40379307
 - 7 Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, **Vernieri C**; Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study. *Ann Oncol* 2025. PMID: 40204155
 - 8 De Placido P, Di Rienzo R, Pietroluongo E, Martinelli C, Tafuro M, Formisano P, D'Esposito V, Poggio FB, Ruelle T, Cardinali B, Di Lauro V, Buono G, Caputo R, Buonaiuto R, Caltavitturo A, Rocco P, Porciello G, De Laurentiis M, Del Mastro L, **Vernieri C**, Veneziani BM, Bianco R, Crispo A, De Angelis C, Arpino G, Giuliano M. Insights on the association of anthropometric and metabolic variables with tumor features

- and genomic risk in luminal early breast cancer: Results of a multicentric prospective study. *Eur J Cancer* 2025. PMID: 40220739
- 9 Lambertini M, Blondeaux E, Tomasello LM, Agostinetti E, Hamy AS, Kim HJ, Franzoi MA, Bernstein-Molho R, Hilbers F, Pogoda K, Wildiers H, Bajpai J, Ignatiadis M, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Criscitiello C, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, **Vernieri C**, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Rodriguez-Wallberg KA, Duhoux FP, Livraghi L, Bruzzone M, Boni L, Balmaña J. Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status. *J Clin Oncol* 2025. PMID: 39993249.
 - 10 Berton Giachetti PPM, Morganti S, Gandini S, Giudici F, Marra A, Nicolò E, Zattarin E, Corti C, Boldrini L, Verrazzo A, Sposetti C, Razeti MG, Carnevale Schianca A, Scafetta R, Taurelli Salimbeni B, Esposito A, Zagami P, Trapani D, Malagutti B, Caputo R, **Vernieri C**, Munzone E, Scagnoli S, Botticelli A, Lambertini M, Giuliano M, De Laurentiis M, Viale G, Bianchini G, Curigliano G, De Angelis C, Criscitiello C. Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. *JAMA Netw Open* 2025. PMID: 39982725.
 - 11 Ligorio F, Vingiani A, Torelli A, Sposetti C, Drufuca L, Iannelli F, Zanenga L, Depretto C, Folli S, Scaperrotta G, Capri G, Bianchi GV, Ferraris C, Martelli G, Maugeri I, Provenzano L, Nichetti F, Agnelli L, Lobefaro R, Fucà G, Fotia G, Mariani L, Morelli D, Ladisa V, De Santis MC, Lozza L, Trecate G, Belfiore A, Brich S, Bertolotti A, Lorenzini D, Ficchi A, Martinetti A, Sottotetti A, Arata A, Corsetto PA, Sorrentino L, Rediti M, Salvadori G, Minucci S, Foiani M, Apolone G, Pagani M, Pruneri G, de Braud F, **Vernieri C**. Early downmodulation of tumour glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients. *Cell Metab* 2025. PMID: 39694040
 - 12 Miglietta F, Collesei A, **Vernieri C**, Giarratano T, Giorgi CA, Girardi F, Griguolo G, Cacciatore M, Botticelli A, Vingiani A, Fotia G, Piacentini F, Massa D, Zanghi F, Marino M, Pruneri G, Fassan M, Dei Tos AP, Dieci MV, Guarneri V. Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study. *ESMO Open* 2025. PMID: 39705838
 - 13 Castagnoli L, Franceschini A, Cancila V, Dugo M, Bigliardi M, Chiodoni C, Toneguzzo P, Regondi V, Corsetto PA, Pietrantonio F, Mazzucchelli S, Corsi F, Belfiore A, Vingiani A, Pruneri G, Ligorio F, Colombo MP, Tagliabue E, Tripodo C, **Vernieri C**, Triulzi T, Pupa SM. CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer. *J Exp Clin Cancer Res* 2025. PMID: 39833955
 - 14 Fabi A, Rossi A, Caputo R, Pisegna S, Scagnoli S, Pantano F, D'Auria G, Fedele P, Fabbri A, **Vernieri C**, Palleschi M, Carbognin L, Ferretti G, Di Monte E, Paris I, Pavese F, Garrone O, Franco A, De Laurentiis M, Franceschini G, Scambia G, Giannarelli D, Masetti R, Botticelli A. Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan. *NPJ Precis Oncol* 2025. PMID: 39843642.
 - 15 Massa D, **Vernieri C**, Nicolò L, Criscitiello C, Boissière-Michot F, Guiu S, Bobrie A, Griguolo G, Miglietta F, Vingiani A, Lobefaro R, Taurelli Salimbeni B, Pinato C, Schiavi F, Brich S, Pescia C, Fusco N, Pruneri G, Fassan M, Curigliano G, Guarneri V, Jacot W, Dieci MV. Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer. *J Natl Cancer Inst.* 2024. PMID: 39083015
 - 16 Koppold DA, Breinlinger C, Hanslian E, Kessler C, Cramer H, Khokhar AR, Peterson CM, Tinsley G, **Vernieri C**, et al. International consensus on fasting terminology. *Cell Metab* 2024. PMID: 39059384
 - 17 Agostinetti E, Bruzzone M, Hamy AS, Kim HJ, Chiodi C, Bernstein-Molho R, Linn S, Pogoda K, Carrasco E, Derouane F, Bajpai J, Nader-Marta G, Lopetegui-Lia N, Partridge

- AH, Cortesi L, Rousset-Jablonski C, Giugliano F, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, **Vernieri C**, et al. Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology. *ESMO Open* 2024. PMID: 39288653
- 18 **Vernieri C**^{*}, Ligorio F, Tripathy D, Longo VD. Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence. *Cell Metab* 2024. PMID: 39059383
 - 19 Arecco L, Bruzzzone M, Bas R, Kim HJ, Di Meglio A, Bernstein-Molho R, Hilbers FS, Pogoda K, Carrasco E, Punie K, Bajpai J, Agostinetto E, Lopetegui-Lia N, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Curigliano G, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, **Vernieri C**, Couch FJ, Dieci MV, Matikas A, Rozenblit M, Aguilar-Y Méndez D, De Marchis L, Puglisi F, Fabi A, Graff SL, Witzel I, Rodriguez Hernandez A, Fontana A, Pesce R, Duchnowska R, Pais HL, Sini V, Sokolović E, de Azambuja E, Ceppi M, Blondeaux E, Lambertini M. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers. *Ann Oncol* 2024. PMID: 38908482
 - 20 Sorrentino L, Daveri E, Belli F, Vigorito R, Battaglia L, Sabella G, Patti F, Randon G, Pietrantonio F, **Vernieri C**, Scaramuzza D, Villa S, Milione M, Gronchi A, Cosimelli M, Guaglio M. Management of patients with locally recurrent rectal cancer with a previous history of distant metastases: retrospective cohort study. *BJS Open* 2024. PMID: 38869237
 - 21 Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, Bernstein Molho R, Linn SC, Pogoda K, Carrasco E, Punie K, Agostinetto E, Lopetegui-Lia N, Phillips KA, Toss A, Rousset-Jablonski C, Acheritogaray M, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, **Vernieri C**, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Vasconcelos de Matos L, Mariño M, Teixeira L, Graffeo R, Rognone A, Chirco A, Antone N, Abdou Y, Marhold M, Božović-Spasojević I, Cortés Salgado A, Carmisciano L, Bruzzzone M, Curigliano G, Prat A, Lambertini M. Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. *Cancer* 2024. PMID: 38752572
 - 22 Raucci F, **Vernieri C**[#], Di Tano M, Ligorio F, Blaževitš O, Lazzeri S, Shmahala A, Fragale G, Salvadori G, Varano G, Casola S, Buono R, Visco E, de Braud F, Longo VD. Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia. *Cancer Res.* 2024. PMID: 38241703
 - 23 Zattarin E, Mariani L, Menichetti A, Leporati R, Provenzano L, Ligorio F, Fucà G, Lobefaro R, Lalli L, Vingiani A, Nichetti F, Griguolo G, Sirico M, Bernocchi O, Marra A, Corti C, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Presti D, Sposetti C, Giorgi C.A., Guarneri V, Pedersini R, Losurdo A, Generali D, Curigliano G, Prunerì G, de Braud F, Dieci M.V. and **Vernieri C**^{*}. Peripheral blood lymphocytes predict clinical outcomes in Hormone Receptor-positive HER2-negative advanced Breast Cancer patients treated with CDK4/6 inhibitors. *Ther Adv Med Oncol* 2023. PMID: 38130467
 - 24 Pusceddu S, Corti F, Prinzi N, Nichetti F, Ljevar S, Busico A, Cascella T, Leporati R, Oldani S, Pircher CC, Coppa J, Resi V, Milione M, Maccauro M, Miceli R, Tamborini E, Perrone F, Spreafico C, Niger M, Morano F, Pietrantonio F, Seregini E, Mariani L, Mazzaferro V, Di Liberti G, Fucà G, de Braud F, **Vernieri C**^{*}. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2. *J Hematol Oncol.* 2023. PMID: 38098114
 - 25 Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-

- Shimon S, Fruscio R, Cui W, Wong SM, **Vernieri C**, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. *JAMA* 2024. PMID: 38059899
- 26 Crispo A, Augustin LSA, Luongo A, Calderaio C, Breda J, Coluccia S, Calabrese A, Marrazzo V, Giannatiempo R, Trasacco P, Palumbo E, Vitale S, Porciello G, Di Gennaro P, Caputo R, Buono G, **Vernieri C**, Schettini F, Grimaldi M, Nocerino F, Celentano E, Amore A, Giuliano M, De Placido P, De Angelis C, Bianco R, De Laurentiis M, La Vecchia C, Arpino G. Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients. *Sci Rep*. 2023. PMID: 38040773
 - 27 Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, **Vernieri C**, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study. *Oncologist* 2024. PMID: 37995313
 - 28 Martelli G, Barretta F, **Vernieri C**, Folli S, Pruneri G, Segattini S, Trapani A, Carolla C, Spatti G, Miceli R, Ferraris C. Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection. *JAMA Surg*. PMID: 37792368
 - 29 Mosconi P, Colombo C, Paletta P, Gangeri L, Pellegrini C, Garralda E, Miceli R, Brunelli C; CEE_DART Consortium. Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project. *BMC Cancer* 2023. PMID: 37648965
 - 30 Zattarin E, Taglialatela I, Lobefaro R, Leporati R, Fucà G, Ligorio F, Sposetti C, Provenzano L, Azzollini J, Vingiani A, Ferraris C, Martelli G, Manoukian S, Pruneri G, de Braud F, **Vernieri C***. Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities. *Crit Rev Oncol Hematol* 2023. PMID: 37643668
 - 31 Ligorio F, Provenzano L and **Vernieri C***. Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer. *Curr Opin Oncol* 2023. PMID 37621169
 - 32 Ligorio F, Lobefaro R, Fucà G, Provenzano L, Zanenga L, Nasca V, Sposetti C, Salvadori G, Ficchi A, Franza A, Martinetti A, Sottotetti E, Formisano B, Depretto C, Scaperrotta G, Belfiore A, Vingiani A, Ferraris C, Pruneri G, de Braud F and **Vernieri C***. Adding Fasting-Mimicking Diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple negative breast cancer patients: a sub-analysis of the NCT03340935 trial. *Int J Cancer* 2023. PMID: 37615485
 - 33 Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, Proto C, Niger M, Nichetti F, Tamborini E, Perrone F, Piccolo A, Manoukian S, Azzollini J, Brambilla M, Colombo E, Lopez S, **Vernieri C**, Marra F, Conca E, Busico A, Capone I, Bozzi F, Angelini M, Devecchi A, Salvatori R, De Micheli V, Baggi A, Pasini S, Jommi C, Ladisa V, Apolone G, De Braud F, Pruneri G. Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care. *JCO Precis Oncol* 2023. PMID: 37487147
 - 34 Valenza C, Trapani S, Trapani D, Gandini S, Sposetti C, Bielo LB, Marra A, Giarratabo T, Favero D, Cortesi L, Moscetti L, Pistelli M, Berardi R, Zambelli A, Lambertini M, Del Mastro L, Guarneri V, **Vernieri C**, Curigliano G. Platinum-based chemotherapy and PARP Inhibitors for patients with a germline BRCA pathogenic variant and advanced

- breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments. *Eur J Cancer* 2023. PMID: 37437366
- 35 Licata L, Viale G, Giuliano M, Curigliano G, Chavez-MacGregor M, Foldi J, Oke O, Collins J, Del Mastro L, Puglisi F, Montemurro F, **Vernieri C**, Gerratana L, Giordano S, Rognone A, Sica L, Gentilini O, Cascinu S, Pusztai L, Giordano A, Criscitiello C, Bianchini G. Oncotype Dx results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer. *NPJ Breast Cancer* 2023. PMID: 37291235
 - 36 Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Giacchetti PPB, Schianca AC, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali D, Criscitiello C, Curigliano G, Pruneri G, de Braud F, Dieci MV, **Vernieri C***. Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. *NPJ Breast Cancer* 2023. PMID: 37069173
 - 37 Provenzano L, Lobefaro R, Ligorio F, Zattarin E, Zambelli L, Sposetti C, Presti D, Montelatici G, Ficchi A, Martinetti A, Arata A, Del Vecchio M, Lauria Pantano C, Formisano B, Bianchi GV, Capri G, de Braud F, **Vernieri C**, Fucà G. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis. *Ther Adv Med Oncol* 2023. PMID: 37063779
 - 38 Lobefaro R, Mariani L, Peverelli G, Ligorio F, Fucà G, Rametta A, Zattarin E, Leporati R, Presti D, Cantarelli B, Depretto C, Vingiani A, Manoukian S, Scaperrotta G, Bianchi GV, Capri G, Pruneri G, de Braud F, **Vernieri C***. Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison. *Clin Breast Cancer* 2023. PMID: 36599769
 - 39 Ferrando L, Vingiani A, Garuti A, **Vernieri C**, Belfiore A, Agnelli L, Dagrada G, Ivanoiu D, Bonizzi G, Munzone E, Lippolis L, Dameri M, Ravera F, Colleoni M, Viale G, Magnani L, Ballestrero A, Zoppoli G, Pruneri G. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). *PLoS Genet.* 2023. PMID: 36595552
 - 40 Di Cosimo S, La Rocca E, Ljevar S, De Santis MC, Bini M, Cappelletti V, Valenti M, Baili P, de Braud FG, Folli S, Scaperrotta G, Volpi C, Vingiani A, **Vernieri C**, Verderio P, Miceli R, Pruneri G. Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world. *Front Mol Biosci.* 2022. PMID: 36225259
 - 41 Zattarin E, Nichetti F, Ligorio F, Mazzeo L, Lobefaro R, Fucà G, Peverelli G, Vingiani A, Bianchi GV, Capri G, de Braud F, **Vernieri C***. Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin. *Front Oncol* 2022. PMID: 36059635
 - 42 Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, **Vernieri C***. Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. *J Natl Cancer Inst.* 2022. PMID: 358789270
 - 43 Ligorio F, Fucà G, Provenzano L, Lobefaro R, Zanenga L, Vingiani A, Belfiore A, Lorenzoni A, Alessi A, Pruneri G, de Braud F, **Vernieri C***. Exceptional tumor responses

- to fasting-mimicking diet combined with standard anticancer therapies: a sub-analysis of the NCT03340935 trial. *Eur J Cancer* 2022. PMID: 35810555
- 44 Green BJ, Marazzini M, Hershey B, Fardin A, Li Q, Wang Z, Giangreco G, Pisati F, Marchesi S, Disanza A, Frittoli E, Martini E, Magni S, Beznoussenko GV, **Vernieri C**, Lobefaro R, Parazzoli D, Maiuri P, Havas K, Labib M, Sigismund S, Fiore PPD, Gunby RH, Kelley SO, Scita G. PillarX: A Microfluidic Device to Profile Circulating Tumor Cell Clusters Based on Geometry, Deformability, and Epithelial State. *Small* 2022. PMID 35344274
 - 45 Ligorio F, Zambelli L, Fucà, Lobefaro R, Santamaria M, Zattarin E, de Braud F, **Vernieri C***. Prognostic Impact of Body Mass Index (BMI) in HER2-positive Breast Cancer Treated with Anti-HER2 Therapies: from preclinical rationale to clinical implications. *Ther Adv Med Oncol* 2022; 14:17588359221079123. PMID: 35281350
 - 46 Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Lorient Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, **Vernieri C**, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. *Nat Cancer*. 2022;3(2):251-261. PMID: 35221333
 - 47 Pusceddu S, **Vernieri C**, Di Maio M, Prinzi N, Torchio M, Corti F, Coppa J, Buzzoni R, Di Bartolomeo M, Milione M, Regnault B, Truong Thanh XM, Mazzaferro V, de Braud F. Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. *Cancers (Basel)*. 2021;14(1):69. PMID: 35008233
 - 48 **Vernieri C***, Fucà G, Ligorio F, Huber V, Vingiani A, Iannelli F, Raimondi A, Rinchai D, Frigè G, Belfiore A, Lalli L, Chiodoni C, Cancila V, Zanardi F, Ajazi A, Cortellino S, Vallacchi V, Squarcina P, Cova A, Pesce S, Frati P, Mall R, Corsetto PA, Rizzo AM, Ferraris C, Folli S, Garassino MC, Capri G, Bianchi G, Colombo MP, Minucci S, Foiani M, Longo VD, Apolone G, Torri V, Prunerì G, Bedognetti D, Rivoltini L, de Braud F. Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients. *Cancer Discov*. 2022;12(1):90-107. PMID: 34789537
 - 49 Salvadori G, Zanardi F, Iannelli F, Lobefaro R, **Vernieri C**, Longo VD. Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape. *Cell Metab*. 2021;33(11):2247-2259. PMID: 34731655.
 - 50 Pupa SM, Ligorio F, Cancila V, Franceschini A, Tripodo C, **Vernieri C**, Castagnoli L. HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. *Cancers (Basel)*. 2021;13(19):4778. PMID: 34638263.
 - 51 Ajazi A, Bruhn C, Shubassi G, Lucca C, Ferrari E, Cattaneo A, Bachi A, Manfrini N, Biffo S, Martini E, Minucci S, **Vernieri C**, Foiani M. Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis. *Dev Cell* 2021;56(18):2607-2622. PMID: 34534458.
 - 52 Valdemarin F, Caffà I, Persia A, Cremonini AL, Ferrando L, Tagliafico L, Tagliafico A, Guijarro A, Carbone F, Ministrini S, Bertolotto M, Becherini P, Bonfiglio T, Giannotti C, Khalifa A, Ghanem M, Cea M, Sucameli M, Murialdo R, Barbero V, Gradassi R, Bruzzone F, Borgarelli C, Lambertini M, **Vernieri C**, et al. Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. *Cancers (Basel)*. 2021;13(16):4013. PMID: 34439167.

- 53 Dameri M, Ferrando L, Cirmena G, **Vernieri C**, Pruneri G, Ballestrero A, Zoppoli G. Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. *Int J Mol Sci*. 2021;22(13):7154. PMID: 34281208.
- 54 Ligorio F, Fucà G, Zattarin E, Lobefaro R, Zambelli L, Leporati R, Rea C, Mariani G, Bianchi GV, Capri G, de Braud F, **Vernieri C***. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. *Cancers (Basel)*. 2021;13(8):1964.
- 55 Ligorio F, Pellegrini I, Castagnoli L, Vingiani A, Lobefaro R, Zattarin E, Santamaria M, Pupa SM, Pruneri G, de Braud F, **Vernieri C***. Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. *Cancer Lett*. 2021;511:77-87. PMID: 33961924.
- 56 **Vernieri C*#**, Nichetti F, Lalli L, Moschetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer: the EVERMET study. *Clin Cancer Res*. 2021. PMID: 33785482
- 57 Ligorio F, Zambelli L, Bottiglieri A, Castagnoli L, Zattarin E, Lobefaro R, Ottini A, Vingiani A, Pupa S.M., Bianchi, G.V., Capri G, Pruneri G, de Braud F, **Vernieri C***. Hormone receptor status influences the impact of Body Mass Index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. *Ther Adv Med Oncol*. 2021;13:17588359211006960. PMID: 33948122
- 58 Lobefaro R, Zattarin E, Nichetti F, Prisciandaro M, Ligorio F, Brambilla M, Sepe P, Corti F, Peverelli G, Ottini A, Beninato T, Mazzeo L, Rea C.G, Mariani G, de Braud F, Bianchi GV, **Vernieri C***, Capri G. Antitumor activity and efficacy of shorter vs. longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a ten-year, retrospective analysis. *Ther Adv Med Oncol*. 2020;12:1758835920970081. PMID: 33335565
- 59 Zattarin E, Leporati R, Ligorio F, Lobefaro R, Vingiani A, Pruneri G, **Vernieri C***. Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings and Therapeutic Implications. *Cells* 2020; 9(12), 2644. PMID: 33316954
- 60 Borzi C, Galli G, Ganzinelli M, Signorelli D, **Vernieri C**, Garassino MC, Sozzi G, Moro M. Beyond *LKB1* Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. *Pharmaceuticals (Basel)*. 2020;13(11):385. PMID: 33202760
- 61 Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, **Vernieri C**, et al. Early Changes of the Standardized Uptake Values (SUV_{max}) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. *Cancers (Basel)* 2020;12(11):3314. PMID: 33182575
- 62 Borreani C, Alfieri S, Infante G, Miceli R, Mariani P, Bosisio M, **Vernieri C**, Bianchi GV, Capri G. Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters. *Oncology*. 2020;1-12. PMID: 32992318
- 63 **Vernieri C*#**, Ligorio F, Zattarin E, Rivoltini L, de Braud F. Fasting-mimicking diet plus chemotherapy in breast cancer treatment. *Nat Commun*. 2020;11(1):4274. PMID: 32848145

- 64 Pusceddu S, **Vernieri C**, et al. The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. *Therap Adv Gastroenterol*. 2020;13:1756284820927271. PMID: 32821286
- 65 Caffa I, Spagnolo V, **Vernieri C**, et al. Fasting-mimicking diet and hormone therapy induce breast cancer regression. *Nature* 2020;583(7817):620-624. PMID: 32669709
- 66 Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, **Vernieri C**, et al. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. *Nat Med*. 2020;26(7):992-994. PMID: 32632195
- 67 D'Amico S, Krasnowska EK, Manni I, Toietta G, Baldari S, Piaggio G, Ranalli M, Gambacurta A, **Vernieri C**, et al. DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. *Cells* 2020;9(5):1260. PMID: 32438775
- 68 **Vernieri C**[#], Ganzinelli M, Rulli E, et al. *LKB1* mutations are not associated with the efficacy of first- and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. *ESMO Open* 2020;5(3):e000748. PMID: 32467099
- 69 Di Tano M, Raucci F, **Vernieri C**, et al. Synergistic effect of Fasting-mimicking diet and vitamin C against *KRAS* mutated cancers. *Nat Commun*. 2020;11(1):2332. PMID: 32393788
- 70 Mirabile A, Rivoltini L, Daveri E, **Vernieri C**, et al. Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. *Cancers (Basel)* 2020; 12(5). PMID: 32375310
- 71 Zattarin E and **Vernieri C**^{*}. Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer. *Ann Transl Med*. 2020;8(12):737. PMID: 32647662
- 72 **Vernieri C**[#], Corti F, Nichetti F, et al. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeding different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. *Breast Cancer Res*. 2020;22(1):33. PMID 3225811
- 73 **Vernieri C**[#], Prisciandaro M, Nichetti F, et al. Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breat Cancer. *Cancers (Basel)*. 2020;12(3). PMID 32155941
- 74 Castagnoli L, De Santis F, Volpari T, **Vernieri C**, at al. Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure. *Cells*. 2020;9(3). PMID 32120774
- 75 Kong WJ, **Vernieri C**, Foiani M, Jiang JD. Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. *Pharmacol Ther*. 2020 May;209:107496. PMID: 32001311
- 76 **Vernieri C**[#], Pusceddu S, de Braud F. Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. *Front Oncol* 2019;9:902
- 77 Fucà G, Mariani L, Lo Vullo S, Galli G, Berardi R, Di Nicola M, **Vernieri C** et al. Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. *Sci Rep* 2019;9(1):12993. PMID: 31506579
- 78 Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Lodomery M, **Vernieri C**, et al. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. *Cell Oncol (Dordr)* 2019. PMID: 31376137

- 79 Rivoltini L, **Vernieri C**, Huber V. The *AURORA* of a New Way to Value Myeloid Immunosuppression in Cancer. *Cancer Res.* 2019;79(13):3169-3171. PMID: 31262832
- 80 **Vernieri C**[#], Milano M, Brambilla M, et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives. *Crit Rev Oncol Hematol* 2019;139:53-66. PMID: 31112882
- 81 Corno A, Chiroli E, Gross F, **Vernieri C**, et al. Cellular response upon proliferation in the presence of an active mitotic checkpoint. *Life Science Alliance* 2019;2(3). PMID: 31068378
- 82 Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, **Vernieri C**, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open* 2019;4(1). PMID: 30964126
- 83 Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, **Vernieri C**, et al. Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. *Cancers (Basel)* 2019 Feb 14;1(2). PMID: 30769874
- 84 **Vernieri C**[#], Prisciandaro M, Milano M, et al. Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. *Clin Breast Cancer* 2019;19(2):e306-e318. PMID: 30635175
- 85 **Vernieri C**[#], Signorelli D, Galli G, et al. Exploiting Fasting-mimicking Diet and METformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. *Clin Lung Cancer* 2019;20(3):e413-e417. PMID 30617039
- 86 **Vernieri C**[#], Galli F, Ferrari L, et al. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. *Oncologist* 2019;24(3):385-393. PMID: 30606884
- 87 **Vernieri C**[#], Pusceddu S, Fucà G, et al. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). *Int J Cancer* 2019;144(7):1704-1712. PMID: 30520016
- 88 De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, **Vernieri C**, Zitvogel L, Pupa SM, Di Nicola M. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eight annual meeting. *Cytokine Growth Factor Rev* 2018;44:1-10
- 89 Moro M, Caiola E, Ganzinelli M, Zulato E, Rulli E, Marabese M, Centonze G, Busico A, Pastorino U, de Braud FG, **Vernieri C**, et al. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. *J Thorac Oncol* 2018;13(11):1692-1704. PMID: 30149143
- 90 Castagnoli L, Iorio E, Dugo M, Koschorke A, Faraci S, Canese R, Casalini P, Nanni P, **Vernieri C**, et al. Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. *J Cell Physiol* 2019; 234(2):1768-1779. PMID: 30132876
- 91 Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, Spada F, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, **Vernieri C**, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D. Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. *Ann Surg.* 2018 Jul 10. PMID: 29995678

- 92 **Vernieri C[#]**, Mennitto A, Prisciandaro M. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. *Sci Rep*. 2018 Jun 7;8(1):8703. PMID: 29880896
- 93 Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Carteni G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, **Vernieri C** et al. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clin Genitourin Cancer*. 2018 Apr 19. pii: S1558-7673(18)30084-3. PMID: 29753637
- 94 Pusceddu S, **Vernieri C** et al. Metformin Use Associates With Longer Progression-free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology* 2018;155(2):479-489. PMID: 29655834
- 95 Pusceddu S, Barretta F, Trama A, Botta L, Milione M et al. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocr Relat Cancer*. 2018 Jun;25(6):607-618. PMID: 29559553
- 96 **Vernieri C[#]**, Nichetti F et al. Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. *Crit Rev Oncol Hematol*. 2018 Mar;123:57-73. PMID: 29482780
- 97 Bonaiuti P, Chirolì E, Gross F, Corno A, **Vernieri C** et al. Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process. *Curr Biol*. 2018 Jan 8;28(1):28-37.e7. PMID: 29249657
- 98 Oddo D, Siravegna G, Gloghini A, **Vernieri C** et al. Emergence of MET hyperamplification at progression to MET and BRAF inhibition in colorectal cancer. *Br J Cancer*. 2017 Jul 25;117(3):347-352. PMID: 28654634
- 99 **Vernieri C[#]**, Milano M, Mennitto A et al. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, moncentric, retrospective study. *Breast Cancer Res Treat*. 2017 Sep;165(2):365-373. PMID: 28616768
- 100 Pusceddu S, Prinzi N, Lo Russo G, Femia D, Milione M, Perrone F, Tamborini E, Concas L, Pulice I, **Vernieri C**, Corti F, Buzzoni R, de Braud F. Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. *Future Oncol*. 2017 Aug;13(19):1677-1683. PMID: 28580793
- 101 Pusceddu S, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, **Vernieri C**, Lo Russo G, Procopio G. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. *Ther Adv Med Oncol*. 2017 Mar;9(3):183-188. PMID: 28344663
- 102 **Vernieri C[#]**, Casola S, Foiani M, et al: Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. *Cancer Discovery* 2016;6(12):1315-1333. PMID: 27872127
- 103 Mennitto A, **Vernieri C** and Procopio G. Urachal carcinoma: towards a precision medicine. *Translational Cancer research* 2016; Vol 5, Supplement 7.
- 104 Pietrantonio F, **Vernieri C**, Siravegna G, et al: Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. *Clin Cancer Res* 2017;23(10):2414-2422. PMID: 27780856
- 105 **Vernieri C[#]**, Femia D, Pusceddu S, et al: Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. *Case reports in oncology* 9:432-439, (2016). PMID: 27721764
- 106 Pusceddu S, Femia D, Lo Russo G, Ortolani S, Milione M, Maccauro M, **Vernieri C** et al: Update on medical treatment of small intestinal neuroendocrine tumors. *Expert review of anticancer therapy* 2016;16:969-76. PMID: 27353232

- 107 Pusceddu, S., de Braud, F., Lo Russo, G., Concas, L., Femia, D., **Vernieri, C.** et al. How do results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. *Oncotarget* 2016;7(28):44841-44847. PMID: 27057638
- 108 Pusceddu, S., Buzzoni, R., **Vernieri, C.** et al. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. *Future Oncol* 2016;12(10):1251-60. PMID:26890290
- 109 Crespo, C. L., **Vernieri, C.** et al. The PAR complex controls the spatiotemporal dynamics of F-actin and the MTOC in directionally migrating leukocytes. *J Cell Sci* 2014;127:4381-4395. PMID: 25179599
- 110 **Vernieri, C[#]**, Chirolì, E., Francia, V., Gross, F. & Ciliberto, A. Adaptation to the spindle checkpoint is regulated by the interplay between Cdc28/Clbs and PP2A^{Cdc55}. *J Cell Biol* 2013;202, 765-778. PMID: 23999167
- 111 Santaguida S, **Vernieri C**, Villa F, Ciliberto A, Musacchio A. Evidence that Aurora B is implicated in spindle checkpoint signaling independently or error correction. *EMBO J*. 2011 Apr 20;30(8):1508- 19. PMID: 21407176

* **Corresponding author**

First-co-first author

H-index (Scopus: <https://www.scopus.com/authid/detail.uri?authorId=42962495400>): **30**

ORAL COMMUNICATIONS AT CONFERENCES

05.07.2025: 21th International Fasting Congress (Berlin, Germany). Invited Speaker for a talk entitled: “Fasting in Immunotherapy”

04.07.2025: Scientific Symposium on Fasting Research (Berlin, Germany). Invited speaker for a talk entitled: “Workshop Fasting and Oncology: Harmonization of Clinical Practice”

26.06.2025: Optimal shared management in patients with HR+ HER2- BC (Milan, Italy). Scientific chair

5.5.2025: 3rd Milan “Me(e)t immune Conference - how metabolism meets the immune system in human malignancies” (Milan, Italy). Scientific chair.

11.4.2025: HER Challenge meeting (Bergamo, Italy). Scientific chair.

7.4.2025: B.I.T. Breast In Translation 2.0 International congress (Padova, Italy). Scientific chair.

25.3.2025: Scientific chair of the meeting “abBRaCciAmi: abbracciare la comunicazione e la cura dei tumori legati a BRCA” (Milan, Italy).

10.11.2024: Annual Meeting of the “Associazione Italiana di Oncologia Medica” (AIOM). Oral communication with a presentation entitled: “Effectiveness of first-line palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: real-world comparison from the multicenter, Italian study PALMARES-2”.

24.10.2024: “20th MEET THE PROFESSOR: Advanced International Breast Cancer Course (AIBCC)” meeting (Padua, Italy). Awardee lecture entitled “Boosting Academic Research to Meet the Unmet Needs in Breast Cancer Therapy”. Invited speaker for a presentation entitled “HR+ disease: current algorithm”

11.10.2024: “2024 CARCINOMA MAMMARIO METASTATICO: QUALI NOVITÀ?” meeting organized by AIGOM (Associazione Italiana Gruppi Oncologici Multidisciplinari)

(Rome, Italy). Invited speaker for a presentation entitled “Fasting-mimicking diet and metformin: the BREAKFAST trial”.

26.09.2024: “64th Annual Meeting of the Italian Cancer Society” (SIC) (Milan, Italy). Invited speaker for a presentation entitled: “The role of amino acids in cancer progression and response to treatment”

09.09.2024: “DONNA E CANCRO IV Edizione: From bench to bedside” meeting (Milan, Italy). Invited speaker for a presentation entitled: “Neoplasia luminale: nuovi biomarcatori ed algoritmi terapeutici”.

08.09.2024: “46th ESPEN Congress on Clinical Nutrition and Metabolism” (Milan, Italy). Invited speaker for a presentation entitled: “Immune response modulation by nutrition”.

05.09.2024: “INTERNATIONAL SUMMER SCHOOL ON MOLECULAR ONCOLOGY: 4th Edition” (Verbania, Italy). Invited speaker for a presentation entitled: “Fasting-Mimicking diet and cancer metabolism”

30.08.2024: 33rd BioCity Symposium “Unleashing the power of metabolism” (Turku, Finland). Invited speaker for a presentation entitled: “Targeted metabolic interventions in cancer therapy”.

3.6.2024: 2024 ASCO (American Society of Clinical Oncology): Annual Meeting (Chicago, Illinois, U.S.). Oral presentation: “Comparison of antitumor efficacy of first-line Palbociclib, Ribociclib or Abemaciclib in patients with HR+/HER2- aBC: results of the multicenter, real-world, Italian study PALMARES-2”.

31.05.2024: EMBO Workshop “The many faces of cancer evolution” (Rimini, Italy). Invited speaker for a presentation entitled “Optimizing the balance between metabolite restriction and supplementation in cancer therapy”.

3.5.2024: 2nd Milan ME[E]T IMMUNE Conference: How Metabolism Meets the Immune System in Human Malignancies. Scientific Committee and speaker with a presentation entitled: “Balancing metabolite restriction and supplementation in triple-negative breast cancer metabolism”

29.4.2024: B.I.T.: Breast In Translation International meeting (Padova, Italy). Scientific co-chair.

26.4.2024: 4th Protein Calorie Restriction Workshop (Kocaeli, Turkey). Invited speaker for a presentation entitled: “Nutritional and pharmacologic metabolic interventions to reprogram cancer metabolism: from preclinical to clinical evidence”.

22.4.2024: AIRC for Young Scientists conference (IFOM, Milan, Italy). Invited speaker for a presentation entitled: “Targeting amino acid metabolism to boost the anticancer activity of calorie restriction”

08.02.2024: “Clinical Nutrition Pills” congress (Cesena). Invited speaker for a talk entitled: “Role of fasting in cancer patients”

05.02.2024: Cancer Core Europe Annual Meeting (Milan, Italy). Invited speaker for a talk entitled: “Metabolic reprogramming in solid tumors”

14.12.2023: “Shared Decision Making nel tumore della mammella metastatico” (Naples, Italy). Relatore invitato con una relazione dal titolo: “Revisione della letteratura circa i campi applicativi della SDM”

07.12.2023: San Antonio Breast Cancer Symposium (SABCS 2023) (San Antonio, Texas, U.S.). Oral presentation: “Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC”.

13.09.2023: International Summer School on Immuno-Oncology (3rd edition) (Verbania, Italy). Invited speaker for a talk entitled: “Innovative IO in solid tumors: what’s next?”

24.06.2023: 20th International fasting Congress (Berlin, Germany). Invited Speaker for a talk entitled: “Fasting in Oncology”

23.06.2023: Scientific Symposium on Fasting Research (Berlin, Germany). Invited speaker for a talk entitled: “Molecular and Metabolic Mechanisms of Tumor Resistance to Fasting and Fasting Mimicking Diets, from Preclinical to Clinical Studies”

26.05.2023: Novelties from the 18th St. Gallen Breast Cancer Consensus Conference and Focus on Advanced Disease (Bologna, Italy). Invited speaker for a talk entitled: “*Monitoring of disease and risk stratification: Genomics, Transcriptomics and ctDNA*”.

07.05.2023: “Preceptorship Programme on BREAST CANCER: multidisciplinary management, standards of care, therapeutic targets and future perspectives” organized by the European Institute of Oncology (Milan, Italy). Invited Speaker for a talk entitled “*Management of gBRCA carriers in early breast cancer*”.

27.04.2023: “1st ME[E]T IMMUNE CONFERENCE: How Metabolism Meets the Immune System in Human Malignancies” organized by the Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy). Director of the Scientific Committee and speaker for a talk entitled “Severe calorie restriction in breast and lung cancer treatment: past, present and future”.

13.04.2023: Atelier of the Accademia di Senologia “Umberto Veronesi” (Inveruno, Italy). Invited speaker for a talk entitled: “*Multidisciplinary approach in locally advanced disease*”.

12.11.2022: “Preceptorship Programme on BREAST CANCER: multidisciplinary management, standards of care, therapeutic targets and future perspectives” organized by the European Institute of Oncology (Milan, Italy). Invited Speaker for a talk entitled “*Management of gBRCA carriers in early breast cancer*”.

07.10.2022: Conference organized by the Azienda Ospedaliero-Universitaria di Modena, and entitled: “Ottimizzare la scelta della terapia adiuvante nelle neoplasie della mammella: tra linee guida e studi clinici”. Invited speaker for a talk entitled: “*Prognostic and predictive factors in adjuvant therapy: HER2-positive breast cancer*”.

02.10.2022: Annual Meeting of the “Associazione Italiana di Oncologia Medica” (AIOM). Oral communication with a presentation entitled: “*Precocious modulation of peripheral blood lymphocytes predicts long-term outcomes in patients with advanced hormone receptor-positive HER2-negative breast cancer treated with CDK4/6 inhibitors (PALMARES)*”.

12.05.2022: CRICK-MSKCC-IFOM meeting (London), organized by the Francis Crick Institute. Invited speaker for a talk entitled “*Targeting metabolic reprogramming in breast cancer: from molecular mechanisms to clinical trials*”.

01.02.2022: “Biomarkers summit in breast cancer: escalating and de-escalating treatment”. 2nd International Meeting. Virtual meeting organized by IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST S.R.L. Invited Speaker for a talk entitled “*Integrating supportive care: bone health and energy metabolism*”

08.10.2021: “Metabolism-Based Cancer Therapy” (Virtual Symposium organized by Technische Universität Dresden, Germany). Invited Speaker for a talk entitled “*Hypoglycemic diet reshapes systemic metabolism and intratumor immunity in cancer patients*”.

03.12.2020: “KALEIDOSCOPE OF NUTRITIONAL INTERVENTION IN ONCOLOGY” (Virtual event organized by Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy). Invited Speaker for a talk entitled “*Breakfast Project, main results*”.

01.11.2020: Annual Meeting of the “Associazione Italiana di Oncologia Medica” (AIOM) (Virtual Congress). Oral communication with a presentation entitled: “*Blood glucose levels are associated with the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2-negative breast cancer: the Italian study EVERMET*”.

01.10.2020: “Protein Calorie Restriction Workshop” (International Workshop organized by ETH Zurich and Harvard T.H. Chan School of Public Health) (Virtual Event)). Invited Speaker for a talk entitled “*Metabolic and immunological effects of fasting-mimicking diets in cancer patients*”

28.11.2019: “Learning at the Leaning Tower 2019: GONO Congress on Colorectal Cancer” (Scuola Superiore S. Anna, Pisa, Italy). Invited Speaker. Title of the Presentation: *Discovering tumor cells’ metabolism: a new-old hallmark of cancer*.

15.11.2019: “Breaking Boundaries Metabolism at the Cross-Roads” Conference (IFOM, Milan, Italy). Invited Speaker. Title of the Presentation: *Targeting cancer metabolism: facts, controversies and therapeutic perspectives*.

07.10.2019: Cancer Core Europe Summer School in translational Cancer Research (Albufeira, Portugal). Invited Speaker. Title of the Presentation: *Reprogramming cancer metabolism: current research and potential therapeutic implications*.

27.6.2019: MASTERLUNG (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy). Invited Speaker. Title of the Presentation: *Cellular Metabolism: vulnerabilities and potentially novel combinations*.

09.04.2019: “Protein Calorie Restriction Workshop” (International Workshop organized by Harvard T.H. Chan School of Public Health in Leiden, Netherlands). Invited Speaker for a talk entitled “*Safety and metabolic effects of cyclic calorie restriction in cancer patients: promising findings and potential risks*”

17.11.2018: Annual Meeting of the “Associazione Italiana di Oncologia Medica” (AIOM, Rome, Italy). Invited Speaker in the Educational Session. Title of the Presentation: *Metabolic disruption: a new hallmark of cancer*.

9.11.2018: 1st International Conference on Fasting, Dietary Restriction, Longevity and Disease (Los Angeles, USA). Invited Speaker. Title of the Presentation: *Periodic Fasting and Fasting-Mimicking Diet tin Chemotherapy of Cancers*.

12.10.2018: Conference on “Treatment of metastatic HER2-negative breast cancer” (Rezzato, Italy). Invited speaker. Title of the presentation: *Metabolism and Breast Cancer: Myth or Reality?*

7.10.2018: Cancer Core Europe Summer School in translational Cancer Research (Albufeira, Portugal). Invited Speaker. Title of the Presentation: *Metabolic reprogramming in cancer: current knowledge and potential therapeutic implications*.

25.5.2018: ANDID National Congress (Turin, Italy). Invited Speaker. Title of the Presentation: *Fasting in Oncology*.

26.01.2018: Congress on “Innovative therapy, Monoclonal Antibodies and beyond” (Milan, Italy). Invited speaker. Title of the presentation: *Impact of cyclic fasting mimicking diet (FMD) on cancer patient metabolism*.

17.01.2018: Workshop on Molecular Diagnostics and Innovative Drugs (Trieste, Italy). Invited Speaker. Title of the presentation: *Immunity in Oncology: targets, therapy and nutritional aspects*.

27.05.2017: Nutrition and Longevity Workshop (Genova, Italy). Invited Speaker. Title of the presentation: *The Fasting Mimicking Diet in Cancer Patients: Preliminary Results of the INT 10/17 “Basket” Study*.

26.05.2017: Supportive Care in Oncology: “Systemic Strategy at the Patient Service” (Milan, Italy). Invited Speaker. Title of the Presentation: *Complementary Therapies in Oncology: when and why*.

24.05.2016: 2nd Milan NET Conference. A meeting among active Italian Neuroendocrine Tumor Boards. Presentation of a Clinical Case.

26.6.2013: CHROMO2013: EMBO workshop on Chromosome Segregation and Aneuploidy (Breukelen, The Netherlands). Title of the presentation: *Adaptation to the mitotic checkpoint in budding yeast requires APC/C^{Cdc20} activity and is regulated by the interplay between Cdc28/Clbs and PP2A^{Cdc55}*.

I authorise the use of my personal data in compliance with Legislative Decree 196/03.

Date: September 22nd 2025

Signature

A handwritten signature in black ink, appearing to be 'C. M.' followed by a long horizontal stroke.

FRANCESCO GIGANTI

University College London
Division of Surgery and Interventional Science
3rd Floor Charles Bell House
43-45 Foley Street
London, United Kingdom, W1W 7TS

+ 44 0 7474 858022

f.giganti@ucl.ac.uk

PROFESSIONAL HISTORY

07/2021 - present	Associate Professor of Radiology (UCL) and Honorary Consultant Radiologist (UCLH)
06/2018 – 06/2021	Consultant Radiologist for the UCLH NHS Trust Bank
09/2016 – 06/2021	Honorary Clinical Research fellow, Department of Radiology, UCLH, London, UK
03/2015 - 08/2016	Specialty Registrar in Clinical Radiology, San Raffaele Hospital, Milan, Italy
02/2014 - 02/2015	Honorary Clinical Research fellow, Department of Radiology, UCLH, London,
06/2011 - 01/2014	Specialty Registrar in Clinical Radiology, San Raffaele Hospital, Milan, Italy - General conduct and reporting of different imaging techniques (conventional radiology, ultrasound, computed tomography, magnetic resonance imaging) + interventional procedures (draining, placing catheters, needle biopsies and aspirations)
07/2010 - 05/2011	Honorary Clinical Research fellow, Department of Radiology, San Raffaele Hospital, Milan, Italy

ACADEMIC EDUCATION and QUALIFICATIONS

09/2017 - 06/2021	PhD Student and Clinical Research Associate, University College London (UCL), London, UK (PhD awarded in June 2021)
09/2016 – 06/2021	Clinical Research fellow in Clinical Radiology, University College London Hospital (UCLH), London, UK
09/2016	Specialist qualification in Clinical Radiology, San Raffaele University, Milan, Italy (score: 70/70 cum laude)
03/2015 - 08/2016	Radiology trainee, San Raffaele Hospital, Milan, Italy
02/2014 - 02/2015	Clinical Research fellow, UCLH, London, UK
06/2011 - 01/2014	Radiology trainee, San Raffaele Hospital, Milan, Italy
02/2011	Medical licence to practise examination (score: 270/270)
07/2010	Degree in Medicine and Surgery (score: 110/110), San Raffaele University, Milan, Italy
10/2004 - 06/2010	Medical student, San Raffaele University, Milan, Italy

ACADEMIC WORK EXPERIENCE

09/2017 - 06/2021	PhD Student, UCL, London, UK - Prostate MRI: active surveillance (PRECISE recommendations) and MRI quality (PI-QUAL score)
09/2016 - 08/2017	Clinical Research fellow, UCL, London, UK
03/2015 - 08/2016	Clinical Research fellow, San Raffaele Hospital, Milan, Italy
02/2014 - 02/2015	Clinical Research fellow, UCL, London, UK - MRI and active surveillance in prostate cancer
06/2011 - 01/2014	Clinical Research fellow, San Raffaele Hospital, Milan, Italy - Focused research on MRI and gastro-oesophageal cancer

ABROAD EXPERIENCE

08/2010	Medical volunteer, Sao Rafael Hospital, Salvador de Bahia, Brazil
08/2008	Visiting medical student, St. Francis Hospital, Kampala, Uganda
08/2008	Visiting medical student, Lacor Hospital, Gulu, Uganda

PRIZES, AWARDS and HONOURS

- 2022: Winner of the ESR/EIBIC Research Seed Grant
- 2021: Winner of the ISMRM (International Society for Magnetic Resonance in Medicine) Junior Fellow Programme
- 2021: Winner of the ESOR 'Nicholas Gourtsoyiannis' Teaching Fellowship (Sorbonne Université / Harvard Medical School)
- 2021: Winner of the ISMRM 2021 Clinical Stipend Programme, ISMRM, Toronto, Canada (virtual)
- 2020: European Urology Oncology Top 10 Reviewer for 2020
- 2020: Social Media (SoME) Award for most influential paper in European Urology Oncology
- 2020: Winner of the 2021 ARRS Lee Rogers International Fellowship in Radiology Journalism
- 2020: Winner of the Prostate Cancer Foundation (PCF) Young Investigator Award
- 2020: Winner of UCL Cities Partnership Programme Award (London/Paris)
- 2019: British Medical Journal (BMJ) Best paper award (collaborative work for PRECISION, NEJM 2018)
- 2019: Best poster at European Congress of Urology 2019, Barcelona, Spain
- 2019: Winner of the Erasmus UCL Talent Staff Mobility Programme (London/Rome)
- 2018: Winner of the ESOR Bracco Fellowship (London/Rome)
- 2018: Winner of the ISMRM 2018 Clinical Stipend Programme, ISMRM, Paris, France
- 2017: Winner of the UCL Graduate Research Scholarship for PhD students (2017-2020)
- 2015: Best oral presentation at European Congress of Radiology 2015, Vienna, Austria
- 2015: British Medical Journal (BMJ) Team award for Innovation (collaborative work UCL/UCLH Prostate team)
- 2014: Winner of the 'Invest in the Youth' award at European Congress of Radiology
- 2013: Winner of the 'Invest in the Youth' award at European Congress of Radiology

INVITED TALKS

- November 2022: EMUC (Budapest, Hungary)
- November 2022 (virtual): Brazilian Society of Radiology
- July 2021: EAU Congress 2021 (virtual) - *Characteristics of MRI lesions allowing active surveillance and how to monitor.*
- May 2021: Masterclass in focal therapy for localised prostate cancer (virtual) - *Role of MRI in focal therapy.*
- March 2021: European Congress of Radiology 2021 (virtual) - *Role of MRI for each therapeutic option in prostate cancer follow up*
- October 2020: Convegno Nazionale Società Italiana di Radiologia Medica 2020 (virtual) - *MRI and active surveillance.*
- September 2020: XXVII Congresso Nazionale AURO (virtual) – *Prostate MRI during active surveillance.*
- March 2020: European Association of Urology Webinar - *MRI and active surveillance.*
- May 2019: 9th ESUR Prostate MRI Course - *MRI and active surveillance.* Rome, Italy.
- March 2019: Microstructural characterisation of prostate cancer: MRI and active surveillance. ISMRM Italian Chapter. Milan, Italy
- February 2019: *MpMRI standards: ruling in and out malignant disease and reporting protocols.* Manchester, UK.
- June 2018: 8th ESUR Prostate MRI Course - *Role of the PRECISE recommendations.* Lille, France.
- April 2018: SIURO Congresso Nazionale. *The PRECISE recommendations.* Milan, Italy.
- December 2017: *Big Data, Radiomics & AI: state of the art of imaging biomarkers in gastric cancer.* Reggio Emilia, Italy.
- April 2017: 12th International Gastric Cancer Congress – *Imaging biomarkers from MRI and CT in gastric cancer.* Beijing, China.

ACADEMIC SUPERVISION

- Academic Year 2015-2016: Mr. Adam Retter, Medical Student - co-supervised with Professor Caroline M Moore and Dr Alex Kirkham
- Academic Year 2018-2019: Mr. Alessandro Pellegrini, Medical Student - co-supervised with Mr. Clément Orczyk

RESEARCH CAREER

- All research outputs are available through Open Access wherever possible.
- ORCID ID: <http://orcid.org/0000-0001-5218-6431>
- SCOPUS ID: <https://www.scopus.com/authid/detail.uri?authorId=55646665800>
- Google Scholar: <https://scholar.google.com/citations?user=C-aywnoAAAAJ&hl=en>
- UCL IRIS: <https://iris.ucl.ac.uk/iris/browse/profile?upi=FGIGA51>

TEACHING CAREER

- May 2021: EAU masterclass in focal therapy for localised prostate cancer (virtual)
- May 2021: EAU prostate MRI teaching course (virtual)
- October 2020: EAU prostate MRI teaching course (virtual)
- May 2020: Prostate MR course for radiologists. Rome, Italy (virtual)
- November 2019: Prostate MR course for radiologists. Rome, Italy
- November 2019: EAU prostate MRI teaching course. Coimbra, Portugal
- September 2019: EAU prostate MRI teaching course. Madrid, Spain
- September 2019: UCL masterclass in prostate MRI. London, United Kingdom
- June 2019: ESUR prostate MRI course. Rome, Italy
- March 2019: EAU prostate MRI teaching course. Barcelona, Spain
- November 2018: EAU prostate MRI teaching course. Dubai, United Arab Emirates
- September 2018: EAU prostate MRI teaching course. Madrid, Spain
- September 2018: UCL masterclass in prostate MRI. London, United Kingdom
- March 2018: EAU prostate MRI teaching course. Copenhagen, Denmark

FIVE MOST SIGNIFICANT PUBLICATIONS

- Giganti, F., Kirkham, A., Kasivisvanathan, et al (2021). Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists. *Insights Imaging*, 12(1), 59. doi:[10.1186/s13244-021-00996-6](https://doi.org/10.1186/s13244-021-00996-6)
- Giganti, F., Allen, C., Emberton, M., Moore, C. M., & Kasivisvanathan, V (2020). Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. *European Urology Oncology*. doi:[10.1016/j.euo.2020.06.007](https://doi.org/10.1016/j.euo.2020.06.007)
- Giganti, F., Stabile, A., Stavrinides, et al (2020). Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. *European Radiology*. doi:[10.1007/s00330-020-07256-z](https://doi.org/10.1007/s00330-020-07256-z)
- Giganti, F., Allen, C., Piper, J. W., et al (2019). Sequential prostate MRI reporting in men on active surveillance: initial experience of a dedicated PRECISE software program. *Magnetic Resonance Imaging*. doi:[10.1016/j.mri.2018.10.013](https://doi.org/10.1016/j.mri.2018.10.013)
- Moore, C. M., Giganti, F., Albertsen, P., et al (2017). Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. *European Urology*, 71(4), 648-655. doi:[10.1016/j.eururo.2016.06.011](https://doi.org/10.1016/j.eururo.2016.06.011)

Dr. Francesco Giganti



**EMORY UNIVERSITY SCHOOL OF MEDICINE
STANDARD CURRICULUM VITAE**

RESUME

Carlo N. De Cecco, MD, PhD, FSCCT, FNASCI, FSABI, FESGAR is a Professor of Radiology and Biomedical Informatics, and the Director of the Cardiothoracic Imaging Division at Emory University School of Medicine. He is board certified from the American College of Radiology and the American College of Nuclear Medicine. He is also the Founder and Director of the Translational Lab for Cardiothoracic Imaging and AI (>\$4M research fundings awards from NIH/NSF/Private Foundation/Industry), and Co-Director of the Emory Medical Imaging, Informatics and AI Core. A pioneer in cardiac imaging, multienergy CT imaging, and Artificial Intelligence, Dr. De Cecco's actual research interest is the development and application of advanced clinical imaging analysis and AI solutions to improve the understanding, diagnosis, and follow-up of cardiac disease. Author and editor of the Springer textbooks Artificial Intelligence in Cardiothoracic Imaging, MDCT and MRI of the Heart, Dual Energy CT in Oncology, and series editor of A-Z Notes in Radiological Practice and Reporting (5 books), he has authored or co-authored more than 300 peer-reviewed publications and 300 conference abstracts, has given more than 150 invited lectures to national and international conferences, and has trained and mentored some 40 clinical and research fellows, residents, PhD students, and medical students resulting in publications. Dr. De Cecco's work has been recognized with research awards from several scientific societies including the Academy for Radiology & Biomedical Imaging Research, the American Heart Association, the North American Society of Cardiovascular Imaging, and the Society of Computed Body Tomography and Magnetic Resonance. He is a fellow of numerous scientific societies, and he serves as Chair of the Cardiac Radiology Use Case Panel at the Data Science Institute - American College of Radiology, Chair of the Electronic Communication Committee at the North American Society of Cardiovascular Imaging, and Scientific Session Program Committee at the American Heart Association. Additionally, he serves as the Artificial Intelligence/Machine Learning section editor at the European Journal of Radiology, associate editor at the European Heart Journal Cardiovascular Imaging, and topical content advisor for Data Sciences/AI Applications at Circulation: Cardiovascular Imaging. He is also on the editorial board of Radiology: Cardiothoracic Imaging, Investigative Radiology, and the Journal of Cardiovascular Computed Tomography. He is a member of the American College of Radiology Cardiothoracic section and the Appropriateness Criteria Expert Panel, the Board of Experts of the Italian Ministry of Education, University and Research, and served in the Clinical Imaging and Translational Imaging Science (CTIS) NIH Study Section.

1. Name: Carlo Nicola De Cecco, MD, PhD

2. Office Address:

Emory University
1365 Clifton Road NE
Suite - AT503-B
Atlanta, GA 30322
Telephone: 404-712-1868

3. E-mail Address: carlo.dececco@emory.edu

4. Current Titles and Affiliations:

a. Academic Appointments:

Primary Appointments:

- | | |
|--|----------------|
| 1. Professor of Radiology,
Department of Radiology and Imaging Sciences,
ESOM, Atlanta, GA, US | 2023 - present |
| 2. Founder and Director, Emory Translational Laboratory for
Cardiothoracic Imaging and Artificial Intelligence,
Department of Radiology and Imaging Sciences,
ESOM, Atlanta, GA, US | 2020 - present |

Secondary Appointments:

- | | |
|---|----------------|
| 1. Professor of Biomedical Informatics,
Department of Biomedical Informatics,
ESOM, Atlanta, GA, US | 2023 - present |
| 3. Associate Faculty
Emory Empathetic AI for Health Institute, ESOM, Atlanta, GA, US | 2023 - present |
| 4. Co-Director, Emory Medical Imaging, Informatics and AI Core
Department of Biomedical Informatics, ESOM, Atlanta, GA, US | 2022 - present |
| 2. Adjunct Assistant Professor of Radiology, Department of Radiology,
Medical University of South Carolina, Charleston, SC, US | 2018 - present |

b. Clinical Appointments:

- | | |
|---|----------------|
| 1. Director, Cardiothoracic Imaging Division
Department of Radiology & Imaging Sciences
ESOM, Atlanta, GA, US | 2023 - present |
|---|----------------|

5. Previous Academic and Professional Appointments:

- | | |
|---|-------------|
| 1. Research Assistant Professor, Department of Radiology & Radiological
Sciences, Medical University of South Carolina, Charleston, SC, US | 2013 - 2015 |
|---|-------------|

2. Associate Professor of Radiology, Division of Cardiothoracic Imaging,
Department of Radiology and Imaging Sciences,
ESOM, Atlanta, GA, US 2018 - 2023
3. Associate Professor of Biomedical Informatics, ESOM,
Atlanta, GA, US 2018 - 2023

6. Previous Administrative and/or Clinical Appointments:

1. Consultant in Radiology, Department of Radiological Sciences, Oncology
and Pathology, University of Rome "Sapienza", Rome, IT 2011 - 2014
2. Director of Cardiac CT Research, Department of Radiology & Radiological
Sciences, Medical University of South Carolina, Charleston, SC, US 2013 - 2018

7. Licensures:

Italian Medical License	2006 (Active)
ECForeign Medical Graduate Board	2014
South Carolina Medical License	2015 (Active)
Georgia Medical License	2017 (Active)

8. Boards and Specialty Boards:

1. Italian Board of Radiology 2011
2. Italian Board of Associate Professor 2017
3. Italian Board of Professor 2017
4. American Board of Radiology 2018
5. American Board of Nuclear Medicine 2018

9. Education:

1. University of Rome Sapienza, Rome, Italy, MD, Medicine
Summa cum Laude 2000-2006
2. Doctoral Degree (PhD), Innovative Technologies in Translational Medicine,
University of Rome Sapienza – Polo Pontino, Latina, Italy 2011-2014

10. Postgraduate Training:

1. Clinical Training, Department of Clinical Medicine, University of Rome
Sapienza – Policlinico Umberto I Hospital, Rome, IT.
Supervisor: Prof. Antonio Amoroso 2006-2007
2. Radiology Training, Department of Radiology and
Radiological Sciences, University of Rome Sapienza –
Sant' Andrea Hospital, Rome, IT.
Supervisor: Prof. Vincenzo David 2007-2011
3. Research Fellow in Cardiac Imaging, Department of
Radiology & Radiological Sciences,
Medical University of South Carolina,
Supervisor: Prof. U. Joseph Schoepf 2013-2015
4. Clinical Fellow in Cardiothoracic Imaging, Department of Radiology &

Curriculum Vitae

Personal information

Umberto Romeo

Department of Oral and Maxillofacial Sciences – Via Caserta, 6 -00161 Roma ITALIA

umberto.romeo@uniroma1.it

Job position held

- Head of the Department of Oral and Maxillofacial Sciences Sapienza University of Rome
- Director of the Unit of Oral Surgery of the “Umberto I” University Hospital
- Full Professor at the Sapienza University of Rome

Professional experience

- o **1988** Degree in Dentistry and Dental Prosthetics at the University of Messina
- o **1993** Specialist in Oral Surgery at Sapienza - University of Rome
- o **2000** Winner of the competition for Researcher at Sapienza - University of Rome (D.R. 01/24/2000).
- o **2003** Confirmed Researcher
- o **2005** Associate Professor at Sapienza - University of Rome
- o **2008** Confirmed Associate Professor at Sapienza - University of Rome
- o **2022** Full Professor at Sapienza – University of Rome

Occupation or job position held

Former Vice President of the Course Degree in Assistive Technical Health Professions at Sapienza, University of Rome

Former Vice President of the Course Degree in Dentistry and Dental Prosthetics at Sapienza, University of Rome

Director of the Laser Master in Dentistry in partnership with European Master Degree on Oral Laser Applications (EMDOLA) at Sapienza, University of Rome

Director of the Higher Education Course of "Pathology and Oral Medicine: from diagnosis to therapy" at Sapienza, University of Rome

From 2012 to date Member of the Monitoring Committee on behalf of the Faculty of Medicine and Dentistry

Academic Coordinator for Erasmus+ International Mobility for the Faculty of Medicine and Dentistry in reference to the CLMOPD

Member of the Quality and Innovation of Teaching (QuID) working group with tutor function for the CLMOPD

Education and training

Title or qualification obtained

Professor at the Degree Course in Dentistry and Dental Prosthetics since 2000

Professor at the Degree Course in Dental Hygiene since 2000 at the Policlinico Umberto I and Cassino campus

Professor of the EMDOLA Master in Nice, Barcelona, Liège and Parma

Professor at the Specialization Schools of Oral Surgery, Orthodontics and Maxillofacial Surgery

Personal skills

Mother tongue: Italian

Other languages Self-assessment European level:

English B2

More information

- Former Treasurer of CDUO (Collegio dei Docenti Universitari di Discipline Odontostomatologiche) 2022-2024
- Secretary of CDUO (Collegio dei Docenti Universitari di Discipline Odontostomatologiche) 2024-
- Vice President of SIPMO (Italian Society of Pathology and Oral Medicine) 2018-
- Member of the Board of SIPMO (Società Italiana di Patologia e Medicina Orale) 2014-
- Member of the Board of SILO (Società Italiana Laser in Odontostomatologia)
- Member of the Board of WFLD (Word Federation for Laser Dentistry)
- Former President of WFLD-ED (Word Federation for Laser Dentistry-European Division) 2014-2016
- Former Past-Chairman of WFLD-ED (Word Federation for Laser Dentistry-European Division) 2016-2018
- Former Treasurer of WFLD (Word Federation for Laser Dentistry) 2019-2021
- Former President of SILO (Società Italiana Laser in Odontostomatologia) 2013-2015
- Former Past President SILO (Società Italiana Laser in Odontostomatologia) 2015-2017
- Member of EMDOLA (European Master Degree on Oral Laser Applications)
- Member of Editorial Committee for the Journal "La clinica Terapeutica"
- Member of Editorial Committee for the Journal "Laser in Dental Sciences"
- Member of Editorial Committee for the Journal "Medicina Oral, Patologia Oral Y Cirurgia bucal"
- Member of Editorial Committee for the Journal "Journal of Clinical and experimental dentistry"
- Member of Editorial Committee for the Journal "Annali di Stomatologia"
- Member of Editorial Committee for the Journal "Dental Cadmos"
- Member of Editorial Committee for the Journal Open Access Senses & Sciences S&S –
- Member Editorial Committee for the Magazine "Laser"
- Guest Editor for "ORTI" del Scientific World Journal (Hindawi Publishing Corporation)
- Reviewer for the journal "Lasers in Medical Sciences"
- Reviewer for the journal "Brazilian Dental Journal"
- Reviewer for the journal "Medicina Oral, Patologia Oral Y Cirurgia bucal" - Revisore per il Giornale "International Dental Journal"
- Reviewer for the journal "Photomedicine and Laser Surgery"
- Reviewer for the journal "Indian Journal of Dental research"

- Romeo U, Libotte F, Palaia G, Tenore G, Galanakis A, Annibali S. Is erbium:yttrium-aluminum-garnet laser versus conventional rotary osteotomy better in the postoperative period for lower third molar surgery? Randomized split-mouth clinical study. *J Oral Maxillofac Surg.* 2015 Feb;73(2):211-8.

Textbooks (Chapters, etc.)

1. Biopsy of oral soft and bone tissue with different lasers devices [364292] – 2010 U. Romeo; Del Vecchio A; Maggiore C; Ripari M Ed. MARTINA – Bologna
2. I dispositivi laser in endodonzia: possibilità e limiti. (cap.3) [178372] - 2004 U. Romeo; Ripari M; Gambarini G; Palaia G Ed. Erre e Erre AD
3. Lezioni di Clinica Odontostomatologica per gli studenti di Medicina. L. Pacifici, Romeo U, Brugnoletti O, De Biase A - 2012 Ed. Ariesdue
4. Laser e Odontoiatria Pediatrica. A cura di A. Polimeni e R. Kornblit Interazione della luce laser con I tessuti orali molli e duri (cap. II) Le lunghezze d'onda maggiormente utilizzate in Odontoiatria (cap. III) Il laser nella patologia orale in età evolutiva (cap. IX) La biomodulazione, I laser terapeutici e la Low Level Laser Therapy (LLLT) (cap.XI). 2012 - Ed. TUEOR.
5. Laser terapia in odontoiatria pediatrica. Cap. 18 del testo ODONTOIATRIA PEDIATRICA di Polimeni A. Ed. Elsevier
6. Volume FACT CHECK (il vero e il falso sul laser in odontoiatria). Ed. Senses&Sciences Roma 2015

Textbook editor

- Oral Pathology for the Dental Hygienist. Di Ibsen OAC, Phelan JA. Ed. Elsevier. Edizione italiana CIC - ISBN 978-88-7141-931-2
- Oral Pathology: Clinical Pathologic Correlations. Di Regezi JA, Sciubba JJ, Jordan RCK. Ed. Elsevier 7th Edition. Edizione Italiana Antonio Delfino – ISBN 978-88-7287-587-2

"I authorize the processing of my personal data present in my CV pursuant to Legislative Decree 30 June 2003, n°196 "Code regarding the protection of personal data" and the GDPR (EU Regulation 2016/679)".

Roma, 03/01/2025

F.to Umberto Romeo





Curriculum Vitae Europass

Informazioni personali

Nome(i) / Cognome(i)	Nome Cognome Giovanni Pellacani
Indirizzo(i)	155, viale del Policlinico, 00185, Roma, Italy.
Fax	
E-mail	pellacani.giovanni@uniroma1.it
Cittadinanza	Italiana
Data di nascita	18/11/1970
Sesso	maschio
C.F.	

Occupazione desiderata/Settore professionale

Professore Ordinario di Dermatologia presso l'Università La Sapienza di Roma da gennaio 2021

Direttore della Struttura Complessa di Dermatologica dell'Azienda Ospedaliero Universitaria Policlinico Umberto I di Roma da febbraio 2021

Direttore f.f. del Dipartimento di Ematologia, Oncologia e Dermatologia dell'Azienda Ospedaliero Universitaria Policlinico Umberto I di Roma da novembre 2023

Iscritto all'albo dei medici chirurghi ed odontoiatri di Modena n. 4956 del 25.1.1996



Esperienza professionale

Dal 1 Novembre 2000 è **Ricercatore** presso la Clinica Dermatologica dell' Università di Modena e Reggio Emilia.

Dal 30 Dicembre 2004 è **Professore Associato** presso la Clinica Dermatologica dell' Università di Modena e Reggio Emilia.

Dal 1 Novembre 2007 è **Professore Ordinario** presso la Clinica Dermatologica dell' Università di Modena e Reggio Emilia.

Dal 1 Febbraio 2012 al 3 Gennaio 2021 è **Direttore della Struttura Complessa** Universitaria di Dermatologia, Dipartimento Integrato di Chirurgie Specialistiche Testa e Collo, Università di Modena e Reggio Emilia - Policlinico di Modena

Dal 15 Febbraio 2015 al 3 Gennaio 2021 è stato **Presidente della Facoltà di Medicina e Chirurgia della facoltà di Modena e Reggio Emilia** (triennio 2015-2017 / 2018-2021)

Da Maggio 2021 a maggio 2024 è stato **Direttore della Scuola di Specializzazione di Dermatologia e Venereologia**

Dal 5 novembre 2020 al 2024 è stato membro dell' **Osservatorio nazionale della formazione sanitaria specialistica**

Da novembre 2019 è **Presidente del Collegio dei Professori di Dermatologia e Venereologia**

Dal 1995 si è dedicato di ricerca nel campo della fisiologia cutanea, bioingegneria cutanea per la valutazione di patologie infiammatorie, e nella diagnosi non invasiva di tumori cutanei. In particolare, si occupa di melanoma e lesioni pigmentate, rivolto al miglioramento della accuratezza diagnostica per l'identificazione precoce attraverso l'utilizzo di dermoscopia in combinazione con sistemi di analisi di immagine e diagnosi automatica, e di microscopia laser confocale in vivo per lo studio degli aspetti citologici ed architetturali delle lesioni cutanee, correlato alla dermoscopia ed alla istologia. Inoltre si è dedicato alla integrazione di tecnologie di imaging cutaneo alla pratica clinica, compresa la Tomografia a Coerenza Ottica tradizionale e speckled-variance e la microscopia confocale a fluorescenza ex vivo per gli impieghi chirurgici allo scopo di ottenere una rapida istopatologia dei tessuti. La correlazione della morfologia tissutale con gli aspetti genetici e biomolecolari dei tessuti neoplastici rappresenta inoltre un altro importante indirizzo di ricerca.

E' stato Presidente del **World Congress of Dermatology 2019**

E' presidente del **International Congress of Dermatology 2025**

Pubblicazioni

Giovanni Pellacani ha pubblicato a partire dal 1996 ad oggi di **oltre 800 articoli originali su riviste scientifiche presenti in "Science Citation Index"** e 40 capitoli di libro, e oltre 500 abstracts presentati in congressi nazionali ed internazionali.

Indici Bibliometrici

Dati SCOPUS:

H-INDEX: 68

NUMERO TOTALE DI DOCUMENTI: 853

NUMERO TOTALE DI CITAZIONI: 21.243

3 su 3 criteri per Commissario in concorsi per l'area 06/D4

Attività clinica

E' stato responsabile delle attività del Reparto di degenza ordinaria della Dermatologia di Modena, poi del Day Hospital e Day Surgery, dedicate principalmente al trattamento di tumori cutanei. Si è dedicato inoltre alla attività chirurgica presso l'Unità di Chirurgia Dermatologica. Si è occupato di diagnosi precoce di melanoma e tumori cutanei mediante dermoscopia e microscopia confocale in vivo.

Ha diretto la Struttura Complessa di Dermatologica dell'Azienda Ospedaliero Universitaria Policlinico di Modena.

Dal 2021 dirige la Struttura Complessa di Dermatologica dell'Azienda Ospedaliero Universitaria Policlinico Umberto I di Roma

Insegnamento

Dal 2002 al 2020 è titolare dell'insegnamento di **Dermatologia e Venereologia** per il **Corso di Laurea in Medicina e Chirurgia** e, dal 2005, per il **corso di Laurea Specialistica in Scienze Infermieristiche** (Sede di Reggio Emilia) e, dal 2007 al 2012, Per il Corso di Laurea Specialistica in Igiene Dentale. E' inoltre titolare dell'insegnamento di **Dermatologia per le Scuole di Specializzazione** di Dermatologia, Allergologia, Pediatria, Tossicologia e Chirurgia Plastica.

Dal 2021 ad oggi è titolare dell'insegnamento di **Dermatologia e Venereologia** per il **Corso di Laurea in Medicina e Chirurgia dell'Università La Sapienza, Roma**, corso A in lingua italiana e corso F in lingua inglese.

Principali
tematiche/competenze
professionali possedute

Nome e tipo
d'organizzazione
erogatrice dell'istruzione e
formazione

Livello nella
classificazione nazionale
o internazionale

**Capacità e
competenze
personali**

Madrelingua(e) **Italiano**

Altra(e) lingua(e) **Inglese**

Autovalutazione

Livello europeo ()*

Lingua

Lingua

Comprensione			Parlato		Scritto
Ascolto	Lettura		Interazione orale	Produzione orale	
C2		C2	C2	C2	C2

(*) [Quadro comune europeo di riferimento per le lingue](#)

**Ulteriori
informazioni**

Allegati

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali (facoltativo)".

I dati personali saranno trattati in ottemperanza a quanto richiesto dal Dgs 196/2003 e Regolamento Europeo 679/2016. Si attesta inoltre la consapevolezza del rispetto alle responsabilità connesse a dichiarazioni mendaci (DPR 445/2000 ar. 76)

Firma

Giovanni Pellacani

Roma, 22/05/2025





Curriculum Vitae Europass

Informazioni personali

Cognome(i) / Nome(i)

Indirizzo(i) professionale

Durante Cosimo

Sapienza Università di Roma - Dipartimento di Medicina Traslazionale e di Precisione
Viale del Policlinico, 155, 00161 Roma (Italia)

Posizione attuale

Date 31/03/2022 →

Lavoro o posizione ricoperti Professore di ruolo di I fascia (Professore Ordinario)

Nome e indirizzo del datore di lavoro Sapienza Università di Roma - Dipartimento di Medicina Traslazionale e di Precisione
Viale dell'Università 37, 00185 Roma (Italia)

Tipo di attività o settore Settore concorsuale: 06/B1 - Medicina Interna.
Settore Scientifico Disciplinare: MED/09 – Medicina Interna

Date 01/11/2023 →

Lavoro o posizione ricoperti Presidente del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "A"

Nome e indirizzo del datore di lavoro Sapienza Università di Roma – Facoltà di Farmacia e Medicina

Istruzione e formazione

Date 1994 - 2000

Titolo della qualifica rilasciata Laurea in Medicina e Chirurgia

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione Università di Roma Sapienza

Date 2000 - 2005

Titolo della qualifica rilasciata Specializzazione in Endocrinologia e Malattie del Ricambio

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione Università di Roma Sapienza

Date 2005 - 2008

Titolo della qualifica rilasciata Dottore di Ricerca in "Endocrinologia e Medicina Molecolare"

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione Università di Roma Sapienza

Fellowships

Date 2003 - 2004

Incarico Clinical and Research Fellowship

Nome e tipo d'organizzazione erogatrice dell'incarico Nuclear Medicine and Endocrine Tumor Department, Cancer Institut "Gustave Roussy", Villejuif, France – Responsabile: Martin Schlumberger, MD

Esperienza professionale

Posizioni accademiche

Date	01/11/2008 – 17/01/2019
Lavoro o posizione ricoperti	Ricercatore Universitario in Medicina Interna
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma - Dipartimento di Medicina Traslazionale e di Precisione Viale dell'Università 37, 00185 Roma (Italia)
Tipo di attività o settore	Settore concorsuale: 06/B1 - Medicina Interna. Settore Scientifico Disciplinare: MED/09 – Medicina Interna
Date	21/09/2018 – 21/09/2024
Titolo	Abilitazione Scientifica Nazionale per la I Fascia
Tipo di attività o settore	Settore concorsuale: 06/D2 - Endocrinologia, nefrologia e scienze della alimentazione e del benessere Settore Scientifico Disciplinare: MED/13 – Endocrinologia
Date	19/10/2018 – 19/10/2024
Titolo	Abilitazione Scientifica Nazionale per la I Fascia
Tipo di attività o settore	Settore concorsuale: 06/B1 - Medicina Interna. Settore Scientifico Disciplinare: MED/09 – Medicina Interna
Date	18/01/2019 – 31/03/2022
Lavoro o posizione ricoperti	Professore di ruolo di II fascia
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma - Dipartimento di Medicina Traslazionale e di Precisione Viale dell'Università 37, 00185 Roma (Italia)
Tipo di attività o settore	Settore concorsuale: 06/B1 - Medicina Interna. Settore Scientifico Disciplinare: MED/09 – Medicina Interna
Date	31/03/2022 →
Lavoro o posizione ricoperti	Professore di ruolo di I fascia
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma - Dipartimento di Medicina Traslazionale e di Precisione Viale dell'Università 37, 00185 Roma (Italia)
Tipo di attività o settore	Settore concorsuale: 06/B1 - Medicina Interna. Settore Scientifico Disciplinare: MED/09 – Medicina Interna
Incarichi. Attività clinica	
Date	17/10/2011 →
Lavoro o posizione ricoperti	Dirigente Medico di I Livello
Nome e indirizzo del datore di lavoro	Policlinico Umberto I. Sapienza Università di Roma - Dipartimento di Medicina Traslazionale e di Precisione Viale del Policlinico 155, 00161 Roma (Italia)
Tipo di attività o settore	Medicina Interna.
Date	14/12/2016 → 26/03/2020
Lavoro o posizione ricoperti	Responsabile Unità Operativa Semplice (UOS) sulla Gestione dei Carcinomi Avanzati della Tiroide
Nome e indirizzo del datore di lavoro	Policlinico Umberto I. Sapienza Università di Roma - Dipartimento di Medicina Traslazionale e di Precisione Viale del Policlinico 155, 00161 Roma (Italia)
Tipo di attività o settore	Medicina Interna. Oncologia endocrina.

Date	27/03/2020 →
Lavoro o posizione ricoperti	Responsabile Unità Operativa Semplice Dipartimentale (UOSD) di medicina Traslazionale e di Precisione
Nome e indirizzo del datore di lavoro	Policlinico Umberto I. Sapienza Università di Roma - Dipartimento di Medicina Traslazionale e di Precisione Viale del Policlinico 155, 00161 Roma (Italia)
Tipo di attività o settore	Medicina Interna. Oncologia endocrina.
Incarichi. Commissioni Scientifiche Nazionali ed Internazionali	
Date	2014 - 2015
Attività	Membro della Task Force incaricata dalla "Commissione Linee-Guida" della Società Italiana di Endocrinologia di stilare il documento: "Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology"
Nome e tipo d'organizzazione erogatrice dell'attività	Società Italiana di Endocrinologia (SIE)
Date	2015 - 2017
Attività	Membro della Commissione Scientifica della Società Italiana di Endocrinologia
Nome e tipo d'organizzazione erogatrice dell'attività	Società Italiana di Endocrinologia (SIE)
Date	2015 - 2019
Attività	Segretario Scientifico delle Linee Guida dei Tumori della Tiroide della Associazione Italiana di Oncologia Medica
Nome e tipo d'organizzazione erogatrice dell'attività	Associazione Italiana di Oncologia Medica (AIOM)
Date	2016 - 2017
Attività	Membro della Task Force incaricata dalla European Thyroid Association di stilare le linee guida: "Ultrasound malignancy risk stratification of thyroid nodule"
Nome e tipo d'organizzazione erogatrice dell'attività	European Thyroid Association (ETA)
Date	2016 - 2018
Attività	Membro della Task Force della Associazione Italiana Tiroide (AIT), Associazione Medici Endocrinologi (AME), Società Italiana di Endocrinologia (SIE), Associazione Italiana di Medicina Nucleare ed Imaging Molecolare (AIMN), Società Italiana Unitaria di Endocrino Chirurgia (SIUEC), Società Italiana di Anatomia Patologica e Citologia diagnostica (SIAPEC) per la preparazione del documento: "Italian Consensus on Diagnosis and Treatment of Differentiated Thyroid Cancer: Joint Statements of Six Italian Societies"
Nome e tipo d'organizzazione erogatrice dell'attività	Società Italiana di Endocrinologia (SIE)
Date	2017 - 2018
Attività	Membro della Task Force della Associazione Italiana Tiroide (AIT), Società Italiana di Endocrinologia (SIE), Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Società Italiana di Radiologia Medica per la preparazione del documento: "Thyroid ultrasonography reporting: consensus of Italian Thyroid Association (AIT), Italian Society of Endocrinology (SIE), Italian Society of Ultrasonography in Medicine and Biology (SIUMB) and Ultrasound Chapter of Italian Society of Medical Radiology (SIRM)"
Nome e tipo d'organizzazione erogatrice dell'attività	Società Italiana di Endocrinologia (SIE)
Date	2017 →
Pagina 3 / 25 - Curriculum vitae di Durante Cosimo	Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu © Unione europea, 2002-2010 24082010

Attività	Membro della Task Force della European Society For Medical Oncology (ESMO) per la preparazione del documento: "ESMO Clinical Practice Guidelines on Thyroid Cancer"
Nome e tipo d'organizzazione erogatrice dell'attività	European Society For Medical Oncology (ESMO)
Date	2018 →
Attività	Membro della Task Force dell'International Thyroid Oncology Group (ITOG) per la creazione di un Registro Internazionale dei Carcinomi Avanzati della Tiroide
Nome e tipo d'organizzazione erogatrice dell'attività	International Thyroid Oncology Group (ITOG)
Date	2019 →
Attività	Membro della Commissione Didattica della Società Italiana di Endocrinologia
Nome e tipo d'organizzazione erogatrice dell'attività	Società Italiana di Endocrinologia (SIE)
Date	2019 →
Attività	Membro della Task Force International Thyroid Nodule Work Group (ITN WG) per la preparazione del documento: "Universal Thyroid Imaging Reporting And Data System (TIRADS)". Ruolo: Lexicon Project Leader
Nome e tipo d'organizzazione erogatrice dell'attività	American Association of Clinical Endocrinologists (AACE), American College of Radiology (ACR), American Thyroid Association (ATA), European Thyroid Association (ETA), Korean Society of Thyroid Radiology (KSThR), Korean Society of Ultrasound in Medicine (KSUM)
Date	2019 →
Attività	Membro della Task Force dell'American Thyroid Association (ATA) per la preparazione del documento: "American Thyroid Association Thyroid Nodules Guidelines".
Nome e tipo d'organizzazione erogatrice dell'attività	American Thyroid Association (ATA)
Date	2020 →
Attività	Estensore per la stesura delle Linee Guida dei Tumori della Tiroide della Associazione Italiana di Oncologia Medica
Nome e tipo d'organizzazione erogatrice dell'attività	Associazione Italiana di Oncologia Medica (AIOM)
Date	2022 →
Attività	Coordinatore della Task Force incaricata dalla European Thyroid Association di stilare le linee guida: "2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management"
Nome e tipo d'organizzazione erogatrice dell'attività	European Thyroid Association (ETA)
Incarichi. Commissioni Scientifiche Locali	
Date	01/11/2015 – 31/10/2017
Attività	Membro della Commissione Ricerca
Nome e tipo d'organizzazione erogatrice dell'attività	Sapienza Università di Roma
Date	02/04/2021 – 09/05/2023
Attività	Membro della Commissione giudicatrice Concorso Perfezionamento estero – Area CUN 6
Nome e tipo d'organizzazione erogatrice dell'attività	Sapienza Università di Roma

Date	09/05/2023 →
Attività	Presidente della Commissione giudicatrice Concorso Perfezionamento estero – Area CUN 6
Nome e tipo d'organizzazione erogatrice dell'attività	Sapienza Università di Roma
Incarichi. Clinical trials	
Date	2004-2005
Posizione	Sub-Investigator
Titolo della sperimentazione	A Phase 2, Open-Label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer who are not Candidate for Radioactive Iodine Therapy (ClinicalTrials.gov: NCT00121628)
Date	2006-2016
Posizione	Sub-Investigator (2006-2015) – Principal Investigator (from September 1 st , 2015)
Titolo della sperimentazione	An International, Phase II/III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (Zactima) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer (ClinicalTrials.gov: NCT0041076. Study ID Number: D4200C00058)
Date	2009-2014
Posizione	Sub-Investigator
Titolo della sperimentazione	A Phase II, Multicenter, Open Label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology (ClinicalTrials.gov: NCT00784303. Study ID Number: E7080-G000-201)
Date	2009-2014
Posizione	Sub-Investigator
Titolo della sperimentazione	An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer (ClinicalTrials.gov: NCT00704730. Study ID Number: XL184-301)
Date	2010-2018
Posizione	Sub-Investigator (2010-2015) – Principal Investigator (from September 1 st , 2015)
Titolo della sperimentazione	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer (ClinicalTrials.gov: NCT01321554. Study ID Number: E7080-G000-303)
Date	2011-2014
Posizione	Sub-Investigator
Titolo della sperimentazione	A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib (ClinicalTrials.gov: NCT01298323. Study ID Number: D4200C00088)
Date	2012-2015
Posizione	Sub-Investigator
Titolo della sperimentazione	An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300 mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease (ClinicalTrials.gov: NCT01496313. Study ID Number: D4200C00097)
Date	2013-2017
Posizione	Sub-Investigator (2013-2015) – Principal Investigator (from September 1 st , 2015)

Titolo della sperimentazione	A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy (ClinicalTrials.gov: NCT01876784. Study ID Number: D4203C00011)
Date	2013 -2018
Posizione	Sub-Investigator (2013-2015) – Principal Investigator (from September 1 st , 2015)
Titolo della sperimentazione	A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer (ClinicalTrials.gov: NCT01843062. Study ID Number: D1532C00065)
Date	2017 - 2021
Posizione	Principal Investigator
Titolo della sperimentazione	A Randomized, Double-Blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients (ClinicalTrials.gov: NCT01896479. Study ID Number: XL184-401)
Date	2019 - 2020
Posizione	Sub-Investigator
Titolo della sperimentazione	A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (ClinicalTrials.gov: NCT03037385. Study ID Number: BLU-667-1101)
Date	2019 →
Posizione	Principal Investigator
Titolo della sperimentazione	A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR Targeted Therapy (ClinicalTrials.gov: NCT03690388. Study ID Number: XL184–311)
Date	2020→
Posizione	Principal-Investigator
Titolo della sperimentazione	A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) (ClinicalTrials.gov: NCT04211337. Study ID Number: J2G-MC-JZJB)
Note: tutti i clinical trials riportati includevano un modulo formativo di Good Clinical Practice con relativa certificazione	
Incarichi. Attività editoriale	
Date	01/01/2014 – 31/12/2016
Attività	Membro dell'Editorial Board della rivista scientifica "The Journal of Endocrinological Investigation" (InCites Journal Impact Factor Quartile: Q2)
Date	01/01/2014 – 31/12/2017
Attività	Membro dell'Editorial Board della rivista scientifica "The Journal of Clinical Endocrinology & Metabolism" (InCites Journal Impact Factor Quartile: Q1)
Date	01/10/2018 – 31/12/2021
Attività	Associate Editor della rivista scientifica "Endocrine" (InCites Journal Impact Factor Quartile: Q2)
Date	01/01/2019 – 31/12/2021

Attività	Membro dell'Editorial Board della rivista scientifica "Thyroid" (InCites Journal Impact Factor Quartile: Q1)
Date	01/01/2020 – 31/12/2021
Attività	Membro dell'Editorial Board della rivista scientifica "The Journal of Clinical Endocrinology & Metabolism" (InCites Journal Impact Factor Quartile: Q1)
Date	01/01/2022 →
Attività	Associate Editor della rivista scientifica "Thyroid" (InCites Journal Impact Factor Quartile: Q1)
Date	01/01/2022 →
Attività	Membro dell'Editorial Board della rivista scientifica "Endocrine" (InCites Journal Impact Factor Quartile: Q2)

Incarichi. Attività didattica

Ruoli di coordinamento

Date	01/11/2011 – 31/10/2016
Lavoro o posizione ricoperti	Vice-Presidente presso il Corso di Laurea in Tecnica della Riabilitazione Psichiatrica (codice corso: 15986)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Medicina ed Odontoiatria
Date	01/11/2009 – 31/10/2016
Lavoro o posizione ricoperti	Coordinatore del Corso Integrato di "Riabilitazione Psichiatrica in Ambito Medico – Medicina Interna", presso il Corso di Laurea in Tecnica della Riabilitazione Psichiatrica (codice corso: 15986)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Medicina ed Odontoiatria
Date	01/11/2012 – 31/10/2016
Lavoro o posizione ricoperti	Coordinatore del Corso Integrato di "Infermieristica Clinica in Area Medica – Medicina Interna", presso il Corso di Laurea in Ostetricia (codice corso: 15963)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Medicina ed Odontoiatria
Date	01/11/2016 →
Lavoro o posizione ricoperti	Membro della Commissione Medical Education Interfacoltà (CMEI)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Medicina
Date	01/11/2019 →
Lavoro o posizione ricoperti	Coordinatore del Corso Integrato di "Internal Medicine and General Surgery III", del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "F" (codice corso: 15342)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Farmacia e Medicina
Date	26/03/2021 →
Lavoro o posizione ricoperti	Membro del Gruppo di Lavoro Qualità e Innovazione della Didattica (GdL- QuID) e Responsabile del coordinamento dei docenti tuor
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma
Date	01/11/2022 →
Lavoro o posizione ricoperti	Coordinatore del Corso Integrato di "Medicina Interna e Chirurgia Generale I", del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "A" (codice corso: 10596540)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Farmacia e Medicina
Date	01/11/2022 →

Lavoro o posizione ricoperti	Coordinatore di Semestre (VI anno, II semestre) del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "C" (codice corso: 30895)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Medicina e Odontoiatria
Date	01/11/2023 →
Lavoro o posizione ricoperti	Presidente del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "A"
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Farmacia e Medicina
Laurea magistrale a ciclo unico. Laurea. Laurea Magistrale	
Date	01/11/2009 – 31/10/2016
Lavoro o posizione ricoperti	Titolare dell'insegnamento di "Riabilitazione Psichiatrica in Ambito Medico – Medicina Interna", del Corso di Laurea in Tecnica della Riabilitazione Psichiatrica (codice corso: 15986)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Medicina ed Odontoiatria
Date	01/11/2012 – 31/10/2016
Lavoro o posizione ricoperti	Titolare dell'insegnamento di "Infermieristica Clinica in Area Medica – Medicina Interna", del Corso di Laurea in Ostetricia (codice corso: 15963)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Medicina ed Odontoiatria
Date	01/11/2013 – 31/10/2016
Lavoro o posizione ricoperti	Titolare dell'insegnamento di "Metodologia Medico Scientifica Clinica VI", del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "A" (codice corso: 26647)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Farmacia e Medicina
Date	01/11/2014 →
Lavoro o posizione ricoperti	Titolare dell'insegnamento di "Medicina Interna e Chirurgia Generale I", del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "A" (codice corso: 26647)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Farmacia e Medicina
Date	01/11/2016 →
Lavoro o posizione ricoperti	Titolare dell'insegnamento di "Internal Medicine and General Surgery III", del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "F" (codice corso: 15342)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Farmacia e Medicina
Date	01/11/2017 →
Lavoro o posizione ricoperti	Titolare dell'insegnamento di "Medicina Interna e Chirurgia Generale III", del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "A" (codice corso: 26647)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Farmacia e Medicina
Date	01/11/2020 →
Lavoro o posizione ricoperti	Titolare dell'insegnamento di "Medicina Interna e Chirurgia Generale III", del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "C" (codice corso: 30895)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Medicina e Odontoiatria
Date	01/11/2021 →
Lavoro o posizione ricoperti	Titolare dell'insegnamento di "Metodologia Tecnico Medica", del Corso di Laurea Magistrale in Medicina e Chirurgia, Corso di Laurea "HT" (codice corso: 30789)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Medicina e Odontoiatria
Scuola di specializzazione. Dottorato di ricerca. Master.	

Date	01/11/2011 →
Lavoro o posizione ricoperti	Membro del Collegio dei Docenti del Corso di Specializzazione in Medicina Interna (codice corso: 28270)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma
Date	01/11/2011 →
Lavoro o posizione ricoperti	Membro del Collegio dei Docenti del Dottorato di Ricerca in Tecnologie Biomediche in Medicina Clinica (codice corso: 11124)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma – Facoltà di Medicina ed Odontoiatria
Date	01/11/2011 →
Lavoro o posizione ricoperti	Membro del Collegio dei Docenti del Master di II Livello in Ecografia Internistica (codice corso: 15299)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma
Date	01/11/2017 →
Lavoro o posizione ricoperti	Membro del Collegio dei Docenti del Master di II Livello in Ricerca clinica: metodologia, farmacovigilanza, aspetti legali e regolamentari (codice corso: 27695)
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma
Date	01/11/2023 →
Lavoro o posizione ricoperti	Membro del Collegio dei Docenti del Master di II Livello in Endocrinochirurgia
Nome e indirizzo del datore di lavoro	Sapienza Università di Roma

Corsi telematici

Date	18/06/2019 →
Lavoro o posizione ricoperti	Membro del Comitato Tecnico Scientifico per i corsi di Formazione ECM - Educazione continua in medicina
Nome e indirizzo del datore di lavoro	UnitelmaSapienza, Sapienza Università di Roma

Premi

Premi internazionali

Data	20/06/2019
Premio	Premio Internazionale "Gaetano Salvatore" per la Fisiopatologia della tiroide. Anno 2019
Nome e tipo d'organizzazione erogatrice del premio	Accademia Nazionale dei Lincei

Grant

Progetti di ricerca internazionali

Date	01/01/2024 – 31/12/2028
Titolo del progetto	Federated virtual twins for privacy-preserving personalised outcome prediction of type 2 diabetes treatment - DAIBetes (code: 101136305)
Ruolo	Responsabile scientifico di Unità Sapienza Università di Roma
Programma	HORIZON-HLTH-2023-TOOL-05 Integrated, multi-scale computational models of patient pathophysiology ('virtual twins') for personalised disease management - Anno 2023

Progetti di ricerca nazionali

Date	01/12/2010 – 01/03/2010
------	-------------------------

Titolo del progetto	Ex vivo evaluation of targeted therapies against the tyrosine kinase receptor MET: Identification of genetic and biological determinants for prediction of treatment efficacy (code: RBFR082XL7_003)
Ruolo	Responsabile scientifico di Unità Operativa
Programma	Bando Fondo per gli Investimenti della Ricerca di Base (FIRB), Programma "Futuro in Ricerca", Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), Anno 2008
Date	31/12/2016 – 05/02/2020
Titolo del progetto	Thyroid cancer and cytologically indeterminate thyroid nodules: new diagnostic and therapeutic strategies for a more precise patient tailored medicine and a more sustainable management of a disease with a great social impact (code: 2015HPMLFY_013)
Ruolo	Responsabile scientifico di Unità Operativa
Programma	Bando Progetti di Rilevante Interesse Nazionale (PRIN), Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), Anno 2015
Date	29/08/2019 – 28/08/2023
Titolo del progetto	New insights into the molecular signature of differentiated thyroid cancer: implications for diagnosis, prognosis and therapy (code: 2017YTWKWH_005)
Ruolo	Responsabile scientifico di Unità Operativa
Programma	Bando Progetti di Rilevante Interesse Nazionale (PRIN), Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), Anno 2017
Date	10/2020 →
Titolo del progetto	Multiarray molecular strategy for the analysis of fine needle aspiration biopsies in the preoperative diagnosis of thyroid cancer (code: RF-2019-12370266)
Ruolo	Responsabile scientifico di Unità Operativa
Programma	Bando Ricerca Finalizzata, tipologia di ricerca "Change Promoting", Ministero della Salute, Anno 2019

Pubblicazioni

Numero lavori su banche dati internazionali	183
Impact factor	1639 (InCites Journal Impact Factor)
Numero citazioni	9928 (Scopus)
H-index	44 (Scopus)

Articoli in extenso

(internazionali, su banche dati internazionali)

1. Corneli G, Baldelli R, Di Somma C, Grottoli S, **Durante C**, Gasco V, Ferretti E, Colao A, Tamburrano G, Lombardi G, Aimaretti G, Ghigo E. Evaluation of GH deficiency by GHRH + arginine test and IGF-I levels in a large population of young, middle-aged and elderly patients who had undergone neurosurgery for tumor masses in the hypothalamus-pituitary area. *J Endocrinol Invest.* 2002;25(10 Suppl):38-9.
2. Tamburrano G, **Durante C**, Baldelli R. Therapy of diabetes and dyslipidemia in acromegaly. *Pituitary.* 2002;5(1):27-31.
3. Corneli G, Baldelli R, Di Somma C, Rovere S, Gaia D, Pellegrino M, Gasco V, **Durante C**, Grottoli S, Colao A, Tamburrano G, Lombardi G, Ghigo E, Aimaretti G. Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses. *Growth Horm IGF Res.* 2003;13(2-3):104-108.
4. Aimaretti G, Corneli G, Baldelli R, Di Somma C, Gasco V, **Durante C**, Ausiello L, Rovere S, Grottoli S, Tamburrano G, Ghigo E. Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency. *Clin Endocrinol (Oxf).* 2003;59(1):56-61.
5. Baldelli R, **Durante C**, D'Amico E, Diacono F, Tamburrano G, Casanueva FF. Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. *J Endocrinol Invest.* 2003;26(12):1219-24.

6. **Durante C**, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. *J Clin Endocrinol Metab.* 2006;91(8):2892-9.
7. **Filetti S**, Durante C, Torlontano M. Nonsurgical approaches to the management of thyroid nodules. *Nat Clin Pract Endocrinol Metab.* 2006;2(7):384-94.
8. Costante G, Meringolo D, **Durante C**, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. *J Clin Endocrinol Metab.* 2007;92(2):450-455.
9. Ronga G, Bruno R, Puxeddu E, Calcinaro F, Montesano T, Travascio L, Colandrea M, **Durante C**, Maranghi M, Filetti S, Russo D. Radioiodine uptake in non-lactating mammary glands: evidence for a causative role of hyperprolactinemia. *Thyroid.* 2007;17(4):363-6.
10. **Durante C**, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. *J Clin Endocrinol Metab.* 2007;92(7):2840-3.
11. Montesano T*, **Durante C***, Attard M, Crocetti U, Meringolo D, Bruno R, Tumino S, Ribello D, Al-Nahhas A, Colandrea M, Maranghi M, Tralascio L, Ronga G, Torlontano M. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. *Biomed Pharmacother.* 2007;61(8):468-71. ***Equal contribution**
12. Scipioni A, Ferretti E, Soda G, Tosi E, Bruno R, Costante G, Meringolo D, Arturi F, **Durante C**, Amorosi A, Foschini MP, Nardi F, Russo D, Filetti S. hNIS protein in thyroid: the iodine supply influences its expression and localization. *Thyroid.* 2007;17(7):613-8.
13. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, **Durante C**, Botta G, D'Agostino M, Brullo C, Filetti S, Botta M, Russo D. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivatives. *J Endocrinol Invest.* 2007;30(10):RC31-4.
14. Torlontano M*, **Durante C***, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D'Arcangelo P, Dallapiccola B, Filetti S, Trischitta V. Type 2 deiodinase polymorphism (thr92ala) predicts l-thyroxine dose to achieve target TSH levels in thyroidectomized patients. *J Clin Endocrinol Metab.* 2008;93(3):910-913. ***Equal contribution**
15. Puxeddu E, **Durante C**, Avenia N, Filetti S, Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. *Trends Endocrinol Metab.* 2008;19(4):138-145.
16. Ferretti E, Tosi E, Po A, Scipioni A, Morisi R, Espinola MS, Russo D, **Durante C**, Schlumberger M, Screpanti I, Filetti S, Gulino A. Notch signaling is involved in expression of thyrocyte differentiation markers and is downregulated in thyroid tumors. *J Clin Endocrinol Metab.* 2008;93(19):4080-4087.
17. Capezzone M, Cantara S, Marchisotta S, Filetti S, De Santi MM, Rossi B, Ronga G, **Durante C**, Pacini F. Short telomeres, hTERT gene amplification and increased telomerase activity in the blood of familial non-medullary thyroid cancer patients. *J Clin Endocrinol Metab.* 2008;93(10):3950-3957.
18. Crocetti U, **Durante C**, Attard M, Maniglia A, Tumino S, Bruno R, Bonfitto N, Dicembrino F, Varraso A, Meringolo D, Filetti S, Trischitta V, Torlontano M. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. *Thyroid.* 2008;18(10):1049-1053.
19. Costante G, **Durante C**, Zelia Francis, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. *Nat Clin Pract Endocrinol Metab.* 2009;5(1):35-44.

20. **Durante C**, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D, de Baere T, Malka D, Lumbroso J, Guigay J, Schlumberger M, Ducreux M, Baudin E. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. *Endocr Relat Cancer*. 2009;16(2):585-97.
21. Sponziello M, Scipioni A, **Durante C**, Verrienti A, Maranghi M, Giacomelli L, Ferretti E, Celano M, Filetti S, Russo D. Regulation of sodium/iodide symporter and lactoperoxidase expression in four human breast cancer cell lines. *J Endocrinol Invest*. 2010;33(1):2-6.
22. Maranghi M, Pugliese F, Cianci R, Colotto M, **Durante C**, Anatra MG, Coletta P, Mercuri S, Rossetti M, Morano S, Filetti S. Atherosclerosis renal artery stenosis and in-stent restenosis in a diabetic patient: Targeting on diabetic dyslipidemia is a key intervention. *J Endocrinol Invest*. 2010;33(4):284-5.
23. Castellone MD, Verrienti A, Rao DM, Sponziello M, Fabbro D, Muthu M, **Durante C**, Maranghi M, Damante G, Pizzolitto S, Costante G, Russo D, Santoro M, Filetti S. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with pheochromocytoma and medullary thyroid carcinoma: Functional characterization. *Clin Endocrinol (Oxf)*. 2010;73(4):529-534.
24. **Durante C**, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D, Bruno R, De Toma G, Crocetti U, Montesano T, Dardano A, Lamartina L, Maniglia A, Giacomelli L, Filetti S; on behalf of the Papillary Thyroid Cancer Study Group. Identification and Optimal Postsurgical Follow-Up of Patients with Very Low-Risk Papillary Thyroid Microcarcinomas. *J Clin Endocrinol Metab*. 2010;95(11):4882-8.
25. Sponziello ML, Bruno R, **Durante C**, D'Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D. Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. *Horm Metab Res*. 2011;43(1):22-5.
26. Colotto M, Maranghi M, Epifania A, Totaro M, Giura R, **Durante C**. Unmasking aortic dissection in patients of transient global amnesia: case report and diagnostic algorithm for the emergency department. *BMJ Case Rep*. 2011 Jan 25;2011. pii: bcr0720103151. doi: 10.1136/bcr.07.2010.3151.
27. Colotto M, Maranghi M, **Durante C**, Rossetti M, Renzi A, Anatra MG. PFAPA Syndrome in a Young Adult with a History of Tonsillectomy. *Intern Med*. 2011;50(3):223-5.
28. **Durante C**, Russo D, Verrienti A, Filetti S. XL184 (cabozantinib) for medullary thyroid carcinoma. *Expert Opin Investig Drugs*. 2011;20(3):407-413.
29. Russo D, Damante G, Puxeddu E, **Durante C**, Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. *J Mol Endocrinol*. 2011;46(3):R73-81.
30. Russo D, Scipioni A, **Durante C**, Ferretti E, Gandini L, Maggisano V, Paoli D, Verrienti A, Costante G, Lenzi A, Filetti S. Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. *Endocrine*. 2011;40(1):35-40.
31. **Durante C**, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. *Eur J Endocrinol*. 2011 Sep;165(3):455-63.
32. Mastroianno S, Torlontano M, Scillitani A, D'Aloiso L, Verrienti A, Bonfitto N, De Bonis A, D'Agruma L, Muscarella LA, Guarnieri V, Dicembrino F, Maranghi M, **Durante C**, Filetti S. Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. *Endocrine*. 2011 Dec;40(3):481-5.
33. **Durante C**, Filetti S. Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography. *J Clin Endocrinol Metab*.

2011 Oct;96(10):3059-61.

34. Voce P, D'Agostino M, Moretti S, Sponziello M, Rhoden K, Calcinaro F, Tamburrano G, Tallini G, Puxeddu E, Filetti S, Russo D, **Durante C**. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors. *Oncol Rep*. 2011 Nov;26(5):1075-80.
35. Russo D, Costante G, Bruno R, Sponziello M, Tamburrano G, Dima M, Sacco R, Giacomelli L, **Durante C**, Filetti S. TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation. *Endocrine*. 2011 Dec;40(3):492-4.
36. D'Agostino M, Voce P, Celano M, Sponziello M, Moretti S, Maggisano V, Verrienti A, **Durante C**, Filetti S, Puxeddu E, Russo D. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. *Thyroid*. 2012 Feb;22(2):138-44
37. Passon N, Puppini C, Lavarone E, Bregant E, Franzoni A, Hershman JM, Fenton MS, D'Agostino M, **Durante C**, Russo D, Filetti S, Damante G. CREM inhibits promoter activity of NIS gene in thyroid cancer cells. *Thyroid*. 2012 May;22(5):487-93
38. **Durante C**, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L, Paciaroni A, Massa M, Giacomelli L, Ronga G, Filetti S; on behalf of the PTC Study Group. Long-Term Surveillance of Papillary Thyroid Cancer Patients Who Do Not Undergo Postoperative Radioiodine Remnant Ablation: Is There a Role for Serum Thyroglobulin Measurement? *J Clin Endocrinol Metab*. 2012 Aug;97(8):2748-53
39. Colotto M, Renzi A, **Durante C**. Into the wardrobe of Narnia: beyond HIV infection a world of cardiovascular risk. *BMJ Case Rep*. 2012 Jul 17;2012. pii: bcr2012006230. doi: 10.1136/bcr-2012-006230
40. Celano M, Sponziello M, Tallini G, Maggisano V, Bruno R, Dima M, Di Oto E, Redler A, **Durante C**, Sacco R, Filetti S, Russo D. Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations. *Endocrine*. 2013 Feb;43(1):147-53
41. D'Elia AV, Grimaldi F, Pizzolitto S, De Maglio G, Bregant E, Passon N, Franzoni A, Verrienti A, Tamburrano G, **Durante C**, Filetti S, Fogolari F, Russo D, Damante G. A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytoma. *Clin Endocrinol (Oxf)*. 2013 Mar;78(3):391-7
42. Russo D, **Durante C**, Bulotta S, Puppini C, Puxeddu E, Filetti S, Damante G. Targeting histone deacetylase in thyroid cancer. *Expert Opin Ther Targets*. 2013 Feb;17(2):179-93
43. **Durante C**, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R, Trulli F, Massa M, Maniglia A, D'Apollo R, Giacomelli L, Ronga G, Filetti S; on behalf of the PTC Study Group. Papillary Thyroid Cancer: Time Course of Recurrences During Postsurgery Surveillance. *J Clin Endocrinol Metab*. 2013 Feb;98(2):636-42.
44. **Durante C**, Costante G, Filetti S. Differentiated thyroid carcinoma: defining new paradigms for the post-operative management. *Endocr Relat Cancer*. 2013 Jun 24;20(4):R141-54.
45. **Durante C**, Paciaroni A, Plasmati K, Trulli F, Filetti S. Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. *Endocrine*. 2013 Oct;44(2):334-42.
46. Sponziello M, Lavarone E, Pegolo E, Di Loreto C, Puppini C, Russo MA, Bruno R, Filetti S, **Durante C**, Russo D, Di Cristofano A, Damante G. Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. *Endocrinology*. 2013 Sep;154(9):3043-53.
47. D'Agostino M, Sponziello M, Puppini C, Celano M, Maggisano V, Baldan F, Biffoni M, Bulotta S, **Durante C**, Filetti S, Damante G, Russo D. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. *J Mol Endocrinol*. 2014 Jan 30;52(2):121-31.

48. Puppini C, **Durante C**, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, Russo D, Filetti S, Damante G. Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. *Endocrine*. 2014 Nov;47(2):528-36.
49. **Durante C**, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F, Totada M, Redler A, Ronga G, Filetti S, Monzani F. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. *Thyroid*. 2014 Jul;24(7):1139-45.
50. Sponziello M*, **Durante C***, Boichard A, Dima M, Puppini C, Verrienti A, Tamburrano G, Di Rocco G, Redler A, Lacroix L, Bidart JM, Schlumberger M, Damante G, Russo D, Filetti S. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. *Mol Cell Endocrinol*. 2014 Jul 5;392(1-2):8-13. ***Equal contribution**
51. Maranghi M, Carnovale A, **Durante C**, Tarquini G, Tiseo G, Filetti S. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. *Expert Opin Drug Metab Toxicol*. 2015 Jan;11(1):125-37.
52. Lamartina L, **Durante C**, Filetti S, Cooper DS. Low and intermediate Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A systematic review of the literature. *J Clin Endocrinol Metab*. 2015 May;100(5):1748-61.
53. **Durante C**, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Filetti S. The natural history of benign thyroid nodules. *JAMA*. 2015 Mar 3;313(9):926-35.
54. Sponziello M, Verrienti A, Rosignolo F, De Rose RF, Pecce V, Maggisano V, **Durante C**, Bulotta S, Damante G, Giacomelli L, Di Gioia CR, Filetti S, Russo D, Celano M. PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. *Endocrine*. 2015 Nov;50(2):434-41.
55. Passon N, Bregant E, Sponziello M, Dima M, Rosignolo F, **Durante C**, Celano M, Russo D, Filetti S, Damante G. Somatic amplifications and deletions in genome of papillary thyroid carcinomas. *Endocrine*. 2015 Nov;50(2):453-64.
56. Rosignolo F, Maggisano V, Sponziello M, Celano M, Di Gioia CR, D'Agostino M, Giacomelli L, Verrienti A, Dima M, Pecce V, **Durante C**. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression. *J Endocrinol Invest*. 2015 Dec;38(12):1283-9.
57. de Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei GP, **Durante C**, Costante G, Bruno R, Torlontano M, Paschke R, Filetti S, Piana S, Frasoldati A, Tallini G, Ciarrocchi A. TERT promoter mutations in thyroid papillary microcarcinomas. *Thyroid*. 2015 Sep;25(9):1013-9.
58. Verrienti A, Carbone A, Bellitti P, Fabiano MC, De Rose RF, Maranghi M, Lucia P, **Durante C**, Rosignolo F, Pecce V, Sponziello M, Puppini C, Costante G, Bruno R. A novel double mutation VAL648ILE and VAL804LEU of RET proto-oncogene in Multiple Endocrine Neoplasia type 2. *Endocr Pract*. 2015 Nov;21(11):1248-54.
59. Tallini G*, de Biase D*, **Durante C***, Acquaviva G, Bisceglia M, Bruno R, Bacchi Reggiani ML, Casadei GP, Costante G, Cremonini N, Lamartina L, Meringolo D, Nardi F, Pession A, Rhoden KJ, Ronga G, Torlontano M, Verrienti A, Visani M, Filetti S. BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. *Mod Pathol*. 2015 Oct;28(10):1343-59. ***Equal contribution**
60. Sponziello M, **Durante C**, Filetti S. HABP2 Mutation and Nonmedullary Thyroid Cancer. *N Engl J Med*. 2015 Nov 19;373(21):2085-6.
61. Pacini F, Brianzoni E, **Durante C**, Elisei R, Ferdeghini M, Fugazzola L, Mariotti S, Pellegriti G.

Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. *J Endocrinol Invest*. 2016 Mar;39(3):341-7.

62. Dima M, Pecce V, Biffoni M, Di Gioia CR, Tallini G, Biffoni M, Rosignolo F, Verrienti A, Sponziello M, Damante G, Russo D, **Durante C**. Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers. *Endocrine*. 2016 Jul;53(1):145-56.
63. Mio C, Lavarone E, Conzatti K, Baldan F, Toffoletto B, Puppini C, Filetti S, **Durante C**, Russo D, Orlacchio A, Di Cristofano A, Di Loreto C, Damante G. MCM5 as a target of BET inhibitors in thyroid cancer cells. *Endocr Relat Cancer*. 2016 Apr;23(4):335-347.
64. Sponziello M, Rosignolo F, Celano M, Maggisano V, Pecce V, De Rose RF, Lombardo GE, **Durante C**, Filetti S, Damante G, Russo D, Bulotta S. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. *Mol Cell Endocrinol*. 2016 Aug 15;431:123-32.
65. Lamartina L, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M, Plasmati K, Sponziello M, Trulli F, Verrienti A, Filetti S, **Durante C**. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. *J Clin Endocrinol Metab*. 2016 Aug;101(8):3036-44.
66. Cabanillas ME, McFadden DG, **Durante C**. Thyroid cancer. *Lancet*. 2016 Dec 3;388(10061):2783-2795.
67. Rosignolo F, Sponziello M, **Durante C**, Puppini C, Mio C, Baldan F, Di Loreto C, Russo D, Filetti S, Damante G. Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma. *PLoS One*. 2016 Jun 1;11(6):e0156658
68. Lamartina L, Deandrea D, **Durante C**, Filetti S. ENDOCRINE TUMOURS: Imaging in the follow up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. *Eur J Endocrinol*. 2016 Nov;175(5):R185-202
69. Verrienti A, Tallini G, Colato C, Boichard A, Checquolo S, Pecce V, Sponziello M, Rosignolo F, de Biase D, Rhoden K, Casadei GP, Russo D, Visani M, Acquaviva G, Ferdeghini M, Filetti S, **Durante C**. RET mutation and increased angiogenesis in medullary thyroid carcinomas. *Endocr Relat Cancer*. 2016 Aug;23(8):665-76.
70. Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, **Durante C**. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. *Endocrine*. 2016 Nov;54(2):467-475.
71. Rosignolo F, Sponziello M, Giacomelli L, Russo D, Pecce V, Biffoni M, Bellantone R, Lombardi CP, Lamartina L, Grani G, **Durante C**, Filetti S, Verrienti A. Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up. *J Endocr Soc*. 2017 Jan 12;1(1):3-13. doi: 10.1210/js.2016-1032.
72. Giannetta E, Isidori AM, **Durante C**, Di Gioia C, Longo F, Tombolini V, Bulzonetti N, Graziadio C, Pofi R, Gianfrilli D, Verrienti A, Carletti R, Filetti S, Lenzi A, Baroli A. Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report. *Medicine* (Baltimore). 2017 Feb;96(6):e5621. doi: 10.1097/MD.0000000000005621.
73. Rosignolo F, Memeo L, Monzani F, Colarossi C, Pecce V, Verrienti A, **Durante C**, Grani G, Lamartina L, Forte S, Martinetti D, Giuffrida D, Russo D, Basolo F, Filetti S, Sponziello M. MicroRNA-based molecular classification of papillary thyroid carcinoma. *Int J Oncol*. 2017 May;50(5):1767-1777. doi: 10.3892/ijo.2017.3960.
74. Maggisano V, Celano M, Lombardo GE, Lepore SM, Sponziello M, Rosignolo F, Verrienti A, Baldan F, Puxeddu E, **Durante C**, Filetti S, Damante G, Russo D, Bulotta S. Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. *Mol Cell Endocrinol*. 2017 Jun 15;448:34-40. doi: 10.1016/j.mce.2017.03.007

75. Grani G, Lamartina L, Ascoli V, Bosco D, Nardi F, D'Ambrosio F, Rubini A, Giacomelli L, Biffoni M, Filetti S, **Durante C**, Cantisani V. Ultrasonography scoring systems can rule out malignancy in cytologically indeterminate thyroid nodules. *Endocrine*. 2017 Aug;57(2):256-261. doi: 10.1007/s12020-016-1148-6.
76. Russ G, Bonnema SJ, Erdogan MF, **Durante C**, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. *Eur Thyroid J*. 2017 Sep;6:225–237. doi: 10.1159/000478927.
77. Grani G, Bruno R, Lucisano G, Costante G, Meringolo D, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Cooper DS, Filetti S, **Durante C**. Temporal Changes in Thyroid Nodule Volume: Lack of Effect on Paranodular Thyroid Tissue Volume. *Thyroid*. 2017 Nov;27(11):1378-1384. doi: 10.1089/thy.2017.0201
78. Lamartina L, **Durante C**, Lucisano G, Grani G, Bellantone RA, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Crocetti U, Montesano T, Giubbini R, Orlandi F, Aimaretti G, Monzani F, Attard M, Francese C, Antonelli A, Limone PP, Rossetto R, Fugazzola L, Meringolo D, Bruno R, Tumino S, Ceresini G, Centanni M, Monti S, Salvatore D, Mian C, Spiazzi G, Persani L, Barbaro D, Nicolucci A, Filetti S. Are evidence-based guidelines reflected in clinical practice? An analysis of prospectively collected data of the Italian Thyroid Cancer Observatory. *Thyroid*. 2017 Dec;27(12):1490-1497. doi: 10.1089/thy.2017.0299.
79. Celano M, Mignogna C, Rosignolo F, Sponziello M, Iannone M, Lepore SM, Lombardo GE, Maggisano V, Verrienti A, Bulotta S, **Durante C**, Di Loreto C, Damante G, Russo D. Expression of YAP1 in aggressive thyroid cancer. *Endocrine*. 2018 Jan;59(1):209-212. doi: 10.1007/s12020-017-1240-6.
80. Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, **Durante C**, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. *Endocrine*. 2018 Jan;59(1):90-101. doi: 10.1007/s12020-017-1455-6.
81. Grani G, Lamartina L, Cantisani V, Maranghi M, Lucia P, **Durante C**. Interobserver agreement of various thyroid imaging reporting and data systems. *Endocr Connect*. 2018 Jan;7(1):1-7. doi: 10.1530/EC-17-0336.
82. Lamartina L, Grani G, **Durante C**, Filetti S. Recent advances in managing differentiated thyroid cancer. *F1000Res*. 2018 Jan 18;7:86. doi: 10.12688/f1000research.12811.1.
83. Sponziello M, Benvenuti S, Gentile A, Pecce V, Rosignolo F, Virzi AR, Milan M, Comoglio PM, Londin E, Fortina P, Barnabei A, Appetecchia M, Marandino F, Russo D, Filetti S, **Durante C**, Verrienti A. Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer. *Hum Mutat*. 2018 Mar;39(3):371-377. doi: 10.1002/humu.23378.
84. Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M, Bellantone R, Pontecorvi A, Montesano T, Pagano L, Daniele L, Fugazzola L, Ceresini G, Bruno R, Rossetto R, Tumino S, Centanni M, Meringolo D, Castagna MG, Salvatore D, Nicolucci A, Lucisano G, Filetti S, **Durante C**. 8th edition of AJCC/TNM staging system of thyroid cancer: what to expect. *Endocr Relat Cancer*. 2018 Mar;25(3):L7-L11. doi: 10.1530/ERC-17-0453.
85. **Durante C**, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The Diagnosis and Management of Thyroid Nodules: A Review. *JAMA*. 2018 Mar 6;319(9):914-924. doi: 10.1001/jama.2018.0898.
86. Lombardo GE, Maggisano V, Celano M, Cosco D, Mignogna C, Baldan F, Lepore SM, Allegri L, Moretti S, **Durante C**, Damante G, Fresta M, Russo D, Bulotta S, Puxeddu E. Anti-hTERT siRNA-loaded nanoparticles block the growth of anaplastic thyroid cancer xenograft. *Mol Cancer Ther*. 2018 Jun;17(6):1187-1195. doi: 10.1158/1535-7163.MCT-17-0559.

87. Grani G, Lamartina L, **Durante C**, Filetti S, Cooper DS. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. *Lancet Diabetes Endocrinol*. 2018 Jun;6(6):500-514. doi:10.1016/S2213-8587(17)30325-X.
88. Falcone R, Ramundo V, Lamartina L, Ascoli V, Bosco D, Di Gioia C, Montesano T, Biffoni M, Bononi M, Giacomelli L, Minni A, Segni M, Maranghi M, Cantisani V, **Durante C**, Grani G. Sonographic Presentation of Metastases to the Thyroid Gland: A Case Series. *J Endocr Soc*. 2018 Jun 21;2(8):855-859. doi:10.1210/js.2018-00124.
89. Pacini F, Basolo F, Bellantone R, Boni G, Cannizzaro MA, De Palma M, **Durante C**, Elisei R, Fadda G, Frasoldati A, Fugazzola L, Guglielmi R, Lombardi CP, Miccoli P, Papini E, Pellegriti G, Pezzullo L, Pontecorvi A, Salvatori M, Seregini E, Vitti P. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. *J Endocrinol Invest*. 2018 Jul;41(7):849-876. doi: 10.1007/s40618-018-0884-2.
90. Celano M, Mio C, Sponziello M, Verrienti A, Bulotta S, **Durante C**, Damante G, Russo D. Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer. *Mol Cell Endocrinol*. 2018 Jul 5;469:38-47. doi: 10.1016/j.mce.2017.05.036.
91. Grani G, Lamartina L, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, **Durante C**. Sonographically Estimated Risks of Malignancy for Thyroid Nodules Computed with Five Standard Classification Systems: Changes over Time and Their Relation to Malignancy. *Thyroid*. 2018 Sep;28(9):1190-1197. doi: 10.1089/thy.2018.0178
92. Lamartina L, Grani G, **Durante C**, Borget I, Filetti S, Schlumberger M. Follow-up of differentiated thyroid cancer - what should (and what should not) be done. *Nat Rev Endocrinol*. 2018 Sep;14(9):538-551. doi: 10.1038/s41574-018-0068-3.
93. Pecce V, Sponziello M, Damante G, Rosignolo F, **Durante C**, Lamartina L, Grani G, Russo D, di Gioia CR, Filetti S, Verrienti A. A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency. *PLoS Genet*. 2018 Oct 15;14(10):e1007678. doi: 10.1371/journal.pgen.1007678.
94. Sponziello M, Silvestri G, Verrienti A, Perna A, Rosignolo F, Brunelli C, Pecce V, Rossi ED, Lombardi CP, **Durante C**, Filetti S, Fadda G. A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma. *Endocrine*. 2018 Nov;62(2):492-495. doi: 10.1007/s12020-018-1611-7.
95. Zatelli MC, Lamartina L, Meringolo D, Arvat E, Damiani L, Grani G, Nervo A, **Durante C**, Giacomelli L. Thyroid nodule recurrence following lobo-isthmectomy: incidence, patient's characteristics, and risk factors. *J Endocrinol Invest*. 2018 Dec;41(12):1469-1475. doi: 10.1007/s40618-018-0946-5.
96. Rago T, Cantisani V, Ianni F, Chiovato L, Garberoglio R, **Durante C**, Frasoldati A, Spiezia S, Farina R, Vallone G, Pontecorvi A, Vitti P. Thyroid ultrasonography reporting: consensus of Italian Thyroid Association (AIT), Italian Society of Endocrinology (SIE), Italian Society of Ultrasonography in Medicine and Biology (SIUMB) and Ultrasound Chapter of Italian Society of Medical Radiology (SIRM). *J Endocrinol Invest*. 2018 Dec;41(12):1435-1443. doi: 10.1007/s40618-018-0935-8.
97. Grani G, Lamartina L, Montesano T, Ronga G, Maggisano V, Falcone R, Ramundo V, Giacomelli L, **Durante C**, Russo D, Maranghi M. Lack of association between obesity and aggressiveness of differentiated thyroid cancer. *J Endocrinol Invest*. 2019 Jan;42(1):85-90. doi: 10.1007/s40618-018-0889-x.
98. Grani G, Lamartina L, Ascoli V, Bosco D, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, **Durante C**. Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS. *J Clin Endocrinol Metab*. 2019 Jan 1;104(1):95-102. doi: 10.1210/jc.2018-01674.
99. Lamartina L, Montesano T, Falcone R, Biffoni M, Grani G, Maranghi M, Ciotti L, Giacomelli L, Ramundo V, Lo Monaco C, Di Gioia Cira R, Lucia P, Ronga G, **Durante C**. IS IT WORTH

SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT? *Endocr Pract.* 2019 Feb;25(2):165-169. doi: 10.4158/EP-2018-0393.

100. Celano M, Maggisano V, Lepore SM, Sponziello M, Pecce V, Verrienti A, **Durante C**, Maranghi M, Lucia P, Bulotta S, Damante G, Russo D. Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells. *Int J Endocrinol.* 2019 Feb 14;2019:5031696. doi: 10.1155/2019/5031696
101. Falcone R, Conte F, Fiscon G, Pecce V, Sponziello M, **Durante C**, Farina L, Filetti S, Paci P, Verrienti A. BRAF(V600E)-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response. *Endocrine.* 2019 May;64(2):406-413. doi: 10.1007/s12020-019-01890-4.
102. Ramundo V, Lamartina L, Falcone R, Ciotti L, Lomonaco C, Biffoni M, Giacomelli L, Maranghi M, **Durante C**, Grani G. Is thyroid nodule location associated with malignancy risk? *Ultrasonography.* 2019 Jul;38(3):231-235. doi: 10.14366/usg.18050.
103. Cantisani V, David E, Grazhdani H, Rubini A, Radzina M, Dietrich CF, **Durante C**, Lamartina L, Grani G, Valeria A, Bosco D, Di Gioia C, Frattaroli FM, D'Andrea V, De Vito C, Fresilli D, D'Ambrosio F, Giacomelli L, Catalano C. Prospective Evaluation of Semiquantitative Strain Ratio and Quantitative 2D Ultrasound Shear Wave Elastography (SWE) in Association with TIRADS Classification for Thyroid Nodule Characterization. *Ultraschall Med.* 2019 Aug;40(4):495-503. doi: 10.1055/a-0853-1821.
104. Locati LD, Piovesan A, **Durante C**, Bregni M, Castagna MG, Zovato S, Giusti M, Ibrahim T, Puxeddu E, Fedele G, Pellegriti G, Rinaldi G, Giuffrida D, Verderame F, Bertolini F, Bergamini C, Nervo A, Grani G, Rizzati S, Morelli S, Puliafito I, Elisei R. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. *Eur J Cancer.* 2019 Sep;118:35-40. doi:10.1016/j.ejca.2019.05.031.
105. Rullo E, Minelli G, Bosco D, Nardi F, Grani G, **Durante C**, Ascoli V. Indeterminate thyroid nodules (TIR3A/TIR3B) according to the new Italian Reporting System for Thyroid Cytology: a cytomorphological study. *Cytopathology.* 2019 Sep;30(5):475-484. doi: 10.1111/cyt.12732.
106. Bongiovanni M, Faquin W, Giovanella L, **Durante C**, Kopp P, Trimboli P. Impact of non-invasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) on risk of malignancy in patients undergoing lobectomy/thyroidectomy for suspicious for malignancy or malignant fine-needle aspiration cytology findings: a systematic review and meta-analysis. *Eur J Endocrinol.* 2019 Oct;181(4):389-396. doi: 10.1530/EJE-19-0223.
107. Grani G, Ramundo V, Verrienti A, Sponziello M, **Durante C**. Thyroid hormone therapy in differentiated thyroid cancer. *Endocrine.* 2019 Oct;66(1):43-50. doi:10.1007/s12020-019-02051-3.
108. Appetecchia M, Lauretta R, Barnabei A, Pieruzzi L, Terrenato I, Cavedon E, Mian C, Castagna MG, Elisei R; SIE (Italian Society of Endocrinology) Working Group. Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study. *Cancers (Basel).* 2019 Oct 9;11(10). pii:E1516. doi: 10.3390/cancers11101516.
109. Grani G, Ramundo V, Falcone R, Lamartina L, Montesano T, Biffoni M, Giacomelli L, Sponziello M, Verrienti A, Schlumberger M, Filetti S, **Durante C**. Thyroid cancer patients with no evidence of disease: the need for repeat neck ultrasound. *J Clin Endocrinol Metab.* 2019 Nov 1;104(11):4981-4989. doi:10.1210/jc.2019-00962.
110. Trimboli P, Palermo A, Deandrea M, Piccardo A, Campenni A, Valabrega S, Grani G, Santolamazza G, Bottoni G, Barnabei A, Ramundo V, Lauretta R, Monte L, Ferrarazzo G, Paone G, Crosetto C, Ruggeri RM, Baldari S, Chieffari A, Vottari S, Giarnieri E, Perrella E, Limone P, **Durante C**, Giovanella L, Appetecchia M, Crescenzi A. Prognosis of patients with differentiated thyroid carcinomas having a preoperative cytological report of indeterminate at low or high risk. A multicenter study. *Endocrine.* 2019 Dec;66(3):557-562. doi: 10.1007/s12020-019-

111. Grani G, Tumino D, Ramundo V, Ciotti L, Lomonaco C, Armillotta M, Falcone R, Lucia P, Maranghi M, Filetti S, **Durante C**. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments. *J Endocrinol Invest*. 2019 Dec;42(12):1485-1490. doi: 10.1007/s40618-019-01074-x.
112. McLeod DSA, Zhang L, **Durante C**, Cooper DS. Contemporary debates in adult papillary thyroid cancer management. *Endocr Rev*. 2019 Dec 1;40(6):1481-1499. doi:10.1210/er.2019-00085.
113. Filetti S, **Durante C**, Hartl D, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A; ESMO Guidelines Committee. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019 Dec 1;30(12):1856-1883. doi: 10.1093/annonc/mdz400.
114. Mio C, Grani G, **Durante C**, Damante G. Molecular defects in thyroid dysgenesis. *Clin Genet*. 2020 Jan;97(1):222-231. doi: 10.1111/cge.13627.
115. Lamartina L, Grani G, **Durante C**, Filetti S, Cooper DS. Screening for differentiated thyroid cancer in selected populations. *Lancet Diabetes Endocrinol*. 2020 Jan;8(1):81-88. doi: 10.1016/S2213-8587(19)30324-9.
116. Tallini G, De Leo A, Repaci A, de Biase D, Bacchi Reggiani ML, Di Nanni D, Ambrosi F, Di Gioia C, Grani G, Rhoden KJ, Solaroli E, Monari F, Filetti S, **Durante C**. Does the Site of Origin of the Microcarcinoma with Respect to the Thyroid Surface Matter? A Multicenter Pathologic and Clinical Study for Risk Stratification. *Cancers (Basel)*. 2020 Jan 19;12(1):246. doi: 10.3390/cancers12010246.
117. Grani G, Lamartina L, Ramundo V, Falcone R, Lomonaco C, Ciotti L, Barone M, Maranghi M, Cantisani V, Filetti S, **Durante C**. Taller-Than-Wide Shape: A New Definition Improves the Specificity of TIRADS Systems. *Eur Thyroid J*. 2020 Feb;9(2):85-91. doi: 10.1159/000504219.
118. **Durante C**, Grani G. Clinically silent thyroid cancers: drop those needles and scalpels! *J Clin Endocrinol Metab*. 2020 Mar 1;105(3):dgz129. doi: 10.1210/clinem/dgz129.
119. Castellana M, Piccardo A, Virili C, Scappaticcio L, Grani G, **Durante C**, Giovannella L, Trimboli P. Can ultrasound systems for risk stratification of thyroid nodules identify follicular carcinoma? *Cancer Cytopathol*. 2020 Apr;128(4):250-259. doi: 10.1002/cncy.22235.
120. Falcone R, Sponziello M, Carletti R, Di Gioia C, Nardi F, Mio C, Pecce V, Abballe L, Grani G, Ramundo V, Damante G, **Durante C**, Filetti M, Roberto M, Marchetti P, Verrienti A. Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma. *Endocrine*. 2020 Apr;68(1):230-232. doi: 10.1007/s12020-020-02221-8.
121. Verrienti A, Sponziello M, **Durante C**, Filetti S, Grani G. Comment on: BRAF mutation analysis by ARMS-PCR refines thyroid nodule management. *Clin Endocrinol (Oxf)*. 2020 May;92(5):482-483. doi: 10.1111/cen.14103.
122. Ramundo V, Sponziello M, Falcone R, Verrienti A, Filetti S, **Durante C**, Grani G. Low-risk papillary thyroid microcarcinoma: Optimal management toward a more conservative approach. *J Surg Oncol*. 2020 May;121(6):958-963. doi: 10.1002/jso.25848
123. Sponziello M, Brunelli C, Verrienti A, Grani G, Pecce V, Abballe L, Ramundo V, Damante G, Russo D, Lombardi CP, **Durante C**, Rossi ED, Straccia P, Fadda G, Filetti S. Performance of a dual-component molecular assay in cytologically indeterminate thyroid nodules. *Endocrine*. 2020 May;68(2):458-465. doi: 10.1007/s12020-020-02271-y.
124. Barone M, Grani G, Ramundo V, Garritano T, **Durante C**, Falcone R. Fournier's gangrene during lenvatinib treatment: A case report. *Mol Clin Oncol*. 2020 Jun;12(6):588-591. doi: 10.3892/mco.2020.2031
125. Falcone R, Grani G, Ramundo V, Melcarne R, Giacomelli L, Filetti S, **Durante C**. Cancer Care

During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies. *Front Oncol*. 2020 Jun 23;10:1128. doi: 10.3389/fonc.2020.01128.

126. Trimboli P, **Durante C**. Ultrasound risk stratification systems for thyroid nodule: between lights and shadows, we are moving towards a new era. *Endocrine*. 2020 Jul;69(1):1-4. doi: 10.1007/s12020-020-02196-6
127. Pecce V, Verrienti A, Abballe L, Carletti R, Grani G, Falcone R, Ramundo V, **Durante C**, Di Gioia C, Russo D, Filetti S, Sponziello M. Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hürthle Cell Carcinomas of the Thyroid. *Cancers (Basel)*. 2020 Jul 14;12(7):E1892. doi: 10.3390/cancers12071892.
128. Ramundo V, Di Gioia CRT, Falcone R, Lamartina L, Biffoni M, Giacomelli L, Filetti S, **Durante C**, Grani G. Diagnostic Performance of Neck Ultrasonography in the Preoperative Evaluation for Extrathyroidal Extension of Suspicious Thyroid Nodules. *World J Surg*. 2020 Aug;44(8):2669-2674. doi: 10.1007/s00268-020-05482-6.
129. Grani G, Brenta G, Trimboli P, Falcone R, Ramundo V, Maranghi M, Lucia P, Filetti S, **Durante C**. Sonographic Risk Stratification Systems for Thyroid Nodules as Rule-Out Tests in Older Adults. *Cancers (Basel)*. 2020 Aug 30;12(9):2458. doi: 10.3390/cancers12092458
130. Grani G, Sponziello M, Pecce V, Ramundo V, **Durante C**. Contemporary thyroid nodule evaluation and management. *J Clin Endocrinol Metab*. 2020 Sep 1;105(9):dgaa322. doi: 10.1210/clinem/dgaa322.
131. Castellana M, Grani G, Radzina M, Guerra V, Giovannella L, Deandrea M, Ngu R, **Durante C**, Trimboli P. Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules: a meta-analysis. *Eur J Endocrinol*. 2020 Sep;183(3):255-264. doi: 10.1530/EJE-20-0204.
132. Sodo A, Verri M, Palermo A, Naciu AM, Sponziello M, **Durante C**, Di Gioacchino M, Paolucci A, di Masi A, Longo F, Crucitti P, Taffon C, Ricci, MA, Crescenzi A. Raman Spectroscopy Discloses Altered Molecular Profile in Thyroid Adenomas. *Diagnostics*. 2020 Dec 29;11(1):43. <https://doi.org/10.3390/diagnostics11010043>
133. Grani G, Zatelli MC, Alfò M, Montesano T, Torlontano M, Morelli S, Deandrea M, Antonelli A, Francese C, Ceresini G, Orlandi F, Maniglia CA, Bruno R, Monti S, Santaguida MG, Repaci A, Tallini G, Fugazzola L, Monzani F, Giubbini R, Rossetto R, Mian C, Crescenzi A, Tumino D, Pagano L, Pezzullo L, Lombardi CP, Arvat E, Petrone L, Castagna MG, Spiazzi G, Salvatore D, Meringolo D, Solaroli E, Monari F, Magri F, Triggiani V, Castello R, Piazza C, Rossi R, Ferraro Petrillo U, Filetti S, **Durante C**. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients. *Thyroid*. 2021 Feb;31(2):264-271. doi: 10.1089/thy.2020.0272.
134. Giani C, Valerio L, Bongiovanni A, **Durante C**, Grani G, Ibrahim T, Mariotti S, Massa M, Pani F, Pellegriti G, Porcelli T, Salvatore D, Tavarelli M, Torlontano M, Locati L, Molinaro E, Elisei R. Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer. *Thyroid*. 2021 Feb;31(2):224-232. doi: 10.1089/thy.2020.0276.
135. Grani G, Lamartina L, Alfò M, Ramundo V, Falcone R, Giacomelli L, Biffoni M, Filetti S, **Durante C**. Selective use of radioactive iodine therapy for papillary thyroid cancers with low or lower-intermediate recurrence risk. *J Clin Endocrinol Metab*. 2021 Mar 25;106(4):e1717-e1727. doi: 10.1210/clinem/dgaa973.
136. Grani G, Sponziello M, Filetti S, **Durante C**. Molecular analysis of fine-needle aspiration cytology in thyroid disease: where are we? *Curr Opin Otolaryngol Head Neck Surg*. 2021 Apr 1;29(2):107-112. doi: 10.1097/MOO.0000000000000698.
137. Trimboli P, Castellana M, Piccardo A, Romanelli F, Grani G, Giovannella L, **Durante C**. The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis. *Rev Endocr Metab Disord*. 2021 Jun;22(2):453-460. doi: 10.1007/s11154-020-09592-3.

138. Pecce V, Verrienti A, Fiscon G, Sponziello M, Conte F, Abballe L, **Durante C**, Farina L, Filetti S, Paci P. The role of FOSL1 in stem-like cell reprogramming processes. *Sci Rep*. 2021 Jul 19;11(1):14677. doi: 10.1038/s41598-021-94072-0.
139. Fresilli D, David E, Pacini P, Del Gaudio G, Dolcetti V, Lucarelli GT, Di Leo N, Bellini MI, D'Andrea V, Sorrenti S, Mascagni D, Biffoni M, **Durante C**, Grani G, De Vincentis G, Cantisani V. Thyroid Nodule Characterization: How to Assess the Malignancy Risk. Update of the Literature. *Diagnostics (Basel)*. 2021 Jul 30;11(8):1374. doi: 10.3390/diagnostics11081374.
140. Celletti I, Fresilli D, De Vito C, Bononi M, Cardaccio S, Cozzolino A, **Durante C**, Grani G, Grimaldi G, Isidori AM, Catalano C, Cantisani V. TIRADS, SRE and SWE in INDETERMINATE thyroid nodule characterization: Which has better diagnostic performance? *Radiol Med*. 2021 Sep;126(9):1189-1200. doi: 10.1007/s11547-021-01349-5
141. Sibilio P, Bini S, Fiscon G, Sponziello M, Conte F, Pecce V, **Durante C**, Paci P, Falcone R, Norata GD, Farina L, Verrienti A. In silico drug repurposing in COVID-19: A network-based analysis. *Biomed Pharmacother*. 2021 Oct;142:111954. doi: 10.1016/j.biopha.2021.111954.
142. Grani G, Cera G, Conzo G, Del Gatto V, di Gioia CRT, Maranghi M, Lucia P, Cantisani V, Metere A, Melcarne R, Borcea MC, Scorziello C, Menditto R, Summa M, Biffoni M, **Durante C**, Giacomelli L. Preoperative Ultrasonography in the Evaluation of Suspected Familial Non-Medullary Thyroid Cancer: Are We Able to Predict Multifocality and Extrathyroidal Extension? *J Clin Med*. 2021 Nov 13;10(22):5277. doi: 10.3390/jcm10225277.
143. Forleo R, Grani G, Alfò M, Zilioli V, Giubbini R, Zatelli MC, Gagliardi I, Piovesan A, Ragni A, Morelli S, Puxeddu E, Pagano L, Deandrea M, Ceresini G, Torlontano M, Puligheddu B, Antonelli A, Centanni M, Fugazzola L, Spiazzi G, Monti S, Rossetto R, Monzani F, Tallini G, Crescenzi A, Sparano C, Bruno R, Repaci A, Tumino D, Pezzullo L, Lombardi CP, Ferraro Petrillo U, Filetti S, **Durante C**, Castagna MG. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). *Thyroid*. 2021 Dec;31(12):1814-1821. doi: 10.1089/thy.2021.0248.
144. **Durante C**, Pecce V, Grani G. Management of cytologically indeterminate thyroid nodules: primum non nocere. *Pol Arch Intern Med*. 2021 Dec 22;131(12):16166. doi: 10.20452/pamw.16166.
145. Capriglione F, Verrienti A, Celano M, Maggisano V, Sponziello M, Pecce V, Gagliardi A, Giacomelli L, Aceti V, **Durante C**, Bulotta S, Russo D. Analysis of serum microRNA in exosomal vehicles of papillary thyroid cancer. *Endocrine*. 2022 Jan;75(1):185-193. doi: 10.1007/s12020-021-02847-2.
146. Prieditis P, Radzina M, Mikijanska M, Liepa M, Stepanovs K, Grani G, **Durante C**, Lamartina L, Trimboli P, Cantisani V. Non-Marked Hypoechoic Nodules: Multicenter Study on the Thyroid Malignancy Risk Stratification and Accuracy Based on TIRADS Systems Comparison. *Medicina (Kaunas)*. 2022 Feb 9;58(2):257. doi: 10.3390/medicina58020257.
147. Cantisani V, De Silvestri A, Scotti V, Fresilli D, Tarsitano MG, Polti G, Guiban O, Polito E, Pacini P, **Durante C**, Grani G, Isidori AM, Giannetta E, Sorrenti S, Trimboli P, Catalano C, Cirocchi R, Lauro A, D'Andrea V. US-Elastography With Different Techniques for Thyroid Nodule Characterization: Systematic Review and Meta-analysis. *Front Oncol*. 2022 Mar 16;12:845549. doi: 10.3389/fonc.2022.845549.
148. Maggisano V, Capriglione F, Verrienti A, Celano M, Gagliardi A, Bulotta S, Sponziello M, Mio C, Pecce V, **Durante C**, Damante G, Russo D. Identification of Exosomal microRNAs and Their Targets in Papillary Thyroid Cancer Cells. *Biomedicines*. 2022 Apr 21;10(5):961. doi: 10.3390/biomedicines10050961.
149. Pagano L, **Durante C**, Tufano RP. Editorial: Radiofrequency Ablation as an Alternative to Conventional Treatment. *Front Endocrinol (Lausanne)*. 2022 Apr 27;13:883809. doi: 10.3389/fendo.2022.883809
150. Hoang JK, Asadollahi S, **Durante C**, Hegedüs L, Papini E, Tessler FN. An International Survey

on Utilization of Five Thyroid Nodule Risk Stratification Systems: A Needs Assessment with Future Implications. *Thyroid*. 2022 Jun;32(6):675-681. doi: 10.1089/thy.2021.0558.

151. Cozzolino A, Filardi T, Simonelli I, Grani G, Virili C, Stramazzo I, Santaguida MG, Locantore P, Maurici M, Gianfrilli D, Isidori AM, **Durante C**, Pozza C. Diagnostic accuracy of ultrasonographic features in detecting thyroid cancer in the transition age: a meta-analysis. *Eur Thyroid J*. 2022 Jun 14;11(3):e220039. doi: 10.1530/ETJ-22-0039
152. Pecce V, Sponziello M, Bini S, Grani G, **Durante C**, Verrienti A. Establishment and maintenance of thyroid organoids from human cancer cells. *STAR Protoc*. 2022 May 15;3(2):101393. doi: 10.1016/j.xpro.2022.101393
153. Filetti S, **Durante C**, Hartl DM, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. *Ann Oncol*. 2022 Jul;33(7):674-684. doi: 10.1016/j.annonc.2022.04.009
154. Wirth LJ, **Durante C**, Topliss DJ, Winkquist E, Robenshtok E, Iwasaki H, Luster M, Elisei R, Leboulleux S, Tahara M. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. *Oncologist*. 2022 Jul 5;27(7):565-572. doi: 10.1093/oncolo/oyac065.
155. Sorrenti S, Dolcetti V, Radzina M, Bellini MI, Frezza F, Munir K, Grani G, **Durante C**, D'Andrea V, David E, Calò PG, Lori E, Cantisani V. Artificial Intelligence for Thyroid Nodule Characterization: Where Are We Standing? *Cancers (Basel)*. 2022 Jul 10;14(14):3357. doi: 10.3390/cancers14143357
156. Verrienti A, Grani G, Sponziello M, Pecce V, Damante G, **Durante C**, Russo D, Filetti S. Precision oncology for RET-related tumors. *Front Oncol*. 2022 Aug 24;12:992636. doi: 10.3389/fonc.2022.992636
157. Grani G, Filetti S, **Durante C**. New hope for patients with BRAF V600E-mutant anaplastic thyroid cancer: lights and shadows. *Ann Palliat Med*. 2022 Aug;11(8):2796-2801. doi: 10.21037/apm-22-603.
158. Trimboli P, Ferrarazzo G, Piccardo A, Lucchini B, **Durante C**. Operation rate and cancer prevalence among thyroid nodules with FNAC report of suspicious for malignancy (TIR4) or malignant (TIR5) according to Italian classification system: a systematic review and meta-analysis. *Endocrine*. 2022 Oct;78(1):24-31. doi: 10.1007/s12020-022-03165-x.
159. Grani G, Ciotti L, Del Gatto V, Montesano T, Biffoni M, Giacomelli L, Sponziello M, Pecce V, Lucia P, Verrienti A, Filetti S, **Durante C**. The COVID-19 outbreak and de-escalation of thyroid cancer diagnosis and treatment. *Endocrine*. 2022 Nov;78(2):387-391. doi: 10.1007/s12020-022-03131-7
160. Grani G, Lamartina L, Montesano T, Giacomelli L, Biffoni M, Trulli F, Filetti S, **Durante C**. Prevalence of Thyroid Nodules and Thyroid Cancer in Individuals with a First-Degree Family History of Non-Medullary Thyroid Cancer: A Cross-Sectional Study Based on Sonographic Screening. *Thyroid*. 2022 Nov;32(11):1392-1401. doi: 10.1089/thy.2022.0253.
161. Grani G, Ciotti L, Del Gatto V, Montesano T, Biffoni M, Giacomelli L, Sponziello M, Pecce V, Verrienti A, Filetti S, **Durante C**. The legacy of the COVID-19 pandemics for thyroid cancer patients: towards the application of clinical practice recommendations. *Endocrine*. 2023 Jan;79(1):45-48. doi: 10.1007/s12020-022-03132-6.
162. Koot A, Soares P, Robenshtok E, Locati LD, de la Fouchardiere C, Luster M, Bongiovanni M, Hermens R, Ottevanger P, Geenen F, Bartès B, Rimmel H, **Durante C**, Nieveen-van Dijkum E, Stalmeier P, Dedecjus M, Netea-Maier R. Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma. *Eur J Cancer*. 2023 Jan;179:98-112. doi: 10.1016/j.ejca.2022.11.005.

163. Capezzone M, Tosti Balducci M, Morabito EM, **Durante C**, Piacentini P, Torregrossa L, Materazzi G, Giubolini G, Mancini V, Rossi M, Alessandri M, Cartocci A. High Incidence of Thyroid Cancer in Southern Tuscany (Grosseto Province, Italy): Potential Role of Environmental Heavy Metal Pollution. *Biomedicines*. 2023 Jan 20;11(2):298. doi: 10.3390/biomedicines11020298.
164. Maggisano V, Capriglione F, Verrienti A, Celano M, Sponziello M, Pecce V, Russo D, **Durante C**, Bulotta S. Expression of miR-31-5p affects growth, migration and invasiveness of papillary thyroid cancer cells. *Endocrine*. 2023 Mar;79(3):517-526. doi: 10.1007/s12020-022-03267-6.
165. Chou R, Dana T, Mayson SE, Cibas ES, **Durante C**, Solórzano CC, Mandel SJ, Orloff LA. Ultrasound Follow-Up of Benign Thyroid Nodules: A Scoping Review. *Thyroid*. 2023 Apr;33(4):420-427. doi: 10.1089/thy.2022.0692.
166. Scorziello C, **Durante C**, Biffoni M, Borcea MC, Consorti F, Laca A, Melcarne R, Ventrone L, Giacomelli L. The Size of a Thyroid Nodule with ACR TI-RADS Does Not Provide a Better Prediction of the Nature of the Nodule: A Single-Center Retrospective Real-Life Observational Study. *Healthcare (Basel)*. 2023 Jun 7;11(12):1673. doi: 10.3390/healthcare11121673
167. Grani G, Gentili M, Siciliano F, Albano D, Zilioli V, Morelli S, Puxeddu E, Zatelli MC, Gagliardi I, Piovesan A, Nervo A, Crocetti U, Massa M, Samà MT, Mele C, Deandrea M, Fugazzola L, Puligheddu B, Antonelli A, Rossetto R, D'Amore A, Ceresini G, Castello R, Solaroli E, Centanni M, Monti S, Magri F, Bruno R, Sparano C, Pezzullo L, Crescenzi A, Mian C, Tumino D, Repaci A, Castagna MG, Triggiani V, Porcelli T, Meringolo D, Locati L, Spiazzi G, Di Dalmazi G, Anagnostopoulos A, Leonardi S, Filetti S, **Durante C**. A data-driven approach to refine predictions of differentiated thyroid cancer outcomes: a prospective multicenter study. *J Clin Endocrinol Metab*. 2023 Jul 14;108(8):1921-1928. doi: 10.1210/clinem/dgad075.
168. Scorziello C, Borcea MC, Biffoni M, Pernazza A, Arienzo F, Melcarne R, Ventrone L, Laca A, Grani G, **Durante C**, Consorti F, Giacomelli L. Laterocervical lymph node metastases from suspected thyroidal primary site that turned out to be metastases of lung cancer: A case report. *Clin Case Rep*. 2023 Jul 21;11(7):e7417. doi: 10.1002/ccr3.7417.
169. Grani G, Del Gatto V, Cantisani V, Mandel SJ, **Durante C**. A reappraisal of suspicious sonographic features of thyroid nodules: shape is not an independent predictor of malignancy. *J Clin Endocrinol Metab*. 2023 Aug 18;108(9):e816-e822. doi: 10.1210/clinem/dgad092.
170. Trocchianesi S, Po A, Citarella A, Spinello Z, Rugghetti A, Besharat ZM, Autilio TM, Pecce V, Verrienti A, Elisei R, **Durante C**, Catanzaro G, Ferretti E. Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH- Gli signaling pathway in acquired resistance. *Biomed Pharmacother*. 2023 Aug;164:114995. doi: 10.1016/j.biopha.2023.114995
171. **Durante C**, Hegedüs L, Czarniecka A, Paschke R, Russ G, Schmitt F, Soares P, Solymosi T, Papini E. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. *Eur Thyroid J*. 2023 Aug 14;12(5):e230067. doi: 10.1530/ETJ-23-0067. PMID: 37358008; PMCID: PMC10448590.
172. Capdevila J, Deandrea D, **Durante C**, Lebouleux S, Luster M, Netea-Maier R, Newbold K, Singer S, Sykiotis GP, Bartes B, Farnell K, Locati LD. Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice. *Eur Thyroid J*. 2023 Aug 8;12(5):e230068. doi: 10.1530/ETJ-23-0068.
173. Citarella A, Besharat ZM, Trocchianesi S, Autilio TM, Verrienti A, Catanzaro G, Splendiani E, Spinello Z, Cantara S, Zavattari P, Loi E, Romei C, Ciampi R, Pezzullo L, Castagna MG, Angeloni A, Elisei R, **Durante C**, Po A, Ferretti E. Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value. *Biomark Res*. 2023 Sep 19;11(1):82. doi: 10.1186/s40364-023-00522-4.
174. Pecce V, Sponziello M, Verrienti A, Grani G, Abballe L, Bini S, Annunziata S, Perotti G, Salvatori M, Zagaria L, Maggisano V, Russo D, Filetti S, **Durante C**. The role of miR-139-5p in radioiodine-

resistant thyroid cancer. *J Endocrinol Invest*. 2023 Oct;46(10):2079-2093. doi: 10.1007/s40618-023-02059-7.

175. Durante C, Hegedüs L, Na DG, Papini E, Sipos JA, Baek JH, Frasoldati A, Grani G, Grant E, Horvath E, Hoang JK, Mandel SJ, Middleton WD, Ngu R, Orloff LA, Shin JH, Trimboli P, Yoon JH, Tessler FN. International Expert Consensus on US Lexicon for Thyroid Nodules. *Radiology*. 2023 Oct;309(1):e231481. doi: 10.1148/radiol.231481.
176. Pita JM, Raspé E, Coulonval K, Decaussin-Petrucci M, Tarabichi M, Dom G, Libert F, Craciun L, Andry G, Wicquart L, Leteurtre E, Trésallet C, Marlow LA, Copland JA, Durante C, Maenhaut C, Cavaco BM, Dumont JE, Costante G, Roger PP. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas. *Front Endocrinol (Lausanne)*. 2023 Oct 26;14:1247542. doi: 10.3389/fendo.2023.1247542.
177. Grani G, Lamartina L, Montesano T, Maranghi M, Filetti S, Durante C, Lopatriello S. Ultrasound screening for thyroid nodules and cancer in individuals with family history of thyroid cancer: a micro-costing approach. *J Endocrinol Invest*. 2023 Nov;46(11):2327-2330. doi: 10.1007/s40618-023-02087-3.
178. De Leo S, D'Elia S, Grani G, Dondi F, Bertagna F, Puxeddu E, Morelli S, Piovesan A, Nervo A, Zatelli MC, Gagliardi I, Samà MT, Aimaretti G, Crocetti U, Massa M, Deandrea M, Retta F, Pagano L, Rossi M, Solaroli E, Pezzullo L, Chiofalo MG, Pontecorvi A, Lombardi CP, Antonelli A, Patrizio A, Messuti I, Magri F, Spiazzi G, Ceresini G, Bruno R, Sparano C, Centanni M, Crescenzi A, Tallini G, Marotta V, Madeo B, Mian C, Filetti S, Durante C, Fugazzola L. A Prospective Multicenter Study Examining the Relationship Between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis. *Thyroid*. 2023 Nov;33(11):1318-1326. doi: 10.1089/thy.2023.0052.
179. Besharat ZM, Trocchianesi S, Verrienti A, Ciampi R, Cantara S, Romei C, Sabato C, Noviello TMR, Po A, Citarella A, Caruso FP, Panariello I, Gianni F, Carpino G, Gaudio E, Chiacchiarini M, Masuelli L, Sponziello M, Pecce V, Ramone T, Maino F, Dotta F, Ceccarelli M, Pezzullo L, Durante C, Castagna MG, Elisei R, Ferretti E. Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients. *J Endocrinol Invest*. 2023 Dec;46(12):2583-2599. doi: 10.1007/s40618-023-02115-2.

Articoli in extenso (nazionali, su banche dati nazionali o internazionali)

1. Filetti S, Durante C, Maranghi M. A genetic based disease management in inherited cancer syndromes: the multiple endocrine neoplasia model. *Supportive & Palliative Cancer Care*. 2006 Jan; 2 (suppl. 2): 13-16.
2. Durante C, Romagnoli E, Maranghi M, D'Aloiso L, Minisola S, D'Erasmo E, Filetti S. Hyperparathyroidism in multiple endocrine neoplasia type IIA. *Clinical Cases in Mineral and Bone Metabolism*. 2006 May- Aug; 3 (2): 162-6. [Indexed in Scopus]
3. Maranghi M, Coletta P, Durante C, Pergolini D, Filetti S. Cardiovascular disease and metabolic syndrome. *Recenti Prog Med*. 2006;97(12):719-26. [Indexed in PubMed, ISI Web of Science, Scopus]
4. Durante C, Cava F, Paciaroni A, Filetti S. Benign thyroid nodules: diagnostic and therapeutic approach. *Recenti Prog Med*. 2008;99(5):263-70. [Indexed in PubMed, ISI Web of Science, Scopus]

Editore di libri

1. David S Cooper, Durante C. Thyroid Cancer: A Case-Based Approach. Springer: ISBN: 978-3-319-22400-8 (Print) 978-3-319-22401-5 (Online)
2. Grani G, David S Cooper, Durante C. Thyroid Cancer: A Case-Based Approach. Second Edition. Springer: ISBN: 978-3-030-61918-3 (Print) 978-3-030-61919-0 (Online)

Autorizzo il trattamento dei miei dati personali presenti nel curriculum vitae ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 e del GDPR (Regolamento UE 2016/679).

Firma	
Data	06/01/2024



Curriculum Vitae Europass

Informazioni personali

Nome(i) / Cognome(i) **Paolo Graziano**
Indirizzo(i) Via dell'Imbrecciato 95, 00149 Roma
Telefono(i) cell 338 75 90078
CF GRZPLA67C24H501C
E-mail paologratz@gmail.com
Cittadinanza Italiana
Data di nascita 24/03/1967
Sesso M

Esperienza professionale

Date 1/03/2024 ad oggi
Lavoro o posizione ricoperti Professore di ruolo di I fascia presso il Dipartimento di Scienze Radiologiche, Oncologiche ed Anatomico-Patologiche, Facoltà di Medicina ed Odontoiatria, Sapienza Università di Roma

Nome e indirizzo del datore di lavoro Sapienza, Università di Roma

Date 1/10/2013-29/02/2024
Lavoro o posizione ricoperti Direttore U.O.C. Anatomia Patologica

Principali attività e responsabilità 1/1/2020 -31/12/2023
Direttore Dipartimento dei Servizi di diagnosi e cura e Medicina Trasfusionale

12/7/2023 ad oggi
Coordinatore Molecular Tumot Board

1/04/2018 31/12/2019
Direttore Dipartimento Oncologia ed Ematologia

Nome e indirizzo del datore di lavoro IRCCS "Casa Sollievo della Sofferenza" - San Giovanni Rotondo (FG)
Tipo di attività o settore Sanità

Date 1-06-2022

Lavoro e posizione ricoperti Abilitazione Professore I Fascia Anatomia Patologica
Tipo di attività o settore Università

Date 12-04 2017
Lavoro o posizione ricoperti Abilitazione Professore II Fascia Anatomia Patologica
Tipo di attività o settore Università

Principali attività e responsabilità	2020 ad oggi Coordinatore Pre-Clinico Working Group Lung, Alleanza Contro il Cancro (ACC), Ministero Italiano della Salute
	2015-2018 Coordinatore Lung Unit, IRCCS 'Casa Sollievo della Sofferenza', San Giovanni Rotondo (FG), Provvedimento N.33 del 13 Aprile 2016
Date	2024
Principali attività e responsabilità	Docenza
Nome ed indirizzo del datore di lavoro	Anatomia Patologica, Corso di Laurea Magistrale in Medicina e Chirurgia "D" Facoltà di Medicina e Odontoiatria
Tipo di attività o settore	Sapienza Università di Roma
Date	2000 a 2013
Principali attività e responsabilità	Docenza
Nome ed indirizzo del datore di lavoro	Scuola di Specializzazione in Malattie dell'Apparato Respiratorio - Facoltà di Medicina e Chirurgia Università degli Studi "La Sapienza" di Roma
Tipo di attività o settore	Sapienza Università di Roma
Date	1999-2013
Lavoro o posizione ricoperti	Dirigente Medico
Principali attività e responsabilità	Responsabile del controllo di qualità della patologia toraco- polmonare dell'UOC di Anatomia Patologica
Nome ed indirizzo del datore di lavoro	Azienda Ospedaliera S Camillo Forlanini, Roma
Tipo di attività o settore	Sanità
Date	04/06/2008
Lavoro o posizione ricoperti	Fellow presso Department of Pathology, Mayo Clinic, Scottsdale, AZ, USA
Principali attività e responsabilità	Ricerca
Nome ed indirizzo del datore di lavoro	Department of Pathology, Mayo Clinic, Scottsdale, AZ, USA
Tipo di attività o settore	Sanità
Date	04/2007
Lavoro o posizione ricoperti	Workshop coordinator of "International workshop on interstitial lung diseases. A practical, patient-oriented, multidisciplinary course. Rome, Italy
Date	09/2002
Lavoro o posizione ricoperti	Fellow presso Department of Histopathology (Dr. AG. Nicholson), Royal Brompton Hospital, London, UK.
Principali attività e responsabilità	Ricerca
Nome ed indirizzo del datore di lavoro	Royal Brompton Hospital, London, UK.
Tipo di attività o settore	Sanità
Date	15/6/1997-31/3/1999
Lavoro o posizione ricoperti	Collaboratore di ricerca per lo studio e la cura dei tumori
Principali attività e responsabilità	Ricerca

Nome e indirizzo del datore di lavoro	Istituto Nazionale Tumori, Regina Elena, Roma
Tipo di attività o settore	Sanità

Istruzione e formazione

Date	06/12/1996
Titolo della qualifica rilasciata	Specializzazione in Anatomia Patologica
Principali tematiche/competenze professionali possedute	Discutendo una tesi sperimentale su "Angiogenesi nel carcinoma colorettale. Analisi morfometrica e correlazioni clinico patologiche". Relatori proff. V. Marinozzi e S. Stipa.
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Roma "La Sapienza"
Livello nella classificazione nazionale o internazionale	70/70 e lode

Date	11/1992
Titolo della qualifica rilasciata	Abilitazione all'esercizio professionale di Medico Chirurgo
Principali tematiche/competenze professionali possedute	
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Roma "La Sapienza".

Date	22/07/1992
Titolo della qualifica rilasciata	Laurea in Medicina e Chirurgia.
Principali tematiche/competenze professionali possedute	Discutendo una tesi sperimentale su "Epidemiologia ed Istologia dei tumori nei trapiantati". Relatore prof. U. Di Tondo
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Roma "La Sapienza"
Livello nella classificazione nazionale o internazionale	110/ 110 e lode

Capacità e competenze personali

Madrelingua(e)	Italiano				
Altra(e) lingua(e)	Inglese				
Autovalutazione	Comprensione		Parlato		Scritto
<i>Livello europeo (*)</i>	Ascolto	Lettura	Interazione orale	Produzione orale	
LINGUA	Ottima	Ottima	Ottima	Ottima	Ottimo
LINGUA					

(*) [Quadro comune europeo di riferimento per le lingue](http://europass.cedefop.europa.eu)

- **Società Scientifiche**

Membro Ordinario SIAPEC-IAP

(Società Italiana di Anatomia Patologica e Citodiagnostica - International Academy of Pathology).

Componente del Gruppo Italiano di Patologia Pleuro – Polmonare (SIAPEC – IAP).

Componente del Gruppo Italiano Digipath (SIAPEC – IAP).

Consigliere GOIM (Gruppo Oncologico Italia Meridionale)

Componente del Molecular Tumor Board, Regione Puglia

Membro dell'Editorial Board delle seguenti riviste scientifiche internazionali: Histopathology, Cancers, Frontiers in Oncology, Precision Cancer Medicine, Journal of Clinical and Medical Images, CaseReports.

Membro del Reviewing Panel delle seguenti riviste scientifiche internazionali: Lung Cancer, Frontiers in Medicine, Cancers, Frontiers in Molecular Biosciences, Precision Cancer Medicine, Pathologica, Respiration, Sarcoidosis, Vasculitis and Diffuse Lung Diseases, Frontiers Oncology, International Journal of Molecular Sciences.

Interessi di diagnostica e ricerca

Gli ambiti diagnostici istopatologici di maggior interesse del Dott. Graziano riguardano la diagnostica oncologica ed in particolare la patologia toraco-polmonare, con particolare attenzione ai tumori ed alle malattie interstiziali polmonari.

Nell'ambito delle attività diagnostiche ritiene di fondamentale importanza l'attuazione di procedure uniformi e di percorsi diagnostici all'interno della U.O. di Anatomia Patologica, l'attività multidisciplinare con la programmazione di incontri periodici per la discussione di casi clinici sia all'interno della U. O. di Anatomia Patologica sia con i professionisti coinvolti nel processo diagnostico/terapeutico ed integrati nei Gruppi Multidisciplinari come quello della Lung Unit di cui è stato nominato Coordinatore nel periodo 2015-2018 presso l'IRCCS 'Casa Sollievo della Sofferenza'.

Il Dott. Graziano è inoltre coinvolto nello studio delle alterazioni molecolari nell'ambito della patologia neoplastica toraco polmonare, gastro-entero-pancreatica, mammaria, del distretto testa-collo e dell'apparato uroginecologico in particolare attraverso indagini di immunoistochimica, di ibridazione in situ fluorescente (FISH) e di biologia molecolare.

Il percorso formativo ed in particolare l'approfondimento nel campo della patologia toraco-polmonare, si è sviluppato mediante:

- fellowship (Novembre-Dicembre 2002) presso Department of Histopathology (Prof. AG. Nicholson), Royal Brompton Hospital, Londra, Gran Bretagna;
- Coordinatore (2007) del Workshop "International workshop on interstitial lung diseases. A practical, patient-oriented, multidisciplinary course, Roma, Italia che ha coinvolto i principali esperti patologi, radiologi e pneumologi italiani sotto la guida dei relativi esperti internazionali (Kevin Leslie, James Gruden e Jay Ryu) di Mayo Clinic Scottsdale, AZ e Mayo Clinic Rochester, MN, USA;
- fellowship (Aprile-Luglio 2008) presso Department of Pathology (Prof. Thomas V Colby), Mayo Clinic, Scottsdale, Arizona, USA. Tale fellowship ha condotto alla pubblicazione di:

*Distinctive Pulmonary Histopathology With Increased IgG4-positive Plasma Cells in Patients With Autoimmune Pancreatitis: Report of 6 and 12 Cases With Similar Histopathology. Shrestha B, Sekiguchi H, Colby TV, **Graziano P**, Aubry MC, Smyrk TC, Feldman AL, Cornell LD, Ryu JH, Chari ST, Dueck AC, Yi ES. Am J Surg Pathol. 2009 Oct;33(10):1450-62.*

*Immunodetection of occult eosinophils in lung tissue biopsies may help predict survival in acute lung injury. Willetts L, Parker K, Wesselius LJ, Protheroe CA, Jaben E, **Graziano P**, Moqbel R, Leslie KO, Lee NA, Lee JJ. Respir Res. 2011 Aug 26;12 116.*

*Validation of Interobserver Agreement in Lung Cancer Assessment Hematoxylin-Eosin Diagnostic Reproducibility for Non-Small Cell Lung Cancer-The 2004 World Health Organization Classification and Therapeutically Relevant Subsets Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA, Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, Borczuk AC, Cagle PT, Christensen R, Colby TV, Deblois GG, Elmberger G, **Graziano P**, Hart CF, Jones KD, Maia DM, Miller CR, Nance KV, Travis WD, Funkhouser WK. Arch Pathol Med Lab. 2013 Jan;137(1):32-40*

In ambito nazionale, il dott. Graziano è in stretta collaborazione con i principali Centri di riferimento di patologia polmonare neoplastica ed interstiziopatie polmonari ed è indicato come uno degli esperti di riferimento a cui sono affidate second opinion di patologia neoplastica con particolare riguardo alla determinazione dell'istotipo tumorale ed all'ottimizzazione dei campioni biologici dei pazienti affetti da tumore polmonare in stadio avanzato da cui ottenere il maggior numero di informazioni relative ai fattori biologici predittivi di risposta terapeutica.

Il dott. Graziano è il referente patologo del Centro-Sud Italia per la diagnostica delle pneumopatie interstiziali (Progetto PerFECT 2.0).

In ambito internazionale, il dott. Graziano ha collaborazioni in corso con:

- Mayo Clinic, Scottsdale, AZ, anche quale coautore di Practical Pulmonary Pathology: A Diagnostic Approach, 4th edition;
- IARC/WHO nel progetto di caratterizzazione delle neoplasie neuroendocrine (carcinoidi polmonari, carcinoma neuroendocrino a grandi cellule e carcinoma a piccole cellule);
L'attività di ricerca svolta è riportata in 219 lavori pubblicati su riviste scientifiche impattate internazionali che hanno consentito al Dott. Graziano di raggiungere parametri bibliometrici (H –index: 40, numero di lavori: 219; numero di citazioni: 5252 sec. Scopus al 14/1/2026).

Ulteriori informazioni

PROGETTI DI RICERCA

Unità collaborante

BREMIR, Transcan Joint Transnational Call 2013

MicroRNA methylation and expression profiling for identification of breast cancer patients at high risk to develop distant metastases.

Principal Investigator: Manel Esteller

Unità collaborante

Ministero della Salute Italiano (Codice Progetto. RC1603MX34) Ricerca Corrente 2015-2016

Implicazioni diagnostiche e terapeutiche di nuovi marcatori molecolari nei tumori squamosi del distretto testa-collo.

Principal Investigator: Roberto Cocchi

Unità collaborante

Ministero della Salute Italiano. (Codice Progetto. RC1503LO51) Ricerca Corrente 2015

pNET Landscape: alterazione dei meccanismi di controllo di detossificazione e apoptosi cellulare nei tumori neuroendocrini del polmone.

Principal Investigator: Lucia Anna Muscarella.

Principal Investigator

Ministero della Salute Italiano (Codice Progetto RC1602AP14- RC1502AP18)

Ricerca Corrente 2015-2016 **Budget: 20.000,00** euro

Fibrosi Polmonare Idiopatica: ruolo di SPARC nell'eziopatogenesi di malattia.

Unità collaborante

Ministero della Salute Italiano (Codice Progetto. RF10LOGR), (GR-2010-2316264)

Ricerca Finalizzata-Progetto Giovani Ricercatori

Deregulation of molecular cross-talk between NRF2/KEAP1 and BCL2 pathways in Non Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC): implications for patients treatment.

Budget: 180.000,00 euro

Principal Investigator: Lucia Anna Muscarella.

Unità collaborante**Fondazione BNC 2015-2016 (Codice Progetto. RV15LOFONBNC)**

Molecular targeting of NRG1 Fusions in Lung Invasive Mucinous Adenocarcinoma.

Budget: 20.000,00 euro

Principal Investigator: Lucia Anna Muscarella

Unità collaborante**MFAG_12983**

Inside the Dysfunctional Nrf2/keap1 pathway in Lung Cancer: implications for Patients Treatment.

Principal Investigator: Lucia Anna Muscarella

Budget: 210.700,00 euro

Unità collaborante

STUDIO PROSPETTICO OSSERVAZIONALE MULTICENTRICO SULLA DETERMINAZIONE DELLE ALTERAZIONI MOLECOLARI NEI PAZIENTI CON NUOVA DIAGNOSI DI CARCINOMA POLMONARE NON A PICCOLE CELLULE IN STADIO AVANZATO.

Principal Investigator: Silvia Novello.

Unità collaborante

MARIE SKŁODOWSKA-CURIE ACTIONS, Individual Fellowships (IF) Call: H2020-MSCA-IF-2016

Metabolic characterization of ILCs under homeostatic or stress conditions.

Principal Investigator: Laura Surace.

Unità collaborante**IARC (The International Agency for Research on Cancer)**

Molecular profiling of pNET tumour of the Lung (Carcinoids, LCNEC)

Principal Investigator: Lynnette Fernandez-Cuesta.

Unità collaborante**Bando "Aiuti a Sostegno Cluster Tecnologici Regionali". (Codice Progetto. RR14LODICLIM)**

DICLIMAX: STRUMENTAZIONE PER DIAGNOSTICA CLINICA BASATA SU NEXT GENERATION SEQUENCING DI ACIDI NUCLEICI".

Principal Investigator/Capofila: Masmec

Unità collaborante**Ministero della Salute Italiano. (Codice Progetto. RC1603ON39-RC1703ON39) Ricerca Corrente 2016-2017**

Monitoraggio Molecolare dei Pazienti affetti da Adenocarcinoma polmonare come Fattore Predittivo di Risposta ai Farmaci a Bersaglio Molecolare.

Principal Investigator: Evaristo Maiello-Antonio Rossi

Principal Investigator**Alleanza Contro il Cancro (ACC) Ministero della Salute Italiano**

Validation of the Alliance Against Cancer lung panel in patients with Non Small Cell Lung Cancer. ACC Lung 2.0

Budget: 49.000,00 euro

Principal Investigator

Ministero della Salute Italiano. (Codice Progetto. RCRC1703AP44) Ricerca Corrente 2017

Budget: 5000,00 euro

Studio delle cascate cellulari e identificazione di nuovi target molecolari prognostici implicati nella resistenza ai trattamenti farmacologici dei tumori delle vie biliari.

Principal Investigator: Paola Parente

Principal Investigator

Ministero della Salute Italiano. (Codice Progetto. RC1703AP30) Ricerca Corrente 2017

Budget: 15.000,00

Studio delle basi molecolari di risposta agli inibitori degli Immunocheckpoints nel tumore polmonare non a piccole cellule e correlazione con l'andamento di malattia.

Unità collaborante

Ministero della Salute Italiano. (Codice Progetto. RC1603LO41-RC1703LO41) Ricerca Corrente 2016-2017

Basi molecolari del *cross-talking* tra le cascate molecolari Nrf2- e Notch-mediata nel carcinoma polmonare a piccole cellule.

Principal Investigator: Lucia Anna Muscarella

Unità collaborante

Ricerca Finalizzata Ministero della Salute Italiano (Codice Progetto. RF 2013 02357028)

Budget: 450.000,00

MOLECULAR DISSECTION OF THE PI3K/AKT PATHWAY IN GLIOBLASTOMA: IMPLICATIONS FOR THE DEVELOPMENT OF NOVEL TARGET THERAPIES BASED ON SMALL MOLECULES.

Principal Investigator: Paola Parrella

Local Principal Investigator

Studio osservazionale retrospettivo sulla prevalenza di alterazioni molecolari rare suscettibili di trattamenti agnostici (instabilità microsatellitare, riarrangiamenti dei geni NTRK, ALK1, ROS1, mutazioni del gene BRAF) in pazienti giovani affetti da tumori solidi maligni.

Principal Investigator

Alleanza Contro il Cancro (ACC) Ministero della Salute Italiano

Studio osservazionale retrospettivo multicentrico Locally Advanced NSCLC perioperative assessment based on multidimensional and integrated prognostic models.

Principal Investigator

Ministero della Salute Italiano. (Codice Progetto. RC2103AP27, RC1903AP29)

Ricerca Corrente 2017-2021

Budget: 113.000,00

Studio delle basi molecolari di risposta agli inibitori degli Immunocheckpoints nel tumore polmonare non a piccole cellule e correlazione con l'andamento di malattia.

Unità collaborante

Alleanza Contro il Cancro (ACC) Ministero della Salute Italiano (Codice Progetto RCR-2020-23670066)

Budget: 252.359,58 euro

Revisione della cascata cellulare Neureguline/HER nell'adenocarcinoma invasivo del polmone: confronto tra percorsi diagnostici su campioni biologici di pazienti italiani

Principal Investigator: Lucia Anna Muscarella

Unità collaborante

Fondazione AIRC (Codice Progetto IG 2021 ID 25706)

Budget: 599.000,00 euro

Amplified gene transcripts as new biomarkers for patient stratification in Small Cell Lung Cancer with MYCL/MYC gains

Principal Investigator: Clelia Tiziana Storlazzi

Unità collaborante

Fondazione AIRC (Codice Progetto IG 2021 ID 25758)

Budget: 616.000,00 euro

Dissecting the role of miR-3916 and miR3613-5p in breast cancer and developing a metastases predictor PORTENT algorithm

Principal Investigator: Paola Parrella

Local Principal Investigator

"Studio Retrospettivo-Prospettico Osservazionale Multicentrico Sulla Determinazione Delle Alterazioni Molecolari Nei Pazienti Con Nuova Diagnosi Di Carcinoma Polmonare (Atlas)"

Principal Investigator: Silvia Novello

Co-Principal Investigator

Ministero della Salute Italiano (Codice Progetto RF 2021-12373900)

Budget: 450.000,00 euro

"LEARNING: neureguLin/hEr pAthway RevisioN In luNG mucinous adenocarcinoma"

Co-Principal Investigator

Unione Europea (Codice Progetto PNRR-TR1-2023-12377907)

Budget: 800.000 euro

"RECOUNT: tRanslational profiling of Epidermal growth factor reCeptOrs network in rare malignant mUciNous Tumors".

Principal investigator

Ricerca di Ateneo 2024, Sapienza Università di Roma (Codice Progetto B83C25000880005)

Budget: 12000 euro

'Serous effusion supernatant: a potential biosource of cf-DNA for molecular cancer profiling'

LIBRI E CAPITOLI DI LIBRI

Acute Lung Injury in "Practical Pulmonary Pathology: A diagnostic approach", Elsevier Health Sciences 2th (2011), 3th (2017) e 4th edition (2022) (n. citazioni: **14 (Scopus)**)

Le carcinosi peritoneali. Manuale di trattamento chirurgico integrato.
Garofano A, Valle M, Cavaliere F, Delfino Editore 2005

"Pattern istologici e di imaging delle interstiziopatie: Differenti pattern istologici" Trattato di Pneumologia, Autori: Fiorani CM, Fiorucci F, Munafò G, Pasqua F, Puglisi G Verduci Editore, 2006

I Tumori polmonari. Linee guida per la gestione integrata del paziente con tumore polmonare, De Marinis F, Gridelli C, 2018.

Ecografia Toracica: Diagnosi e tecniche interventistiche. Edra-Masson, 2015.

Linee Guida AIOT (Associazione Italiana di Oncologia Toracica) ed. 2018

Linee Guida Tumori Epiteliali Primitivi Occulti (TEPO), AIOM (ed. 2018, 2019, 2020 e 2022)

Linee Guida Mesotelioma Pleurico, AIOM (ed. 2020, 2021, 2022 e 2024)

Linee Guida Neoplasie del Polmone, AIOM (ed 2024 e 2025)

ARTICOLI SU RIVISTE

1. Subsolid Nodule Management: "To Be Or Not To Be" Lung Cancer....Anile M, Bassi M, **Graziano P**, Venuta F. **Chest**. 2026 Jan;169(1):e43. doi: 10.1016/j.chest.2025.09.124.PMID: 41519580 (IF=9.2)
2. Mucoepidermoid carcinoma of the thymus: a case report with emphasis on the differential diagnosis. Pernazza A, Andreoli GM, Vittori L, Carillo C, Diso D, **Graziano P**. **Pathologica**. 2025 Dec;117(5):519-522. doi: 10.32074/1591-951X-1271.PMID: 41454771 (IF=2.9, ruolo: *senior*)
3. Comprehensive Molecular Screening by Next Generation Sequencing of Gastrointestinal Stromal Tumors (GISTs): In Silico Analysis and Classification of Rare KIT Exon 11 Mutations. Rodriquenz MG, Pasculli B, Rendina M, Petrizzelli F, Mazza T, Petracca A, Augello B, Coco M, Balsamo T, Troiano A, Zanelli M, Maiello E, **Graziano P**, Parente P, Parrella P. **Cancer Med**. 2025 Dec;14(23):e71430. doi: 10.1002/cam4.71430.PMID: 41355515 (IF=3.1)
4. Development of a microRNA-based prognostic model for accurate prediction of distant metastasis in breast cancer patients. Fontana A, Barbano R, Pasculli B, Mazza T, Palumbo O, Binda E, Trivieri N, Mencarelli G, Laurenzana I, Lamorte D, De Luca L, Caivano A, Biagini T, Rendina M, Lo Mele A, Prencipe G, Bravaccini S, Murgo R, Ciuffreda L, Morriti M, Valori VM, Di Lisa FS, Vici P, Castelvete M, Carella M, **Graziano P**, Maiello E, Copetti M, Esteller M, Parrella P. **Breast Cancer Res**. 2025 Sep 29;27(1):170. doi: 10.1186/s13058-025-02124-4.PMID: 41024243 (IF=5.6)
5. SPARC aberrant methylation in idiopathic pulmonary fibrosis: an explorative study. Fabrizio FP, Sparaneo A, Centra F, Delli Muti F, Parente P, Copetti M, Delcuratolo MD, Rossi A, Gili E, Rossi G, **Graziano P**, Muscarella LA. **Front Cell Dev Biol**. 2025 Sep 3;13:1639844. doi: 10.3389/fcell.2025.1639844. eCollection 2025.PMID: 40970095 (IF=4.3)
6. Part II - Analytical phase. Guerini-Rocco E, Venetis K, Bessi S, Buglioni S, Chiappetta C, de Biase D, De Maglio G, **Graziano P**, Macerola E, Marchiò C, Melucci E, Nacchio M, Natoni F, Vingiani A, Fusco N, Malapelle U, Pruner G, Pagni F. **Pathologica**. 2025 May 9;117(2(Suppl.1)):S18-S35. doi: 10.32074/1591-951X-1216.PMID: 40964764 (IF=4.4)
7. NRG/ErbB signaling: on the trail of a molecular fingerprint in mucinous carcinoma. Trombetta D, Fabrizio FP, Di Maio M, Parente P, Melocchi L, Martini M, Sparaneo A, Latiano TP, **Graziano P**, Rossi G, Muscarella LA. **Expert Opin Ther Targets**. 2025 Jul;29(7):423-434. doi: 10.1080/14728222.2025.2532390. Epub 2025 Jul 20.PMID: 40632577 (IF=4.4)
8. Loss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma. Quaranta A, Marzullo A, Fortarezza F, Maniglio S, Caporusso C, Pentimone F, Pezzuto F, Cavone D, Lettini T, Magistro M, Salzillo C, Vimercati L, **Graziano P**, Serio G, d'Amati A. **Histopathology**. 2025 Jun 25. doi: 10.1111/his.15502. Online ahead of print. PMID: 40566743 (IF=4.1)
9. Bilateral Spontaneous Hemothorax: A Rare Case of Primary Pleural Angiosarcoma and Literature Review. Piamonti D, Giannone S, D'Antoni L, Sanna A, Landini N, Pernazza A, Bassi M, Carillo C, Diso D, Venuta F, **Graziano P**, Pignatelli P, Corbetta L, Bonini M, Palange P. **J Clin Med**. 2025 May 12;14(10):3377. doi: 10.3390/jcm14103377.PMID: 40429373 (IF=2.9)
10. Unveiling the origin and functions of diagnostic circulating microRNAs in lung cancer. Colangelo T, Mazzarelli F, Cuttano R, Dama E, Melocchi V, Afanga MK, Perrone RM, **Graziano P**, Bianchi F. **Br J Cancer**. 2025 Apr 4. doi: 10.1038/s41416-025-02982-x. PMID: 40185877 (IF=6.4)
11. Distribution of *EGFR* and *KRAS* Mutations in Patients with Surgically Resected Non-Small Cell Lung Cancer from Southern Italy: Real-Life Data from a Single Institution and Literature Review. Piazzolla M, Parente P, Centra F, Fabrizio FP, Delcuratolo MD, Centonza A, Di Micco CM, Mastroianno M, Delli Muti F, Fiordelisi F, Ferretti G, **Graziano P**, Muscarella LA. **Cancers** (Basel). 2025 Feb 21;17(5):730. doi: 10.3390/cancers17050730.PMID: 40075579 (IF=4.5)

12. InterobServer AgreeMent in Pd-I1 evaLuatioN on cytoloGical samples-SAMPLING project: A multi-institutional, international study. Acanfora G, Iaccarino A, Cerbelli B, Di Cristofano C, Bellevicine C, Barberis M, Bonoldi E, Bubendorf L, Calaminus A, Campione S, Canberk S, Cavazza A, Cazzaniga G, Chijioke O, Clery E, Eccher A, Engels M, Fiorentino V, **Graziano P**, Kern I, Kholova I, Laatta J, Labiano T, Leopizzi M, Lozano MD, Luis R, Maffei E, Marando A, Martini M, Merenda E, Montella M, Morales AA, Nishino M, Pagni F, Hofman P, Pernazza A, Roy-Chowdhuri S, Saieg M, Savic Prince S, Siddiqui MT, Stoos-Veic T, Stojan Fležar M, Sundov D, VanderLaan P, Vrdoljak-Mozetič D, Zeppa P, Troncone G, Vigliar E. **Cancer Cytopathol.** 2025 Mar;133(3):e70003. doi: 10.1002/cncy.70003. PMID: 39992702 (IF=2.6)
13. Mutational profiling of SMARCA4 and SMARCB1 in ampullary adenocarcinoma: a preliminary study. Parente P, Pepe F, Covelli C, Russo G, Russo F, Troncone G, **Graziano P**, Malapelle U. **Pathologica.** 2024 Oct;116(5):331-334. doi: 10.32074/1591-951X-1028. PMID: 39748717 (IF=4.4; ruolo: **senior**)
14. Posterior iliac crest vs. proximal tibia: distinct sources of anti-inflammatory and regenerative cells with comparable 6-month clinical outcomes in treatment of osteoarthritis. Mormone E, Savastano L, Rossi G, Maruccia F, Di Maggio G, Sinisi NP, Sandri M, Copetti M, De Santis E, Guerra V, Biancofiore G, Cisternino C, Caradonna E, **Graziano P**, Gorgoglione FL. **J Transl Med.** 2024 Dec 4;22(1):1101. doi: 10.1186/s12967-024-05924-y. PMID: 39633422 (IF=6,1)
15. Tumor Suppressor miR-27a-5p and Its Significance for Breast Cancer. Parrella P, Barbano R, Jonas K, Fontana A, Barile S, Rendina M, Lo Mele A, Prencipe G, Ciuffreda L, Morriti MG, Valori VM, **Graziano P**, Maiello E, Copetti M, Pichler M, Pasculli B. **Biomedicines.** 2024 Nov 17;12(11):2625. doi: 10.3390/biomedicines12112625. PMID: 39595190. (IF=3,9)
16. Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes. Bertolaccini L, Tralongo AC, Del Re M, Facchinetti F, Ferrara R, Franchina T, **Graziano P**, Malapelle U, Menis J, Passaro A, Pilotto S, Ramella S, Rossi G, Trisolini R, Cinquini M, Passiglia F, Novello S. **Lung Cancer.** 2024 Oct 21;197:107990. doi: 10.1016/j.lungcan.2024.107990. PMID: 39461280 Review. (IF=4,5)
17. TERT Expression and Clinical Outcome in Pulmonary Carcinoids. Werr L, Bartenhagen C, Rosswog C, Cartolano M, Voegelé C, Sexton-Oates A, Di Genova A, Ernst A, Kahlert Y, Hemstedt N, Höppner S, Mansuet Lupo A, Pelosi G, Bric L, Papotti M, George J, Bosco G, Quaas A, Tang LH, Robzyk K, Kadota K, Roh MS, Fanaroff RE, Falcon CJ, Büttner R, Lantuejoul S, Rekhtman N, Rudin CM, Travis WD, Alcalá N, Fernandez-Cuesta L, Foll M, Peifer M, Thomas RK, Fischer M; **Lung NEN Network.** **J Clin Oncol.** 2024 Sep 30; JCO2302708. doi: 10.1200/JCO.23.02708. PMID: 39348606 (IF=42)
18. Clinical and Molecular Traits of a Novel SPECC1L-ALK Fusion in a Patient with Advanced Non-Small Cell Lung Cancer. Centonza A, Mazza T, Trombetta D, Sparaneo A, Petrizzelli F, Castellana S, Centra F, Fabrizio FP, Di Micco CM, Benso F, Tabbò F, Righi L, Merlini A, **Graziano P**, Muscarella LA. **J Pers Med.** 2024 Jun 21;14(7):670. doi: 10.3390/jpm14070670. PMID: 39063924 (IF=3)
19. Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project. Mathian É, Drouet Y, Sexton-Oates A, Papotti MG, Pelosi G, Vignaud JM, Bric L, Mansuet-Lupo A, Damiola F, Altun C, Berthet JP, Fournier CB, Brustugun OT, Centonze G, Chalabreysse L, de Montpréville VT, di Micco CM, Fadel E, Gadot N, **Graziano P**, Hofman P, Hofman V, Lacomme S, Lund-Iversen M, Mangiante L, Milione M, Muscarella LA, Perrin C, Planchard G, Popper H, Rousseau N, Roz L, Sabella G, Tabone-Eglinger S, Voegelé C, Volante M, Walter T, Dingemans AM, Moonen L, Speel EJ, Derks J, Girard N, Chen L, Alcalá N, Fernandez-Cuesta L, Lantuejoul S, Foll M. **ESMO Open.** 2024 Jun 14;9(6):103591. doi: 10.1016/j.esmoop.2024.103591. PMID: 38878324 (IF=8.7)
20. Markedly raised CA 19-9 levels in an asymptomatic patient: the role of Helicobacter pylori infection. D'Agruma A, D'Agruma L, Piscitelli P, Parente P, **Graziano P**, Vendemiale G, Castori M, Gasbarrini GB, DE Cosmo S, Mirijello A. **Minerva Gastroenterol (Torino).** 2024 Jun 5. doi: 10.23736/S2724-5985.24.03704-5. PMID: 38842040 (IF=3.186)

21. Effects of *KEAP1* Silencing on NRF2 and NOTCH Pathways in SCLC Cell Lines. Fabrizio FP, Sparaneo A, Gorgoglione G, Battista P, Centra F, Delli Muti F, Trombetta D, Centonza A, **Graziano P**, Rossi A, Fazio VM, Muscarella LA. **Cancers** (Basel) 2024 May 15;16(10):1885. doi: 10.3390/cancers16101885.PMID: 38791966 (IF=4.5).
22. Nrf2 and Her3 co-expression in cholangiocarcinoma: Possible biological pathways for potential therapeutic approach. Parente P, Angerilli V, Zamboni G, Sparaneo A, Fiordelisi F, Di Candia L, Fassan M, **Graziano P**. **Hepatobiliary Pancreat Dis Int**. 2024 Jun;23(3):317-321. doi: 10.1016/j.hbpd.2023.02.010. PMID: 36882359 (IF=3.355; ruolo: **senior**)
23. Pulmonary pathology in vasculitis. Ambrogio E, Cavazza A, Smith ML, **Graziano P**. **Pathologica**. 2024 Apr;116(2):93-103. doi: 10.32074/1591 951X988. PMID: 38767542 (IF=3.5; ruolo: **senior**)
24. The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database. Malapelle U, Passiglia F, Pepe F, Pisapia P, Lucia Reale M, Cortinovis D, Fraggetta F, Galetta D, Garbo E, **Graziano P**, Pagni F, Pasello G, Piovano P, Pilotto S, Tiseo M, Genova C, Righi L, Troncone G, Novello S. **Lung Cancer**. 2024 May;191:107787. doi: 10.1016/j.lungcan.2024.107787. Epub 2024 Apr 5. PMID: 38593479 (IF=4.7)
25. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores. Ivanova M, Frascarelli C, Cerbelli B, Pignataro MG, Pernazza A, Venetis K, Sajjadi E, Criscitiello C, Curigliano G, Guerini-Rocco E, **Graziano P**, Martini M, d'Amati G, Fusco N. **Hum Pathol**. 2024 Jan 24;144:22-27. doi: 10.1016/j.humpath.2024.01.008. Online ahead of print.PMID: 38278450 (IF=3.526)
26. Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer. Marchiò C, Criscitiello C, Scatena C, Santinelli A, **Graziano P**, Malapelle U, Cursano G, Venetis K, Fanelli GN, Pepe F, Berrino E, Angelis C, Perrone G, Curigliano G, Fusco N. **Pathologica**. 2023 Dec;115(6):292-301. doi: 10.32074/1591-951X-942.PMID: 38180137 (IF=3.5 n. citazioni: 2 (Scopus))
27. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey. Fusco N, Ivanova M, Dainese E, De Camilli E, Dell'Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, **Graziano P**, Castellano I, d'Amati G. **Crit Rev Oncol Hematol**. 2023 Oct;190:104103. doi: 10.1016/j.critrevonc.2023.104103. Epub 2023 Aug 16.PMID: 37595344 (IF=6.2 n. citazioni: 3 (Scopus))
28. Clinical impact of mixed pulmonary carcinoma and carcinoid: the driver from their mono-clonal origin. **Graziano P**, Parente P, Centra F, Milione M, Centonze G, Volante M, Cavazza A, Urbano D, Di Maggio G, Balsamo T, Di Micco C, Rossi G, Rossi A, Muscarella LA. **Virchows Arch**. 2023 Sep 29. doi: 10.1007/s00428-023-03663-x. Online ahead of print. PMID: 37773451 (IF=4.535 ruolo= first author) n. citazioni: 1 (Scopus)
29. Update in Lung Cancer Molecular Pathology: Technological Advances and Clinical Practice. **Graziano P**, Rossi G. **Cancers** (Basel). 2023 Jul 27;15(15):3812. doi: 10.3390/cancers15153812.PMID: 37568629 (IF=5.2 ruolo= first author)
30. MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice. Parente P, Malapelle U, Angerilli V, Balistreri M, Lonardi S, Pucciarelli S, De Luca C, Pepe F, Russo G, Vigliar E, Danza A, Scaramuzzi F, Troncone G, **Graziano P**, Fassan M. **J Clin Pathol**. 2023 Jul;76(7):492-496. doi: 10.1136/jclinpath-2022-208143. Epub 2022 Feb 10.PMID: 35145019 (IF=3.4 n. citazioni: 6 (Scopus))
31. Thoracic ultrasound combined with low-dose computed tomography may represent useful screening strategy in highly exposed population in the industrial city of Taranto (Italy). Quarato CMI, Dama E, Maggi M, Feragalli B, Borelli C, Del Colle A, Taurichini M, Maiello E, De Cosmo S, Lacedonia D, Barbaro MPF, Carpagnano GE, Scioscia G, **Graziano P**, Termine R, Frongillo E, Santamaria S, Venuti M, Grimaldi MA, Notarangelo S, Saponara A, Copetti M, Colangelo T, Cuttano R, Macrodimitris D, Mazzarelli F, Talia M, Mirijello A, Paziienza L, Perna R, Simeone A, Vergara D, Varriale A, Carella M, Bianchi F, Sperandeo M. **Front Med** (Lausanne). 2023 May 16;10:1146807. doi: 10.3389/fmed.2023.1146807. eCollection 2023.PMID: 37261121 (IF=5.058)

32. Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units. Lazzaro C, Fattore G, Barberis M, Buttitta F, Cassoni P, **Graziano P**, Marchetti A, Crema S, Dal Pero F, Papotti MG. **Pathologica**. 2023 Feb 15. doi: 10.32074/1591-951X-837: 36790110 (IF= 3.5 n. citazioni: 1 (Scopus))
33. Contrast-Enhanced Ultrasound in Distinguishing between Malignant and Benign Peripheral Pulmonary Consolidations: The Debated Utility of the Contrast Enhancement Arrival Time. Quarato CMI, Feragalli B, Lacedonia D, Rea G, Scioscia G, Maiello E, Di Micco C, Borelli C, Mirijello A, **Graziano P**, Dimitri L, Villani R, Sperandeo M. **Diagnostics** (Basel). 2023 Feb 10;13(4):666. doi: 10.3390/diagnostics13040666.PMID: 36832153 (IF=3.992 n. citazioni: 5 (Scopus))
34. Abdominal Lymphadenopathies: Lymphoma, Brucellosis or Tuberculosis? Multidisciplinary Approach-Case Report and Review of the Literature. Mirijello A, Ritrovato N, D'Agruma A, de Mattheis A, Paziienza L, Parente P, Cassano DP, Biancofiore A, Ambrosio A, Carosi I, Serricchio E, **Graziano P**, Bazzocchi F, Piscitelli P, De Cosmo S. **Medicina** (Kaunas). 2023 Feb 4;59(2):293. doi: 10.3390/medicina59020293.PMID: 36837494 (IF=2.355)
35. Microsatellite instability evaluation of patients with solid tumour: routine practice insight from a large series of Italian referral centre. Russo G, Pepe F, Pisapia P, Palumbo L, Nacchio M, Vigliar E, Pallante P, Parente P, Fassan M, **Graziano P**, Bellevicine C, Troncone G, Malapelle U, Iaccarino A. **J Clin Pathol**. 2023 Feb;76(2):133-136. doi: 10.1136/jclinpath-2022-208203. Epub 2022 May 11. PMID: 35545354 (IF=3.4 n. citazioni: 1 (Scopus))
36. Robust Performance of the Novel Research-Use-Only Idylla GeneFusion Assay Using a Diverse Set of Pathological Samples with a Proposed 1-Day Workflow for Advanced NSCLC Evaluation. Leone A, Muscarella LA, **Graziano P**, Tornese A, Grillo LR, Di Lorenzo A, Bronzini M, Scarpino S, Sparaneo A, Rossi G. **Cancers** (Basel). 2022 Dec 31;15(1):292. doi: 10.3390/cancers15010292.PMID: 36612287 (IF=6.575 n. citazioni: 5 (Scopus))
37. miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response. Cuttano R, Colangelo T, Guarize J, Dama E, Cocomazzi MP, Mazzarelli F, Melocchi V, Palumbo O, Marino E, Belloni E, Montani F, Vecchi M, Barberis M, **Graziano P**, Pasquier A, Sanz-Ortega J, Montuenga LM, Carbonelli C, Spaggiari L, Bianchi F. **J Hematol Oncol**. 2022 Dec 31;15(1):178. doi: 10.1186/s13045-022-01394-1.PMID: 36587234 (IF=23.168 n. citazioni: 4 (Scopus))
38. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer? Malapelle U, Parente P, Pepe F, Di Micco MC, Russo A, Clemente C, **Graziano P**, Rossi A. **Int J Mol Sci**. 2022 Dec 16;23(24):16077. doi: 10.3390/ijms232416077.PMID: 36555714 (IF=6.208 n. citazioni: 5 (Scopus))
39. What does MYC, BCL2, and BCL6 genes 'rearranged' mean in large cell/diffuse B-cell lymphomas? Trombetta D, Zanelli M, Garuti A, Carosi I, Mastracci L, Ascani S, **Graziano P**, Parente P. **Pathol Res Pract**. 2022 Nov 2; 240:154199. doi: 10.1016/j.prp.2022.154199. PMID: 36368276 (IF=3.309)
40. DOG-1 positive primary acinic cell carcinoma of the lung and investigation of molecular status. Nibid L, Frasca L, Sabarese C, Righi D, Taccogna S, Crucitti P, **Graziano P**, Perrone G. **Pathologica**. 2022 Oct;114(5):385-390. doi: 10.32074/1591-951X-786.PMID: 36305026 (IF=2.06 n. citazioni: 2 (Scopus))
41. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TI sequences. Tabbò F, Muscarella LA, Gobbi E, Trombetta D, Castellana S, Rigutto A, Galetta D, Maiello E, Martelli O, Tiseo M, Scotti V, Ghilardi L, Gregorc V, Sergi C, Pilotto S, Del Conte A, Cappuzzo F, Cortinovis D, Osman G, Bareggi C, Di Maio M, Rossi A, Rossi G, Bria E, Volante M, Scagliotti GV, **Graziano P**, Novello S, Righi L. **Eur J Cancer**. 2022 Aug 28;174:200-211. doi: 10.1016/j.ejca.2022.07.026. PMID: 36044814 (IF=10.002 n. citazioni: 10 (Scopus))
42. A simple and cheap workflow to standardize cell block method in non small cell lung cancer patients. Parente P, Biancofiore G, **Graziano P**. **Virchows Arch**. 2022 Oct;481(4):677-678. doi: 10.1007/s00428-022-03399-0. Epub 2022 Aug 23.PMID: 35997824 (IF=3.5; ruolo: **senior**)

43. Handling and standardization of EBUS needle aspiration in NSCLC patients: The value of the cell block, a monoinstitutional experience. Parente P, Carbonelli C, Biancofiore G, Sukthi A, Di Micco CM, Vairo M, Fuso P, Taurichini M, **Graziano P**. *Thorac Cancer*. 2022 Sep;13(17):2480-2488. doi: 10.1111/1759-7714.14581. Epub 2022 Jul 22. PMID: 35868633 (IF=2.9 ruolo=*senior*) n. citazioni: 5 (Scopus)
44. Extremely late-onset pulmonary metastasis from uterine PEComa. Ascione A, Martignoni G, d'Amati G, Rocca CD, **Graziano P**, Pernazza A. *Pathologica*. 2022 Sep 9. doi: 10.32074/1591-951X-762. PMID: 36083244 (IF=2.06 n. citazioni: 2 (Scopus))
45. Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study. Bironzo P, Melocchi L, Monica V, Trebeschi D, Barbieri F, Maiello E, Migliorino MR, Lombardi A, Tiseo M, Righi L, **Graziano P**, Rossi G, Novello S. *Pathologica*. 2022 Sep 9. doi: 10.32074/1591-951X-756. PMID: 36083243 (IF=2.06 n. citazioni: 1 (Scopus))
46. Design and experimental validation of OPERA_MET-A panel for deep methylation analysis by next generation sequencing. Fabrizio FP, Castellana S, Centra F, Sparaneo A, Mastroianno M, Mazza T, Coco M, Trombetta D, Cingolani N, Centonza A, **Graziano P**, Maiello E, Fazio VM, Muscarella LA. *Front Oncol*. 2022 Aug 11;12:968804. doi: 10.3389/fonc.2022.968804. eCollection 2022. PMID: 36033501 (IF=4.7 n. citazioni: 2 (Scopus))
47. Colorectal adenocarcinoma: Peculiar morphologic features and distinct immunoprofiles in squamous and glandular components. Parente P, Mastracci L, Vanoli A, Businello G, Paudice M, Angerilli V, Castelvetero M, **Graziano P**, Fassan M, Grillo F. *Pathol Res Pract*. 2022 May 30;236:153967. doi: 10.1016/j.prp.2022.153967. PMID: 35662040 (IF=3.309; n. citazioni: 3 (Scopus))
48. Loss of circadian gene Timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism. Colangelo T, Carbone A, Mazzarelli F, Cuttano R, Dama E, Nittoli T, Albanesi J, Barisciano G, Forte N, Palumbo O, **Graziano P**, di Masi A, Colantuoni V, Sabatino L, Bianchi F, Mazzoccoli G. *Cell Death Differ*. 2022 Jan 15. doi: 10.1038/s41418-022-00935-y. PMID: 35034102 (IF=12.067; n. citazioni: 21 (Scopus))
49. Watch the Mime Carefully! A Refractory Interstitial Lung Disease. **Graziano P**, Fuso P, Carbonelli C. *Diagnostics* (Basel). 2022 Jul 19;12(7):1743. doi: 10.3390/diagnostics12071743. PMID: 35885646 (IF=3.992; first author)
50. Lung cancer diagnosis. Rossi, G., **Graziano, P**. *Journal of Xiangya Medicine*, 2022, 7, 16
51. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. Spada F, Bossi P, Caracò C, Sileni VC, Dei Tos AP, Fazio N, Grignani G, Maio M, Quagliano P, Queirolo P, Ascierto PA; **DELPHI Panel Members**. *J Immunother Cancer*. 2022 Jun;10(6):e004742. doi: 10.1136/jitc-2022-004742. PMID: 35701070 (IF=12.485 n. citazioni: 4 (Scopus))
52. Rapid *EGFR* evaluation from used H&E, IHC and FISH diagnostic slides with the Idylla platform. Nunnari J, **Graziano P**, Muscarella LA, Rossi A, Grillo LR, Montrone G, Di Lorenzo A, Bronzini M, Leone A. *J Clin Pathol*. 2022 May;75(5):338-344. doi: 10.1136/jclinpath-2020-207315. Epub 2021 Feb 17. PMID: 33597223 (IF=4.467 n. citazioni: 2 (Scopus))
53. When idiopathic retroperitoneal fibrosis mimics Castleman disease: a challenging differential diagnosis. Covelli C, Carosi I, **Graziano P**, Ascani S. *BMJ Case Rep*. 2022 Apr 7;15(4):e248051. doi: 10.1136/bcr-2021-248051. PMID: 35393274
54. Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice. Vavala T, Malapelle U, Veggiani C, Ludovini V, Papotti M, Leone A, **Graziano P**, Minari R, Bono F, Sapino A, Manotti L, Troncone G, Pisapia P, Girlando S, Buffoni L, Righi L, Colantonio I, Bertetto O, Novello S. *J Clin Pathol*. 2022 Apr;75(4):234-240. doi: 10.1136/jclinpath-2020-207339. Jan 28. PMID: 33509945 (IF=4.467; n. citazioni: 2 (Scopus))

55. Pattern-based Histologic Approach in Very Early Onset IBD: Main Features and Differential Diagnosis. Parente P, Mastracci L, Vanoli A, Fassan M, Pastore M, Bossa F, Francalanci P, Alaggio R, **Graziano P**, Grillo F. **Adv Anat Pathol**. 2022 Mar 1;29(2):71-80. doi: 10.1097/PAP.0000000000000323.PMID: 34620740 (IF=4.571; n. citazioni: 8 (Scopus))
56. Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study. Guerini Rocco E, Eccher A, Girolami I, **Graziano P**, Fontanini G, Vigliar E, Troncone G, Barberis M, Morbini P, Martini M. **Diagnostics** (Basel). 2022 Feb 13;12(2):477. doi: 10.3390/diagnostics12020477.PMID: 35204568 (IF=3.992; n. citazioni: 13 (Scopus))
57. CT-Guided Transthoracic Biopsy of Pulmonary Lesions: Diagnostic versus Nondiagnostic Results. Borelli C, Vergara D, Simeone A, Paziienza L, Castorani G, **Graziano P**, Di Micco C, Quarato CMI, Sperandeo M. **Diagnostics** (Basel). 2022 Jan 31;12(2):359. doi: 10.3390/diagnostics12020359.PMID: 35204450 (IF=3.992; n. citazioni: 3 (Scopus))
58. Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology. Girolami I, Lucenteforte E, Eccher A, Marletta S, Brunelli M, **Graziano P**, Pisapia P, Malapelle U, Troncone G, Scarpa A, Huang T, Pantanowitz L. **Cancer Cytopathol**. 2022 Feb;130(2):96-109. doi: 10.1002/cncy.22509. PMID: 34478240 (IF=3.4 n. citazioni: 32 (Scopus))
59. Mixed Pulmonary Adenocarcinoma and Atypical Carcinoid: A Report of Two Cases of a Non-codified Entity With Biological Profile. Parente P, Rossi A, Sparaneo A, Fabrizio FP, Centonza A, Turchini M, Mazza T, Cassano M, Miscio G, Centra F, Ferretti GM, Di Micco CM, **Graziano P**, Muscarella LA. **Front Mol Biosci**. 2021 Dec 3;8:784876. doi: 10.3389/fmolb.2021.784876. eCollection 2021.PMID: 34926584 (IF=6.113 n. citazioni: 2 (Scopus))
60. A New Intraepithelial $\gamma\delta$ T-Lymphocyte Marker for Celiac Disease Classification in Formalin-Fixed Paraffin-Embedded (FFPE) Duodenal Biopsies. Popp A, Taavela J, **Graziano P**, Parente P, Covelli C, Lamacchia C, Andriulli A, Mäki M, Isola J. **Dig Dis Sci**. 2021 Dec;66(12):4572. doi: 10.1007/s10620-020-06731-3.PMID: 33236317 (IF=3.487 n. citazioni: 4 (Scopus))
61. Assessing value of contrast-enhanced ultrasound vs. conventional transthoracic ultrasound in improving diagnostic yield of percutaneous needle biopsy of peripheral lung lesions. Quarato CMI, Cipriani C, Dimitri L, Lacedonia D, **Graziano P**, Copetti M, De Cosmo S, Simeone A, Scioscia G, Foschino Barbaro M, Sperandeo M. **Eur Rev Med Pharmacol Sci**. 2021 Sep;25(18):5781-5789. doi: 10.26355/eurrev_202109_26796. PMID: 34604969 (IF=3.784; n. citazioni: 7 (Scopus))
62. Intraoperative Lung Ultrasound (ILU) for the Assessment of Pulmonary Nodules. Turchini M, Quarato CMI, Frongillo EM, Ferretti GM, Cipriani C, Bizzarri M, Foschino Barbaro MP, Lacedonia D, Simeone A, **Graziano P**, Dimitri L, Maiello E, Cavaliere L, De Cosmo S, Sperandeo M. **Diagnostics** (Basel). 2021 Sep 16;11(9):1691. doi: 10.3390/diagnostics11091691. PMID: 34574032 (IF=3.992 n. citazioni: 4 (Scopus))
63. Effectiveness and Safety of Transthoracic Ultrasound in Guiding Percutaneous Needle Biopsy in the Lung and Comparison vs. CT Scan in Assessing Morphology of Subpleural Consolidations. Sperandeo M, Maiello E, **Graziano P**, Simeone A, De Cosmo S, Dimitri L, Di Micco C, Perrone E, Turchini M, Ferretti G, Mirijello A, Varriale A, Grimaldi MA, Lacedonia D, Quarato CMI. **Diagnostics** (Basel). 2021 Sep 7;11(9):1641. doi: 10.3390/diagnostics11091641.PMID: 34573981 (IF=3.992; n. citazioni: 6 (Scopus))
64. Transthoracic Ultrasound in Infectious Organizing Pneumonia: A Useful Guide for Percutaneous Needle Biopsy. Lacedonia D, Quarato CMI, Borelli C, Dimitri L, **Graziano P**, Foschino Barbaro MP, Scioscia G, Mirijello A, Maggi MM, Rea G, Ferragalli B, De Cosmo S, Sperandeo M. **Front Med** (Lausanne). 2021 Jul 19;8:708937. doi: 10.3389/fmed.2021.708937. eCollection 2021.PMID: 34350202 (IF=5.058; n. citazioni: 1 (Scopus))
65. Aggressive early-stage lung adenocarcinoma is characterized by epithelial cell plasticity with acquirement of stem-like traits and immune evasion phenotype. Melocchi V, Dama E, Mazzarelli F, Cuttano R, Colangelo T, Di Candia L, Lugli E, Veronesi G, Pelosi G, Ferretti GM, Turchini M, **Graziano P**, Bianchi F. **Oncogene**. 2021 Aug;40(31):4980-4991. doi: 10.1038/s41388-021-01909-z. Epub 2021 Jun 25.PMID: 34172935 (IF=8.756; n. citazioni: 8 (Scopus))

66. Primary Epithelioid Hemangioma of the Central Nervous System: A Case Report and Review of the Literature. Covelli C, Parente P, Icolaro N, Dimitri LMC, Vigna B, Popolizio T, **Graziano P.** *J Neuropathol Exp Neurol.* 2021 Aug 11;80(7):717-719. doi: 10.1093/jnen/nlaa163.PMID: 33411905 (IF=3.148 ruolo=*senior*)
67. Synchronous primary gastric triple-hit high-grade B-cell lymphoma and gastric adenocarcinoma: endoscopic and pathological findings. Covelli C, Parente P, Trombetta D, **Graziano P.** *BMJ Case Rep.* 2021 Jul 20;14(7):e244643. doi: 10.1136/bcr-2021-244643.PMID: 34285036 (ruolo=*senior*)
68. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. Malapelle U, Parente P, Pepe F, De Luca C, Pisapia P, Sgariglia R, Nacchio M, Gragnano G, Russo G, Conticelli F, Bellevicine C, Vigliar E, Iaccarino A, Covelli C, Balistreri M, Clemente C, Perrone G, Danza A, Scaramuzzi F, Fassan M, Troncone G, **Graziano P.** *Cells.* 2021 Jul 24;10(8):1878. doi: 10.3390/cells10081878.PMID: 34440647 (IF=7.666 ruolo=*senior*) **n. citazioni: 29 (Scopus)**
69. Accuracy and inter-observer agreement of the nice and kudo classifications of superficial colonic lesions: a comparative study. Cocomazzi F, Gentile M, Perri F, Bossa F, Merla A, Ippolito A, Cubisino R, Carparelli S, Marra A, Mileti A, Piazzolla M, Paolillo R, Copetti M, Parente P, **Graziano P,** Di Leo A, Andriulli A. *Int J Colorectal Dis.* 2021 Jul;36(7):1569. doi: 10.1007/s00384-021-03905-x.PMID: 33712905 (IF=2.796 **n. citazioni: 4 (Scopus)**)
70. Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer. Gregorc V, Mazzarella L, Lazzari C, **Graziano P,** Vigneri P, Genova C, Toschi L, Ciliberto G, Bonanno L, Delmonte A, Bucci G, Rossi A, Motta G, Coco S, Marinello A, Buglioni S, Cangi MG, Di Micco C, Bandiera A, Bonfiglio S, Pecciarini L, Guida A, Ceol A, Frige' G, De Maria R, Pelicci PG. *Clin Lung Cancer.* 2021 Jul;22(4):e637-e641. doi: 10.1016/j.clcc.2020.12.007. Epub 2021 Feb 26.PMID: 33642178 (IF=4.84 **n. citazioni: 4 (Scopus)**)
71. Transabdominal ultrasound-guided pancreatic biopsy: a neglected but safe, effective and inexpensive procedure that needs to be re-juvenalized. Terracciano F, Marra A, Ippolito AM, Bossa F, Sitajolo K, Amoroso A, Parente P, Valvano MR, **Graziano P,** Andriulli A. *J Ultrasound.* 2021 Jun;24(2):175-182. doi: 10.1007/s40477-020-00542-y. Epub 2021 Feb 1.PMID: 33521888 (IF=3.13 **n. citazioni: 2 (Scopus)**)
72. Which are the limiting factors in lung tissue sampling and diagnostic accuracy for a new Interventional Pulmonology Unit? From expert consensus-based evidence to results of a new-born Unit. Carbonelli C, Rossi A, Ciliberti G, Grimaldi MA, Notarangelo S, Parente P, Copetti M, Zanforlin A, Lococo F, Turchini M, Maiello E, De Cosmo S, **Graziano P.** *J Thorac Dis* 2021 May;13(5):2942-2951. doi: 10.21037/jtd-20-2990.PMID: 34164185 (IF=3.005; ruolo=*senior*)
73. A 'Galactic' Chest X-Ray. Carbonelli C, de Matthaeis A, Mirijello A, Di Micco C, Maiello E, De Cosmo S, **Graziano P.** *Diagnostics* (Basel). 2021 May 18;11(5):899. doi: 10.3390/diagnostics11050899.PMID: 34070198 (IF=3.992; ruolo=*senior*)
74. Ultrasound-guided fine needle aspiration biopsy (FNAB) demonstrating upper distal extremity metastasis of lung adenocarcinoma: a case report and review of the literature. La Marca A, **Graziano P,** Simeone A, Maiello E, Serviddio G, Vendemiale G, Sperandeo M. *Eur Rev Med Pharmacol Sci.* 2021Apr;25(8):3221-3225. doi:10.26355/eurrev_202104_25730. PMID: 33928607 (IF=3.784)
75. Artificial Intelligence & Tissue Biomarkers: Advantages, Risks and Perspectives for Pathology. Lancellotti C, Cancian P, Savevski V, Kotha SRR, Fraggetta F, **Graziano P,** Di Tommaso L. *Cells.* 2021 Apr 2;10(4):787. doi: 10.3390/cells10040787.PMID: 33918173 (IF=7.666; **n. citazioni: 28 (Scopus)**)
76. Combined analysis of miR-200 family and its significance for breast cancer. Fontana A, Barbano R, Dama E, Pasculli B, Rendina M, Morritti MG, Melocchi V, Castelvete M, Valori VM, Ravaioli S, Bravaccini S, Ciuffreda L, **Graziano P,** Maiello E, Copetti M, Fazio VM, Esteller M, Bianchi F, Parrella P. *Sci Rep.* 2021 Feb 3;11(1):2980. doi: 10.1038/s41598-021-82286-1.PMID: 33536459 (IF=4.996 **n. citazioni: 21 (Scopus)**)

77. Gene expression profile in metastatic and non-metastatic parathyroid carcinoma. Condello V, Cetani F, Denaro M, Torregrossa L, Pardi E, Piaggi P, Borsari S, Poma AM, Muscarella LA, **Graziano P**, Chiofalo MG, Repaci A, Tallini G, Boi F, Materazzi G, Basolo F, Marcocci C. *Endocr Relat Cancer*. 2021 Feb;28(2):111-134. doi: 10.1530/ERC-20-0450.PMID: 33290252 (IF=5.900 n. citazioni: 14 (Scopus))
78. Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the "Programmed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinoma". Eccher A, Fontanini G, Fusco N, Girolami I, **Graziano P**, Rocco EG, Martini M, Morbini P, Pantanowitz L, Parwani A, Pisano AM, Troncone G, Vigliar E. *J Pathol Inform*. 2021 Jan 8; 12:1 doi: 10.4103/jpi.jpi_63_20. eCollection 2021.PMID: 34012705 (IF=0.962 n. citazioni: 22 (Scopus))
79. Non-Coding RNAs as Prognostic Biomarkers: A miRNA Signature Specific for Aggressive Early-Stage Lung Adenocarcinomas. Dama E, Melocchi V, Mazzarelli F, Colangelo T, Cuttano R, Di Candia L, Ferretti GM, Turchini M, **Graziano P**, Bianchi F. *Noncoding RNA*. 2020 Dec 15;6(4):48. doi: 10.3390/ncrna6040048.PMID: 33333738 (IF=7.35 n. citazioni: 12 (Scopus))
80. Hodgkin Reed-Sternberg-Like Cells in Non-Hodgkin Lymphoma. Parente P, Zanelli M, Sanguedolce F, Mastracci L, **Graziano P**. *Diagnostics* (Basel). 2020 Nov 27;10(12):1019. doi: 10.3390/diagnostics10121019.PMID: 33261174 (IF=3.706; ruolo=senior n. citazioni: 14 (Scopus))
81. Mediastinal Nodular Lesions Synchronous to Lung Carcinoma on Frozen Section: Trap and Lesson Parente P, Turchini M, Castelvete M, Di Micco CM, Greco D, **Graziano P**. *Diagnostics* (Basel). 2020 Oct 31;10(11):E893. doi: 10.3390/diagnostics10110893.PMID: 33142919 (IF=3.706; ruolo=senior)
82. Diagnosis of Hodgkin Lymphoma from Cell Block: A Reliable and Helpful Tool in "Selected" Diagnostic Practice. Parente P, Covelli C, Zanelli M, Trombetta D, Carosi I, Carbonelli C, Sperandeo M, Mastracci L, Biancofiore G, Zizzo M, Turchini M, Ascani S, **Graziano P**. *Diagnostics* (Basel). 2020 Sep 25;10(10):E748. doi: 10.3390/diagnostics10100748.PMID: 32992679 (IF=3.706; ruolo=senior n. citazioni: 4 (Scopus))
83. Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. Malapelle U, Parente P, Pepe F, De Luca C, Cerino P, Covelli C, Balestrieri M, Russo G, Bonfitto A, Pisapia P, Fiordelisi F, D'Armiento M, Bruzzese D, Loupakis F, Pietrantonio F, Triassi M, Fassan M, Troncone G, **Graziano P**. *Cells*. 2020 Sep 2;9(9):E2019. doi: 10.3390/cells9092019.PMID: 32887373 (IF=6.600; ruolo=senior, n. citazioni: 31 (Scopus))
84. Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors. Pasculli B, Barbano R, Fontana A, Biagini T, Di Vestì MP, Rendina M, Valori VM, Morriti M, Bravaccini S, Ravaioli S, Maiello E, **Graziano P**, Murgo R, Copetti M, Mazza T, Fazio VM, Esteller M, Parrella P. *Front Oncol*. 2020 Aug 12;10:1415. doi: 10.3389/fonc.2020.01415. eCollection 2020.PMID: 32903519 (IF=5.738 n. citazioni: 32 (Scopus))
85. Pro-Fibrotic Phenotype in a Patient with Segmental Stiff Skin Syndrome via TGF- β Signaling Overactivation. Fusco C, Nardella G, Augello B, Boccafoschi F, Palumbo O, Fusaro L, Notarangelo A, Barbano R, Parrella P, Annicchiarico G, De Meco C, Micale L, **Graziano P**, Castori M. *Int J Mol Sci*. 2020 Jul 20;21(14):E5141. doi: 10.3390/ijms21145141.PMID: 32698527 (IF=6.208 n. citazioni: 12 (Scopus))
86. Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. Pagni F, Malapelle U, Doglioni C, Fontanini G, Fraggetta F, **Graziano P**, Marchetti A, Guerini Rocco E, Pisapia P, Vigliar EV, Buttitta F, Jaconi M, Fusco N, Barberis M, Troncone G. *Cancers* (Basel). 2020 Jul 5;12(7):E1800. doi: 10.3390/cancers12071800.PMID: 32635634 (IF=6.126 n. citazioni: 12 (Scopus))

87. Primary Effusion Lymphoma Metachronous to Multicentric Castleman Disease in an Immunocompetent Patient Parente P, Zanelli M, Zizzo M, Covelli C, Carosi I, Ascani S, **Graziano P.** *Pathol Res Pract.* 2020 Jul;216(7):153024. doi: 10.1016/j.prp.2020.153024. Epub 2020 May 20.PMID:32534717 (IF=3.309; ruolo=**senior**; n. citazioni: 4 (Scopus))
88. Potential Prognostic Role of SPARC Methylation in Non-Small-Cell Lung Cancer. Fabrizio FP, Sparaneo A, Fontana A, Mazza T, **Graziano P**, Pantalone A, Parente P, Centra F, Orlando N, Trombetta D, Torre A, Ferretti GM, Turchini M, Micco CMD, Maiello E, Fazio VM, Rossi A, Muscarella LA. *Cells.* 2020 Jun 22;9(6):E1523. doi: 10.3390/cells9061523.PMID: 32580473 (IF=6.600; n. citazioni: 10 (Scopus))
89. Brentuximab-related apoptotic colopathy. Parente P, **Graziano P**, Scalzulli P, Mastracci L, Grillo F. *Pathology.* 2020 Jun;52(4):483-484. doi: 10.1016/j.pathol.2020.02.011. Epub 2020 Apr 25.PMID: 32345520 (IF=5.335; n. citazioni: 5 (Scopus))
90. Biosafety in surgical pathology in the era of SARS-Cov2 pandemia. A statement of the Italian Society of Surgical Pathology and Cytology. Barbareschi M, Ascoli V, Bonoldi E, Cavazza A, Colombari R, Cozzi I, Dainese E, Facchetti F, Fadda G, Ferrara G, Frassetto F, **Graziano P**, Murer G, Rossi ED, Rossi G, Negri G, Zannoni G, Sapino A. *Pathologica.* 2020 Jun;112(2):59-63. doi: 10.32074/1591-951X-14-20. Epub 2020 Apr 1.PMID: 32324726 (IF=0.72; n. citazioni: 32 (Scopus))
91. miR375-3p Distinguishes Low-Grade Neuroendocrine From Non neuroendocrine Lung Tumors in FFPE Samples. Detassis S, Del Vescovo V, Grasso M, Masella S, Cantaloni C, Cima L, Cavazza A, **Graziano P**, Rossi G, Barbareschi M, Ricci L, Denti MA. *Front Mol Biosci.* 2020 May 19;7:86. doi: 10.3389/fmolb.2020.00086. eCollection 2020.PMID: 32528971 (IF=5.098; n. citazioni: 7 (Scopus))
92. Rare Somatic MEN1 Gene Pathogenic Variant in a Patient Affected by 32 Atypical Parathyroid Adenoma. Cinque L, Pugliese F, Clemente C, Castellana S, Leone MP, de Martino D, Balsamo T, Battista C, Biagini T, **Graziano P**, Castori M, Scillitani A, Guarnieri V. *Int J Endocrinol.* 2020 Apr 27;2020: 2080797. doi: 10.1155/2020/2080797 PMID:32411220 (IF=2.803; n. citazioni: 2 (Scopus))
93. Primary pulmonary Hodgkin lymphoma presenting as multiple cystic lung lesions: diagnostic usefulness of cell block. Parente P, Zanelli M, Zizzo M, Carosi I, Di Candia L, Sperandeo M, Lacedonia D, Fesce VF, Ascani S, **Graziano P.** *Cytopathology.* 2020 May;31(3):236-239. doi: 10.1111/cyt.12814. Epub 2020 Apr 12.PMID: 32112490 (IF=2.073; ruolo=**senior**; n. citazioni: 9 (Scopus))
94. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. Gobbi E, Chiari R, Pizzutillo P, Bordini P, Ghilardi L, Pilotto S, Osman G, Cappuzzo F, Cecere F, Riccardi F, Scotti V, Martelli O, Borra G, Maiello E, Rossi A, **Graziano P**, Gregorc V, Casartelli C, Sergi C, Del Conte A, Delmonte A, Bareggi C, Cortinovis D, Rizzo P, Tabbò F, Rossi G, Bria E, Galetta D, Tiseo M, Di Maio M, Novello S. *Clin Transl Oncol.* 2020 Mar;22(3):294-301. doi: 10.1007/s12094-019-02222-8. Epub 2019 Oct 19.PMID:31630357 (IF=3.405; n. citazioni: 5 (Scopus))
95. Intestinal adenosquamous carcinoma with a synchronous skin metastasis: a immunohistochemical and molecular analysis. Parente P, Covelli C, Parrella P, Latiano TP, Fiordelisi F, Pellico MT, Maiello E, **Graziano P.** *Int J Colorectal Dis.* 2019 Dec 10. doi: 10.1007/s00384-019-03464-2. PubMed PMID: 31823050 (IF=2.571; ruolo=**senior**; n. citazioni: 5 (Scopus))
96. Inpatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment. Iacono D, Osman GA, Migliorino MR, Grillo L, Remotti D, Nunnari J, Ricciardi S, Rossi A, Mancuso A, **Graziano P**, Di Lorenzo A, Bronzini M, Signora M, Leone A. *Am J Clin Oncol.* 2019 Nov;42(11):845-850. doi: 10.1097/COC.0000000000000615.PMID: 31644442 (IF=2.339 n. citazioni: 5 (Scopus))

97. Automated Workflow for Somatic and Germline Next Generation Sequencing Analysis in Routine Clinical Cancer Diagnostics. Muscarella LA, Fabrizio FP, De Bonis M, Mancini MT, Balsamo T, **Graziano P**, Centra F, Sparaneo A, Trombetta D, Bonfitto A, Scagliusi V, Larizza P, Capoluongo ED, Fazio VM. **Cancers** (Basel). 2019 Oct 30;11(11):1691. doi: 10.3390/cancers11111691.PMID: 31671666 (**IF=6.126 n. citazioni: 6 (Scopus)**)
98. Diagnostic and Prognostic Value of B4GALT1 Hypermethylation and Its Clinical Significance as a Novel Circulating Cell-Free DNA Biomarker in Colorectal Cancer. Picardo F, Romanelli A, Muinelo-Romay L, Mazza T, Fusilli C, Parrella P, Barbazán J, Lopez-López R, Barbano R, De Robertis M, Taffon C, Bordoni V, Agrati C, Costantini M, Ricci F, **Graziano P**, Maiello E, Muscarella LA, Fazio VM, Poeta ML. **Cancers** (Basel). 2019 Oct 19;11(10). pii: E1598. doi: 10.3390/cancers11101598. PubMed PMID: 31635093; PubMed Central PMCID: PMC6826707 (**IF=6.126 n. citazioni: 28 (Scopus)**)
99. Hsa- miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel. Pasculli B, Barbano R, Rendina M, Fontana A, Copetti M, Mazza T, Valori VM, Morriti M, 30 Maiello E, **Graziano P**, Murgo R, Fazio VM, Esteller M, Parrella P. **Sci Rep**. 2019 Oct 17;9(1):14913. doi: 10.1038/s41598-019-51581-3. PubMed PMID: 31624308; PubMed Central PMCID: PMC6797767 (**IF=4.379 n. citazioni: 21 (Scopus)**)
100. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Alcalá N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, Sertier AS, Ferrari A, Derks J, Ghantous A, Delhomme TM, Chabrier A, Cuenin C, Abedi Ardekani B, Boland A, Olaso R, Meyer V, Altmüller J, Le Calvez-Kelm F, Durand G, Voegelé C, Boyault S, Moonen L, Lemaitre N, Lorimier P, Toffart AC, Soltermann A, Clement JH, Saenger J, Field JK, Brevet M, Blanc Fournier C, Galateau-Salle F, Le Stang N, Russell PA, Wright G, Sozzi G, Pastorino U, Lacomme S, Vignaud JM, Hofman V, Hofman P, Brustugun OT, Lund-Iversen M, Thomas de Montpreville V, Muscarella LA, **Graziano P**, Popper H, Stojšić J, Deleuze JF, Herceg Z, Viari A, Nuernberg P, Pelosi G, Dingemans AMC, Milione M, Roz L, Brcic L, Volante M, Papotti MG, Caux C, Sandoval J, Hernandez-Vargas H, Brambilla E, Speel EJM, Girard N, Lantuejoul S, McKay JD, Foll M, Fernandez-Cuesta L. **Nat Commun**. 2019 Aug 20;10(1):3407. doi: 10.1038/s41467-019-11276-9. PubMed PMID: 31431620; PubMed Central PMCID: PMC6702229 (**IF=12.121 n. citazioni: 117 (Scopus)**)
101. Endothelial cell clonal expansion in the development of cerebral cavernous malformations. Malinverno M, Maderna C, Abu Taha A, Corada M, Orsenigo F, Valentino M, Pisati F, Fusco C, **Graziano P**, Giannotta M, Yu QC, Zeng YA, Lampugnani MG, Magnusson PU, Dejana E. **Nat Commun**. 2019 Jun 24;10(1):2761. doi: 10.1038/s41467-019-10707-x. PubMed PMID: 31235698; PubMed Central PMCID: PMC6591323 (**IF=12.121 n. citazioni: 76 (Scopus)**)
102. Methylation Density Pattern of KEAP1 Gene in Lung Cancer Cell Lines Detected by Quantitative Methylation Specific PCR and Pyrosequencing. 29 Fabrizio FP, Sparaneo A, Centra F, Trombetta D, Storlazzi CT, **Graziano P**, Maiello E, Fazio VM, Muscarella LA. **Int J Mol Sci**. 2019 May 31;20(11):2697. doi: 10.3390/ijms20112697.PMID: 31159323 (**IF=4.556 n. citazioni: 15 (Scopus)**)
103. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors. Sparaneo A, Fabrizio FP, la Torre A, **Graziano P**, Di Maio M, Fontana A, Bisceglia M, Rossi A, Pizzolitto S, De Maglio G, Tancredi A, Grimaldi F, Balsamo T, Centra F, Manzorra MC, Trombetta D, Pantalone A, Bonfitto A, Maiello E, Fazio VM, Muscarella LA. **Int J Mol Sci**. 2019 May 23;20(10). pii: E2531. doi: 10.3390/ijms20102531. PubMed PMID: 31126053; PubMed Central PMCID: PMC6566555 (**IF=4.556 n. citazioni: 11 (Scopus)**)

104. REDOXI-miRNA of Keap1/Nrf2 axis in lung tumors. Fabrizio FP, Sparaneo A, Castellana S, Mazza T, Trombetta D, **Graziano P**, Rossi A, Fazio VM, Muscarella LA. *Ann Oncol*. 2019 Apr;30 Suppl 2:ii5. doi: 10.1093. PMID:32131262.
105. Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. Parente P, Parcesepe P, Covelli C, Olivieri N, Remo A, Pancione M, Latiano TP, **Graziano P**, Maiello E, Giordano G. *Gastroenterol Res Pract*. 2018 Dec 18;2018: 7530619. doi: 10.1155/2018/7530619. eCollection 2018. Review. PubMed PMID: 30662458; PubMed Central PMCID: PMC6312626 (IF=1.82; n. citazioni: 27 (Scopus))
106. Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications. Funkhouser WK Jr, Hayes DN, Moore DT, Funkhouser WK 3rd, Fine JP, Jo H, Nikolaishvili-Feinberg N, Eeva M, Grilley-Olson JE, Banks PM, **Graziano P**, Boswell EL, Elmberger G, Raparia K, Hart CF, Sholl LM, Nolan NJ, Fritchie KJ, Pouagare E, Allen TC, Volmar KE, Biddinger PW, Kleven DT, Papez MJ, Spencer DV, Rekhtman N, Mino-Kenudson M, Harii L, Driver B, Cagle PT. *Arch Pathol Lab Med*. 2018 Dec;142(12):1537-1548. doi: 10.5858/arpa.2017-0481-OA. Epub 2018 Apr 30. PubMed PMID: 29708428 (IF=3.64 n. citazioni: 10 (Scopus))
107. The kinetics of (18)F-FDG in lung cancer: compartmental models and voxel analysis. Silvestri E, Scolozzi V, Rizzo G, Indovina L, Castellaro M, Mattoli MV, **Graziano P**, Cardillo G, Bertoldo A, Calcagni ML. *EJNMMI Res*. 28 2018 Aug 29;8(1):88. doi: 10.1186/s13550-018-0439-8. PubMed PMID: 30159686; PubMed Central PMCID: PMC6115323 (IF=2.79 n. citazioni: 3 (Scopus))
108. Exogenous Lipoid Pneumonia due to Chronic Inhalation of Oily Product Used as a Lubricant of Tracheotomy Cannula. Tancredi A, **Graziano P**, Scaramuzzi R, Scaramuzzi G, Carosi I, Attino V, Cuttitta A, Taurichini M. *Eurasian J Med*. 2018 Jun;50(2):125-127. doi: 10.5152/eurasianjmed.2018.17325. Epub 2018 Jun 1. PubMed PMID: 30002581; PubMed Central PMCID: PMC6039138 (IF=0.99 n. citazioni: 2 (Scopus))
109. Large deletion at the CDC73 gene locus and search for predictive markers of the presence of a CDC73 genetic lesion. Muscarella LA, Turchetti D, Fontana A, Baoda F, Palumbo O, la Torre A, de Martino D, Franco R, Losito NS, Repaci A, Pagotto U, Cinque L, Copetti M, Chiofalo MG, Pezzullo L, **Graziano P**, Scillitani A, Guarnieri V. *Oncotarget*. 2018 Apr 17;9(29):20721-20733. doi: 10.18632/oncotarget.25067.eCollection 2018 Apr 17. PubMed PMID: 29755684; PubMed Central PMCID: PMC5945533 (IF=3.67 n. citazioni: 14 (Scopus))
110. The 2015 World Health Organization Classification of lung tumors: new entities since the 2004 Classification. Mengoli MC, Longo FR, Fraggetta F, Cavazza A, Dubini A, Ali G, Guddo F, Gilioli E, Bogina G, Nannini N, Barbisan F, De Rosa N, Falconieri G, Rossi G, **Graziano P**. *Pathologica*. 2018 Mar;110(1):39-67. Review. PubMed PMID: 30259912 (IF=0.43 ruolo=senior; n. citazioni: 34 (Scopus))
111. Left Supraclavicular Swelling: Sclerosing Perineurioma. Tancredi A, **Graziano P**, Dimitri L, Impagnatiello E, Taurichini M. *Eurasian J Med*. 2018 Feb;50(1):47-49. doi: 10.5152/eurasianjmed.2018.17214. Epub 2018 Feb 1. PubMed PMID: 29531493; PubMed Central PMCID: PMC5843454 (IF=0.99 n. citazioni: 3 (Scopus))
112. Isolated fungus ball in sphenoid sinus: tips and pitfalls of T (1) hyperintense lesions. Popolizio T, Perri M, Balzano RF, Al-Badayneh B, Izzo R, **Graziano P**, Guglielmi G. *BJR Case Rep*. 2018 Jan 10;4(2):20170081. doi: 10.1259/bjrcr.20170081. eCollection 2018. PubMed PMID: 30363174; PubMed Central PMCID: PMC6159120 (IF=0.6)
113. Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. Trombetta D, **Graziano P**, Scarpa A, Sparaneo A, Rossi G, Rossi A, Di Maio M, Antonello D, Mafficini A, Fabrizio FP, Manzorra MC, Balsamo T, Centra F, Simbolo M, Pantalone A, Notarangelo M, Parente P, Lucia Dimitri MC, Bonfitto A, Fiordelisi F, Storlazzi CT, L'Abbate A, Taurichini M, Maiello E, Fazio VM, Muscarella LA. *Oncotarget*. 2018 Jan 3;9(11):9661-9671. doi: 10.18632/oncotarget.23800. eCollection 2018 Feb 9. PubMed PMID: 29515761; PubMed Central PMCID: PMC5839392 (IF=3.67; ruolo= first author; n. citazioni: 39 (Scopus))

114. Pharmacokinetic drug evaluation of osimertinib for the treatment of non small cell lung cancer. Rossi A, Muscarella LA, Di Micco C, Carbonelli C, D'alessandro V, Notarangelo S, Palomba G, Sanpaolo G, Taurichini M, **Graziano P**, Maiello E. *Expert Opin Drug MetabToxicol*. 2017 Dec;13(12):1281-1288. Doi: 10.1080/17425255.2017.1401064. Epub 2017 Nov 12. Review. PubMed PMID: 29095090 (**IF=3.487 n. citazioni: 10 (Scopus)**)
115. MEN1 gene mutation with parathyroid carcinoma: first report of a familial case. Cinque L, Sparaneo A, Salcuni AS, de Martino D, Battista C, Logoluso F, Palumbo O, Cocchi R, Maiello E, **Graziano P**, Hendy GN, Cole DEC, Scillitani A, Guarnieri V. *Endocr Connect*. 2017 Nov;6(8):886-891. doi: 10.1530/EC-17-0207. Epub 2017 Nov 2. PubMed PMID: 29097378; PubMed Central PMCID: PMC5704445 (**IF=2.67 n. citazioni: 15 (Scopus)**)
116. Increased frequency of bronchiolar histotypes in lung carcinomas 25 associated with idiopathic pulmonary fibrosis. Calìo A, Lever V, Rossi A, Gilioli E, Brunelli M, Dubini A, Tomassetti S, Piciocchi S, Nottegar A, Rossi G, Kambouchner M, Cancellieri A, Barbareschi M, Pelosi G, Doglioni C, Cavazza A, Carella R, **Graziano P**, Murer B, Poletti V, Chilosi M. *Histopathology*. 2017 Nov;71(5):725-735. doi: 10.1111/his.13269. Epub 2017 Aug 4. PubMed PMID: 28556957 (**IF=4.486 n. citazioni: 31 (Scopus)**)
117. ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma. Muscarella LA, Trombetta D, Fabrizio FP, Scarpa A, Fazio VM, Maiello E, Rossi A, **Graziano P**. *J Thorac Oncol*. 2017 Oct;12(10):e161-e163. doi: 10.1016/j.jtho.2017.05.014. PubMed PMID: 28939148 (**IF=6.595 ruolo=senior; n. citazioni: 16 (Scopus)**)
118. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. Gobbini E, Galetta D, Tiseo M, **Graziano P**, Rossi A, Bria E, Di Maio M, Rossi G, Gregorc V, Riccardi F, Scotti V, Ceribelli A, Buffoni L, Delmonte A, Franchina T, Migliorino MR, Cortinovis D, Pisconti S, Bordi P, Catino A, Maiello E, Arizio F, Novello S; other Co-Authors. *Lung Cancer*. 2017 Sep;111:30-37. doi: 10.1016/j.lungcan.2017.06.009. Epub 2017 Jun 16. PubMed PMID: 28838394 (**IF=4.486 n. citazioni: 26 (Scopus)**)
119. NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer? Trombetta D, Rossi A, Fabrizio FP, Sparaneo A, **Graziano P**, Fazio VM, Muscarella LA. *CurrMedChem*. 2017;24(38):4213-4228 doi:10.2174/0929867324666170911170554 Review PubMed PMID: 2890126 (**IF=3.469 n. citazioni: 17 (Scopus)**)
120. Engineered Resistant-Starch (ERS) Diet Shapes Colon Microbiota Profile in Parallel with the Retardation of Tumor Growth in In Vitro and In Vivo Pancreatic Cancer Models. Panebianco C, Adamberg K, Adamberg S, Saracino C, Jaagura M, Kolk K, Di Chio AG, **Graziano P**, Vilu R, Pazienza V. *Nutrients*. 2017 Mar 27;9(4). pii: E331. doi: 10.3390/nu9040331. PubMed PMID: 28346394; PubMed Central PMCID: PMC5409670 (**IF=5.788; n. citazioni: 49 (Scopus)**)
121. BRAF mutations in sarcomatoid and large cell carcinoma of the lung. Mengoli MC, Bettelli S, Gasparri P, Bertolini F, Barbieri F, Spaltro AA, Manfredini S, Muscarella LA, **Graziano P**. *Hum Pathol*. 2017 May;63:218-220. doi: 10.1016/j.humpath.2016.10.027. Epub 2016 Dec 8. PubMed PMID: 27939777 (**IF=3.014 ruolo=senior**)
122. Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients. Barbano R, Pasculli B, Rendina M, Fontana A, Fusilli C, Copetti M, Castellana S, Valori VM, Morriti M, **Graziano P**, Luigi C, Coco M, Picardo F, Mazza T, Evron E, Murgo R, Maiello E, Esteller M, Fazio VM, Parrella P. *Sci Rep*. 2017 Mar 27;7:45283. doi: 10.1038/srep45283. PubMed PMID: 28345661; PubMed Central PMCID: PMC5366901 (**IF=4.61; n. citazioni: 41 (Scopus)**)

123. Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, Serafini N, Puel A, Bustamante J, Surace L, Masse-Ranson G, David E, Strick-Marchand H, Le Bourhis L, Cocchi R, Topazio D, **Graziano P**, Muscarella LA, Rogge L, Norel X, Sallenave JM, Allez M, Graf T, Hendriks RW, Casanova JL, Amit I, Yssel H, Di Santo JP. *Cell*. 2017 Mar 9;168(6):1086-1100.e10. doi: 10.1016/j.cell.2017.02.021. PubMed PMID: 28283063 (IF=31.398; n. citazioni: 379 (Scopus))
124. A malignant inflammatory myofibroblastic tumor of the hypopharynx harboring the 3a/b variants of the EML4-ALK fusion gene. Muscarella LA, Rossi G, Trombetta D, La Torre A, Di Candia L, Mengoli MC, Sparaneo A, Fazio VM, **Graziano P**. *Oncol Lett*. 2017 Feb;13(2):593-598. doi: 10.3892/ol.2016.5504. Epub 2016 Dec 14. PubMed PMID: 28356934; PubMed Central PMCID: PMC5351184 (IF=1.664 ruolo=senior; n. citazioni: 4 (Scopus))
125. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. Martinelli E, Cardone C, Troiani T, Normanno N, Piscconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli V, Nasti G, Nappi A, Botti G, Tatangelo F, Chicchinelli N, Montrone M, Sebastio A, Guarino T, Simone G, **Graziano P**, Chiarazzo C, Maggio G, Longhitano L, Manusia M, Carteni G, Nappi O, Micheli P, Leo L, Rossi S, Cassano A, Tommaselli E, Giordano G, Sponziello F, Marino A, Rinaldi A, Romito S, Muda AO, Lorusso V, Leo S, Barni S, Grimaldi G, Aieta M. *ESMO Open*. 2017 Feb 20;1(6):e000086. doi: 10.1136/esmoopen-2016-000086. eCollection 2016. PMID: 28848656 (IF=2.67)
126. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Fabrizio FP, Costantini M, Copetti M, la Torre A, Sparaneo A, Fontana A, Poeta L, Gallucci M, Sentinelli S, **Graziano P**, Parente P, Pompeo V, De Salvo L, Simone G, Papalia R, Picardo F, Balsamo T, Flammia GP, Trombetta D, Pantalone A, Kok K, Paranita F, Muscarella LA, Fazio VM. *Oncotarget*. 2017 Feb 14;8(7):11187- 11198. doi: 10.18632/oncotarget.14492. PubMed PMID: 28061437; 24 PubMed Central PMCID: PMC5355256 (IF=4.64; n. citazioni: 60 (Scopus))
127. EZH2 and ZFX oncogenes in malignant behaviour of parathyroid neoplasms. Sanpaolo E, Miroballo M, Corbetta S, Verdelli C, Baorda F, Balsamo T, **Graziano P**, Fabrizio FP, Cinque L, Scillitani A, Muscarella LA, Guarnieri V. *Endocrine*. 2016 Oct;54(1):55-59. Epub 2016 Feb 15. PubMed PMID: 26876532 (IF=3.131; n. citazioni: 19 (Scopus))
128. Gene expression of muscular and neuronal pathways is cooperatively dysregulated in patients with idiopathic achalasia. Palmieri O, Mazza T, Merla A, Fusilli C, Cuttitta A, Martino G, Latiano T, Corritore G, Bossa F, Palumbo O, Muscarella LA, Carella M, **Graziano P**, Andriulli A, Latiano A. *Sci Rep*. 2016 Aug 11;6:31549. doi: 10.1038/srep31549. PubMed PMID: 27511445; PubMed Central PMCID: PMC4980661 (IF=4.259; n. citazioni: 27 (Scopus))
129. BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. Roma C, Rachiglio AM, Pasquale R, Fenizia F, Iannaccone A, Tatangelo F, Antinolfi G, Parrella P, **Graziano P**, Sabatino L, Colantuoni V, Botti G, Maiello E, Normanno N. *Cancer Biol Ther*. 2016 Aug 2;17(8):840-8. doi: 10.1080/15384047.2016.1195048. PubMed PMID: 27261210; PubMed Central PMCID: PMC5004691 (IF=3.256; n. citazioni: 19 (Scopus))
130. Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Facchinetti F, Tiseo M, Di Maio M, **Graziano P**, Bria E, Rossi G, Novello S. *Transl Lung Cancer Res*. 2016 Jun;5(3):301-21. doi: 10.21037/tlcr.2016.06.10. Review. PubMed PMID: 27413712; PubMed Central PMCID: PMC4931127 (IF=2.959; n. citazioni: 45 (Scopus))

131. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ciardiello F, Normanno N, Martinelli E, Troiani T, Piscanti S, Cardone C, Nappi A, Bordonaro AR, Rachiglio M, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E; **CAPRI-GOIM investigators**. *Ann Oncol*. 2016 Jun;27(6):1055- 23 61doi: 10.1093/annonc/mdw136. Epub 2016 Mar 21.PMID:27002107 (IF=11.855; n. citazioni: 79 (Scopus))
132. Diagnostic Performance of (18)F- Fluorodeoxyglucose in 162 Small Pulmonary Nodules Incidentally Detected in Subjects Without a History of Malignancy. Calcagni ML, Taralli S, Cardillo G, **Graziano P**, Ialongo P, Mattoli MV, Di Franco D, Caldarella C, Carleo F, Indovina L, Giordano A *Ann Thorac Surg*. 2016 Apr;101(4):1303-9. doi: 10.1016/j.athoracsur.2015.10.072. Epub 2016 Jan 26. PubMed PMID: 26822348 (IF=1.76; n. citazioni: 9 (Scopus))
133. Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients. Barbano R, Pasculli B, Coco M, Fontana A, Copetti M, Rendina M, Valori VM, **Graziano P**, Maiello E, Fazio VM, Parrella P. *Sci Rep*. 2015 Dec 22;5:18592. doi: 10.1038/srep18592. PubMed PMID: 26690267; PubMed Central PMCID: PMC4686972 (IF=5.228; n. citazioni: 28 (Scopus))
134. Cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma. Bossa F, Perri F, Niro G, Parente P, **Graziano P**, Andriulli A. *Aliment Pharmacol Ther*. 2016 Jan;43(1):174-5. doi: 10.1111/apt.13451. PubMed PMID: 26638939 (IF=4.04; n. citazioni: 4 (Scopus))
135. EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology. **Graziano P**, de Marinis F, Gori B, Gasbarra R, Migliorino R, De Santis S, Pelosi G, Leone A. *J Clin Oncol*. 2015 Nov 1;33(31):e115-8. doi: 10.1200/JCO.2013.49.5697. Epub 2014 Apr 21. PubMed PMID: 2475205 (IF=20.982 ruolo=first author; n. citazioni: 12 (Scopus))
136. Endoscopic treatment of primary benign central airway tumors: Results from a large consecutive case series and decision making flow chart to address bronchoscopic excision. Scarlata S, **Graziano P**, Lucantoni G, Battistoni P, Batzella S, Dello Jacono R, Antonelli Incalzi R, Galluccio G. *Eur J Surg Oncol*. 2015 Oct;41(10):1437-42. doi: 10.1016/j.ejso.2015.08.157. Epub 2015 Aug 24. PubMed PMID: 26329785 (IF=3.091; n. citazioni: 12 (Scopus))
137. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; **CAPRI-GOIM investigators**. *Ann Oncol*. 2015 Aug;26(8):1710-4. doi: 10.1093/annonc/mdv176. Epub 2015 Apr 7.PMID: 25851630 (IF=9.269 n. citazioni: 114 (Scopus))
138. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. D'Aronzo M, Vinciguerra M, Mazza T, Panebianco C, Saracino C, Pereira SP, **Graziano P**, Paziienza V. *Oncotarget*. 2015 Jul 30;6(21):18545-57. PubMed PMID: 26176887; PubMed Central PMCID: PMC4621909 (IF=5.008; n. citazioni: 69 (Scopus))
139. Artifacts, Noise and Interference: Much Ado about Ultrasound. Trovato GM, Catalano D, Sperandeo M, **Graziano P**. *Respiration*. 2015;90(1):85. doi: 10.1159/000375316. Epub 2015 Mar 20. PubMed PMID: 25824977 (IF=2.54 ruolo=senior; n. citazioni: 6 (Scopus))
140. Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal. Pelosi G, Barbareschi M, Cavazza A, **Graziano P**, Rossi G, Papotti M. *Lung Cancer*. 2015 Mar;87(3):226-31. doi: 10.1016/j.lungcan.2015.01.008. Epub 2015 Jan 17. Review. PubMed PMID: 25620799 (IF=4.34; n. citazioni: 43 (Scopus))

141. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid. Lococo F, Perotti G, Cardillo G, De Waure C, Filice A, **Graziano P**, Rossi G, Sgarbi G, Stefanelli A, Giordano A, Granone P, Rindi G, Versari A, Rufini V. *Clin Nucl Med*. 2015 Mar;40(3):e183-9. doi: 10.1097/RLU.0000000000000641. PubMed PMID: 25608152 (IF=4.278; n. citazioni: 53 (Scopus))
142. A miRNA signature for defining aggressive phenotype and prognosis in gliomas. Barbano R, Palumbo O, Pasculli B, Galasso M, Volinia S, D'Angelo V, Icolaro N, Coco M, Dimitri L, **Graziano P**, Copetti M, Valori VM, Maiello E, Carella M, Fazio VM, Parrella P. *PLoS One*. 2014 Oct 3;9(10):e108950. doi: 10.1371/journal.pone.0108950. eCollection 2014. PubMed PMID: 25279461; PubMed Central PMCID: PMC4184816 (IF=3.234; n. citazioni: 59 (Scopus))
143. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. Tavano F, Fontana A, Pellegrini F, Burbaci FP, Rappa F, Cappello F, Copetti M, Maiello E, Lombardi L, **Graziano P**, Vinciguerra M, di Mola FF, di Sebastiano P, Andriulli A, Pazienza V. *J Transl Med*. 2014 Sep 10;12:248. doi: 10.1186/s12967-014-0248-4. PubMed PMID: 25199538; PubMed Central PMCID: PMC4172900 (IF=4.38; n. citazioni: 10 (Scopus))
144. A rare case of primary pulmonary epithelioid angiosarcoma detected by (18)F-FDG PET/CT. Treglia G, Cardillo G, **Graziano P**. *Clin Nucl Med*. 2014 May;39(5):450-2. doi: 10.1097/RLU.0b013e318292f3b3. PubMed PMID: 23657141 (IF=3.931; ruolo= senior; n. citazioni: 13 (Scopus))
145. Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids. Daddi N, Schiavon M, Filosso PL, Cardillo G, Ambrogio MC, De Palma A, Luzzi L, Bandiera A, Casali C, Ruffato A, De Angelis V, Andriolo LG, Guerrera F, Carleo F, Davini F, Urbani M, Mattioli S, Morandi U, Zannini P, Gotti G, Loizzi M, Puma F, Mussi A, Ricci A, Oliaro A, Rea F; **Multi-Institutional Italian Pathology Group**. *Eur J Cardiothorac Surg*. 2014 Apr;45(4):677-86. doi: 10.1093/ejcts/ezt470. Epub 2013 Oct 6. PMID: 2409 (IF=3.048; n. citazioni: 51 (Scopus))
146. Chickenpox in unexplained pulmonary necrotizing granulomas. Rossi G, **Graziano P**, Cavazza A. *Chest*. 2014 Feb;145(2):433-4. doi: 10.1378/chest.13-2394. PubMed PMID: 24493548 (IF=7.483; n. citazioni: 2 (Scopus))
147. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Rossi G, Mengoli MC, Cavazza A, Nicoli D, Barbareschi M, Cantaloni C, Papotti M, Tironi A, **Graziano P**, Paci M, Stefani A, Migaldi M, Sartori G, Pelosi G. *Virchows Arch*. 2014 Jan;464(1):61-8. doi: 10.1007/s00428-013-1501-6. Epub 2013 Nov 13. PubMed PMID: 24221342 (IF=2.651; n. citazioni: 91 (Scopus))
148. Single lung and bone metastasis 30 years after thyroid cancer onset | Singola metastasi polmonare ed ossea a 30 anni dall'insorgenza di un tumore tiroideo. Sini V, De Iulius F, **Graziano P**, Mandolini PL, Cursano C, Menghi A, Taglieri L, Lanza R, Scarpa S. *European Journal of Oncology*, 2014, 19(3), pp. 185–189
149. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. Rossi G, **Graziano P**, Leone A, Migaldi M, Califano R. *Semin Diagn Pathol*. 2013 Nov;30(4):298-312. doi: 10.1053/j.semdp.2013.11.007. Epub 2013 Nov 13. Review. PubMed PMID: 24342286 (IF=1.796; n. citazioni: 15 (Scopus))
150. The first case of lung carcinosarcoma harboring in-frame deletions at exon19 in the EGFR gene. Toyokawa G, Takenoyama M, Taguchi K, Arakaki K, Inamasu E, Toyozawa R, Kojo M, Shiraishi Y, Morodomi Y, Takenaka T, Hirai F, Yamaguchi M, Seto T, Leone A, **Graziano P**, Ichinose Y. *Lung Cancer*. 2013 Sep;81(3):491-494. doi: 10.1016/j.lungcan.2013.06.013. Epub 2013 Jul 26. PubMed PMID: 23891513 (IF=3.737; n. citazioni: 12 (Scopus))

151. Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. Rossi G, Pelosi G, Barbareschi M, **Graziano P**, Cavazza A, Papotti M. *Int J Surg Pathol*. 2013 Aug;21(4):326-36. doi: 10.1177/1066896913489346. Epub 2013 Jun 5. Review. PubMed PMID: 23740564 (IF=0.961; n. citazioni: 36 (Scopus))
152. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Pelosi G, Rossi G, Cavazza A, Righi L, Maisonneuve P, Barbareschi M, **Graziano P**, Pastorino U, Garassino M, de Braud F, Papotti M. *Int J Surg Pathol*. 2013 Jun;21(3):229-39. doi: 10.1177/1066896913476750. Epub 2013 Mar 12. PubMed PMID: 23486764 (IF=0.961; n. citazioni: 49 (Scopus))
153. Homeodomain- interacting protein kinase2 in human idiopathic pulmonary fibrosis. Ricci A, Cherubini E, Ulivieri A, Lavra L, Sciacchitano S, Scozzi D, Mancini R, Ciliberto G, Bartolazzi A, Bruno P, **Graziano P**, Mariotta S. *J Cell Physiol*. 2013 Jan;228(1):235-41. doi: 10.1002/jcp.24129. PubMed PMID: 22689412 (IF=3.874; n. citazioni: 26 (Scopus))
154. Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA, Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, Borczuk AC, Cagle PT, Christensen R, Colby TV, Deblais GG, Elmberger G, **Graziano P**, Hart CF, Jones KD, Maia DM, Miller CR, Nance KV, Travis WD, Funkhouser WK. *Arch Pathol Lab Med*. 2013 Jan;137(1):32-40. doi: 10.5858/arpa.2012-0033-OA. Epub 2012 May 14. PubMed PMID: 22583114; PubMed Central PMCID: PMC5787023 (IF=2.884; n. citazioni: 51 (Scopus))
155. Malignant solitary fibrous tumors of the pleura: retrospective review of a multicenter series. Lococo F, Cesario A, Cardillo G, Filosso P, Galetta D, Carbone L, Oliaro A, Spaggiari L, Cusumano G, Margaritora S, **Graziano P**, Granone P. *J Thorac Oncol*. 2012 Nov;7(11):1698-706. doi: 10.1097/JTO.0b013e3182653d64. PubMed PMID: 23070244 (IF=4.473; n. citazioni: 72 (Scopus))
156. Chickenpox-related pulmonary granulomas in immunocompetent adults: clinicopathologic and molecular features of an underrated occurrence. Rossi G, Cavazza A, Gennari W, Marchioni A, **Graziano P**, Caminati A, Mengoli MC, Magnani R, Colby TV. *Am J Surg Pathol*. 2012 Oct;36(10):1497-502. doi: 10.1097/PAS.0b013e31825fa4d8. PubMed PMID: 22982893 (IF=4.868; n. citazioni: 4 (Scopus))
157. Primary neuroendocrine tumors of the thymus: a multicenter experience of 35 patients. Cardillo G, Rea F, Lucchi M, Paul MA, Margaritora S, Carleo F, Marulli G, Mussi A, Granone P, **Graziano P**. *Ann Thorac Surg*. 2012 Jul;94(1):241-5; discussion 245-6. doi: 10.1016/j.athoracsur.2012.03.062. Epub 2012 May 26. PubMed PMID: 22632882. (IF=3.454; ruolo=senior; n. citazioni: 54 (Scopus))
158. Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. Marchetti A, Del Grammastro M, Filice G, Felicioni L, Rossi G, **Graziano P**, Sartori G, Leone A, Malatesta S, Iacono M, Guetti L, Viola P, Mucilli F, Cuccurullo F, Buttitta F. *PLoS One*. 2012;7(7):e42164. doi: 10.1371/journal.pone.0042164. Epub 2012 Jul 27. PubMed PMID: 22848739; PubMed Central PMCID: PMC3407088 (IF=3.730; n. citazioni: 51 (Scopus))
159. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma 18 kinase (ALK) gene. Pelosi G, Gasparini P, Cavazza A, Rossi G, **Graziano P**, Barbareschi M, Perrone F, Barberis M, Takagi M, Kunimura T, Yamada T, Nakatani Y, Pastorino U, Scanagatta P, Sozzi G, Garassino M, De Braud F, Papotti M. *Lung Cancer*. 2012 Sep;77(3):507-14. doi: 10.1016/j.lungcan.2012.05.093. Epub 2012 Jun 16. PubMed PMID: 22705117 (IF=3.352; n. citazioni: 61 (Scopus))
160. A modified vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples. Pelosi G, Melotti F, Cavazza A, Rossi G, Maisonneuve P, **Graziano P**, Barbareschi M, Nakatani Y, Papotti M. *Anticancer Res*. 2012 Apr;32(4):1463-73. PubMed PMID: 22493387 (IF=1.713; n. citazioni: 22 (Scopus))

161. A rare case of synchronous bilateral pulmonary neuroendocrine tumor detected by 68Ga-DOTANOC PET/CT. Taralli S, Treglia G, Perotti G, **Graziano P**, Cardillo G, Castaldi P, Calcagni ML, Rufini V, Giordano A. *Clin Nucl Med*. 2012 Apr;37(4):e91-4. doi: 10.1097/RLU.0b013e3182444252. PubMed PMID: 22391733 (IF=2.955; n. citazioni: 2 (Scopus))
162. mTOR/p70S6K in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Rossi G, Cavazza A, **Graziano P**, Papotti M. *Am J Respir Crit Care Med*. 2012 Feb 1;185(3):341; author reply 341-2. PubMed PMID: 22298367 (IF=11.071; n. citazioni: 20 (Scopus))
163. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Gridelli C, Stahel R, Besse B, Ciardiello F, Felip E, Gasparini S, **Graziano P**, Rossi A, de Marinis F. *Lung Cancer*. 2011 Dec;74(3):544-8. doi: 10.1016/j.lungcan.2011.08.013. Epub 2011 Sep 28. PubMed PMID: 21958448 (IF=3.434; n. citazioni: 1 (Scopus))
164. Long-term disease-free survival of a patient with synchronous bilateral lung adenocarcinoma displaying different EGFR and C-MYC molecular characteristics. **Graziano P**, Cardillo G, Mancuso A, Paone G, Gasbarra R, De Marinis F, Leone A. *Chest*. 2011 Nov;140(5):1354-1356. doi: 10.1378/chest.10-2276. PubMed PMID: 22045881 (IF=5.854; ruolo=first author; n. citazioni: 4 (Scopus))
165. Occult mediastinal node involvement in non-small cell lung cancer after negative uptake on PET/CT: ripples through staging and therapy. Case report and critical review. Trodella L, Salvati F, Martelli M, Mattia P, **Graziano P**, Ippolito E. *Clin Ter*. 2011;162(6):559-61. Review. Italian. PubMed PMID: 22262330 (IF=0.328; n. citazioni: 2 (Scopus))
166. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. Pelosi G, Fabbri A, Bianchi F, Maisonneuve P, Rossi G, Barbareschi M, **Graziano P**, Cavazza A, Rekhtman N, Pastorino U, Scanagatta P, Papotti M. *J Thorac Oncol*. 2012 Feb;7(2):281-90. doi: 10.1097/JTO.0b013e31823815d3. PubMed PMID: 22071786 (IF=4.473; n. citazioni: 121 (Scopus))
167. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Barbareschi M, Cantaloni C, Del Vescovo V, Cavazza A, Monica V, Carella R, Rossi G, Morelli L, Cucino A, Silvestri M, Tirone G, Pelosi G, **Graziano P**, Papotti M, Dalla Palma P, Doglioni C, Denti MA. *Am J Clin Pathol*. 2011 Nov;136(5):773-82. doi: 10.1309/AJCPYY79XAGRAYCJ. PubMed PMID: 22031317 (IF=2.598; n. citazioni: 48 (Scopus))
168. Immunohistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, Sonzogni A, Veronesi G, Spaggiari L, Papotti M, Barbareschi M, **Graziano P**, Decensi A, Cavazza A, Viale G. *J Thorac Oncol*. 2011 Jun;6(6):1039-49. doi: 10.1097/JTO.0b013e318211dd16. PubMed PMID: 21512408 (IF=3.661; n. citazioni: 58 (Scopus))
169. Immunodetection of occult eosinophils in lung tissue biopsies may help predict survival in acute lung injury. Willetts L, Parker K, Wesselius LJ, Protheroe CA, Jaben E, **Graziano P**, Moqbel R, Leslie KO, Lee NA, Lee JJ. *Respir Res*. 2011 Aug 26;12:116. doi: 10.1186/1465-9921-12-116. PubMed PMID: 21871108; PubMed Central PMCID: PMC3176486 (IF=3.360 n. citazioni: 38 (Scopus))
170. miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Del Vescovo V, Cantaloni C, Cucino A, Girlando S, Silvestri M, Bragantini E, Fasanella S, Cuorvo LV, Palma PD, Rossi G, Papotti M, Pelosi G, **Graziano P**, Cavazza A, Denti MA, Barbareschi M. *Am J Surg Pathol*. 2011 Feb;35(2):268-75. doi: 10.1097/PAS.0b013e3182068171. PubMed PMID: 21263248 (IF=4.352; n. citazioni: 49 (Scopus))

171. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Righi L, **Graziano P**, Fornari A, Rossi G, Barbareschi M, Cavazza A, Pelosi G, Scagliotti GV, Papotti M. **Cancer**. 2011 Aug 1;117(15):3416-23. doi: 10.1002/cncr.25830. Epub 2011 Jan 18. PubMed PMID: 21246522 (IF=3.256; n. citazioni:124 (Scopus))
172. Identification of EGFR mutations in lung sarcomatoid carcinoma. Leone A, **Graziano P**, Gasbarra R, Paone G, Cardillo G, Mancuso A, De Marinis F, Ricciardi S, Portalone L, Pisa R. **Int J Cancer**. 2011 Feb 1;128(3):732-5; author reply 736. doi: 10.1002/ijc.25335. PubMed PMID: 20309946 (IF=5.444; n. citazioni: 37 (Scopus))
173. Smoking-related interstitial lung diseases. Caminati A, **Graziano P**, Sverzellati N, Harari S. **Pathologica**. 2010 Dec;102(6):525-36. PubMed PMID: 21428116 n. citazioni: 12 (Scopus)
174. Primary neuroendocrine tumours of the thymus: a clinicopathologic and prognostic study in 19 patients. Cardillo G, Treggiari S, Paul MA, Carleo F, De Massimi AR, Remotti D, **Graziano P**, Martelli M. **Eur J Cardiothorac Surg**. 2010 Apr;37(4):814-8. doi: 10.1016/j.ejcts.2009.10.026. Epub 2009 Dec 1. PubMed PMID: 19954997 (IF=2.293; n. citazioni: 35 (Scopus))
175. Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation. Cirombella R, Montrone G, Stoppacciaro A, Giglio S, Volinia S, **Graziano P**, Huebner K, Vecchione A. **Cancer Lett**. 2010 May 28;291(2):230-6. doi:10.1016/j.canlet.2009.10.017. Erratum in: Cancer Lett. 2015 Dec 1;369(1):259. PubMed PMID: 19931269; PubMed Central PMCID: PMC2849884 (IF=4.864; n. citazioni: 8 (Scopus))
176. Solitary fibrous tumors of the pleura: an analysis of 110 patients treated in a single institution. Cardillo G, Carbone L, Carleo F, Masala N, **Graziano P**, Bray A, Martelli M. **Ann Thorac Surg**. 2009 Nov;88(5):1632-7. doi: 10.1016/j.athoracsur.2009.07.026. PubMed PMID: 19853123 (IF=2.262; n. citazioni: 142 (Scopus))
177. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. Rossi G, Papotti M, Barbareschi M, **Graziano P**, Pelosi G. **J Clin Oncol**. 2009 Oct 1;27(28):e141-2; author reply e143-4. doi: 10.1200/JCO.2009.24.0515. Epub 2009 Aug 31. PubMed PMID: 19720885 (IF=9.795; n. citazioni: 40 (Scopus))
178. Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology. Shrestha B, Sekiguchi H, Colby TV, **Graziano P**, Aubry MC, Smyrk TC, Feldman AL, Cornell LD, Ryu JH, Chari ST, Dueck AC, Yi ES. **Am J Surg Pathol**. 2009 Oct;33(10):1450-62. doi: 10.1097/PAS.0b013e3181ac43b6. PubMed PMID: 19623032 (IF=4.829; n. citazioni: 168 (Scopus))
179. A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Rossi G, Pelosi G, **Graziano P**, Barbareschi M, Papotti M. **Int J Surg Pathol**. 2009 Jun;17(3):206-18. doi: 10.1177/1066896909336178. Review. PubMed PMID: 19443885 (IF=0.977; n. citazioni: 79 (Scopus))
180. Human neutrophil peptides stimulate tumor necrosis factor-alpha release by alveolar macrophages from patients with sarcoidosis. Paone G, Lucantoni G, Leone A, **Graziano P**, Gasbarra R, Galluccio G, D'Antoni S, Puglisi G, Girardi E, Schmid G. **Chest**. 2009 Feb;135(2):586-587. doi: 10.1378/chest.08-2585. PubMed PMID: 19201729 (IF=5.462; n. citazioni: 9 (Scopus))
181. The important role of pathologist in the rare pulmonary diseases. **Graziano P**. *Annali Degli Ospedali San Camillo e Forlanini* Volume 11, Issue 1, Pages 58 – 60 January 2009
182. HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. Rogliani P, Mura M, Mattia P, Ferlosio A, Farinelli G, Mariotta S, **Graziano P**, Pezzuto G, Ricci A, Saltini C, Orlandi A. **Respir Med**. 2008 Dec;102(12):1753-61. doi: 10.1016/j.rmed.2008.07.010. Epub 2008 Aug 23. PubMed PMID: 18723334 (IF=2.939; n. citazioni: 53 (Scopus))

183. Jejunal perforation secondary to metastatic sarcomatoid carcinoma of the lung. Baldassarre. E, Maggi P., Ramieri M.T., Torino G, **Graziano P**, Barone, M., Siani, A. **Minerva Gastroenterologica e Dietologica**, 2008, 54(2), pp. 225–228 (IF=0.952; n. citazioni: 3 (Scopus))
184. Follow-up retrospective study FONICAP in octogenarians treated with lung curative resection for non-small cell lung carcinoma. Salvati F, Signora M, Cardillo G; Orsetti R; Pisa R; **Graziano P**; Portalone L; Martelli M. **Annali Degli Ospedali San Camillo e Forlanini** Volume 9, Issue 3, Pages 11 - 18 July 2007 n. citazioni: 1 (Scopus)
185. Increased pulmonary neurotrophin protein expression in idiopathic interstitial pneumonias. Ricci A, **Graziano P**, Bronzetti E, Saltini C, Sciacchitano S, Cherubini E, Renzoni E, Du Bois RM, Grutters JC, Mariotta S. **Sarcoidosis Vasc Diffuse Lung Dis.** 2007 Mar;24(1):13-23. PubMed PMID: 18069415 (IF=1.958; n. citazioni: 31 (Scopus))
186. Association of mutations of K-RAS oncogene and deletions of 18Q with lymph node metastasis of colorectal cancer]. Leone A, Pisa R, Gasbarra R, **Graziano P**, Remotti D, Valle M, Garofalo A. [**Suppl Tumori.** 2005 May Jun;4(3):S207. Italian. PubMed PMID: 16437991
187. [Assessment of the presence of mutations of the epidermal growth factor receptors in tumors of various histologies]. Leone A, Pisa R, Gasbarra R, Costanzi-Porrini S, Cavazzana A, Bevilacqua G, **Graziano P**, Remotti D, Valle M, Garofalo A. **Suppl Tumori.** 2005 May-Jun;4(3):S203. Italian. PubMed PMID: 16437988
188. Neurotrophin system expression in human pulmonary carcinoid tumors. Ricci A, **Graziano P**, Mariotta S, Cardillo G, Sposato B, Terzano C, Bronzetti E. **Growth Factors.** 2005 Dec;23(4):303-12. PubMed PMID: 16338793 (IF=2.039; n. citazioni: 17 (Scopus))
189. Neurotrophin system activation in bronchoalveolar lavage fluid immune cells in pulmonary sarcoidosis. Ricci A, Mariotta S, Saltini C, Falasca C, Giovagnoli MR, Mannino F, **Graziano P**, Sciacchitano S, Amenta F. **Sarcoidosis Vasc Diffuse Lung Dis.** 2005 Oct;22(3):186-94. PubMed PMID: 16315781 (IF=3.613; n. citazioni: 18 (Scopus))
190. Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer. Ferroni P, Spila A, Martini F, D'Alessandro R, Mariotti S, Del Monte G, **Graziano P**, Buonomo O, Guadagni F, Roselli M. **Oncology.** 2005;69(2):145-53. Epub 2005 Aug 24. PubMed PMID: 16127285 (IF=2.455; n. citazioni: 37 (Scopus))
191. Dual role of VEGF in pretreated experimental ePTFE arterial grafts. Randone B, Cavallaro G, Polistena A, Cucina A, Coluccia P, **Graziano P**, Cavallaro A. **J Surg Res.** 2005 Aug;127(2):70-9. PubMed PMID: 15922362 (IF=2.296; n. citazioni: 37 (Scopus))
192. Difficult diagnosis of infliximab-related miliary tuberculosis. Contini S, Raimondi G, **Graziano P**, Saltini C, Bocchino M. **Monaldi Arch Chest Dis.** 2004 Apr Jun;61(2):128-30. PubMed PMID: 15510715 (IF=0.443; n. citazioni: 5 (Scopus))
193. Bronchial carcinoid tumors: nodal status and long-term 12 survival after resection. Cardillo G, Sera F, Di Martino M, **Graziano P**, Giunti R, Carbone L, Facciolo F, Martelli M. **Ann Thorac Surg.** 2004 May;77(5):1781-5. PubMed PMID: 15111186 (IF=2.251; n. citazioni: 188 (Scopus))
194. A new human tumor-associated antigen (TLP) is naturally expressed in rat DHD-K12 colorectal tumor cells. Rasi G, Sinibaldi-Vallebona P, Serafino A, Bernard P, Pierimarchi P, Guarino E, Faticanti-Scucchi L, **Graziano P**, Guadagni F, Garci E. **Int J Cancer.** 2000 Feb 15;85(4):540-4. doi: 10.1002/(sici)1097-0215(20000215)85:4<540::aid-ijc16>3.0.co;2-v.PMID: 10699928 (IF=3.928; n. citazioni: 8 (Scopus))
195. Neuroendocrine tumors of the gastroenteric canal. Anatomopathological and diagnostic-therapeutic definition. Description of a case with a rare cecal localisation. Bonomi M, De Cesare A, Atella F, Angelini M, **Graziano P**, Piat G. **Minerva Endocrinol.** 1999 Sep-Dec;24(3-4):135-42. PubMed PMID: 10953730

196. Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis. Guadagni F, **Graziano P**, Roselli M, Mariotti S, Bernard P, Sinibaldi-Vallebona P, Rasi G, Garaci E. *Am J Pathol.* 1999 Apr;154(4):993-9. PubMed PMID: 10233837; PubMed Central PMCID: PMC1866543 (IF=6.276; n. citazioni: 12 (Scopus))
197. Basic fibroblast growth factor and myointimal hyperplasia after experimental polytetrafluoroethylene arterial grafting. Sterpetti AV, Cucina A, Randone B, **Graziano P**, Stipa F, Corvino V, Cavallaro G, Palmieri I, Amato D, Polistena A, Cavallaro A. *Eur J Surg.* 1999 Aug;165(8):772-6. PubMed PMID: 10494644 (IF=0.467; n. citazioni: 4 (Scopus))
198. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia CEA virus. Kass E, Schlom J, Thompson J, Guadagni F, **Graziano P**, Greiner JW. *Cancer Res.* 1999 Feb 1;59(3):676-83. PubMed PMID: 9973217 (IF=8.834; n. citazioni: 160 (Scopus))
199. Local invasion of gastric cancer: CT findings and pathologic correlation using 5- incremental scanning, hypotonia, and water filling. Rossi M, Broglia L, **Graziano P**, Maccioni F, Bezzi M, Masciangelo R, Rossi P. *AJR Am J Roentgenol.* 1999 Feb;172(2):383-8. PubMed PMID: 9930788 (IF=1.624; n. citazioni: 42 (Scopus))
200. Suppression of smooth muscle cell proliferation after experimental PTFE arterial grafting: a role for polyclonal anti-basic fibroblast growth factor (bFGF) antibody. Randone B, Cucina A, **Graziano P**, Corvino V, Cavallaro G, Palmieri I, 11 Cavallaro A, Sterpetti AV. *Eur J Vasc Endovasc Surg.* 1998 Nov;16(5):401-7. PubMed PMID: 9854551 (IF=1.200 n. citazioni: 4 (Scopus))
201. Neuroendocrine tumors of the gastroenteric canal. Anatomopathological and diagnostic-therapeutic definition. Description of a case with a rare cecal localisation. Bononi M, De Cesare A, Atella F, Angelini M, **Graziano P**, Piat G. *Panminerva Med.* 1998 Jun;40(2):146-53. PubMed PMID: 9689837
202. [Inflammatory fibroid polyp of the stomach. Report of a case]. Tocchi A, Mazzoni G, Liotta G, Costa G, Lepre L, Maggiolini F, **Graziano P**. *G Chir.* 1997 Aug- Sep;18(8-9):413-6. Italian. PubMed PMID: 9471217 n. citazioni: 5 (Scopus)
203. Scintigraphic imaging of hepatic epithelioid hemangioendothelioma. Gianni W, De Vincentis G, **Graziano P**, Ierardi M, Fimognari FL, Banci M, Gazzaniga P, Cacciafesta M, Di Tondo U, Scopinaro F, Marigliano V. *Digestion.* 1997;58(5):498- 500. PubMed PMID: 9383644 (IF=1.414; n. citazioni: 9 (Scopus))
204. Hydro-CT in patients with gastric cancer: preoperative radiologic staging. Rossi M, Broglia L, Maccioni F, Bezzi M, Laghi A, **Graziano P**, Mingazzini PL, Rossi P. *Eur Radiol.* 1997;7(5):659-64. PubMed PMID: 9166562 (IF=0.560; n. citazioni: 43 (Scopus))
205. [Adrenal cysts. Description of a clinical case]. Bononi M, De Cesare A, Atella F, Angelini M, Fiori E, Cangemi V, **Graziano P**, Piat G. *Minerva Chir.* 1997 Jan Feb;52(1-2):117-21. Italian. PubMed PMID: 9102597 n. citazioni: 2 (Scopus)
206. An unusual case of spontaneous rupture of a clinically "silent" pheochromocytoma. Sapienza P, Tedesco M, **Graziano P**, Moretti M, Mingazzini PL, Cavallaro A. *Anticancer Res.* 1997 Jan-Feb;17(1B):717-20. Review. PubMed PMID: 9066607 (IF=0.500; n. citazioni: 12 (Scopus))
207. [Localized fibroma: a rare tumor of pleural origin]. D'Elia G, Lucandri G, Stipa F, **Graziano P**, Gianotti R, Castiglia D, Barreca M, Mingazzini P, Ziparo V, Stipa S. *G Chir.* 1996 Nov-Dec;17(11-12):597-601. Review. Italian. PubMed PMID: 9162184
208. Primary lymphoma of the breast: a case report. Mingazzini PL, Ranieri E, D'Andrea MR, D'Alessio A, **Graziano P**, Virno F. *Anticancer Res.* 1996 Sep-Oct;16(5B):3097-100. PubMed PMID: 8920774 (IF=0.500; n. citazioni: 2 (Scopus))

209. [A case of nodular pseudosarcomatous fasciitis treated with 10 "presuture" technique]. Lombardi A, Spagnoli AM, Leone Sossi F, Caratozzolo M, **Graziano P**, Di Paola M, Marinozzi V. *Minerva Chir.* 1996 May;51(5):365-8. Italian. PubMed PMID: 9072748 **n. citazioni: 1 (Scopus)**
210. [Leiomyosarcoma in jejunal diverticulum. A case report and review of the literature]. Fiori E, Ansali A, Galati G, **Graziano P**, Drudi FM, Maccioni F, Cangemi V. *G Chir.* 1996 May;17(5):269-75. Italian. PubMed PMID: 8755228 **n. citazioni: 3 (Scopus)**
211. Intraocular malignant melanoma. Fiori E, Leone G, Gazzanelli S, **Graziano P**, Baccarini A, Cangemi V, Piat G. *Journal of Experimental and Clinical Cancer Research* Volume 15, Issue 2, Pages 169 - 176 June 1996
212. Peritoneal carcinomatosis in ovarian cancer and synchronous breast cancer. Bonifacino A, Lauro S, Fassone F, Bernardi G, **Graziano P**, Frati L. *Giornale Italiano di Ultrasonologia* Volume 6, Issue 1, Pages 25 – 29 1995 **n. citazioni: 1 (Scopus)**
213. Squamous cell carcinoma of the gallbladder. Lauro S, Bordin F, Fassone F, Mingazzini PL, **Graziano P**, Frati L. *Journal of Experimental and Clinical Cancer Research* Volume 14, Issue 1, Pages 73 – 77 1995
214. Prognostic factors in colorectal cancer. **Graziano, P.**, Limiti, M.R., Mingazzini, P.L. *Journal of Experimental and Clinical Cancer Research*, 14(2 SUPPL.), pp. 5–8 1995.

- **Scopus**

Numero di citazioni: 5252

H-index: 40

- *Il sottoscritto Paolo Graziano, consapevole che le dichiarazioni false comportano l'applicazione delle sanzioni penali previste dall'art.76 del D.P.R. 445/2000, dichiara che le informazioni riportate nel seguente curriculum vitae, redatto in formato europeo, corrispondono a verità. Autorizzo il trattamento dei dati contenuti nel mio cv in base al Regolamento UE 2016/679 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali.*

14 Gennaio 2026

Paolo Graziano



Guido Carpino

Nationality: Italian

 **Home:** Via Alfonso Borelli 50, 00161 Rome (Italy)

WORK EXPERIENCE

 **Sapienza University of Rome** – Rome, Italy

PhD student in Experimental and Clinical Hepatology

[01/11/2003 – 01/11/2006]

 **Catholic University of Leuven** – Leuven, Belgium

University research assistant

[07/01/2007 – 31/08/2007]

 **University of Rome “Foro Italico”** – Rome, Italy

Assistant professor in Human Anatomy (SSD BIO/16 - Anatomia Umana)

[01/10/2007 – 31/10/2015]

 **University of Rome “Foro Italico”** – Rome, Italy

Associate Professor in Human Anatomy (SSD BIO/16 - Anatomia Umana)

[01/11/2015 – 31/10/2022]

 **Sapienza University of Rome** – Rome, Italy

Associate Professor in Human Anatomy (SSD BIO/16 - Anatomia Umana)

[01/11/2022 – Current]

 **Sapienza University of Rome** – Rome, Italy

Full Professor in Human Anatomy. SSD BIOS-12/A – Anatomia Umana (ex BIO/16)

[21/12/2024 – Current]

 **Sapienza University of Rome** – Rome, Italy

Coordinator of the PhD Course in "Epato-Gastroenterologia Sperimentale e Clinica"

[02/2025 – Current]

EDUCATION AND TRAINING

Master Degree cum laude in Medicine and Surgery

Sapienza University of Rome [11/07/2003]

Doctoral degree (Ph.D.) in Experimental and Clinical Hepatology

Sapienza University of Rome [04/2007]

LANGUAGE SKILLS

Mother tongue(s): Italian

Other language(s):

English

LISTENING B2 **READING** C1 **WRITING** B2

SPOKEN PRODUCTION B2 **SPOKEN INTERACTION** B2

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

SKILLS

Microsoft Office / Microsoft Word / Microsoft Excel / Microsoft Powerpoint / Google Docs / Social Media / Zoom / Skype / Facebook / Photoshop / Spss

DIGITAL SKILLS TEST RESULTS

	Information and data literacy	ADVANCED	Level 6 / 6
	Communication and collaboration	ADVANCED	Level 5 / 6
	Digital content creation	ADVANCED	Level 6 / 6
	Safety	ADVANCED	Level 5 / 6
	Problem solving	ADVANCED	Level 5 / 6

Results from a [self-assessment](#) based on [The Digital Competence Framework 2.1](#)

HONOURS AND AWARDS

[2014] Sapienza University of Rome

Distinguished PhD for the Solemn Ceremony for the 30th year of Doctorate at Sapienza University.

[2013] Italian Society of Anatomy and Histology.

Young Researcher Award

[2010] A.I.S.F. Italian Association for the Study of the Liver.

Best oral communication

[2010] Italian Societies of Gastroenterology and Endoscopy

Best oral communication

NETWORKS AND MEMBERSHIPS

Italy

Italian Society of Anatomy and Histology.

European Network for the Study of Cholangiocarcinoma Steering Committee Member

COST ACTION Euro-Cholangionet (CA18122) Working Group Leader

STITCH Steering Committee Member

[01/01/2022 – 31/12/2025] Steering Committee Member

Collegio dei Docenti di Anatomia Umana (Committee of Professors in Human Anatomy)

[01/06/2022 – Current] Research Committee member

Italian Society of Anatomy and Histology.

RESEARCH ACTIVITIES

Bibliometric Indicators

Number of Publications: 194 (Scopus)

H-Index: 66 (Scopus)

Total Number of Citations: 31767 (Scopus)

Selection of 10 representative publications (last 10 years)

1. Cardinale V, **Carpino G***...Reid LM, Alvaro D, Gaudio E. Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential. *J Hepatol* **2023;78(1):165-179**. *co-first and corresponding author.
2. Kennedy L, **Carpino G**, Owen T, Ceci L, Kundu D, Meadows V, Kyritsi K, Franchitto A, Onori P, Isidan A, Zhang W, Ekser B, Alvaro D, Gaudio E, Gershwin ME, Francis H, Glaser S, Alpini G. Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes. *J Hepatol*. **2023 Jan; 78(1):99-113**.
3. Calvisi DF, Boulter L, Vaquero J, Saborowski A, Fabris L, Rodrigues PM, Coulouarn C, Castro RE, Segatto O, Raggi C, van der Laan LJW, **Carpino G**...Fouassier L. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.CCA Model Consortium. *Nat Rev Gastroenterol Hepatol*. **2023**, doi: **10.1038/s41575-022-00739-y**.
4. Izquierdo-Sanchez L, Lamarca A...**Carpino G**...Banales JM.Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. *J Hepatol*. **2022 May;76(5):1109-1121**.
5. **Carpino G**, Cardinale V, Di Giamberardino A, Overi D, Donsante S, Colasanti T, Amato G, Mennini G, Franchitto M, Conti F, Rossi M, Riminucci M, Gaudio E, Alvaro D, Mancone C Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. *J Hepatol* **2021:S0168-8278(21)01947-4**.
6. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, **Carpino G**...Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. *Nat Rev Gastroenterol Hepatol*. **2020;17(9):557-588**.
7. **Carpino G**, Del Ben M, Pastori D, Carnevale R, Baratta F, Overi D, Francis H, Cardinale V, Onori P, Safarikia S, Cammisotto V, Alvaro D, Svegliati-Baroni G, Angelico F, Gaudio E, Violi F. Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. *Hepatology*. **2020 Aug;72(2):470-485**.
8. **Carpino G**, Nevi L, Overi D, Cardinale V, Lu WY, Di Matteo S, Safarikia S, Berloco PB, Venere R, Onori P, Franchitto A, Forbes SJ, Alvaro D, Gaudio E. Peribiliary Gland Niche Participates in Biliary Tree Regeneration in Mouse and in Human Primary Sclerosing Cholangitis. *Hepatology* **2020;71(3):972-989**.
9. **Carpino G**, Cardinale V, Folseraas T, Overi D, Grzyb K, Costantini D, Berloco PB, Di Matteo S, Karlsen TH, Alvaro D, Gaudio E. Neoplastic transformation of peribiliary stem cell niche in cholangiocarcinoma arisen in primary sclerosing cholangitis. *Hepatology*. **2019 Feb;69(2):622-638**.
10. **Carpino G**, Cardinale V, Renzi A, Hov JR, Berloco PB, Rossi M, Karlsen TH, Alvaro D, Gaudio E.Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis. *J Hepatol* **2015;63(5):1220-8**.

Patents

2019: Stem/progenitor cells from duodenal brunner's glands and methods of isolating and using them. US patent application # 20190300849

2018: Cryopreservation method. US patent application #20180295834

2014: Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree. Patent # 20140301985.

2011: Multipotent Stem Cells from the Extrahepatic Biliary Tree and Methods of Isolating Same. Patent #20110135610.

Grants

2020-2022: Forst - Fondazione per la Ricerca Scientifica Termale

Title: Impact of treatment with calcium-sulphate-bicarbonate water on liver steatosis and gut microbiota in NAFLD. **Role:** Principal Investigator

2017: FFABR (Fondo per il Finanziamento delle Attività Base di Ricerca) 2017

2015-2018: Sponsored Research Grant, Vesta Therapeutics, Inc.

Title: Implementation of patent "Multipotent Stem Cells from the Extrahepatic Biliary Tree and Methods of Isolating Same".
Role: co-investigator

Completed Research Support

2011-2016: Italian Ministry of University and Research (MIUR) - FIRB project 2005.

Title: Isolation of multipotent stem cells from extra-hepatic biliary tree and their differentiation in hepatic and pancreatic fate: preclinical studies and potential clinical application **Role:** co-investigator.

2011-2014: Italian Ministry of University and Research (MIUR) - PRIN project 2009.

Title: Differentiation in vitro and in vivo of multipotent Stem Cells from Human Extrahepatic Biliary Tree in cholangiocytes, hepatocytes, pancreatic cells: detection of proliferation and differentiation phenotypic markers. **Role:** co-investigator.

2008-2010 Italian Ministry of University and Research (MIUR) - PRIN project 2007.

Title: Role and mechanisms of IGF1 system in proliferation and activation of resident stem cell compartment in experimental models of liver damage and in chronic liver diseases. **Role:** co-investigator.

2006-2008: Italian Ministry of University and Research (MIUR) - PRIN project 2005.

Title: Role of IGF1 and IGF1 isoforms in the liver in the regulation of stem cells compartment and neoangiogenesis during liver damage. **Role:** co-investigator.

TEACHING ACTIVITIES

Courses at Sapienza University of Rome 2022-2023

Degree: Scienze Farmaceutiche Applicate - **Course:** Human Anatomy

Degree: Biotecnologie Farmaceutiche - **Course:** Physiology and Anatomy

Degree: Medicina e chirurgia "A" - **Course:** Human Anatomy

Degree: Tecniche di laboratorio biomedico - **Course:** Human Anatomy and Physiology

Degree: Biotecnologie - **Course:** Anatomy and General Physiology

Degree: Infermieristica "A" - **Course:** Morphological and Functional Basis of Human Body

Degree: Tecniche di fisiopatologia cardiocircolatoria e perfusione cardiovascolare - **Course:** Human Anatomy

PhD course in experimental and clinical hepato-gastroenterology

Member of Scientific Board

AUTORIZZAZIONE AL TRATTAMENTO DEI DATI PERSONALI

Autorizzazione al trattamento dei dati personali

"Ai sensi e per effetto del Regolamento (UE) 2016/679 DEL PARLAMENTO EUROPEO E DEL CONSIGLIO del 27 aprile 2016 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali, autorizzo al trattamento dei dati e delle informazioni contenute nel curriculum vitae ai fini del procedimento ECM, consapevole che il CV verrà incluso nell'allegato all'atto della validazione della richiesta di accreditamento, e che sarà visibile nella Banca Dati del sito ECM, accessibile a tutti gli utenti e tramite INTERNET (motori di ricerca). Autorizzo altresì il trattamento ai fini della trasmissione (successiva allo svolgimento dell'evento formativo) alla Commissione Nazionale per la Formazione Continua"

DATA PRIVACY STATEMENT

Data Privacy Statement

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV

Roma, 30/01/2026



Guido Carpino

Il Prof. Alessio Molfino è un medico e ricercatore italiano, specializzato in Medicina Interna e Nutrizione Clinica. Attualmente è Assistant Professor (Ricercatore) presso la [Sapienza Università di Roma](#) Department of Translational and Precision Medicine

e opera presso il [Policlinico Umberto I](#), focalizzandosi su nutrizione oncologica, metabolismo e cachessia neoplastica.

Formazione e Carriera Accademica:

- **Laurea in Medicina e Chirurgia (MD):** Conseguita presso la Sapienza Università di Roma (110/110 e lode) nel 2003.
- **Specializzazione in Medicina Interna:** Completata con lode alla Sapienza nel 2008.
- **Dottorato di Ricerca (PhD):** In Nutrizione Clinica e Preventiva presso l'Università di Roma Tor Vergata (2012).
- **Post-Dottorato:** Sapienza Università di Roma (2012-2015).
- **Posizione attuale:** Assistant Professor (MED/05) presso la Sapienza Università di Roma.

Aree di Ricerca e Competenza:

- **Nutrizione Clinica:** Particolare focus sulla malnutrizione e sui percorsi nutrizionali per pazienti oncologici.
- **Tessuto Adiposo:** Studio delle modificazioni del tessuto adiposo (sottocutaneo e viscerale) nella cachessia neoplastica.
- **Malattie Metaboliche:** Ricerca legata alla nutrizione preventiva

Dr. Alberto Breda, MD

Head of the Oncology Urology Unit and Kidney Transplant Surgical Team
Urology Department, Fundació Puigvert, Barcelona



Dr. Alberto Breda is a Urologic Surgeon specialized in uro-oncology and kidney transplantation with special interest in minimally invasive surgery.

He obtained his medical degree from the University of Padova School of Medicine and Surgery where he also completed his Urology Residency and PhD in renal cryotherapy. He then completed a clinical Research Fellowship at the David Geffen School of Medicine at the University of California (UCLA), with a subsequent appointment as Clinical Instructor and Assistant Professor. During this period, Dr. Breda gained expertise in endourology with flexible instruments and lasers and in minimally invasive, laparoscopic and robotic-assisted techniques.

In 2009 he joined the Urology Department of Fundació Puigvert in Barcelona where he currently holds the position of Head of the Oncology Urology Unit and Kidney Transplant Surgical Team.

Dr. Breda has authored over 200 articles in indexed urological journals and 20 chapters in specialized books as well as several videos on surgical techniques. He has more than 300 papers presented in congresses and scientific meetings, some of them awarded and has been invited to participate as guest lecturer and as guest surgeon in many of them. He has organized many national and international urological courses and masterclasses.

He is member of several editorial Boards of international journals and member of several scientific societies, including the Spanish Urological Association (AEU), the European Association of Urology (EAU), the Endourological Society and the Italian Society of Urology (SIU). Furthermore he is Honorary Member of several international societies.

Since 2015 he is Chairman of the European Guidelines in Kidney Transplantation. In 2016 he was appointed as Chairman of the Laparoscopic Group of the ESUT/EAU and Director of Robotic Courses in Kidney Transplantation of the ERUS/EAU. He is currently Chair elect of the ERUS Society (position that he will take in March 2021).

INFORMAZIONI PERSONALI



Benanti Paolo

 Via dei Fori Imperiali 1, 00186 Roma (Italia)



 benanti@unigre.it

 <https://www.paolobenanti.com>

 Skype pbenanti@live.com

POSIZIONE RICOPERTA

Docente universitario e in istituti di insegnamento superiore/Docente universitaria e in istituti di insegnamento superiore

ESPERIENZA
PROFESSIONALE

04/10/2009–alla data attuale

Docente universitario e in istituti di insegnamento superiore/Docente universitaria e in istituti di insegnamento superiore
Pontificia Università Gregoriana, Roma (Italia)

04/10/2008–29/06/2018

Docente universitario e in istituti di insegnamento superiore/Docente universitaria e in istituti di insegnamento superiore
Istituto Teologico di Assisi, Assisi (Italia)

04/10/2008–29/06/2018

Docente universitario e in istituti di insegnamento superiore/Docente universitaria e in istituti di insegnamento superiore
Pontificio Collegio Leoniano, Anagni (Italia)

ISTRUZIONE E FORMAZIONE

2009–2012

Dottorato di ricerca
Pontificia Università Gregoriana, Roma (Italia)
Tesi: "The Cyborg. Corpo e corporeità nell'epoca del postumano"

2006–2008

Licenza in Teologia Morale
Pontificia Università Gregoriana, Roma (Italia)

2001–2006

Baccalaureato in Teologia
Istituto Teologico di Assisi, Assisi (Italia)

1988–1993

Diploma maturità classica
Marco Tullio Cicerone, Frascati (Italia)

COMPETENZE PERSONALI

Lingua madre

italiano

Lingue straniere

COMPRENSIONE	PARLATO	PRODUZIONE SCRITTA
--------------	---------	--------------------

	Ascolto	Lettura	Interazione	Produzione orale	
inglese	C2	C2	C2	C2	C1
tedesco	B2	B2	B2	B2	B2
Deutsche Zertifikate B1					

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato

Quadro Comune Europeo di Riferimento delle Lingue

Competenze comunicative

- buone competenze comunicative acquisite durante l'insegnamento
- buone competenze di public speaking acquisite con conferenze nazionali e internazionali

Competenze digitali

AUTOVALUTAZIONE				
Elaborazione delle informazioni	Comunicazione	Creazione di Contenuti	Sicurezza	Risoluzione di problemi
Utente avanzato	Utente avanzato	Utente avanzato	Utente avanzato	Utente avanzato

Competenze digitali - Scheda per l'autovalutazione



Europass Curriculum Vitae

Informazioni personali

Nome / Cognome **Paola Frati**

Cittadinanza Italiana

Data di nascita 02/09/1968

Sesso F

Settore professionale MED/43 MEDICINA LEGALE

Esperienza professionale

Data 2023

Lavoro o posizione ricoperti Coordinatrice Sezione di Medicina Legale

Principali attività e responsabilità Coordinamento

Nome e indirizzo del datore di lavoro Università Sapienza di Roma

Tipo di attività o settore Medicina Legale

Data 2021

Lavoro o posizione ricoperti Vicepresidente INSH (Italian Network For Safety In Healthcare)

Principali attività e responsabilità Consiglio Direttivo

Nome e indirizzo del datore di lavoro Italian Network for Safety in Healthcare

Tipo di attività o settore Sicurezza e Qualità delle cure

Data 2021

Lavoro o posizione ricoperti Professore Ordinario di Medicina Legale

Principali attività e responsabilità Insegnamento

Nome e indirizzo del datore di lavoro Università La Sapienza di Roma

Tipo di attività o settore Facoltà di farmacia e Medicina

Data	Dal 2001 al 2021
Lavoro o posizione ricoperti	Professore Universitario
Principali attività e responsabilità	Insegnamento in: Università La Sapienza di Roma: Integrated Course in medical science methodology and human science IV , VII e XI Integrated Course Coordinator: Scientific Medical and Human Science Methodology IV. Integrated Course Coordinator: Medical and Scientific Methodology and Human Science VII. Specialization Schools [Forensic Medicine, Neurology, Nuclear Medicine, Pathology, General Pathology, Pharmacology, Otolaryngology, Vascular Surgery, Urology, Neurosurgery] Law Degree Nursing Degree, Integrated Health Law Course, Ethics, applied Ethics and Bioethics; Coordinator of Integrated Course: Health Law, applied Ethics and Bioethics, Professor of Forensic Medicine. Obstetrics Degree: Professor of the Integrated Forensic and Preventive Medical Course; Forensic Medicine Professor Master in Health Economics and Medical Ethics Master in Psycho-Oncology Master in Nursing Science and Theater Master in risk analysis and CBRN emergency management Master in Forensic Psychiatry Master in Geriatric Case Management Master in Prenatal Diagnosis and Fetal Pathology Università di Foggia: Master in Forensic Dentistry Università di Firenze: Master in Forensic Odontology
Nome e indirizzo del datore di lavoro	Università La Sapienza di Roma, Università di Foggia, Università di Firenze
Tipo di attività o settore	Facoltà di Farmacia e Medicina
Data	Dal 2009 al 2021
Lavoro o posizione ricoperti	Coordinatore di progetto
Principali attività e responsabilità	Cofin Project: "Molecular biological techniques in archaeological anthropology for a new disease history", Ateneo Project: "The history of the health organization in Italy: regulatory, jurisprudential, economic and ethical evolution" "New frontiers in forensic chronothanatology: multiparametric characterization of vitreous humor" "Stem cell biology in development, tissue regeneration and ageing and fundamental aspects of stem cell-based therapies", INAIL BRIC Project: "Biological, physical and chemical risk assessment and management during judicial inspection and necropsy activities"
Name and address of employer	Cofin,Ateneo
Tipo di attività o settore	Settore scientifico
Data	2008/2009
Lavoro o posizione ricoperti	Coordinatore di progetto
Principali attività e responsabilità	Ateneo Project: "Forensic Medicine, anthropological and legal history of abortion"
Nome e indirizzo del datore di lavoro	Ateneo
Tipo di attività o settore	Settore scientifico
Data	2007
Lavoro o posizione ricoperti	Coordinatore di progetto
Principali attività e responsabilità	Ateneo Project: "Body and Mind disorders: sadness, anorexia and tuberculosis between medicine and literature"

Nome e indirizzo del datore di lavoro	Ateneo
Tipo di attività o settore	Settore scientifico
Data	From 1998 to 2021
Lavoro o posizione ricoperti	Professore Universitario
Principali attività e responsabilità	Insegnamento in: Biomedical Laboratory Technician Degree, General and Applied Hygiene Integrated Course, Forensic Medicine, Safety and Radiation Protection principles. Physiotherapy Degree, Teaching and Health Management Integrated Course.
Nome e indirizzo del datore di lavoro	Università La Sapienza di Roma
Tipo di attività o settore	I ^A Faculty of Medicine and Surgery /IRCSS Neuromed
Data	2006
Lavoro o posizione ricoperti	Coordinatore di progetto
Principali attività e responsabilità	Ateneo Project: "From medical therapy to rehabilitation: children with disabilities in Italy in the twentieth century"
Nome e indirizzo del datore di lavoro	Ateneo
Tipo di attività o settore	Settore scientifico
Data	2006
Lavoro o posizione ricoperti	Professor of Higher education Courses
Principali attività e responsabilità	Insegnamento in: Management and health information Experimental drugs and bioethics Applied anthropology and bioethics
Nome e indirizzo del datore di lavoro	Università La Sapienza di Roma
Tipo di attività o settore	I ^A Faculty of Medicine and Surgery
Data	2006
Lavoro o posizione ricoperti	Professor of Higher education Courses
Principali attività e responsabilità	Insegnamento in: Risk Management, Health Risk Management and patient safety, Health Responsibility
Nome e indirizzo del datore di lavoro	Academy of Medicine
Tipo di attività o settore	Medicina
Data	2004
Lavoro o posizione ricoperti	Coordinatore di progetto
Principali attività e responsabilità	Progetto di Ateneo: "Human blood form the past to the present: historical, ethical, anthropological and psycho-social aspects"
Nome e indirizzo del datore di lavoro	Ateneo
Tipo di attività o settore	Settore scientifico
Data	Dal 1996 al 2004
Lavoro o posizione ricoperti	University Professor
Principali attività e responsabilità	Insegnamento in: Nursing Degree, Health Law Integrated Course, Ethics, applied Ethics and Bioethics
Nome e indirizzo del datore di lavoro	Università La Sapienza di Roma - ASL
Tipo di attività o settore	Pentria (Isernia Hospital)

Data	Dal 1997 al 1999
Lavoro o posizione ricoperti	Professore Universitario
Principali attività e responsabilità	Insegnamento in: Coordination Course for continuous quality improvement activities in Health Services Companies
Nome e indirizzo del datore di lavoro	Università di Perugia
Tipo di attività o settore	Facoltà di Medicina e Chirurgia

Istruzione e formazione

Date	Dal 2010 al 2019
Titolo della qualifica rilasciata	Member of Ethics Committee, Member of the Council of the Italian Society of Forensic Medicine, Member of the Council of GISDI Member of the Council of the Italian Society of Forensic Dentistry Member of the Committee for the organization of forensic medicine days Member of the National Bioethics Committee
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Italian Society of Forensic Medicine, Italian Society of Forensic Dentistry Policlinico "Umberto I" - Roma

Date	2006
Titolo della qualifica rilasciata	Ordinary Professor for the scientific sector MED/43
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università di Macerata

Date	2001
Titolo della qualifica rilasciata	Associated Professor for the scientific sector F22B Legal Medicine, now MED/43
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università di Firenze

Date	2001
Titolo della qualifica rilasciata	Associated Professor for the scientific sector F02X History of Medicine (for Bioethics discipline), now called MED/02
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Campus Biomedico di Roma

Date	Dal 1999 al 2001
Titolo della qualifica rilasciata	University researcher, scientific-disciplinary sector F22B Forensic Medicine
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università di Macerata, Facoltà di Legge

Date	Dal 1999 al 2003
Titolo della qualifica rilasciata	Member of the Bioethics Commission
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	National Research Council Rome

Date	Dal 1996 al 1997
Titolo della qualifica rilasciata	Member at the Scientific Direction of the health law and bioethics Foundation
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	IRCSS Neurological Institute Foundation C. Mondino, Pavia

Date	Dal 1998 al 2000
------	------------------

Titolo della qualifica rilasciata	Ethics committee consultant
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	ASL 5 Pisa
Date	1997
Titolo della qualifica rilasciata	Mac Lean Center for Medical Ethics, Course on <i>Medical Bioethics applied to Biotechnologies</i> (S. Margherita di Pula, CA) – modulo II
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	National Academy of Medicine, Rome-Chicago University
Date	1997
Titolo della qualifica rilasciata	Mac Lean Center for Medical Ethics, Course on <i>Medical Bioethics applied to Biotechnologies</i> (Chicago, Ill.) – modulo I
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Chicago University
Date	1997
Titolo della qualifica rilasciata	Attainment of Lawyer title
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Roma
Date	1996
Titolo della qualifica rilasciata	Enabling to practice the legal profession
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Corte di Appello di Roma
Date	Dal 1993 al 1996
Titolo della qualifica rilasciata	Health Law and Bioethics researcher, operating unit of the Scientific Direction
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	IRCSS Mediterranean Institute of Neuroscience Neuromed, Pozzilli (IS) - Roma
Date	1993
Titolo della qualifica rilasciata	Course in Civil, Criminal and Administrative Law
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	School of Legal Studies di Roma
Date	Dal 1992 al 1994
Titolo della qualifica rilasciata	Legal Internship
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Avvocatura di Stato di Roma
Date	1992
Titolo della qualifica rilasciata	Criminal and Civil Law Specializing Course
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	CEIDA di Roma
Date	1992
Titolo della qualifica rilasciata	Specializing Course for the electronic search of legal documentation
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Suprema Corte di Roma
Date	Dal 1988 al 1991

Titolo della qualifica rilasciata	Laurea Magistrale
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università La Sapienza di Roma
Date	1988
Titolo della qualifica rilasciata	Diploma di Maturità
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Liceo Cornelio Tacito di Roma

Capacità e competenze personali

Madrelingua (e) **Italiano**

Altra(e) lingua(e)

Autovalutazione

Livello europeo ()*

Inglese

Lingua

Comprensione				Parlato				Scritto	
Ascolto		Lettura		Interazione orale		Produzione orale			
C1	Advanced	C1	Advanced	C1	Advanced	C1	Advanced	C1	Advanced

(*) [Quadro comune europeo di riferimento per le lingue](#)

Firma

Il/la sottoscritto/a, ai sensi degli articoli 46 e 47 del decreto del presidente della repubblica 28 dicembre 2000, n.445, consapevole delle sanzioni penali per dichiarazioni mendaci, falsità in atti ed uso di atti falsi ai sensi dell'articolo 76 del citato decreto del presidente della repubblica n.445/00, dichiara sotto la propria responsabilità che i contenuti del presente CV risultano veritieri.

Autorizzo il trattamento dei miei dati personali presenti nel CV in conformità con l'art. 13 del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e dell'art. 13 del GDPR (Regolamento UE 2016/679)

Paola Frati

Roma, 09 gennaio 2026

Paola Frati
Professore Ordinario di Medicina Legale
Sezione di Medicina Legale
Dipartimento di Scienze Anatomiche, Istologiche,
Medico Legali e dell'Apparato Locomotore
Sapienza Università di Roma
Viale Regina Elena 336
00161 Roma, Italia
tel: +390649912619
fax: +390649912097



Renato Cuocolo

Date of birth: 20/04/1986 | **Nationality:** Italian | **Email address:** rcuocolo@unisa.it | **Website:** <https://rcuocolo.github.io/> | **Address:** Via Salvador Allende, 43, 84081, Baronissi, SA, Italy (Work)

WORK EXPERIENCE

01/03/2022 – CURRENT Baronissi, Italy

ASSOCIATE PROFESSOR DEPARTMENT OF MEDICINE, SURGERY AND DENTISTRY "SCUOLA MEDICA SALERNITANA", UNIVERSITY OF SALERNO

01/03/2023 – CURRENT Salerno, Italy

CONSULTANT RADIOLOGIST SAN GIOVANNI DI DIO E RUGGI D'ARAGONA UNIVERSITY HOSPITAL

Incarico professionale ad alta specializzazione "RM Funzionale Universitaria"

01/10/2022 – CURRENT Salerno, Italy

CONSULTANT RADIOLOGIST SAN GIOVANNI DI DIO E RUGGI D'ARAGONA UNIVERSITY HOSPITAL

Head of the "Tecniche innovative di analisi dei dati nell'imaging radiologico come strumento per l'ottimizzazione dei percorsi assistenziali" program

15/06/2020 – 28/02/2022 Naples, Italy

RESEARCH FELLOW DEPARTMENT OF CLINICAL MEDICINE AND SURGERY, UNIVERSITY OF NAPLES "FEDERICO II"

17/12/2020 – 28/02/2022 Naples

RADIOLOGIST "FEDERICO II" UNIVERSITY HOSPITAL

18/07/2017 – 31/01/2020 Naples, Italy

RADIOLOGIST "FEDERICO II" UNIVERSITY HOSPITAL

04/07/2012 – 04/07/2017 Naples, Italy

RADIOLOGY RESIDENT "FEDERICO II" UNIVERSITY HOSPITAL

EDUCATION AND TRAINING

01/02/2017 – 26/05/2020 Naples, Italy

PHD IN BIOMORPHOLOGICAL AND SURGICAL SCIENCES Department of Advanced Biomedical Sciences, University of Naples "Federico II"

05/07/2012 – 05/07/2017 Naples, Italy

RESIDENCY IN RADIOLOGY Department of Advanced Biomedical Sciences, University of Naples "Federico II"

10/10/2011 Naples, Italy

DOCTOR OF MEDICINE University of Campania "Luigi Vanvitelli"

LANGUAGE SKILLS

Mother tongue(s): **ITALIAN**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
ENGLISH	C2	C2	C2	C2	C2

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

DIGITAL SKILLS

Office Software

Microsoft Word | Microsoft Excel | Microsoft Powerpoint

Scripting

R | Python | Bash | Git | Pandas

Medical Image Analysis

Freesurfer | FSL | OleaSphere | PyRadiomics

Machine Learning

Scikit-Learn | Weka

NETWORKS AND MEMBERSHIPS

CURRENT

Albo professionale dell'Ordine Provinciale dei Medici-Chirurghi e degli Odontoiatri di Napoli

CURRENT

Società Italiana di Radiologia Medica e Interventistica

CURRENT

European Society of Radiology

CURRENT

European Society of Medical Imaging Informatics

CURRENT

European Society of Urogenital Radiology

CONFERENCES AND SEMINARS

02/10/2017 – 10/11/2018 Genova, Italy

48th National Congress SIRM 2018

Member of the Neuroradiology Scientific Subcommittee

23/10/2021

European Society of Medical Imaging Informatics Virtual Annual Meeting 2021

Invited Speaker: "Assessing research quality in radiomics and AI"

12/11/2021 – 14/11/2021

27th European Symposium on Urogenital Radiology

Invited Speaker: "Radiomics and AI in Genitourinary Imaging: Basic Concepts and State of the Art"

2020 – 2022 Lecce, Italy

1st International Workshop on Artificial Intelligence and Radiomics in Computer-Aided Diagnosis (AIRCAD 2022)

In conjunction with the 21st International Conference on Image Analysis and Processing (ICIAP 2021)

Member of the Technical Program Committee

2020 – 2022 Rome, Italy

2022 IEEE International Conference on Metrology for Extended Reality, Artificial Intelligence and Neural Engineering

Member of the International Scientific Program Committee

13/10/2022 – 16/10/2022

28th European Symposium on Urogenital Radiology

Invited Speaker: "How to interpret Radiomics/AI papers"

01/03/2023 – 05/03/2023 Vienna, Austria

European Congress of Radiology (ECR) 2023

Invited Speaker:

- "AI: where are we and where are we going"
- "Classical signs in urological imaging"
- "Radiomics: level of evidence for the clinical practice"

Moderator:

- "AI in genitourinary imaging: will it improve your performance?"

21/09/2023 – 24/09/2023 Rome, Italy

29th European Symposium on Urogenital Radiology

Invited Speaker: "Radiomics in GU: where do we cross the line?"

05/10/2023 – 07/10/2023 St. Julian's, Malta

ESHNR 2023: 35th Annual Meeting and Refresher Course

Invited Speaker: "Quality control and critical issues in radiomics research and software"

13/10/2023 – 14/10/2023 Pisa, Italy

EuSoMII Annual Meeting 2023. AI: Connecting the Dots

Invited Speaker: "Radiomics Quality - EuSoMII Radiomics Group"

Moderator: "Large Language models in Radiology"

28/02/2024 – 03/03/2024 Vienna, Austria

European Congress of Radiology (ECR) 2024

Member of the "Imaging Informatics/Artificial Intelligence and Machine Learning" scientific subcommittee.

Invited Speaker:

- "Read avidly but think critically: must-have qualities to look for in radiomics research"
- "Radiology and AI: team member or terminator?"

Discussant:

- "Deep learning-aided classification of disease distribution patterns in metastatic ovarian cancer"

27/06/2024 – 29/06/2024 Zeist, Netherlands

12th ESUR MRI Prostate Teaching Course

Invited Speaker: "What are the essentials/basics in AI/CAD tools in MRI assessment?"

19/09/2024 – 22/09/2024 Lisbon, Portugal

30th European Symposium on Urogenital Radiology

Invited Speaker: "New trends and future challenges in Imaging"

11/10/2024 – 12/10/2024 Pisa, Italy

EuSoMII Annual Meeting 2024. AI: Ready for prime time?

Invited Speaker: "Inclusivity and biases in radiology, AI and the workforce"

Moderator: "Burning topics in imaging informatics"

26/02/2025 – 02/03/2025 Vienna, Austria

European Congress of Radiology (ECR) 2025

Member of the "Imaging Informatics/Artificial Intelligence and Machine Learning" scientific subcommittee.

Invited Speaker:

- "Clinical AI products in body imaging: an overview"
- "What to consider when reviewing AI papers"

Panelist:

- "Realising the Quadruple Aim through AI: assessing economic, staffing and accessibility dimensions"

European Congress of Radiology (ECR) 2026

Member of the "Imaging Informatics/Artificial Intelligence and Machine Learning" scientific subcommittee.

HONOURS AND AWARDS

Invest in the Youth – European Congress of Radiology 2017

Voice of EPOS – European Congress of Radiology 2017

Award received for "Potential pachymeningeal pitfalls in metastatic patients: correlative PET, CT and MR imaging findings"

Reviewer of the Year 2019 – European Journal of Radiology

MSK SIRM Catania 2019 Award – Congresso Nazionale della Sezione di Radiologia Muscoloscheletrica

Award received for "T2 Mapping of the Sacroiliac Joints at 1.5 T can Identify Patients with Spondyloarthritis"

MSK SIRM Catania 2019 Award – Congresso Nazionale della Sezione di Radiologia Muscoloscheletrica

Award received for "Machine Learning Classification of Spinal Lesions: Compared Accuracy of Texture Parameters Extracted by Different Software"

Cum Laude Award – 49th National SIRM Congress

Award received for "Classificazione dei condrosarcomi ossei mediante parametri di radiomica estratti con algoritmi di machine learning"

ESNR-Springer Award 2022 Diagnostic Neuroradiology – European Society of Neuroradiology

Co-first author of the paper receiving the award, titled "Prediction of high proliferative index in pituitary macroadenomas using MRI-based radiomics and machine learning".

10/2023

Most Cited Paper Award 2023 – European Society of Medical Imaging Informatics

10/2024

Most Downloaded Paper Award 2024 – European Society of Medical Imaging Informatics

APPOINTMENTS

2018 – CURRENT

Member of the European Network for Assessment of Imaging in Medicine (EuroAIM)

The European Network for Assessment of Imaging in Medicine (EuroAIM) is a joint initiative of the European Institute for Biomedical Imaging Research (EIBIR) whose objective is to systematically assess radiological technology and seek evidence for its best use in clinical practice.

2019 – 2022

Participant in the HosTed project, sponsored by EIT Health (European Institute of Innovation and Technology)

Write here the description...

2020 – CURRENT

Member of the Laboratory of Augmented Reality for Health Monitoring (ARHeMLab)

2020 – 2022

Member of the Interdepartmental Research Center on Management and Innovation in Healthcare - CIRMIS of the University of Naples "Federico II"

2020 – CURRENT

Member of the European Society of Medical Imaging Informatics Young Club Committee

2020 – CURRENT

Member of the European Society of Urogenital Radiology Junior Network Committee

2020 – CURRENT

Member of the Res4Net Laboratory Network

2020 – CURRENT

Scientific Coordinator of the European Society of Medical Imaging Informatics Radiomics Auditing Group

2021 – 2025

Member of the European Society of Medical Imaging Informatics Scientific Committee

2022 – 2025

Member of the European Society of Radiology (ESR) eHealth and Informatics Subcommittee

2023 – 2025

Board Member of the European Society of Medical Imaging Informatics

2024 – CURRENT

ESUR Prostate MRI Working Group

2025 – CURRENT

Chair of the European Society of Medical Imaging Informatics Scientific Committee

2025 – CURRENT

Chair of the European Society of Radiology (ESR) eHealth and Informatics Subcommittee

2025 – CURRENT

Member of the European Society of Radiology (ESR) e-Learning Subcommittee

● GRANTS

01/10/2020 – 31/03/2024

INCISIVE - A multimodal AI-based toolbox and an interoperable health imaging repository for the empowerment of imaging analysis related to the diagnosis, prediction and follow-up of cancer

Participant in the University of Naples "Federico II" unit of the project. The INCISIVE project was funded by the EU HORIZON2020 program (H2020-SC1-FA-DTS-2019-1 sub call), for a total of € 9,995,727.50.

01/04/2023 – CURRENT

COMFORT – COMPUTational Models FOR patient stratification in urologic cancers – Creating robust and trustworthy multimodal AI for healthcare

Participation as lead of the University of Salerno unit (main collaboration partner).
Funded by the European Union's Horizon Europe program (TOPIC ID: HORIZON-HLTH-2022-TOOL-12-01-two-stage) for a total of € 5.9 million.

18/10/2023 – 18/10/2025

PREDICTION OF SHORT-TERM SUBJECTIVE AND OBJECTIVE DISABILITY WORSENING IN MULTIPLE SCLEROSIS: A MACHINE LEARNING APPROACH

Unit lead of the University of Salerno.
Project co-financed by the MIUR - Ministero dell'Istruzione dell'Università e della Ricerca for a total of € 204,776.

31/08/2024 – CURRENT

Advancing Lung Cancer Screening: Artificial Intelligence, Multimodal Imaging and Cutting-Edge Technologies for Early Detection and Characterization

Unit lead for the San Giovanni di Dio e Ruggi d'Aragona University Hospital.
Funded by the Italian Ministry of Health (PNRR: M6/C2_CALL 2023) for a total funding of € 1,000,000.

● EDITORIAL ACTIVITY

2019 – CURRENT

Editorial Board Member, European Radiology

Author of over 180 articles published on indexed journals (Scopus, Web of Science, Pubmed), with an H-index of 36 (Scopus).

2019 – 2023

Editorial Board Member, BMC Medical Imaging

2020 – CURRENT

Editorial Board Member, European Radiology Experimental

2020 – CURRENT

Editorial Board Member, International Journal of Imaging Systems and Technology

2023 – CURRENT

Editorial Board Member, European Journal of Radiology

2023 – CURRENT

Editorial Board Member, Canadian Association of Radiologists Journal

2024 – CURRENT

Editorial Board Member, European Journal of Radiology Artificial Intelligence

Research activity

● **TEACHING ACTIVITY**

2022 – CURRENT

Radiology Residency Program, University of Salerno

Teaching assignment in the 34th, 35th and 36th cycles of the course.

2021 – CURRENT

Degree Course in Medicine, University of Salerno

2022 – CURRENT

Degree Course in Nursing, University of Salerno

2022 – CURRENT

Degree Course in Physical Therapy, University of Salerno

2022 – CURRENT

Degree Course in Radiation Technology, University of Salerno

2023 – CURRENT

Degree Course in Dentistry, University of Salerno

2020 – 2022

PhD program in "Biomorphological and Surgical Sciences" at the University of Naples "Federico II"

2019 – 2022

School of Medicine, University of Naples "Federico II"

2017 – 2022

Radiology residency program, University of Naples "Federico II"

2016 – 2020

Diagnostic Imaging course, University of Naples "Parthenope"

2015 – 2017

Metodologia e studio per la preparazione al concorso di accesso alle Scuole di Specializzazione Medica, Istituto per Ricerche ed Attività Educative

Professor Pietro Liò

Position I am Full Professor of Computational Biology in the Artificial Intelligence Division of the Department of Computer Science and Technology of the University of Cambridge

Personal citizenship: Italian; Married, one daughter

Affiliations

Department of Computer Science and Technology (Cambridge), J. Thomson Avenue, CB03FD
Cambridge

email pl219@cam.ac.uk

tel +441223763604 ; +39 3343696809

Other Affiliations

Cambridge Center for AI and Medicine (Cambridge)

Fellow and member of the Council of Clare Hall College (Cambridge).

Research Interests

Research Interests AI methodology, AI and Medicine, Bioinformatics and Computational Biology

Which AI methodology Graph representation learning and higher order graphs; neurosymbolic; explainability; diffusion models

I focus on

Which targets for AI and medicine I focus on	Develop methodology in Artificial Intelligence and computational Biology that can lead to useful applications and be respectful of societal values particularly cancer and neurodegenerative diseases; developing methods for the integration of multi scale heterogeneous data; model the overall progression of complex diseases which is critical to the timing of therapeutic interventions and design of effective clinical trials; incorporation of models of uncertainties and counterfactuals and go beyond the hypothesis confirmation towards the generation of new hypotheses; develop a fully trustworthy AI, to assist, help doctor and patients
Which targets of Bioinformatics and Computational Biology I focus on	Biological Complexity; Theoretic Information in Biology; Evo-Devo; single cell; dynamical biosystems; Computational Biology as the new AI

Past Positions

Lecturer (part time Lecturer), Chemistry Dept, University Firenze; course held in years: 1988,89,90; fellowship Institute of National Physics of Matter INFM (1995); Research Associate in Statistical Epidemiology, Princess Anne Hospital, University of Southampton. (1996-1997); Research Associate, Dept. of Genetics, Cambridge; (1998-2000); Research Associate Univ. Cambridge Dept. of Zoology, Cambridge, 2001; Research associate at the European Bioinformatics Institute (2002); Lecturer in Bioinformatics algorithms at the Computer Laboratory, University of Cambridge and affiliated Faculty member of the Centre for Computational Biology, Department of Mathematics, University of Cambridge (2004), Director of studies of Computer Science of Fitzwilliam College (2004-2014); Senior Lecturer, The Computer Laboratory, University of Cambridge (2007); Reader in Computational medicine at the Computer Laboratory, University of Cambridge (2013); - Full Professor in Computational Biology (2018).

Visiting Positions (> 1 month)

University of Padova, University of Toronto and Fields Institute (Canada), University of UCSC (USA), University of Texas (College Station, USA).

International Activities

- 2024 Member of Panel for Activities of Pasteur Institutes (France)
- 2022 Member of Panel for Activities of Adapta (Science Foundation Ireland)
- 2021 Member of Panel for Italian ERC Awards (CNR, Italy)

Awards - Honours (recent)

- 2022 Fellow of the Asia-Pacific Artificial Intelligence Association (AAIA)
- 2021 Fellow of the Academia Europaea
- 2019 Member of Ellis, the European Lab for Learning & Intelligent Systems
- 2023 Listed in the "A standardized citation metrics author database annotated for scientific field" (doi.org/10.1371/journal.pbio.3000384)

Listed in the top Italian Scientists: www.topitalianscientists.org/TIS_HTML/Top_Italian_Scientists_Computer_Sciences.htm

Erdos n 3 www.csauthors.net/distance/pietro-lio/paul-erdos

Invited Talks

- 23 April 2024 Invited talk, Department of Computer Science, Bocconi University, Milano
- 15 April 2024 Turing Lecture, Invited talk, Turing-AI, Queen's University, Belfast
- 9 April 2024 Invited talk, Department of Computer Science, University of Padova
- 22 March 2024 Invited talk, AI4H conference, Padova
- 8 September 2023 Invited talk, school of BioPhotonics and AI, Firenze
- August 2023 lecture at the IoT & AI for Sustainable Global Health and Wellbeing 2023 summer school, Cambridge
- 06-07 July Invited, 6th Machine Learning and AI in Bio(Chemical) Engineering Conference
- 21 June Invited, Deep Learning 2023, Trento, Italy
- 7th June Invited talk, 2023 IEEE World AI IoT Congress (AllIoT) (online)
- June 7-10 Teaching First Doctoral Summer School in Data Science, Accounting & Management Summer school, Paestum, Italy
- June 6 Invited talk, WIRN2023, Vietri, Italy
- June 3, 2023 Keynote talk, IEEE AllIoT 2023
- May 2023 Invited talk, IEEE MetroLivEnv
- March 2023 Invited talk - Pujiang Innovation Forum (Online)
- March 2023 Turing Lecture, Invited talk AI- Turing Institute, Teesside
- March 2023 Invited talk - Physics of Life, Harrogate
- 6 March 2023 Invited talk - Statistical learning on LARge scale GRaphs (LARGR), Inria, Universite de Lille
- December 2022 Invited Talk, Istituto Italiano di Cultura Italiano, ENCOUNTERS: across sciences and humanities
- Sept 2022 Invited talk at the Summer School on AI and Medicine, Cambridge (online)
- Sept 2022 Invited talk at the School of Biophotonics, Florence, Italy
- 28 June 2022 Invited talk - ShanghaiTech SIST Distinguished Lecture, at the Jiao Tong University, Shanghai, China
- Jun 2022 Invited talk at CMBE21 (7th International Conference on Computational and Mathematical Biomedical Engineering); Politecnico di Milano
- Dec 2021 Invited talk at Int. Workshop on Future Computing and Networks, Changchun, China
- Jan 2021 Invited talk: Next Generation Internet, NGL.eu, Forward workshop: The Future of search: Search and (hyper) locality, Search in/and Internet of Things, Search and Ethics - European Community

- Jan 2020 Invited talk at the 21st International Conference on Distributed Computing and Networking, ICDCN Conference, Kolkata
- Sept 2019 Invited talk on AI and data social awareness, MyData2019, Helsinki

Research: Active Grants

- 2023 Wisdom, WELL-BEING IMPROVEMENT THROUGH THE INTEGRATION OF HEALTHCARE AND RESEARCH DATA AND MODELS WITHOUT BORDER FOR CHRONIC IMMUNE-MEDIATED DISEASES, Horizon Europe, Trophy (G112412 NRAG/752), Horizon Europe UKRI Underwrite Innovate, Title: Ultrafast Holographic FTIR Microscopy (2022-2026); £ 294k; Charm (G113952 NRAG/750), Horizon Europe UKRI Underwrite Innovate (2022-2026), title: Chemometric Histopathology via Coherent Raman Imaging for Precision Medicine, £ 275k; GO-DS21, European Commission Horizon 2020 (H2020) Societal Challenges, Go-Ds21 : Gene Overdosage And Comorbidities During The Early Lifetime In Down Syndrome (2020-2024), £400k; Few PhD fellowships sponsored by AstraZeneca (2 students; 1 through CCAIM), GSK (2 students; 1 through CCAIM); CMIH: Cambridge Mathematics Of Information In Healthcare (Cmih), EPSRC, 2020-2023

Governance Activities

- 2024 Member of the Student Complaints and Appeal Committee of the University of Cambridge; member of the Postdoc mentorship scheme of the University of Cambridge
- 2021-2023 Member of the Faculty Board of the Dept of Computer Science and Technology; University of Cambridge Steering committee Big Data (The Cambridge Centre for Data-Driven Discovery (C2D3)); University of Cambridge - High performance computing panel; University of Cambridge Computational Biology Steering Committee; Member of the Student Complaints and Appeal Committee of the University of Cambridge; member of the panel for professorships at the Dept of Computer Science and Technology, University of Cambridge; examiner of ACS MPhil, Dept of Computer Science and Technology, University of Cambridge; Member of School of Technology STEC PhD Fellowship Calls Team

Service to the academic community outside the University

- 2023 Member of panel for professorship on Machine Learning and Biology, Copenhagen, Denmark (September 2022); External Examiner at the University of Newcastle for the MSc Bioinformatics, MSc Computational Neuroscience and Neuroinformatics, MSc Computational Systems Biology (2017-2021); Member of the committee of the VPHiUK.Organiser and co-organizer of scientific conferences and workshops: 08/12/2022 Learning on Graph (LoG) Cambridge.

Service to the Underprivileged schools

- 2023 Teaching Sutton College Summer School, Cambridge
- 2022 Teaching Sutton College Cambridge

Collaborations with Industry

2022 member AI panel of GSK

;

Teaching and supervision

- 2023 ACS MPhil course on Graph Representation Networks; Bioinformatics Algorithms
-Undergraduate -Dept Computer science and technology
- 2024 38 PhD students have been awarded the PhD, >40 MPhil students supervised
(MPhil in advanced computing; Part III Systems biology; MPhil in computational
Biology; Part III Physics); >20 PartII students

.

Dissemination to the broader public (only recent)

- 2022-2024 Organisation of CS AI SIG - Special Interest Group, 1/term at Clare Hall College, Cambridge
- Nov 2020 Lecture on AI and medicine, FuturoRemoto exhibition, Napoli
- Oct 2020 Talk on AI and medicine, TEDxCambridge University
- Jul 2019 Bioinformatics for Kids, CambridgeSpark - Cambridge

Publications from Cambridge University Symplectic database

orcid 0000-0001-8956-9815

Erdős number 3

- 2024 >600 publications in journals and international conferences; arxiv and bioarxiv
as preliminary deposit; H-index = 71 (Google Scholar); i10-index=371;
>54000 citations. <https://scholar.google.co.uk/citations?user=3YrWf7EAAAAJ&hl=en&oi=ao>; <https://orcid.org/0000-0002-0540-5053>;
noteanotherOrcidunderforenamewithdifferentaccent

CURRICULUM VITAE BOTTICELLI ANDREA

DATE and PLACE of BIRTH: July, 25 1984 ,

Rome ADDRESS: Via Davila 112 (ROME)-ITALY

TITLE: Medical Doctor, assistant professor

EDUCATION:

Graduation in Medicine - Sapienza of Rome Medical license acquired . University of Rome Medical Register in Rome;

School of Specialization in Medical Oncology

PROFESSIONAL CAREER

Division of Molecular Oncology Prof. Gulino La Sapienza University of Rome

Internship - Division of Medical Oncology - Director: Prof. P. Marchetti

TEACHER IMMUNO-ONCOLOGY MASTER II LEVEL, Sapienza, University of Rome Assistant Professor (RTDA) , Clinical and Molecular Department , Sapienza University of Rome WINNER

PREMIO ATENEO, SAPIENZA UNIVERSITY OF Rome : avvio alla ricerca 2016-2017 Winner Preceptorship ESMO, Immuno-Oncology Congresso 29 September -1 October 2016

Il Dr. Andrea Botticelli è ricercatore oncologo presso il Policlinico Umberto I e docente di Oncologia presso la Sapienza Università di Roma; è autore di più di 100 pubblicazioni su riviste internazionali. L'attività clinica e di ricerca è focalizzata sulla medicina di precisione, sulle neoplasie della mammella e sulle neoplasie della testa e del collo. È ad oggi il principal investigator dello studio Rome trial, che coinvolge 40 centri oncologici italiani di riferimento e che rappresenta la concreta possibilità di dimostrare la validità dell'approccio mutazionale, della terapia agnostica e della discussione nell'ambito dei Molecular Tumor Board nella cura dei tumori solidi.

PERSONAL INFORMATION

ARSELA PRELAJ

 Settima Strada 13, 20054, Segrate (MI) (Italy)

 (+39) 3292187197  (+39) 0223903647

 arsel.prelaj@istitutotumori.mi.it

Sex Female | Date of birth 20/02/1987 | Nationality
Albanian – Italian

C.F: PRLRSI87B60Z100T



JOB APPLIED FOR

Medical Oncologist

WORK EXPERIENCE

- 19/09/2023–Present *AI-ON-Lab (Artificial Intelligence Laboratory) leader*, Fondazione IRCCS Istituto Nazionale Tumori Via Giacomo Venezian, 1, CAP 20133, Milan (Italy)
- 11/07/2023 –Present *Responsible for INT's Research Line 4 program: Big Data, Clinical, Healthcare and outcome research*, Fondazione IRCCS Istituto Nazionale Tumori Via Giacomo Venezian, 1, CAP 20133, Milan (Italy)
- 1/12/2021 –Present *ESMO Working Group Member on Real-World Data and Digital Health as AI expert*
- 21/09/2018–Present *Medical Oncologist at the Thoracic Oncology Unit, Medical Oncology Department 1 (Directed by Prof. de Braud) and PhD Student in Bioengineering and Artificial Intelligence at Politecnico di Milano*
Fondazione IRCCS Istituto Nazionale Tumori Via Giacomo Venezian, 1, CAP 20133, Milan (Italy)
- 01/12/2017–08/08/2018 *Resident Doctor, Thoracic Oncology Division, IRCCS "Giovanni Paolo II" Bari, Directed by Dr. Domenico Galetta*
Bari (Italy)
- 01/04/2017–03/10/2017 *Resident doctor, Thoracic Oncology Division, European Institute of Oncology (IEO), Milan, directed by Prof. Filippo De Marinis*
Milan (Italy)
- 09/10/2017–17/11/2017 *ESMO Clinical Unit Visit awardee, Resident Doctor at the Lung Unit Team, Christie NHC Foundation Trust, under the supervision of Dr. Raffaele Califano*
Manchester (United Kingdom)
- 08/08/2013–31/03/2017 *Resident doctor-in-training in MedicalOncology*
Faculty of "Medicina e Farmacia" "Policlinico Umberto I" Sapienza University of Rome, directed by Prof. Silverio Tomao (Italy)
- 03/08/2018–20/08/2018 *Medical doctor*
ANFFAS Roma Onlus Rehabilitation center for people with disabilities, accredited with the National Health System. Via Aurelia Antica 269, 00165 Rome (Italy), Pesaro (Italy) Care and treatment of people with disabilities: entertainment, organization of social activities, accompanying the patients as a partner- health worker.

EDUCATION AND TRAINING

- 05/08/2019–11/03/2024 *PhD student in Bioengineering at Politecnico di Milano with honors;*
With scholarship. PhD title: MULTIMODAL DATA TO PREDICT
IMMUNOTHERAPY EFFICACY IN NSCLC PATIENTS USING ARTIFICIAL
INTELLIGENCE, Milan (Italy)

Postgraduate Specialization in Medical Oncology (70/70) with Honors.

Sapienza University of Rome, Policlinico Umberto I, Rome (Italy)

08/08/2013–08/08/2018

Medical Oncologist in training

Sapienza University of Rome, Rome (Italy)

11/04/2018–08/05/2019

Certificate of Advanced Studies in Lung Cancer (CAS Lu) program, European School of Oncology and University of Zurich

University of Zurich, Tutor Rolf A. Stahel, Zurich (Swaziland)

Certificate of Lung Cancer lasting 1 year (Vote 5.4/6)

20/09/2012–Present

Master's Degree in Medicine and Surgery (110/110) with honors, at the Sapienza University of Rome. Dissertation title: "Genetic polymorphisms in lung cancer"

Sapienza University, Policlinico Umberto I, Rome (Italy)

14/03/2013–Present

Medical Doctor fully licensed for Italy N. 60318

Ordine Provinciale di Roma dei Medici-Chirurghi e degli Odontoiatri, Rome (Italy)

01/12/2008–10/09/2012

Elective Student

Faculty Of Medicine and Psychology, Sapienza University of Rome, Rome (Italy)

from december 2008 to september 2012: **elective student** at "UOC Medical Oncology" Director Prof. P. Marchetti (S. Andrea Hospital Rome)

01/08/2008–31/08/2012

Volunteer

ANFFAS Roma Onlus Rehabilitation center for people with disabilities credited to the national health system Via Aurelia Antica 269, 00165 Rome (Italy)

Care and treatment of people with disabilities: entertainment, organization of social activities, accompanying the patients as a partner- health worker.

PERSONAL SKILLS

Mother tongue(s)

Albanian

Foreign language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
Italian	C2	C2	C2	C2	C2
	Celis				
English	C2	C2	C2	C2	C2
French	B1	B1	B1	B1	B1

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages - Self-assessment grid

Communication skills

Excellent interpersonal skills with colleagues, even in multicultural environments; adaptation, teamwork

Organizational / managerial skills

Excellent organizational and team management skills, I coordinated two Horizon applications, one Horizon 2020 then one Horizon Europe project that has been granted funding, each with a the direct monitoring and management of large consortia from EU and non-EU countries, involving 15 partners from 10 different countries (EU, US and Israel).

Job-related skills

I expanded the focus of my academic path beyond oncological clinical care activities, to include learning about laboratory techniques and translational work. I dedicated my work to the clinical care of patients with (lung and SNC) cancer, thereby developing a thorough understanding of the global management of the disease.

Digital skills

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem-solving
Proficient user	Proficient user	Proficient user	Proficient user	Proficient user

Digital skills - Self-assessment grid

Computer use. Windows, Apple, Linux and Android, Office, OpenOffice, Adobe Reader, photo editing programs and graphics, browsing the Internet and email. Operating machinery and appliances for communication: Ipad, Iphone, digital cameras, fax machines.

Excellent Knowledge of SPSS program, MatLab, Python, MedStat and extended uses for statistics analyses (descriptive, univariate, multivariate and survival analyses). Machine and Deep Learning Techniques.

Driving Licence

B

ADDITIONAL INFORMATION

H-index 18 Scopus - 20 Google Scholar (accessed January 29, 2024)

Citations 1083 (Scopus, accessed January 29, 2024)

Reviewer Since September 2016, reviewer for more than 20 Cancer Journals

Publications

- Prelaj A**, Tay R, Ferrara R, Chaput-gras N, Besse B and Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in NSCLC. *Eur J Cancer*. 2019 Jan;106:144-159
- Tay R, **Prelaj A** and Califano R. "Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios" *J Thorac Dis*. 2018 May;10(Suppl 13):S1494-S1502.
- Prelaj A**, Rebuzzi SE, Del Bene G, Giròn Berrios JR, Emiliani A, De Filippis L, Prete AA, Pecorari S, Manna G, Ferrara C, Rossini D, Longo F. Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC. *ERJ Open Res*. 2017 Mar 9;3(1). pii: 00128-2016.
- Prelaj A**, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, et al. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. *Clin Lung Cancer*. 2020 Mar 7:S1525-7304(20)30005-X. doi: 10.1016/j.clc.2020.01.005. Online
- Prelaj A**, Rebuzzi SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, et al. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy. *Clin Lung Cancer*. 2020 Mar 7:S1525-7304(19)30334-1. doi: 10.1016/j.clc.2019.11.017.

6. **Prelaj A**, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, et al. *EPSiLoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.* *Cancers (Basel)*. 2019 Dec 5;11(12):1954. doi: 10.3390/cancers11121954.
7. Trama A, Proto C, Signorelli D, Garassino MC, Lo Russo G, Ganzinelli M, **Prelaj A** et al. *Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. LUME study WG.* *Thorac Cancer*. 2020 May 4. doi: 10.1111/1759-7714.13456. Online ahead of print.
8. Babacan NA, Pina IB, Signorelli D, **Prelaj A**, Garassino MC, Tanvetyanon T. *Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.* *Clin Lung Cancer*. 2020 Mar 9:S1525-7304(20)30073-5. doi: 10.1016/j.clcc.2020.02.022. Online ahead of print.
9. Galli G, De Toma A, Pagani F, Randon G, Trevisan B, **Prelaj A**, et al. *Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.* *Lung Cancer*. 2019 Nov;137:38-42. doi: 10.1016/j.lungcan.2019.08.030. Epub 2019 Sep 10. PMID: 31526910
10. Nichetti F, Ligorio F, Zattarin E, Signorelli D, **Prelaj A**, et al. *Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.* *Cancers (Basel)*. 2019 Dec 25;12(1):67. doi: 10.3390/cancers12010067. PMID: 31881699 Free PMC article.
11. Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, **Prelaj A**, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC. *Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.* *Cancer Treat Rev*. 2019 Mar 28;75:39-51.
12. Rossi A, Tay R, Chiramel J, **Prelaj A**, Califano R. *Current and future therapeutic approaches for the treatment of small cell lung cancer.* *Expert Rev Anticancer Ther*. 2018 May;18(5):473-486.
13. Passaro A, **Prelaj A**, Pochesci A, Spitaleri G, Rossi G, Del Signore E, Catania C, de Marinis F. *Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.* *Drugs Today (Barc)*. 2017 Aug;53(8):435-446.
14. Timperi E, Focaccetti C, Gallerano D, Panetta M, Spada S, Gallo E, Visca P, Venuta F, Diso D, **Prelaj A**, Longo F, Facciolo F, Nisticò P, Barnaba V. *IL-18 receptor marks functional CD8+ T cells in non-small cell lung cancer* *Oncoimmunology*. 2017 May 12;6(7):e1328337.
15. Passaro A, **Prelaj A**, Bonanno L, Tiseo M, Tuzi A, Garassino M, Chiari R, Rocco D, Grossi F, Sini C, Cortinovis D, Pilotto S, Camerini A, Toschi L, Spitaleri G, Cappuzzo F, de Marinis F. *Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.* *Clin Lung Cancer*. 2019 Mar;20(2):e186-e194.
16. Proto C, Signorelli D, Mallone S, **Prelaj A**, Lo Russo G, Imbimbo M, Galli G, Ferrara R, Ganzinelli M, Leuzzi G, Greco FG, Calareso G, Botta L, Gatta G, Garassino M, Trama A. *The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.* *Clin Lung Cancer*. 2019 Jun 26. pii: S1525-7304(19)30170-6.
17. Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, **Prelaj A**, De Toma A, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. *Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy.* *Future Oncol*. 2019 Jul 24.
18. **Prelaj A**, Rebuzzi SE, Magliocca FM, Speranza I, Corongiu E, Borgoni G, Perugia G, Liberti M, Bianco V. *Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report.* *Am J*

Case Rep. 2016 Apr 13;17:248-53.

19. **Prelaj A**, Rebuzzi SE, Caffarena G, Giròn Berriós JR, Pecorari S, Fusto C, Caporlingua A et al. Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: Case report and review of the literature. *Oncol Lett.* 2018 May;15(5):6641-6647.

20. **Prelaj A**, Rebuzzi SE, Salvati M, Pecorari S, Pozzi C, Fusto C, Ferrara C, Tomao S, Vincenzo B. Retrospective analysis to evaluate the efficacy and the safety of Bevacizumab in the treatment of recurrent malignant gliomas. *Transl Med Comm April* 2018; 3:6

21. **Prelaj A**, Rebuzzi SE, Salvati M, d'Elia A, Antonelli M, Ferrara C, Tomao S, Bianco V. Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: survival across disease and treatment subgroup analysis and review of the literature. *Mol Clin Oncol.* 2019 Jan;10(1):58-66

22. **Prelaj A**, Rebuzzi SE, Grassi M, Giròn Berriós JR, Pecorari S, Ferrara C, Salvati M, Tomao S, Bianco V. Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy. *Mol Clin Oncol.* 2019 Jan;10(1):49-57.

23. **Prelaj A**, Rebuzzi SE, Pozzi C, Ferrara C, Frantellizzi V, Follacchio GA, De Vincentis G, Tomao S, Bianco V. Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice. *Oncol Lett.* 2019 Feb;17(2):1467-1476

24. De Vincentis G, Follacchio GA, Frantellizzi V, **Prelaj A**, Farcomeni A, Giuli A, Bianco V, Tomao S. 223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature. *Aging Clin Exp Res.* 2017 Aug 30.

25. Paris I, **Prelaj A**, Onesti CE, Baldoni A, Giovagnoli MR, Bassanelli M, Lauro S, Marchetti P. Esophageal stenosis: a differential diagnosis between esophageal cancer and metastasis from other neoplasia. *Anticancer Res.* 2014 Jan;34(1):363-6.

26. Nichetti F, Lo Russo G, **Prelaj A**, Provenzano L, de Braud F, Cabiddu M, Garassino MC, Petrelli F. ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? *Thromb Res.* 2020 Oct;194:176-177. doi: 10.1016/j.thromres.2020.06.041. Epub 2020 Jun 24.

27. **Prelaj A**, Proto C, Lo Russo G, Signorelli D, Ferrara R, Mensah M, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Trevisan B, Trovò F, Torri V, Sozzi G, Garassino MC, Boeri M. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. *Transl Lung Cancer Res.* 2020 Jun;9(3):617-628. doi: 10.21037/tlcr-20-231.

28. Comandini D, Grassi M, **Prelaj A**, Martelli V, Damiani A, Damiano G, Rebuzzi SE. Gastrointestinal stromal tumors and second primary malignancies: a retrospective monocentric analysis. *Neoplasma.* 2020 Nov;67(6):1416-1423. doi: 10.4149/neo_2020_200301N212. Epub 2020 Jul 13.

29. Manglaviti S, Brambilla M, Signorelli D...de Braud FGM, Garassino MC, **Prelaj A**. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. *Clin Lung Cancer.* 2021 Jul 5:S1525-7304(21)00180-7.

30. Ferrara R, Signorelli D, Proto C, **Prelaj A**, Garassino MC, Lo Russo G. Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. *Transl Lung Cancer Res.* 2021 Jun;10(6):2955-2969. doi: 10.21037/tlcr-20-636.

32. Perrone F, Belluomini L, Mazzotta M, Bianconi M, Di Noia V, Meacci F, Montrone M, Pignataro D, **Prelaj A**, et al. Exploring the role of respiratory microbiome in lung cancer: A systematic review. *Crit Rev Oncol Hematol.* 2021 Aug;164:103404.

33. Occhipinti M, Brambilla M, Galli G, Manglaviti S, Giammaruco M, **Prelaj et al.** Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. *J Pers Med.* 2021 May 18;11(5):424. doi: 10.3390/jpm11050424.

34. Longo V, Catino A, Montrone M, Pizzutillo P, Pesola F, Marech I, Capone I, **Prelaj A**, Galetta D. Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib. *Thorac Cancer.* 2021 Jul;12(13):2031-2034.

35. Shi J, Yang F, Zhou N, Jiang Y, Zhao Y, Zhu J, **Prelaj A** et al. Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development. *Transl Lung Cancer Res.* 2021 Mar;10(3):1444-

1456.

36. Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, et al. Pozotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. *Eur J Cancer*. 2021 May;149:235-248.

37. Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, **Prelaj A** et al. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. *Int J Mol Sci*. 2021 Mar 5;22(5):2625.

38. Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, Proto C, et al. Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. *Cancers (Basel)*. 2021 Mar 15;13(6):1300.

39. De Toma A, Lo Russo G, Signorelli D, Pagani F, Randon G, Galli G, **Prelaj A** et al. Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. *Crit Rev Oncol Hematol*. 2021 Apr;160:103299.

40. Liu Y, Yang S, Zhao J, He Z, Ma J, Guo Y, Wang W, Yoshizawa A, **Prelaj A**, et al. Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis. *Transl Lung Cancer Res*. 2021 Feb;10(2):914-925. doi: 10.21037/tlcr-21-62.

41. Ge X, Zhang Z, Zhang S, ... **Prelaj A**, Banna GL, Mutti L, Hu Y, Wang J. Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. *Transl Lung Cancer Res*. 2020 Dec;9(6):2391-2400.

42. Lobefaro R, Viscardi G, Di Liello ... **Prelaj A**, et al. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. *Lung Cancer*. 2021 Feb;152:165-173.

43. Signorelli D, Proto C, Botta L..., **Prelaj A**, et al. SMO mutations confer poor prognosis in malignant pleural mesothelioma. *Transl Lung Cancer Res*. 2020 Oct;9(5):1940-1951. doi: 10.21037/tlcr-19-425.

44. Nichetti F, Lo Russo G, **Prelaj A**, Provenzano L, de Braud F, et al. ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? *Thromb Res*. 2020 Oct;194:176-177

45. **Prelaj A**, Boeri M, Robuschi A, Ferrara R, Proto C, Lo Russo G. et al. Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. *Cancers (Basel)*. 2022 Jan 16;14(2):435. doi: 10.3390/cancers14020435.

46. Spagnoletti A, Platania M, Brambilla M, Occhipinti M, Canziani L, Cabras A, Provenzano L, Leone AG, Ambrosini P, **Prelaj A**. Systemic lupus erythematosus reactivation afterchemoimmunotherapy in preexisting autoimmune disease. *Tumori*. 2022 Jan 6:3008916211067565. doi: 10.1177/03008916211067565.

47. Provenzano L, Cuccarini V, Platania M, Canziani L, Spagnoletti A, Doniselli FM, Eoli M, Prelaj A (**Corresponding**), Anghileri E. Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma. *Tumori*. 2021 Dec;107(6):NP136-NP140. doi: 10.1177/03008916211052330. Epub 2021 Nov 2.

48. Perrone F, Belluomini L, Mazzotta M, Bianconi M, Di Noia V, Meacci F, Montrone M, Pignataro D, **Prelaj A**, et al. Exploring the role of respiratory microbiome in lung cancer: A systematic review. *Crit Rev Oncol Hematol*. 2021 Aug;164:103404. doi: 10.1016/j.critrevonc.2021.103404. Epub 2021

49. Emma Zattarin.... Giuseppe Lo Russo, **Prelaj A (last name)**. Prognostic Role of NLR and EPSiLoN score in advanced NSCLC patients treated with chemo-Immunotherapy. Accepted for publication at *Future Oncology* on 09/05/2022. ID FON-2021-1454.R1.

50. Prelaj A., Bottiglieri A... Proto C. Case report: exceptional response to pozotinib in patient with metastatic Non-Small Cell Lung Cancer. Accepted for publication at *Future Oncology* on 16/05/2022. ID manuscript 902967.

51. Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, Lo Russo G, Proto C, **Prelaj A**, De Toma A, Ferrara R. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. *Eur J Cancer*. 2022 Dec;177:175-185. doi: 10.1016/j.ejca.2022.09.031.

52. Banna GL, Friedlaender A, ... **Prelaj A**, Naqash AR, Auclin E, Garetto L, Mezquita L, Addeo

53. A. Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer. *Curr Oncol Rep.* 2022 Dec;24(12):1851-1862. doi: 10.1007/s11912-022-01335-8.

54. Russo G, Prelaj A, Occhipinti M, Viscardi G, Capizzuto et al. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. *Front Immunol.* 2022 Sep 20;13:987639. doi: 10.3389/fimmu.2022.987639.

55. Rebuzzi SE, **Prelaj A**, Friedlaender A, Cortellini A, et al. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. *Crit Rev Oncol Hematol.* 2022 Nov;179:103806. doi: 10.1016/j.critrevonc.2022.103806

56. Galli G, Corsetto PA, Proto C, Lo Russo G, Ganzinelli M, Rulli E, Legramandi L, Morelli D, Ferrara R, **Prelaj A**, et al. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. *Clin Lung Cancer.* 2022 Nov;23(7):e489-e499. doi: 10.1016/j.clcc.2022.07.010

57. Lo Russo G, Sgambelluri F, **Prelaj A**, Garassino MC. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. *ESMO Open.* 2022 Dec;7(6):100645. doi: 10.1016/j.esmoop.2022.100645.

58. Castelo-Branco L, Morgan G, **Prelaj A**, Scheffler M, Canhão H, Van Meerbeeck JP, Awada A. Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions. *ESMO Open.* 2023 Jan 12;8(1):100764. doi: 10.1016/j.esmoop.2022.100764.

59. **Prelaj A**, Galli EG, Miskovic V, Pesenti M, Viscardi G, Pedica B, Mazzeo L et al. Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients. *Frontiers in Oncology* Pub Date: 2023-01-23, DOI:10.3389/fonc.2022.1078822

60. Zanitti, M. **Prelaj**, et al. (2023). MetaLung: Towards a Secure Architecture for LungCancer Patient Care on the Metaverse. *IEEE MetaCom* 2023. Accepted

61. Senthil Kumar K, Miskovic V, Blasiak A, Sundar R, Pedrocchi ALG, Pearson AT, **Prelaj A**, Ho D. Artificial Intelligence in Clinical Oncology: From Data to Digital Pathology and Treatment. *Am Soc Clin Oncol Educ Book.* 2023 May;43:e390084. doi: 10.1200/EDBK_390084. PMID: 37235822.

62. Lo Russo*, G., **Prelaj, A***, et al. PEOPLE (NCT03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis (2023) *Journal for immunotherapy of cancer*, .
*Same contribution DOI: 10.1136/jitc-2023-006833

63. Prelaj, A., Ganzinelli, M., Trovo, F., Roisman, et al. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy (2023) *Clinical Lung Cancer.* 10.1016/j.clcc.2023.02.005

64. Castelo-Branco, L., Morgan, G., Prelaj, A., Scheffler, M., Canhão, H. et. Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions (2023) *ESMO Open*, . DOI: 10.1016/j.esmoop.2022.100764

65. **Prelaj A***, Miskovic V* et al. (2023) Artificial Intelligence for the discovery of predictive biomarkers in immuno-oncology: a systematic review, submitted to *Annals Of Oncology*

66. Prelaj A et al. (2023) APOLLO11 project, consortium in advance lung cancer patients treated with innovative therapies integration of RWD and translational research, submitted to CLC

67. Cornelissen R, **Prelaj A**, Sun S, Baik C, Wollner M, et al. Pozitotinib in Treatment-Naïve NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). *J Thorac Oncol.* 2023 Aug;18(8):1031-1041. doi: 10.1016/j.jtho.2023.03.016. Epub 2023 Mar 21. PMID: 36958688.

68. Proto C, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, **Prelaj A**. STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines. *J Thorac Oncol.* 2023 Aug;18(8):1070-1081. doi: 10.1016/j.jtho.2023.04.009. Epub 2023 Apr 23.

69. Brambilla M, Beninato T, Piemontese A, Mazzeo L, Pircher CC, Manglaviti S, Ambrosini P, Signorelli D, Lorenzini D, **Prelaj A et al.** Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. *Clin Lung Cancer*. 2023 Nov;24(7):631-640.e2. doi: 10.1016/j.clcc.2023.08.004. Epub 2023 Aug 23. PMID: 37775370.
70. Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, **Prelaj A**, et al. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2023 Nov 22:S1525-7304(23)00242-5. doi: 10.1016/j.clcc.2023.11.007. Epub ahead of print. PMID: 38105153.
71. Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWJ, Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, **Prelaj A et al.** ESMO Guidance for Reporting Oncology real-World evidence (GROW). *Ann Oncol*. 2023 Dec;34(12):1097-1112. doi: 10.1016/j.annonc.2023.10.001. Epub 2023 Oct 15. PMID: 37848160.
72. Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, Proto C, **Prelaj A**, et al. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. *Lung Cancer*. 2023 Dec;186:107417. doi: 10.1016/j.lungcan.2023.107417.
73. **Prelaj A**, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, et al. APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research. *Clin Lung Cancer*. 2023 Dec 22:S1525-7304(23)00269-3. doi: 10.1016/j.clcc.2023.12.012. Epub ahead of print. PMID: 38262770.
74. **Prelaj A**, Miskovic V, Zanitti M, Trovo F, Genova C, et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. *Ann Oncol*. 2024 Jan;35(1):29-65. doi: 10.1016/j.annonc.2023.10.125. Epub 2023 Oct 23. PMID: 37879443.
75. Collaborator as PI: Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, et al; TRIDENT-1 Investigators. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. PMID: 38197815.
76. Horgan D, Van den Bulcke M, Malapelle U, Troncone G, Normanno N, Capoluongo ED, **Prelaj A et al.** Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systemsHeliyon. 2023 Dec 20;10(1):e23914
78. Willis M, Nilsson A, Kellerborg K, Lwin ZMT, **Prelaj A**. Budget impact models for lung cancer interventions: A systematic literature review. *J Manag Care Spec Pharm*. 2024 Sep;30(9):1041-1056. doi: 10.18553/jmcp.2024.30.9.1041
79. Occhipinti M, Brambilla M, Di Liello R, ..., **Prelaj A**, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, Viscardi G. Unleashing precision: A review of targeted approaches in pleural mesothelioma. *Crit Rev Oncol Hematol*. 2024 Aug 17;203:104481.
80. Proto C, Ganzinelli M, Manglaviti S..., **Prelaj A**, ... Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVANT phase II trial (NCT03921671). *Ann Oncol*. 2024 Sep;35(9):817-826.
81. Sebri V, Marzorati C, Dorangricchia P, Monzani D, Grasso R, **Prelaj A**, The impact of the decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project. *Cancer Med*. 2024 May;13(9):e7159. doi: 10.1002/cam4.7159. PMID: 38741546; PMCID: PMC11091486.
82. Horgan D, Van den Bulcke M, Malapelle U, Normanno N, Capoluongo ED, **Prelaj A**, Demographic Analysis of Cancer Research Priorities and Treatment Correlations. *Curr Oncol*. 2024 Mar 29;31(4):1839-1864.
83. Miceli R, Eriksson H, Lo Russo G, Alfieri S, ... **Prelaj A**, Proto C, Franzén J, McDonnell D. Gender Difference in side Effects of Immunotherapy: a possible clue to optimize cancer treatment (G-DEFINER): study protocol of an observational prospective multicenter study. *Acta Oncol*. 2024 Apr 21;63:213-219.
84. Leporati R, Miliziano D, Beninato T, Mazzeo L, Manglaviti S, Brambilla M, Occhipinti M, **Prelaj A**, Proto C, Lo Russo G. Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs. *Tumori*. 2024 Apr
85. Horgan D, Bulcke MVD, Malapelle U, Normanno N, Capoluongo ED, Prelaj A, ... Aligning Cancer Research Priorities in Europe with Recommendations for Conquering Cancer: A Comprehensive Analysis. *Healthcare (Basel)*. 2024 Jan 19;12(2):259.

Acknowledgements:

ESSENTIAL: THORACIC BOOK SECOND EDITION (BY ESMO: Solange Peter, Marina CH. Garassino): *Arsela Prelaj*, for her work on providing the update to the treatment schedules.

Speaker and Oral Presentations (most relevant)

- **Educational session:** "A machine learning framework for treatment selection", **4th June 2023, ASCO 2023, Chicago, USA**
- **Educational session:** "Real World data e Intelligenza Artificiale", **2nd Oct 2023, AIOM 2023, Rome, Italy**
- **Oral presentation:** "Reducing disparities in healthcare and research across Europe", **April 26-27, 2023, European Union Conference**
- **Oral presentation** "ES31.06 - Integration of Biomarkers with Artificial Intelligence", **September 9-12, 2023: IASLC World Conference on Lung Cancer**
- **Oral presentation** "Artificial Intelligence, radiomics and biomarkers of the future: the challenges ahead", **November 11, Italian Association of Medical Oncologists - Annual Conference**
- I3LUNG presentation at EU Commissions' workshop on funded projects on Digital and Data-Sharing topics (October 26, 2023)
- **Oral presentation:** "Artificial intelligence: new perspectives in oncology" **14th Milan Congress on Anticancer Innovative Therapy, January 26th 2024**

Mini Oral section: "MA03.10 Prospective Evaluation of a Prognostic Clinico-Molecular Score (DEMO) to Predict Outcome of Advanced NSCLC Patients Treated with Immunotherapy", 8th Sep 2019, WCLC2019, Barcelona, (Spain)

"Trattamento del NSCLC I linea EGFR mutato e ALK traslocato" 5-6 May 2022, Baveno (Italy)

Young to Young, Intelligenza Artificiale, Genova 21/09/2022

Cocktail with Science, Artificial Intelligence, beyond classical methods, 20 Oct 2022

OncoLive, Expaliable AI, Chicago 31st May 2023

Poster Presentations **More than 100 poster presentations in ASCO, ESMO, IASLC, AIOM etc. covering 1st and last name.**

Honors and awards Esmo Clinical Unit Visit **Award** 2017 with Grant in Manchester, United Kingdom.
Esmo Immuno-Oncology 2018, Abstract **Merit Award with grant**, Ginevra, Switzerland.
Premio Giovani Ricercatori Istituto Tumori di Milano 2021

Clinical trials and Protocols **Principal Investigator and Sub-Investigator in more than 50 PHASE I-III Clinical Trials e.g.: of TRIDENT, ACCELERET, MK013, BRIDGE TRIAL, Sub-Investigator in more than 50 PHASE I-III Clinical Trials e.g.: KYENOTE-189, KEYNOTE-045, CHECKMATE-017, CHECKMATE-057, CA209-227, ALEX, EXELIXIS, JANSEN, ZENITH20, JNJ-61186372. Investigator for many Expanded Access Program e.g.: CA209-169, Pozitotinib, Lorlatinib, Brigatinib, Blu667 etc.**

Preceptorship Preceptorship in Lung Cancer Manchester, 1-3 March 2017 and 07-9 March 2018

Conferences and seminars from 2008 to 2024 attended more than 250 International and Italian conferences and seminars based on Medical Oncology (Basic research, epidemiology, diagnosis and treatment), especially focused on Thoracic Cancers.

Scientific coordinator / president for the "AI for Oncology" conference organized in May 2023 in Milan (250 attendees), a 2nd edition is planned on May 10, 2024.

Certifications The National Institutes of Health (NIH) Office of Extramural Research certifies that ARSELA PRELAJ successfully completed the NIH Web-based training course "Protecting Human Research Participants". 2636272

Training Certificate of Good Clinical Practice version n.1 (18-May-2015), identified by TransCelerate.

Basic Life Support, Hospital Policlinico Umberto I, 2013, Rome, Italy

Basic Life Support, 21st Dec 2018,, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.

Basic Life Support, Dec 2022, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy. Advance Advanced Life Support, 05-06 Nov 2019, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy. Advanced Life Support, 6-7 Oct 2023, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.

Grants

Call: HORIZON-HLTH-DTH-2021-CARE-05-02 (Better Health and care, economic growth and sustainable health systems). Project Title: **"I3LUNG: Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherapy"**

I have recently granted **as principal Investigator and Coordinator** (10 million euro) a recent very Big Horizon Europe (H2021-2027 program) project (I3LUNG) among 16 partners regarding NSCLC, immunotherapy and Artificial Intelligence decision making tools aiming at the development of an EU and extra EU (USA, Israel) platform on real-world and multiomics data.

Bando Istituzionale BRI 2021: I have been granted **as PI and Coordinator** an Italian Pilot project (500.000 euro), **APOLLO 11, a large Italian Network** for research on advanced lung cancer, with a Translational Research and Real-World focus. It has the aim to develop a national database and a standardized virtual biobank among centres. The BRI projects are funded every 3 years by the Scientific Directorate, as projects of particular scientific and strategic value for the Institute.

BuonMarrow: Bone Marrow-on-chip as smart sensor of lung cancer relapse: EIC-PATHFINDER-Open 2023

I have been granted **as CO-PI for INT partner**, at this Horizon Europe project (4 million euro) dedicated to the development of an Organ-On-Chip Sensor to early detect Lung cancer relapse exploiting central signals of the bone marrow. This project is coordinated from POLIMI, and other partners are involved such as LUND university and IBEC.

SHAIPED: DIGITAL-2024-CLOUD- PI for INT, Supporting Health Data Access Bodies to establish AI pathways enabling Deployment of AI as medical device tools.

Memberships

Full Member of American Society of Clinical Oncology (ASCO)

Full Member of European Society for Medical Oncology (ESMO)

Full Member of Lung Cancer Association Research (IASLC)

Full Member of European School of Oncology (ESO)

Full Member of Associazione Italiana Oncologia Medica (AIOM)

Full Member of American Association for Cancer Research (AACR)

Committee Member of ESMO's Real World Data and Digital Hhealth in oncology Working Group

Biosketch

Arsela Prelaj currently works as a Medical Oncologist with both a strong interest and commitment to translational research at the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan (since September 2018), in the Thoracic Oncology Unit. In the last five years she has focused her research on Thoracic Malignancies, especially in NSCLC patients treated with immunotherapy and target therapy, being sub and principal investigator of many clinical studies/trials and closely involved in the coordination of various national and international grant applications on this topic. Indeed, her research focus is also centered on Bioengineering and Artificial Intelligence (AI), as embodied by her PhD study at the Politecnico di Milano's Department of Electronics, Informatics and Bioengineering in 2019, an activity she conducts in parallel with her clinical duties and research activities. In the last three years she has focused her research on collected real world and multiomics (circulating immune profiling, radiomics, digital pathology, genomics and RNA sequencing) data from advanced NSCLC patients treated with Immunotherapy with the aim to develop an AI tool able to design better individualized treatments and predict their efficacy. The source of the data is primarily a 3-years long translational study, APOLLO, which focused on the biobank samples' collection from NSCLC patients. To answer the major unmet need in NSCLC of the identification of efficient biomarkers for immunotherapy, she first co-led a Horizon 2020 grant application in 2020, which was presented anew in 2021 as a large-scale Horizon Europe application which successfully obtained funding - I3LUNG that regards NSCLC, immunotherapy and the implementation of innovative Artificial Intelligence methodologies for the construction of therapeutic decision-making support tools. In the last years, to propose concrete solutions to unify and harmonize data and biological sample collection among centers she successfully applied for funding at the "Bando di Ricerca Istituzionale" (BRI - Institutional Research Call, promoted by the Institute's Scientific Directorate to support innovative translational research projects) in 2021. She is the Principal Investigator and Coordinator of the "APOLLO 11" project, a large Italian network

(15 centers, which will be expanded to over 40 institutes in 2022-2023) of advanced lung cancer units, focusing on Translational Research and Real-World data with the principal aim to develop of a national database and biobank. She also recently participated as PI in a Horizon Project call on: High Value for care and research in Lung Cancer and recently submitted a Grant as CO-PI (PI: Dr. Sangaletti) on Bando di Ricerca Finalizzata 2022 on the development of a Bone Marrow-on Chip (a three-dimensional microfluidic device) for the early detection of Lung and Breast Cancer. She is a very active member of the ESMO Committee ESMO Real world data and digital health in oncology Working Group (RDH WG) to which she was invited in 2020. Her action point focused on three different objectives in the next year: ESMO paper position on guideline regarding Real World Clinical Trials, education and networking, giving her expertise on Big Data and Artificial Intelligence analysis. She is part of a research-collaborative group on ESMO-ESTRO collaboration on defining guideline for concomitant radiotherapy Innovative therapies (immunotherapy and target therapies across cancers).

"I, the undersigned, am aware that, pursuant to Article 76 of Presidential Decree 445/2000, any false declarations, falsification of documents, and use of false documents are punishable under the Penal Code and relevant laws. Furthermore, I authorize the processing of personal data in accordance with Article 13 of Legislative Decree 30 June 2003 No. 196 – 'Code regarding the protection of personal data' and Article 13 of GDPR 679/16 – 'General Data Protection Regulation.'"





Manuel Mitola

Passport: YC4424175 | **Date of birth:** 18/09/1990 | **Place of birth:** Massa, Italy |

Nationality: Italian | **Phone:** (+39) 3938383676 (Mobile) | **Email:** MANUEL.MITOLA@YAHOO.IT |

Address: Via Pisanello, 211/A, 19031, AMEGLIA, Italy (Home)

● ABOUT MYSELF

Founder & Managing Director at ctcHealth | AI for Pharma Advisor, International Keynote Speaker and Trainer | Former Eli Lilly and Menarini

● WORK EXPERIENCE

 **CTCHEALTH** – GENEVE, SWITZERLAND

FOUNDER & MANAGING DIRECTOR – 04/2025 – CURRENT

As a Co-Founder and Managing Director, I bring 9 years of experience in pharma digital innovation and omni-channel marketing to this role.

My mission is to build a solid bridge connecting Pharma and AI, partnering with pharmaceutical companies, AI service providers and Medical Societies.

 **CTCHEALTH** – GENEVA, SWITZERLAND

FOUNDER & HEAD OF AI CONSULTING – 08/2024 – 04/2025

As a shareholder and head of AI Consulting, I bring 9 years of experience in pharma digital innovation and omni-channel marketing to this role.

My mission is to build a solid bridge connecting Pharma and AI, partnering with both pharmaceutical companies and AI service providers.

 **MENARINI** – FLORENCE, ITALY

EMEA HEMATOLOGY MARKETING MANAGER – 01/2024 – 06/2024

 **MENARINI** – FLORENCE, ITALY

GLOBAL DIGITAL INNOVATION MANAGER (ONCOLOGY AND HEMATOLOGY) – 06/2022 – 06/2024

- Define the global digital innovation strategy for the oncology and haematology division
- Select, pilot and drive the adoption of new capabilities and technologies to foster marketing and sales force effectiveness
- Shape and execute the omni-channel strategy for the launch of new products globally

 **ELI LILLY & COMPANY** – FLORENCE, ITALY

INTERNATIONAL OMNI-CHANNEL MARKETING ASSOCIATE DIRECTOR (NEUROLOGY) – 02/2020 – 06/2022

- Contribute to the definition of the marketing strategy of neuroscience products (migraine) in EMEA
- Shape the strategy and lead the execution of omni-channel campaigns
- Organise digital peer-to-peer events involving international KOLs and HCPs
- Lead the Content Factory team in the creation of promotional materials
- Drive the adoption of Content Factory's materials by affiliates and optimise the co-creation process

 **ELI LILLY & COMPANY** – FLORENCE, ITALY

INTERNATIONAL OMNI-CHANNEL MARKETING CAPABILITIES MANAGER – 04/2018 – 02/2020

- Select, pilot and drive the adoption of new technologies to improve marketing and sales effectiveness
- Lead an international team of six omni-channel marketing experts in finding, sharing, and adopting best practices

 **ELI LILLY & COMPANY** – FLORENCE, ITALY

OMNI-CHANNEL MARKETING ASSOCIATE (ONCOLOGY, IMMUNOLOGY) – 05/2017 – 04/2018

- Contribute to the definition and execution of the omni-channel strategy for successful Immunology and Oncology product launches and product life cycle management in Italy

- Listen to HCPs' needs meeting them together with the sales force in order to build solutions able to solve their problems and help patients
- Manage external partner agencies, leading them in the execution of omni-channel campaigns and digital transformation projects

 **ELI LILLY & COMPANY** – FLORENCE, ITALY
DIGITAL MARKETING SR. SPECIALIST (ONCOLOGY) – 11/2015 – 04/2017

- Support brand managers in the definition and implementation of the omni-channel strategy for successful new product launches in oncology in Italy
- Deliver various digital assets to build a meaningful omni-channel experience for HCPs
- Deliver digital marketing training to colleagues and advocate for company digitalisation across different functional areas

● **EDUCATION AND TRAINING**

2019 – 2021 Milan, Italy
MBA MIP - Politecnico Di Milano

Website <https://www.gsom.polimi.it/programmi/mba-executive-mba/> | **Field of study** Management, Digital Transformation

2014 – 2017 Milan, Italy
MASTER'S DEGREE IN "DIGITAL MARKETING MANAGEMENT" IULM

Website <https://www.iulm.it/it/home> | **Field of study** Digital Marketing Management

2014 – 2014 Pisa, Italy
CORPORATE COMMUNICATION SCIENCE BACHELOR'S DEGREE University of Pisa

Website <https://www.unipi.it/> | **Field of study** Corporate Communication

● **LANGUAGE SKILLS**

Mother tongue(s): **ITALIAN**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
ENGLISH	C2	C2	C2	C2	C2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user

● **SKILLS**

Artificial Intelligence | Marketing | lead others | channel marketing | pharmaceutical industry | Pharmaceutical Sales Training

Manuel Mitola

Ameglia (SP) 21/10/2025

CURRICULUMVITAE ET STUDIORUM

GAETANO TIERI



Date of birth: 24/01/1985

Nationality: Italian

e-mail: gaetano.tieri@unitelmasapienza.it

Skype: gaetano.tieri

Gaetano Tieri, Associate Professor in General Psychology, Phd in Cognitive and Social Neuroscience; Head of the Virtual Reality and Digital Neuroscience Lab at University of Rome UnitelmaSapienza. He is an expert in exploring behavioral, physiological and neurophysiological activities by means of Immersive Virtual Reality and conducts research at 1) Virtual Reality and Digital Neuroscience Lab at Unitelma Sapienza of Rome; 2) IRCCS Santa Lucia Foundation of Rome and 3) Social Cognitive and Affective Neuroscience Laboratory at the Department of Psychology, Sapienza University of Rome, head Prof. S.M. Aglioti. He is also expert in developing and programming virtual environments for educational proposal in the fields of Psychology and Neuroscience.

Bibliometric Indexes

Scholar Google: <https://scholar.google.com/citations?user=Kid3Z08AAAAJ&hl=it>

Scopus: <https://www.scopus.com/authid/detail.uri?authorId=37035246500>

ORCID: <https://orcid.org/0000-0002-3037-0526>

EDUCATION

2011 – 2014	PhD in Cognitive Social and Affective Neuroscience, SCN; Department of Psychology, University of Rome La Sapienza, Italy.
2010	Master Degree in “Cognitive Psychology”. Faculty of Psychology, University “G. d’Annunzio”, Chieti.
2008	Bachelor Degree in “Science and Psychological techniques”. Faculty of Psychology, University “G. d’Annunzio”, Chieti.
2003	High school specializing in a technical education: Electronics and automatic systems. Istituto tecnico industriale statale ITIS “Leonardo Da Vinci”, Lanciano (CH)

PROFESSIONAL EXPERIENCE

From 2024	Associate Professor in General Psychology (M-PSI/01) at UnitelmaSapienza of Rome.
From 2023	Assistant Professor RTDB (M-PSI/01) at UnitelmaSapienza of Rome.
From 2021	Rector's Delegate for Inclusion and Learning Services
From 2019	Head of Virtual Reality & Digital Neuroscience Laboratory at UnitelmaSapienza of Rome.

From 2018	Assistant Professor RTDA (M-PSI/01) at UnitelmaSapienza of Rome.
2016 – 2018	Senior Postdoc Fellow at Unitelma Sapienza of Rome.
2014 – 2016	Senior Postdoc Fellow at IRCCS Santa Lucia Foundation, Rome.
Sept 2017 from April 2010	Research Activity with immersive virtual reality in applied neuroscience at Braintrends I.t.d. Rome, Italy.
Oct 2011	Brain Computer Interface Training in g.Tec laboratory, Sierningstrass, Austria.
Aprile 2011 from Dic 2010	Training in Immersive Virtual Reality and devices. PERCRO laboratory, Scuola Superiore Sant'Anna, Pisa, Italy.
Dic 2010 from Sept 2008	Research Activity on Space and Action in Virtual Reality, Neuropsychology laboratory ITAB, Chieti, Italy
Jun 2007 from Jan 2007	Research internship on Effect of senuclein in Parkinson. Consortium Mario Negri Sud, Lanciano, Italy.

NATIONAL QUALIFICATION (“abilitazione scientifica nazionale”)

- Associate Professor – SC: 11/E1 – Bando D.D. 153/2016 – from Nov. 2018

PUBLICATIONS

- 2024** Frisanco, A., Schepisi, M., **Tieri, G.**, & Aglioti, S. M. (2024). Does Embodying a Divine Avatar Influence Moral Decisions? An Immersive Virtual Reality Study. *Cyberpsychology, Behavior, and Social Networking*.
- 2024** **Tieri, G.**, Iosa, M., Fortini, A., Aghilarre, F., Gentili, F., Rubeca, C., ... & De Giorgi, R. (2024). Efficacy of a Virtual Reality Rehabilitation Protocol Based on Art Therapy in Patients with Stroke: A Single-Blind Randomized Controlled Trial. *Brain Sciences*, 14(9), 863..
- 2024** Pascucci, S., Forte, G., Angelini, E., Marinozzi, F., Bini, F., Antonucci, G., ... & **Tieri, G.** (2024). Michelangelo Effect in Virtual Sculpturing: Prospective for Motor Neurorehabilitation in the Metaverse. *Journal of Cognition*, 7(1).
- 2023** Reale, G., Fusco, A., Calciano, R., Vallario, N., Vagnarelli, G., Caliandro, P., Castelli L., Moci M., **Tieri G.**, IasevoliL, & Padua, L. (2023). The Immediate Effects of Immersive Virtual Reality on Autonomic Nervous System Function in Patients with Disorders of Consciousness after Severe Acquired Brain Injury: A Pilot Study. *Journal of Clinical Medicine*, 12(24), 7639.
- 2023** De Giorgi, R., Fortini, A., Aghilarre, F., Gentili, F., Morone, G., Antonucci, G., **Tieri G.**, Iosa, M. (2023). Virtual Art Therapy: Application of Michelangelo Effect to Neurorehabilitation of Patients with Stroke. *Journal of Clinical Medicine*, 12(7), 2590.
- 2023** De Simone, M. S., Costa, A., **Tieri, G.**, Taglieri, S., Cona, G., Fiorenzato, E., ... & Zabberoni, S. (2023). The effectiveness of an immersive virtual reality and telemedicine-based cognitive intervention on prospective memory in Parkinson's disease patients with mild cognitive impairment and healthy

aged individuals: design and preliminary baseline results of a placebo-controlled study. *Frontiers in Psychology*, 14. <https://doi.org/10.3389/fpsyg.2023.1268337>

- 2023** Frisanco, A., Schepisi, M., **Tieri, G.**, & Aglioti, S. M. (2023). Embodying the avatar of an omnipotent agent modulates the perception of one's own abilities and enhances feelings of invulnerability. *Scientific Reports*, 12(1), 21585. <https://doi.org/10.1038/s41598-022-26016-1>
- 2023** Pezzetta, R., Ozkan, D. G., Era, V., **Tieri, G.**, Zabberoni, S., Taglieri, S., ... & Aglioti, S. M. (2023). Combined EEG and immersive virtual reality unveil dopaminergic modulation of error monitoring in Parkinson's Disease. *npj Parkinson's Disease*, 9(1), 3. <https://doi.org/10.1038/s41531-022-00441-5>
- 2022** Fusco, A., & **Tieri, G.** (2022). Challenges and Perspectives for Clinical Applications of Immersive and Non-Immersive Virtual Reality. *Journal of Clinical Medicine*, 11(15), 4540. <https://doi.org/10.3390/jcm11154540>
- 2023** Iosa, M., Bini, F., Marinozzi, F., Antonucci, G., Pascucci, S., Baghini, G., ... & **Tieri, G.** (2022). Inside the Michelangelo effect: The role of art and aesthetic attractiveness on perceived fatigue and hand kinematics in virtual painting. *PsyCh Journal*, 11(5), 748-754. <https://doi.org/10.1002/pchj.606>
- 2022** Moreau, Q., **Tieri, G.**, Era, V., Aglioti, S. M., & Candidi, M. (2022). The performance monitoring system is attuned to others' actions during dyadic motor interactions. *Cerebral Cortex*. <https://doi.org/10.1093/cercor/bhac063>
- 2022** Boukarras, S., Özkan, D. G., Era, V., Moreau, Q., **Tieri, G.**, & Candidi, M. (2022). Midfrontal Theta Transcranial Alternating Current Stimulation Facilitates Motor Coordination in Dyadic Human-Avatar Interactions. *Journal of Cognitive Neuroscience*, 34(5), 897-915. https://doi.org/10.1162/jocn_a_01834
- 2022** Casula, E. P., **Tieri, G.**, Rocchi, L., Pezzetta, R., Maiella, M., Pavone, E. F., ... & Koch, G. (2021). Feeling of ownership over an embodied avatar's hand brings about fast changes of fronto-parietal cortical dynamics. *Journal of Neuroscience*. <https://doi.org/10.1523/JNEUROSCI.0636-21.2021>
- 2021** Iosa, M., Aydin, M., Candelise, C., Coda, N., Morone, G., Antonucci, G., ... & **Tieri, G.** (2021). The Michelangelo Effect: Art Improves the Performance in a Virtual Reality Task Developed for Upper Limb Neurorehabilitation. *Frontiers in psychology*, 3832. <https://doi.org/10.3389/fpsyg.2020.611956>
- 2021** Mello, M., Fusaro, M., **Tieri, G.**, & Aglioti, S. M. (2020). Wearing same-and opposite-sex virtual bodies and seeing them caressed in intimate areas. <https://doi.org/10.1177/17470218211031557>
- 2021** Lisi, M. P., Fusaro, M., **Tieri, G.**, & Aglioti, S. M. (2021). Humans adjust virtual comfort-distance towards an artificial agent depending on their sexual orientation and implicit prejudice against gay men. *Computers in Human Behavior*, 125, 106948. <https://doi.org/10.1016/j.chb.2021.106948>
- 2021** Fusaro, M., Lisi, M. P., **Tieri, G.**, & Aglioti, S. M. (2021). Heterosexual, gay, and lesbian people's reactivity to virtual caresses on their embodied avatars' taboo zones. *Scientific reports*, 11(1), 1-12. <https://doi.org/10.1038/s41598-021-81168-w>
- 2020** Fossataro, C., Sebastiano, A. R., **Tieri, G.**, Poles, K., Galigani, M., Pyasik, M., ... & Garbarini, F. (2020). Immersive virtual reality reveals that visuo-proprioceptive discrepancy enlarges the hand-centred peripersonal space. *Neuropsychologia*, 146, 107540. <https://doi.org/10.1016/j.neuropsychologia.2020.107540>
- 2020** Fusco, G., **Tieri, G. ***, & Aglioti, S. M. (2020). Visual feedback from a virtual body modulates motor illusion induced by tendon vibration. *Psychological Research*. <https://doi.org/10.1007/s00426-020-01366-5> **First Co-author*
- 2020** Pyasik, M., **Tieri, G.**, & Pia, L. (2020). Visual appearance of the virtual hand affects embodiment in the virtual hand illusion. *Scientific Reports*, 10(1), 5412. <https://doi.org/10.1038/s41598-020-62394-0>

- 2020** Moreau, Q., Candidi, M., Era, V., **Tieri, G.**, & Aglioti, S. M. (2020). Midline frontal and occipito-temporal activity during error monitoring in dyadic motor interactions. *Cortex*, 127, 131–149. <https://doi.org/10.1016/j.cortex.2020.01.020>
- 2020** Monti, A., Porciello, G., **Tieri, G.**, & Aglioti, S. M. (2020). The “embreathment” illusion highlights the role of breathing in corporeal awareness. *Journal of Neurophysiology*, 123(1), 420–427. <https://doi.org/10.1152/jn.00617.2019>
- 2020** D’Antonio, E., **Tieri, G.**, Patané, F., Morone, G., & Iosa, M. (2020). Stable or able? Effect of virtual reality stimulation on static balance of post-stroke patients and healthy subjects. *Human Movement Science*, 70(January), 102569. <https://doi.org/10.1016/j.humov.2020.102569>
- 2020** Provenzano, Porciello, Ciccarone, Lenggenhager, **Tieri**, Marucci, ... Bufalari. (2020). Characterizing Body Image Distortion and Bodily Self-Plasticity in Anorexia Nervosa via Visuo-Tactile Stimulation in Virtual Reality. *Journal of Clinical Medicine*, 9(1), 98. <https://doi.org/10.3390/jcm9010098>
- 2019** Fossataro, C., **Tieri, G.***, Grollero, D., Bruno, V., & Garbarini, F. (2019). Hand blink reflex in virtual reality: the role of vision and proprioception in modulating defensive responses. *European Journal of Neuroscience*. <http://publons.com/publon/10.1111/EJN.14601>. *First Co-author
- 2019** Scandola, M., Togni, R., **Tieri, G.**, Avesani, R., Brambilla, M., Aglioti, S. M., & Moro, V. (2019). Embodying their own wheelchair modifies extrapersonal space perception in people with spinal cord injury. <https://doi.org/10.1007/s00221-019-05618-8>
- 2019** Gandolfo, M., Era, V., **Tieri, G.**, Maria, L., & Candidi, M. (2019). Interactor’s body shape does not affect visuo-motor interference effects during motor coordination. *Acta Psychologica*, 196(April), 42–50. <https://doi.org/10.1016/j.actpsy.2019.04.003>
- 2019** Castellano, R., Mancinelli, M., Ponsi, G., & **Tieri, G.** (2019). What if versus probabilistic scenarios: a neuroscientific analysis. *Annals of Operations Research*, (0123456789). <https://doi.org/10.1007/s10479-019-03272-5>
- 2019** Fusaro, M., **Tieri, G.***, & Aglioti, S. M. (2019). Influence of cognitive stance and physical perspective on subjective and autonomic reactivity to observed pain and pleasure: An immersive virtual reality study. *Consciousness and Cognition*, 67(November 2018), 86–97. <https://doi.org/10.1016/j.concog.2018.11.010>. *First Co-author
- 2018** **Tieri, G.**, Morone, G., Paolucci, S., & Iosa, M. (2018). Virtual reality in cognitive and motor rehabilitation: facts, fiction and fallacies. *Expert Review of Medical Devices*, 15(2), 107–117. <https://doi.org/10.1080/17434440.2018.1425613>
- 2018** Sacheli, L. M., **Tieri, G.**, Aglioti, S. M., & Candidi, M. (2018). Transitory Inhibition of the Left Anterior Intraparietal Sulcus Impairs Joint Actions: A Continuous Theta-Burst Stimulation Study. *Journal of Cognitive Neuroscience*, 26(3), 1–16. https://doi.org/10.1162/jocn_a_01227
- 2018** D’Antonio E., **Tieri G.**, Paolucci S., Patané F., Iosa M. (2019) Postural Sway Responses to 3D Virtual Dynamic Visual Stimulation in Post-stroke patients. In: Masia L, Micera S., Akay M., Pons J. (eds) *Converging Clinical and Engineering Research on Neurorehabilitation III*. ICNR 2018. Biosystems & Biorobotics, vol 21. Springer, Cham
- 2017** Spinelli, G., **Tieri, G.**, Pavone, E. F., & Aglioti, S. M. (2017). Wronger than wrong: Graded mapping of the errors of an avatar in the performance monitoring system of the onlooker. *NeuroImage*, 167(August 2017), 1–10. <https://doi.org/10.1016/j.neuroimage.2017.11.019>
- 2017** Candidi, M., Sacheli, L., Era, V., Canzano, L., **Tieri, G.**, Aglioti, S.M. (2017) Come together: human-avatar on-line interactions boost joint-action performance in apraxic patients. *Social Cognitive and Affective Neuroscience*, nsx114, <https://doi.org/10.1093/scan/nsx114>
- 2017** **Tieri, G.**, Gioia, A., Scandola, M., Pavone, E. F., & Aglioti, S. M. (2017). Visual appearance of a virtual upper limb modulates the temperature of the real hand: a thermal imaging study in Immersive Virtual Reality. *European Journal of Neuroscience*, 1–11. <https://doi.org/10.1111/ejn.13545>

- 2016** Fusaro, M., **Tieri, G.***, & Aglioti, S. M. (2016). Seeing pain and pleasure on self and others: behavioral and psychophysiological reactivity in immersive virtual reality. *Journal of Neurophysiology*, 116(6), 2656–2662. <https://doi.org/10.1152/jn.00489.2016>. **First Co-author*
- 2016** Pavone, E. F., **Tieri, G.**, Rizza, G., Tidoni, E., Grisoni, L., & Aglioti, S. M. (2016). Embodying Others in Immersive Virtual Reality: Electro-Cortical Signatures of Monitoring the Errors in the Actions of an Avatar Seen from a First-Person Perspective. *Journal of Neuroscience*, 36(2), 268–279. <http://doi.org/10.1523/JNEUROSCI.0494-15.2016>
- 2016** Jelić, A., **Tieri, G.**, De Matteis, F., Babiloni, F., & Vecchiato, G. (2016). The Enactive Approach to Architectural Experience: A Neurophysiological Perspective on Embodiment, Motivation, and Affordances. *Frontiers in Psychology*, 7(March), 1–20. <http://doi.org/10.3389/fpsyg.2016.00481>
- 2015** **Tieri, G.**, Tidoni, E., Pavone, E. F., & Aglioti, S. M. (2015). Body visual discontinuity affects feeling of ownership and skin conductance responses. *Scientific Reports*, 5, 17139. <http://doi.org/10.1038/srep17139>
- 2015** Vecchiato, G., Jelic, A., **Tieri, G.**, Maglione, A. G., De Matteis, F., & Babiloni, F. (2015). Neurophysiological correlates of embodiment and motivational factors during the perception of virtual architectural environments. *Cognitive Processing*, 3–7. <http://doi.org/10.1007/s10339-015-0725-6>
- 2015** Tidoni, E., **Tieri, G.**, & Aglioti, S. M. (2015). Re-establishing the disrupted sensorimotor loop in deafferented and deafferented people. The case of spinal cord injuries. *Neuropsychologia*, 1–9. <http://doi.org/10.1016/j.neuropsychologia.2015.06.029>
- 2015** **Tieri, G.**, Tidoni, E., Pavone, E. F., & Aglioti, S. M. (2015). Mere observation of body discontinuity affects perceived ownership and vicarious agency over a virtual hand. *Experimental Brain Research*. <http://doi.org/10.1007/s00221-015-4202-3>
- 2015** Vecchiato, G., **Tieri, G.**, Jelic, A., Maglione, A. G., De Matteis, F., & Babiloni, F. (2015). Electroencephalographic Correlates of Sensorimotor Integration and Embodiment during the Appreciation of Virtual Architectural Environments. *Frontiers in Neuroscience*, 16(S1), 425–429. <http://doi.org/10.3389/fpsyg.2015.01944>
- 2010** Costantini, M., Ambrosini, E., **Tieri, G.**, Sinigaglia C., Committeri, G. (2010). Where does an object trigger an action? An investigation about affordances in space. *Experimental Brain Research*, 95–103. <http://doi.org/10.1007/s00221-010-2435-8>

INVITED TALKS

- 2024** Seminar “Cervelli reali in Corpi virtuali: Evidenze comportamentali, Fisiologiche e neurali del Virtual embodiment”, Department of Psychology, University Cattolica Sacro Cuore, Milan.
- 2024** Lecture “Realtà Virtuale in Neuroscienze: dal laboratorio alla clinica”, Various Innovative Technological Experiences 2° edition, Laboratori Nazionali di Frascati, Monte Porzio Catone, Italy.
- 2024** Lecture “Realtà Virtuale in Neuroscienze: dalla ricerca in laboratorio alla pratica clinica”, PhD Course at Italian Institute of Technology IIT, Genova.
- 2024** Lecture “Realtà Virtuale e Aumentata: nuove frontiere per la medicina e le neuroscienze digitali”, Percorsi per le Competenze Trasversali per l'Orientamento (PCTO), Classical high school “Eschilo”, Gela, Italy.
- 2023** Lecture “Realtà Virtuale, Arte e ricerca in psicologia”, Seminar “*Realta' virtuale e percorsi digitali dal museo alla scuola*” Laboratorio Visalberghi, Università La Sapienza, Rome, Italy.
- 2023** Lecture “Realtà Virtuale in Neuroriabilitazione: dalla ricerca in laboratorio alle applicazioni cliniche”, Conference “*Quale tecnologia per quale riabilitazione 3th edition*”. Ospedale Pediatrico Bambino Gesù, Rome, Italy.
- 2023** Lecture “La realtà virtuale nel recupero cognitivo-motorio” Conference SIMFER “*la riabilitazione tra passato presente e futuro*” 51th edition, Bologna.

- 2023** Lecture "Realtà Virtuale in Clinica e Neuroscienza", Seminar UCSC – Scuola di Specializzazione Medicina Fisica e Riabilitativa, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome.
- 2023** Lecture "Realtà Virtuale e Metaverso", Seminar AUS – Community Alumni UnitelmaSapienza, University of Rome UnitelmaSapienza.
- 2023** Lecture "Realtà Virtuale, Arte e Neuroscienza", PhD day Dottorato di Storia, Disegno e Restauro dell'architettura, University of Roma La Sapienza.
- 2023** Lecture "Realtà Virtuale e Neuroriabilitazione: Nuove evidenze scientifiche", PhD Course at Italian Institute of Technology IIT, Genova.
- 2023** Lecture "Realtà Virtuale immersiva e sviluppi di attività didattiche, ricerca scientifica e imprenditoriale", the International School in Genoa, Genoa.
- 2022** Lecture "Realtà Virtuale e i disturbi della rappresentazione corporea: L'arto fantasma", ECM course entitled Il recupero funzionale dell'amputato di arto inferiore, Nomentana Hospital, Rome.
- 2022** Lecture "Realtà Virtuale e Neuroriabilitazione: nuove evidenze scientifiche", Workshop online Extended Reality & Metaverse: opportunità e casi applicativi nel mondo consumer, Osservatorio Realtà Aumentata&Metaverso, Politecnico of Milan.
- 2022** Lecture "Percezione e Azione: Le rappresentazioni del corpo virtuale nella mente reale", National Congress GiS Fisioterapia Neurologica e Neuroscienze. Ospedale Pediatrico Bambino Gesù, Roma, 2022.
- 2021** Tecnologie emergenti, salute e medicina 3° edizione. *Virtual Reality Experience VRE Fest 2021*, Roma, Italy.
- 2021** Scoprire come funziona il nostro cervello attraverso la realtà virtuale immersiva 3° edizione, *Roma Video Game Lab 2021*, Studi di Cinecittà, Rome, Italy.
- 2021** XII Seminar – PhD Day: Happiness is a simple system. Sapienza University, Rome.
- 2021** Realtà virtuale per la neuro-riabilitazione motoria, Webinar online, Milano Digital Week 2021.
- 2021** Cervelli reali in corpi virtuali: nuove frontiere per lo studio del nostro cervello attraverso la realtà virtuale e le sue applicazioni in neuroriabilitazione, Webinar online, Centro di ricerca S.T.I.T.C.H.
- 2021** Il Conferenza di Ateneo Modelli di e-learning a confronto, "Tecnologie Immersive nell'Università del futuro", Webinar online, UnitelmaSapienza.
- 2020** Tecnologie emergenti, salute e medicina. *Virtual Reality Experience VRE Fest 2020*, Roma, Italy.
- 2020** Scoprire come funziona il nostro cervello attraverso la realtà virtuale immersiva: nuove frontiere per la ricerca scientifica, *Roma Video Game Lab 2020*, Studi di Cinecittà, Rome, Italy.
- 2019** Cervello reale e corpo virtuale: la realtà virtuale come nuovo strumento per la neuro-riabilitazione e le neuroscienze, *Conference "Quale tecnologia per quale riabilitazione 2th edition"*. Ospedale Pediatrico Bambino Gesù, Rome, Italy.
- 2019** Cervelli Reali in Corpi Virtuali: nuove frontiere per lo studio del nostro cervello attraverso la realtà virtuale. *Spazio Roma Fotografia. Sguardi umani dal cosmo alla realtà virtuale, 2019*, Roma, Italy.
- 2019** Comprendere il cervello attraverso la realtà virtuale: nuove frontiere per la ricerca in psicologia e neuroscienza. *Virtual Reality Experience VRE Fest 2019*, Roma, Italy.
- 2019** Immersive learning for financial literacy: new virtual reality based approach for children. *International Workshop on Higher Education Learning Methodologies and Technologies Online*, Novedrate (CO), Italy.
- 2019** Embodying virtual body through passive observation: behavioural and physiological evidence. *International symposium: Virtual and Robotic Embodiment – from neuroscience to virtual reality and robotics*, Barcelona University, Spain.
- 2019** Vicarious experience of Social and Intimate touch in virtual reality: behavioural and physiological evidence. *Seminar*, Verona University, Italy.

- 2018** Wearing my virtual body: Immersive virtual reality studies of embodiment and their implications for rehabilitation. *XXVI Congresso Nazionale della Società Italiana di Psicofisiologia*, Turin, Italy.
- 2018** Investigating Social Motor behaviours through Virtual Reality: from human's to avatar's kinematics. *International Conference of Spatial Cognition 2018*, Sapienza University, Rome.
- 2018** Wearing my virtual body: behavioural, physiological and neural reactivities elicited by an embodied virtual avatar, *First Joint Congress of the SEPEX, SEPNECA and AIP experimental*, Madrid, Spain.
- 2018** Risposte reali a carezze virtuali: Indagine neuroscientifica attraverso la realtà virtuale immersiva, *1th edition of "NeuroSpritz"*, Roma, Italy.
- 2017** Behavioural and physiological reactivity to the observation of Pain and Pleasure in virtual reality, *6TH Scientific Meeting of the Federation of the European Societies of Neuropsychology (FESN)*, Maastricht, The Netherlands.
- 2016** Cervello reale e corpo virtuale: la realtà virtuale come strumento per le neuroscienze, *Conference "Quale tecnologia per quale riabilitazione"*. Ospedale Pediatrico Bambino Gesù, Rome, Italy.
- 2016** Controllo corporeo e cerebrale delle azioni di un avatar: studi di EEG e realtà virtuale immersiva. *2th Conference of SCI-Research Group*. IRCCS Fondazione Santa Lucia, Rome, Italy.
- 2015** Wearing my virtual body: behavioral, physiological and neural reactivity to the physical appearance and to the actions of an embodied avatar. *7th Conference of Lithuanian Neuroscience Association*. Vilnius University, Vilnius, Lituania.
- 2015** Skin temperature modulations underlying the feeling of ownership over a virtual hand, *XXIII Congresso Nazionale della Società Italiana di Psicofisiologia*, Lucca, Italy.
- 2015** Il cervello reale e il suo corpo virtuale, *1th edition of Pint of Science Italy*, Rome, Italy.
- 2014** Neuroscienze e Realtà Virtuale, *Conference*, La Sapienza University, Roma, Italy.
- 2014** Realtà Virtuale Immersiva: un nuovo strumento di indagine per le Neuroscienze, *Conference*, La Sapienza University, Roma, Italy.
- 2014** Body visual discontinuity affects feeling of ownership and skin conductance responses. *International VERE Phd symposium*, Barcelona University, Spain.
- 2012** Off-line EEG and BCI studies of motor imagery and real grasps in a tetraplegic patient and healthy controls, *International VERE meeting*, IDC institute Herzliya, Israel.

TEACHING

- 2024** Course "Digital School" (20 hours), In-Person Training Course for High School Teachers, Liceo Sandro Pertini, Bolzano.
- 2023** Course "Psicologia delle relazioni in ambito lavorativo" (20 hours), Master Organizzazione e Gestione delle risorse umane. Università degli Studi di Roma Unitelma Sapienza.
- 2023** Course "Psicologia Sociale e Forense" (32 hours), Corso di laurea triennale Organizzazione, Sicurezza e Investigazioni, Curriculum B. Università degli Studi di Roma Unitelma Sapienza.
- 2021** Master Universitario di II livello in Neuroestetica "La Realtà Virtuale Immersiva: dal laboratorio alla corsia". University of TorVergata, Roma, Italy (8 hours).
- 2020** Workshop organizer of "Tecnologie emergenti, salute e medicina". *Virtual Reality Experience VRE Fest 2020*, Roma, Italy.
- 2020** Workshop organizer of "Scoprire come funziona il nostro cervello attraverso la realtà virtuale immersiva": nuove frontiere per la ricerca scientifica, *Roma Video Game Lab 2020*, Studi di Cinecittà, Rome, Italy.

- 2019** Course “Psicologia delle relazioni in ambito lavorativo” (20 hours), Master Organizzazione e Gestione delle risorse umane. Università degli Studi di Roma Unitelma Sapienza.
- 2019** Course “Psicologia Sociale e Forense” (32 hours), Corso di laurea triennale Organizzazione, Sicurezza e Investigazioni, Curriculum B. Università degli Studi di Roma Unitelma Sapienza.
- 2019** Seminar: "Realtà Virtuale Immersiva: strumento innovativo per la ricerca psicologica e neuroscientifica", G. d'Annunzio University, Chieti, Italy.
- 2019** Course: "II° edizione corso di Realtà Virtuale Immersiva: uno strumento innovativo per la ricerca psicologica, economica, sociale, educativa e neuroscientifica" (40 hours), Unitelma Sapienza di Roma, Rome, Italy.
- 2019** Realtà Virtuale Immersiva: nuove prospettive per le riabilitazioni delle alterazione del sistema visivo, *Lecture*, IRCCS Santa Lucia Foundation, Rome, Italy.
- 2019** Workshop: “Scoprire come funziona il nostro cervello attraverso la realtà virtuale immersiva”: nuove frontiere per la ricerca scientifica (2 days), Roma Video Game Lab, Studi di Cinecittà, Rome, Italy.
- 2019** Course: "Realtà Virtuale Immersiva: uno strumento innovativo per la ricerca psicologica, economica, sociale, educativa e neuroscientifica" (40 hours), Unitelma Sapienza di Roma, Rome, Italy.
- 2019** Course: "Psicologia delle relazioni in ambito lavorativo" (6 hours), Unitelma Sapienza di Roma, Rome, Italy.
- 2019** New Methods for psychological and neuroscientific research: the case of Virtual Reality, *Lecture*, La Sapienza University, Rome, Italy.
- 2018** Course: "Realtà Virtuale Immersiva: uno strumento innovativo per la ricerca psicologica, economica, sociale, educativa e neuroscientifica" (40 hours), Unitelma Sapienza di Roma, Rome, Italy.
- 2018** Virtual Reality as a new tool for Neuroscientists, *Lecture*, La Sapienza University, Rome, Italy.
- 2017** Alternanza-Scuola Lavoro: Virtual Reality for Psychology and Neuroscience. La Sapienza University, Rome, Italy.
- 2017** Virtual Reality, bodily control and brain computer interface, *Lecture*, La Sapienza University, Rome, Italy.
- 2016** Virtual Reality and Body Awareness, *Lecture*, La Sapienza University, Rome, Italy.
- 2015** Virtual Reality as a new tool for Neuroscientists, *Lecture*, La Sapienza University, Rome, Italy.
- 2015** Realtà Virtuale Immersiva: nuove frontiere della Neuroscienza, *Lecture*, G. d'Annunzio University, Chieti, Italy.
- 2013** Neuroscienze e Realtà Virtuale, *Lecture*, G. d'Annunzio University, Chieti, Italy.

AWARDS

- 2023** **Bando PRINN PNRR** (2023-2025) – “Preventing cognitive decline and dementia through an innovative immersive virtual reality and telemedicine-based multi-component intervention: a randomized controlled trial” Role CO-PI (PI: DE SIMONE Maria Stefania).
- 2023** **Bando di Ricerca di Ateneo 2023 Unitelma Sapienza** (2023-2024) – “Didattica immersiva con realtà virtuale: serie di studi sul gender equality, sull'apprendimento, prese di decisione e comportamento economico in studenti e studentesse di istituti scolastici primari e secondari.” Role PI
- 2020** **BIAL Foundation Research Grant** (2020-2021) - "In God's shoes: embodying the avatar of the supreme moral authority modulates psychophysiological indices of one's own morality", Role team member (PI: AGLIOTI Salvatore M.)

- 2020 Young Researcher** – “Innovative upper limb stroke rehabilitation approach combining myoelectric control assistance in virtual reality and cerebellar TBS plasticity enhancement.” Role team member (GR-2019-12370271; PI: BERGER Denise Jennifer).
- 2018 Bando di Ricerca di Ateneo 2018 Unitelma Sapienza**– “Scavo archeologico a Gortina (Creta, Grecia), area a nord del Pretorio. Studio per l’elaborazione di un nuovo modello di didattica interattiva” Member of the Reserch Unit (PI: Rita Sassu).
- 2018 Bando di Ricerca di Ateneo 2018 Unitelma Sapienza**– “Financial Literacy and Neuroscientific Investigation.” Member of the Reserch Unit (PI: Rosella Castellano).
- 2017 Young Researcher** – “Promoting the recovery of higher-order motor functions in brain damaged patients. A novel approach based on the combination of virtual reality and non-invasive brain stimulation.” Role Co-PI (GR-2016-02361008; PI: CANDIDI Matteo).
- 2016 BIAL Foundation Research Grant** (2016-2017) - "Virtual bodies, real empathy: behavioural, bodily, and neural reactivity to the observation of Pain and Pleasure on self and others in immersive virtual reality", Role PI (Num. 218/16)
- 2015 MOTO, the embodied reMOte Tower** (2016-2018) - "High Performing Airport Operations - Improved Visualisation and Awareness". Member of the Reserch Unit (ER-06-2015; PI: POZZI Simone).
- 2014 Best Abstract Award** - Body visual discontinuity affects feeling of ownership and skin conductance responses. *International VERE Phd symposium*, Barcelona University, Spain.
- 2014 BIAL Foundation Research Grant** (2015-2016) - "Measuring the Self: behavioural and neural correlates of bodily awareness" Member of the Reserch Unit (Num. 2014/150; PI: TIDONI Emmanuele).

PEER-REVIEW ACTIVITY

Cortex; Experimental Brain Research; International Journal of Visualized Experiment; Journal of Neuroengineering; Neuropsychologia; Scientific Reports; Symmetry; Royal Society Open Science; Conscious & Cognition; PeerJ; Journal of Cognition; Journal of Neurological Sciences.


EDITORIAL ACTIVITY

- Gest Editor of Special Issue "Clinical Applications of Immersive and Nonimmersive Virtual Reality", Journal of Clinical Medicine (IF: 4.964; ISSN 2077-0383). 2022/23
- Editorial board member of *Nature Scientific Reports* (IF: 4.996; ISSN 2045-2322). From 2017 to 2022.
- Gest Editor of Special Issue "Body Illusions for Clinical Applications", Frontiers in Human Neuroscience (IF: 3.47; ISSN 16625161). 2021/23
- Gest Editor of Special Issue "New Challenges and Perspectives in Cognitive Neuroergonomics: Virtual and Robotic Embodiment", Frontiers in Neuroergonomics (ISSN 2673-6195). 2021/23

AUTORIZZO IL TRATTAMENTO DEI MIEI DATI PERSONALI AI SENSI DELLA LEGGE 196/03
AI SENSI DELL'ART. 46 DEL DPR 445/2000 DICHIARO CHE TUTTE LE INFORMAZIONI CONTENUTE NEL PRESENTE CURRICULUM VITAE
CORRISPONDONO A VERITÀ

Roma, 11/11/2024

Gaetano Tieri



FORMATO EUROPEO
PER IL CURRICULUM
VITAE



INFORMAZIONI PERSONALI

Nome

DOTT. ROBERTO POSCIA

Indirizzo

Via Aprilia 21 00178

Telefono

3388199296

Fax

E-mail

r.poscia@policlinicoumberto1.it

robertoposcia@pec.it

Nazionalità

Italiana

Data di nascita

12/02/1978

CF: PSCRR78B12H501R

ESPERIENZA LAVORATIVA

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

31-7-2018 – ad oggi

AOU Policlinico Umberto I; Via del Policlinico 155 00161 Roma

Azienda Ospedaliero Universitaria

Dirigente Medico I Livello, Disciplina Medicina Interna, Direzione Generale

Responsabile Unità Ricerca Clinica e Clinical Competence
giusta delibera 677 del 30-7-2018

e Responsabile Segreteria Tecnico Scientifica Comitato Etico Lazio Area 1

Direttore Centro Interdipartimentale delle Malattie Rare
Dal 17 gennaio 2024 ad oggi.

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

1-2-2018 – 31-7-2018

AOU Policlinico Umberto I; Via del Policlinico 155 00161 Roma

Azienda Ospedaliero Universitaria

Dirigente Medico I Livello, Disciplina Medicina Interna presso Direzione Sanitaria

Responsabile Scientifico del Clinical Trial Center e Responsabile Farmacovigilanza in
Sperimentazione Clinica

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

1-12-2013 – al 31-1-2018
 AOU Policlinico Umberto I; Via del Policlinico 155 00161 Roma
 Azienda Ospedaliero Universitaria
 Co co co Medico specialista in Cardiologia
 Attività di Coordinamento Scientifico del Clinical Trial Center e Responsabile Farmacovigilanza in Sperimentazione Clinica

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

1-12-2010 – 31-11-2013
 AOU Policlinico Umberto I; Via del Policlinico 155 00161 Roma
 Azienda Ospedaliero Universitaria
 Co co co Medico Specialista in Cardiologia
 Responsabile Farmacovigilanza in Sperimentazione Clinica

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

1-1-2014 – 31-12-2014
 Società Italiana di Cardiologia (SIC), via Po 24 Roma
 Società Scientifica
 Co co co
 Consulente per Centro Studi SIC per il coordinamento nazionale della ricerca scientifica

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità

1-7-2012 – 31-1-2018
 Università di Roma "Sapienza" Dip di Scienze Cardiovascolari, Respiratorie e Morfologiche
 Università Pubblica
 Assegno di Ricerca
 Attività di Ricerca in ambito delle malattie del Circolo Polmonare

Altre Mansioni ed Incarichi

Referente Osservatorio Agenzia Italiana del Farmaco (AIFA) Sperimentazione Clinica (OsSC) per l'AOU Policlinico Umberto I dal 22-10-2014 ad oggi.

Responsabile di Farmacovigilanza per Terapie Cellulari Avanzate AOU Policlinico Umberto I (Prot 0022330 del 15/7/2015 e prot 0009023 del 17/3/2016).

Delegato Del Direttore Sanitario AOU Policlinico Umberto I in Comitato Etico dell'Università "Sapienza" (Prot. 0022155 del 9-6-2017) fino al 31-12-2017

Delegato dal Direttore Generale dell' AOU Policlinico Umberto I al potere di stipula degli atti autorizzativi relativi alla Sperimentazione Clinica (Delibera 0000449 del 23-4-2021)

Componente gruppo di lavoro Regione Lazio per il coordinamento dell'attività dei CE della Regione Lazio con (Atto di Organizzazione N° G00592 del 24 gennaio 2020).

Componente gruppo di lavoro Regione Lazio per la predisposizione di linee di indirizzo tecnico-amministrative Progetti di Ricerca e CCM Determinazione dirigenziale Regione Lazio (Atto di Organizzazione n.G03650 del 2 aprile 2021).

Componente CERT: Comitato Etico Ricerca Transdisciplinare "Sapienza" Università di Roma, Nomina Decreto Rettoriale DR 2014/2021 e 2015/2021; organo di valutazione dell'Università per le attività di ricerca di tutte le facoltà dell'Ateneo.

Commissione per il Prontuario Terapeutico Ospedaliero AOU Policlinico Umberto I (Delibera 989 del 01/12/2022)

Componente Commissione Dispositivi e Medical Device Ordine dei Medici, Chirurghi ed Odontoiatri di Roma. Prot. GE 2022/3350

Abilitazione AIFA alla Piattaforma CTIS Clinical Trial Information System 17-3-2022

Membro del Comitato Scientifico Nazionale Osservatorio Trial Malattie Rare dal 1-3-2021

Componente Tavolo di Lavoro Sperimentazione Clinica di medicinali per uso umano come da Decreto Ministeriale del 13/1/2023 e del 11/1/2024

Presente nell'elenco degli idonei alla nomina di Direttore Sanitario delle Aziende e degli Enti del Servizio Sanitario regionale; Regione Lazio Determinazione 1° febbraio 2024, n. G01094

Componente del "Coordinamento Regionale dei Comitati Etici Territoriali, Regione Lazio": Determina Regionale G02012 del 16/2/2023

Nomina di Coordinatore del "Coordinamento Regionale dei Comitati Etici Territoriali, Regione Lazio" Determina Regionale G01388 del 12/2/2024

Componente del Gruppo di lavoro per il coordinamento degli interventi attuativi aziendali funzionali al conseguimento degli obiettivi del PNRR AOU Policlinico Umberto I. Delibera 122 del 19/2/2024

Referente Regione Lazio per Tavolo Interregionale Malattie Rare e Comitato Nazionale Malattie Rare registro ufficiale regione Lazio N° 0892186 dell'11-7-2024

Vicepresidente del Centro di Coordinamento Nazionale dei Comitati Etici Territoriali Presso AIFA anno 2024

Presidente Comitato Etico Nazionale Terapie Avanzate ATMP – AIFA anno 2025

ISTRUZIONE E FORMAZIONE

- *Date (da – a)*
- *Nome e tipo di istituto di istruzione o formazione*
- *Principali materie / abilità professionali oggetto dello studio*
- *Qualifica conseguita*
- *Livello nella classificazione nazionale (se pertinente)*

Aa 2009-2012 conseguito il 15/07/2013

Università di Roma "Sapienza"

Malattie dell'Apparato Cardiovascolare e Respiratorio

Dottorato di Ricerca in Fisiopatologia Cardio-Respiratoria 25° ciclo

- *Date (da – a)*
- *Nome e tipo di istituto di istruzione o formazione*
- *Principali materie / abilità professionali oggetto dello studio*
- *Qualifica conseguita*
- *Livello nella classificazione nazionale (se pertinente)*

2005-2009 conseguita il 23/11/2009

Università di Roma "Sapienza"

Scuola di Specializzazione in Malattie dell'Apparato Cardiovascolare

Specialista in Malattie dell'Apparato Cardiovascolare con votazione 70/70 e lode

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

1997-2005 conseguita il 22/3/2005
Università di Roma "Sapienza"

Facoltà di Medicina e Chirurgia

Laurea in Medicina e Chirurgia con votazione 110/110 e lode

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

1992-1997

Liceo Scientifico Statale Francesco Borromini

Diploma Maturità Scientifica

Diploma di Maturità Scientifica con votazione 44/60

- Iscrizione Albo di
- Data
- N.

Medici, chirurghi ed odontoiatri di Roma
26/7/2005
54492

CAPACITÀ E COMPETENZE PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

CERTIFICAZIONI E CORSI POST LAUREA CONSEGUITI

Eudravigilance electronic reporting of ICSRs in EEA
EMA European Medicines Agency 30 Churchill PI, London E14 5EU, Regno Unito
Anno 17-3-2014 QPPV number 64743, Qualified Person for Pharmacovigilance;

Certificazione Good Clinical Practice (GCP)
PharmaSchool
Validità anni 2013-2015

Certificazione Good Clinical Practice (GCP)
Center for Clinical Trials (CCTN) Clinical Trials Network (CTN) National Institute on Drug Abuse,
National Institutes of Health, Department of Health and Human Services, under Contract No.
HHSN27201201000024C. USA
Validità anni 2017-2020
Validità anni 2021-2023

Corso di formazione manageriale in ambito sanitario presso "Sapienza" Università di Roma 2023

MADRELINGUA

Italiana

- *Capacità di lettura*
- *Capacità di scrittura*
- *Capacità di espressione orale*

PUBBLICAZIONI SCIENTIFICHE

Inglese

ECCELLENTE

ECCELLENTE

OTTIMA

1544 Citations by 1217 documents

26. *h-index****Tra i lavori più importanti:***

1. E. Nicastri, C.D. Vizza, F. Carletti, S. Cicalini, R. Badagliacca, R. **Poscia**, G. Ippolito, F. Fedele, N. Petrosillo. Human Herpesvirus 8 and pulmonary hypertension. *Emerging Infectious Diseases* 2005; 11 (9): 1480-1482.
2. R. Badagliacca, C.D. Vizza, C. Letizia, S. Sciomer, R. Ciuffa, M. Montano, R. **Poscia**, F. Brandimarte, F. Fedele. Baseline venous endothelin-1 (ET1) plasma levels does not predict clinical response to bosentan in pulmonary arterial hypertension. *Ital Heart J* 2005; 6 (Suppl.8): 85S. Abstract.
3. Badagliacca R, Rischard F, Papa S, Kubba S, Vanderpool R, Yuan JX, Garcia JGN, Airhart S, **Poscia** R, Pezzuto B, Manzi G, Miotti C, Luongo F, Scoccia G, Sciomer S, Torre R, Fedele F, Vizza CD. Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis. *J Heart Lung Transplant*. 2020 Apr;39(4):310-320.
4. Badagliacca R, Papa S, Matsubara H, Lang IM, **Poscia** R, Manzi G, Vizza CD. The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. *Int J Cardiol*. 2020 Feb 15;301:183-189. doi: 10.1016/j.ijcard.2019.10.043. Epub 2019 Nov 13.
5. Vizza CD, Letizia C, Badagliacca R, Sciomer S, **Poscia** R, Della Rocca G, Iacoboni C, Leonardo de L, Quattrucci S, Dario C, Luigi P, Fedele F. Plasma adrenomedullin and endothelin-1 concentration during low-dose dobutamine infusion: Relationship between pulmonary uptake and pulmonary vascular pressure/flow characteristics. *Regul Pept*. 2006 Sep 11;136(1-3):85-91.
6. Vizza CD, Badagliacca R, Sciomer S, **Poscia** R, Battagliese A, Schina M, Agati L, Fedele F. Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study. *Cardiology*. 2006;106(3):168-73.
7. M. D'Alto, C.D. Vizza, E. Romeo, R. Badagliacca, G. Santoro, R. **Poscia**, B. Sarubbi, M. Mancone, P. Argiento, F. Ferrante, M.G. Russo, F. Fedele, R. Calabrò. Long term effect of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. *Heart* 2007; 93:621-625.
8. G. Valli, C.D. Vizza, P. Onorati, R. Badagliacca, R. Ciuffa, R. **Poscia**, F. Brandimarte, F. Fedele, P. Serra, P. Palange. Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension. *Eur J Appl Physiol*. 2008 Mar;102(4):417-24.
9. C.D. Vizza, C. Letizia, L. Petramala, R. Badagliacca, R. **Poscia**, E. Zepponi, E. Crescenzi, A. Nona, G. Benedetti, F. Ferrante, S. Sciomer, F. Fedele. Venous endothelin -1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-months bosentan treatment for pulmonary arterial hypertension. *Regul Pept*. 2008;151:48-53.
10. Vizza CD, Badagliacca R, **Poscia** R, Gambardella C, Pezzuto B, Crescenzi E, Papa S, Fedele F. Unusual presentation for a patent ductus arteriosus. *Eur Respir Rev*. 2009;18(113):174-6.
11. Calabrò P, Limongelli G, Maddaloni V, Vizza CD, D'Alto M, D'Alessandro R, **Poscia** R, Argiento P, Ziello B, Badagliacca R, Romeo E, Pacileo G, Russo MG, Fedele F, Calabrò R. Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. *Intern Emerg Med*. 2011; 7(5):425-30.
12. Vizza CD, Letizia C, Badagliacca R, **Poscia** R, Pezzuto B, Gambardella C, Nona A, Papa S, Marcon S, Mancone M, Iacoboni C, Riccieri V, Volterrani M, Fedele F. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. *Int J Cardiol*. 2013 Jul 15;167(1):220-4.
13. Badagliacca R, **Poscia** R, Pezzuto B, Papa S, Nona A, Mancone M, Mezzapesa M, Nocioni M, Sciomer S, Valli G, Cedrone N, Fedele F, Vizza CD. Pulmonary arterial dilatation in pulmonary hypertension: prevalence and prognostic relevance. *Cardiology*. 2012;121(2):76-82.
14. Badagliacca R, Pezzuto B, **Poscia** R, Mancone M, Papa S, Marcon S, Valli G, Sardella G, Ferrante F, Iacoboni C, Parola D, Fedele F, Vizza CD. Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. *J Heart Lung Transplant*. 2012;31(4):364-72.
15. Vizza CD, Badagliacca R, **Poscia** R, Mezzapesa M, Nocioni M, Fedele F. Therapeutic strategies in pulmonary arterial hypertension. *European Cardiology*, 2012;8(3):198-203.
16. Riccieri V, Vasile M, Iannace N, Stefanantoni K, Sciarra I, Vizza CD, Badagliacca R, **Poscia** R, Papa S, Mezzapesa M, Nocioni M, Valesini G. Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. *Rheumatology (Oxford)*. 2013 Aug;52(8):1525-8.

17. Peacock AJ, Crawley S, McLure L, Blyth K, Vizza CD, **Poscia** R, Francone M, Iacucci I, Olschewski H, Kovacs G, Vonk Noordegraaf A, Marcus JT, van de Veerdonk MC, Oosterveer FP. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. *Circ Cardiovasc Imaging*. 2014 Jan;7(1):107-14. doi: 10.1161/CIRCIMAGING.113.000629. Epub 2013 Oct 30. PMID: 24173272
18. Position Statement BPCO, Board ITALIAN JOURNAL OF PUBLIC HEALTH IJIHPH - 2014, Volume 3, Number 2
19. **Poscia** R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Parisi F, Badagliacca R, Fedele F, Dario Vizza C. 'Real-life' information on pulmonary arterial hypertension: the iPHnet Project. *Curr Med Res Opin*. 2014 Dec;30(12):2409-14.
20. Badagliacca R, **Poscia** R, Pezzuto B, Papa S, Gambardella C, Francone M, Mezzapesa M, Nocioni M, Nona A, Rosati R, Sciomer S, Fedele F, Dario Vizza C. Right ventricular dyssynchrony in idiopathic pulmonary arterial hypertension: Determinants and impact on pump function. *J Heart Lung Transplant*. 2015 Mar;34(3):381-9
21. Badagliacca R, **Poscia** R, Pezzuto B, Nocioni M, Mezzapesa M, Francone M, Giannetta E, Papa S, Gambardella C, Sciomer S, Volterrani M, Fedele F, Dario Vizza C. Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus maladaptive morphology. *J Heart Lung Transplant*. 2015 Mar;34(3):395-403. doi: 10.1016/j.healun.2014.11.002. Epub 2014 Nov 8. PubMed PMID: 25499139.
22. Pezzuto B, Badagliacca R, **Poscia** R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Volterrani M, Fedele F, Vizza CD. Circulating biomarkers in pulmonary arterial hypertension: update and future direction. *J Heart Lung Transplant*. 2015 Mar;34(3):282-305.
23. Stefanantoni K, Sciarra I, Vasile M, Badagliacca R, **Poscia** R, Pendolino M, Alessandri C, Vizza CD, Valesini G, Riccieri V. Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. *Reumatismo*. 2015 Mar 31;66(4):270-6.
24. Badagliacca R, Reali M, **Poscia** R, Pezzuto B, Papa P, Mezzapesa M, Nocioni M, Valli G, Giannetta E, Sciomer S, Iacoboni C, Fedele F, Vizza CD. Right intraventricular dyssynchrony in idiopathic, heritable and anorexigen-induced pulmonary arterial hypertension: clinical impact and reversibility. *JACC Cardiovasc Imaging*. 2015 Jun;8(6):642-52.
25. Badagliacca R, **Poscia** R, Pezzuto B, Papa S, Pesce F, Manzi G, Giannetta E, Raineri C, Schina M, Sciomer S, Parola D, Francone M, Carbone I, Fedele F, Vizza CD. Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension. *J Heart Lung Transplant*. 2016 Nov;35(11):1321-1329.
26. Vitulo P, Stanzola A, Confalonieri M, Libertucci D, Oggionni T, Rottoli P, Paciocco G, Tuzzolino F, Martino L, Beretta M, Callari A, Amaducci A, Badagliacca R, **Poscia** R, Meloni F, Refini RM, Geri P, Baldi S, Ghio S, D'Alto M, Argiento P, Sofia M, Guardamagna M, Pizzuto B, Vizza CD. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. *J Heart Lung Transplant*. 2016 May 7. pii: S1053-2498(16)30114-0. doi: 10.1016/j.healun.2016.04.010. [Epub ahead of print] PubMed PMID: 27329400.
27. Badagliacca R, Papa S, Valli G, Pezzuto B, **Poscia** R, Manzi G, Giannetta E, Sciomer S, Palange P, Naeije R, Fedele F, Vizza CD. Echocardiography Combined With Cardiopulmonary Exercise Testing for the Prediction of Outcome in Idiopathic Pulmonary Arterial Hypertension. *Chest*. 2016 Dec;150(6):1313-1322.
28. Valli G, Palange P, Badagliacca R, Papa S, **Poscia** R, Vizza CD. Exercise energy expenditure in patients with idiopathic pulmonary arterial hypertension: Impact on clinical severity and survival. *Respir Physiol Neurobiol*. 2019 Jun;264:33-39. doi: 10.1016/j.resp.2019.04.003. Epub 2019 Apr 6.
29. Badagliacca R, Reali M, **Poscia** R, Pezzuto B, Papa S, Mezzapesa M, Nocioni M, Valli G, Giannetta E, Sciomer S, Iacoboni C, Fedele F, Vizza CD. Letter to the editor about the paper "Right ventricular dyssynchrony predicts clinical outcomes in patients with pulmonary hypertension" by Murata et al. *Int J Cardiol*. 2017 May 1;234:128. doi: 10.1016/j.ijcard.2017.01.081. PubMed PMID: 28285628.
30. Ghio S, D'Alto M, Badagliacca R, Vitulo P, Argiento P, Mulè M, Tuzzolino F, Scelsi L, Romeo E, Raineri C, Martino L, Tamburino C, **Poscia** R, Vizza CD. Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension. *Int J Cardiol*. 2017 Mar 1;230:53-58.
31. Badagliacca R, Raina A, Ghio S, D'Alto M, Confalonieri M, Correale M, Corda M, Paciocco G, Lombardi C, Mulè M, **Poscia** R, Scelsi L, Argiento P, Sciomer S, Benza RL, Vizza CD. Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. *J Heart Lung Transplant*. 2017 Aug 26. pii: S1053-2498(17)31983-6.
32. Badagliacca R, Papa S, **Poscia** R, Valli G, Pezzuto B, Manzi G, Torre R, Gianfrilli G, Sciomer S, Palange P, Naeije R, Fedele F, Vizza CD. The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. *J Heart Lung Transplant*. 2019 Mar;38(3):306-314. doi:10.1016/j.healun.2018.11.015.
33. Badagliacca R, **Poscia** R, Pezzuto B, Papa S, Reali M, Pesce F, Manzi G, Gianfrilli D, Ciciarello F, Sciomer S, Biondi-Zoccai G, Torre R, Fedele F, Vizza CD. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. *J Heart Lung Transplant*. 2017 Oct 2. pii: S1053-2498(17)32041-7.
34. Roberto **Poscia**, Giovanni Spera, Franco Mandelli. Tesi di Laurea e Comitato Etico, Medicina e Chirurgia – Journal of Italian Medical Education. *Med. Chir*. 75. 3382-3385, 2017

PARTECIPAZIONE A TRIAL CLINICI
INTERNAZIONALI

35. Badagliacca R, Ghio S, Correale M, **Poscia R**, Camporotondo R, Ferraretti A, Papa S, Pezzuto B, Petrone P, Torre R, Di Biase M, Novara P, Guida S, Vizza CD. Prognostic significance of the echocardiographic estimate of pulmonary hypertension and of right ventricular dysfunction in acute decompensated heart failure. A pilot study in HFrEF patients. *Int J Cardiol*. 2018 Nov 15;271:301-305.

36. Araimo F, Imperiale C, Tordiglione P, Ceccarelli G, Borrazzo C, Alessandri F, Santinelli L, Innocenti GP, Pinacchio C, Mauro V, Recchia GE, Zanca S, Calò A, **Poscia R**, Ruberto F, d'Ettore G, Bilotta F, Mastroianni C, Pugliese F. Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial. *J Med Virol*. 2021 Apr;93(4):2210-2220. doi: 10.1002/jmv.26636. Epub 2020 Nov 10.PMID: 33111980 Clinical Trial.

37. Gabrielli S, Mangano V, Furzi F, Oliva A, Vita S, **Poscia R**, Fazii P, Di Paolo J, Marocco R, Mastroianni CM, Bruschi F, Mattiucci S. Molecular Identification of New Cases of Human *Dirofilariosis* (*Dirofilaria repens*) in Italy. *Pathogens*. 2021 Feb 23;10(2):251. doi: 10.3390/pathogens10020251.PMID: 33672411

38. Ceci FM, Fiore M, Gavaruzzi F, Angeloni A, Lucarelli M, Scagnolari C, Bonci E, Gabanella F, Di Certo MG, Barbato C, Petrella C, Greco A, De Vincentiis M, Ralli M, Passananti C, **Poscia R**, Minni A, Ceccanti M, Tarani L, Ferraguti G "Early Routine Biomarkers of SARS-CoV-2 Morbidity and Mortality: Outcomes from an Emergency Section" 2022 Jan 12;12(1):176. Doi 10.3390/diagnostics12010176.

39. Manzi G, Mariani MV, Filomena D, **Poscia R**, Severino P, Iaconelli A, Recchioni T, Madonna R, Vizza CD, Badagliacca R. "Biobanks: The unmet need in heart failure management." *Vascul Pharmacol*. 2023 Jun;150:107179. doi: 10.1016/j.vph.2023.107179. Epub 2023 Apr 28.

40. Manfrini V, Badagliacca R, Messaggio E, **Poscia R**, Torre R, Manunta P, Vizza CD. "Exploratory study on the endogenous ouabain in idiopathic pulmonary arterial hypertension patients" *Ann Ist Super Sanita*. 2023 Jan-Mar;59(1):76-79. doi: 10.4415/ANN_23_01_11.

41. Cinicola BL, Palumbo IM, Pannunzio A, Carnevale R, Bartimoccia S, Cammisotto V, Capponi M, Brindisi G, Salvatori F, Barilla F, Martino F, D'Amico A, **Poscia R**, Spalice A, Zicari AM, Violi F, Loffredo L. "Low Grade Endotoxemia and Oxidative Stress in Offspring of Patients with Early Myocardial Infarction." *Antioxidants* (Basel). 2023 Apr 19;12(4):958. doi:10.3390/antiox12040958.

42. Loffredo L, Soresina A, Cinicola BL, Capponi M, Salvatori F, Bartimoccia S, Picchio V, Forte M, Caputi C, **Poscia R**, Leuzzi V, Spalice A, Pignatelli P, Badolato R, Duse M, Violi F, Carnevale R, Zicari AM "Impaired arterial dilation and increased NOX2 generated oxidative stress in subjects with ataxia-telangiectasia mutated (ATM) kinase"; AT study group. *Redox Biol*. 2024 Nov;77:103347. doi: 10.1016/j.redox.2024.103347. Epub 2024 Sep 12.

43. Messina E, La Torre G, Pecoraro M, Piscioti ML, Sciarra A, **Poscia R**, Catalano C, Panebianco V "Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA)". *Eur Radiol*. 2024 Jan;34(1):204-213. doi: 10.1007/s00330-023-10019-1. Epub 2023 Aug 10.

44. Perrotta N, Fiorito LA, Casini G, Gentile R, Vescovo R, Piciocchi A, Lobello R, Cappelli C, **Poscia R**, Cimino G, Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real-World Evidence From an Italian Single-Center Study; *Pharmacol Res Perspect*. 2025 Apr;13(2):e70083. doi: 10.1002/prp2.70083.

45. Le normative della Ricerca Clinica dal 2001 ad oggi.
Autori: Stefano Lavigranese; **Roberto Poscia**

Start	Institution	Position
April 2004	"Sapienza" University of Rome, Department of Cardiovascular, Respiratory Sponsor: ACTELION Pharmaceutical	Co-Investigator EARLY (Randomized, Double-Blind, Multicenter, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients with Mildly Symptomatic Pulmonary Arterial Hypertension).
April 2005	"Sapienza" University of Rome, Department of Cardiovascular, Respiratory Sponsor: Bayer Pharmaceutical	Co-Investigator Ventavis Observational Study 308120 (Open-label, Uncontrolled, Prospective long-term observation of Ventavis inhalation therapy in the treatment of patients with primary pulmonary hypertension up to 4 years).
August 2005	"Sapienza" University of Rome, Department of Cardiovascular, Respiratory Sponsor: Ely-Lilly	Co-Investigator H6D-MC-LVGY A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension

December 2005	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Ely-Lilly	Co-Investigator H6D-MC-LVGX Open Label Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension
	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: ACTELION Pharmaceutical	Co-Investigator COMPASS-1 N° AC-052-415 Effects of Combination Of bosentan and sildenafil versus sildenafil Monotherapy on morbidity and mortality in symptomatic PATientS with pulmonary arterial hypertenSion
2008	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: AIFA	Co-Investigator Protocollo AIFA Valutazione dell’efficacia e della tollerabilità della terapia combinata Bosentan-Sildenafil in pazienti con ipertensione polmonare severa.
	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory	Co-Investigator CTEPH Registry
December 2008	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Bayer Pharmaceutical	Co-Investigator N° 12934 (PATENT-1): “Randomized, double-blind, placebo-controlled, multicentre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)”
March 2009	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Bayer Pharmaceutical	Co-Investigator N° 12935 (PATENT-2): “Long-term extension, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1,5 mg, 2 mg or 2,5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)”
February 2009	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Bayer Pharmaceutical	Co-Investigator CHEST-1 Study (Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral Riociguat -BAY63-2521- (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension).
July 2009	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Bayer Pharmaceutical	Co-Investigator CHEST-2 Study (Open Label, Multi-centre, Multi-national Study to Evaluate long term the Efficacy and Safety of Oral Riociguat -BAY63-2521- (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension).
Sept 2009	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Novartis Pharmaceutical	Co-Investigator N° CQT1571A2301 (IMPRES): “A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QT1571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study”
April 2010	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Novartis Pharmaceutical	Co-Investigator N° CQT1571A2301E1: “An extension study to CQT1571A2301 to evaluate the long-term safety, tolerability and efficacy of oral QT1571 (imatinib) in the treatment of severe pulmonary arterial hypertension: IMPRES extension”
April 2011	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor:	Co-Investigator N° CQT1571A2102: “A non randomized, multiple dose, three treatment period, open-label, single sequence, single group study to evaluate the pharmacokinetic effect of two doses of QT1571 (imatinib) on the co-

	Novartis Pharmaceutical	administered drugs sildenafil and bosentan in pulmonary arterial hypertension (PAH) patients”
April 2011	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Novartis Pharmaceutical	Co-Investigator N° CQT1571A2102E1: “An open-label extension study to CQT1571A2102 to evaluate the long-term safety, tolerability and efficacy of QT1571 (imatinib) in the treatment of severe pulmonary arterial hypertension”
April 2006	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Novartis Pharmaceutical	Co-Investigator NCT00477269 (A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor Imatinib –STI571- for the Treatment of Pulmonary Arterial Hypertension).
October 2010	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: GSK Pharmaceutical	Co-Investigator N° AMB112565 (AMBITION): “A randomized, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension”
June 2008	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: GSK Pharmaceutical	Co-Investigator N° AMB110094 (VOLT): “A post-marketing observational surveillance programme for ambrisentan”
October 2010	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: AIPO Research Center	Co-Investigator SPHERIC-1: “Studio multicentrico, randomizzato, a doppio cieco, verso placebo, della durata di 16 settimane che valuta l’effetto del sildenafil nel trattamento di paziente con ipertensione polmonare associata a BPCO”
December 2008	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Aires Pharmaceuticals	Co-Investigator AIR 001 Inhalation Solution in patients with Pulmonary Hypertension
	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Novartis Pharmaceuticals	Co-Investigator RELAX-AHFA (Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure).
January 2007	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Cardiokine Biopharma	Co-Investigator BALANCE (Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to determine the safety and efficacy of Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation).
May 2007	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Janssen-Cilag	Co-Investigator ASCEND-HF (Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure).
September 2006	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Pfizer Pharmaceutical	Co-Investigator N° A1481243 A multinational, multicentre, randomised, double-blind study to assess the efficacy and safety of oral sildenafil 20mg tid or placebo tid when added to bosentan in the treatment of subjects, aged 18 years and above, with pulmonary arterial hypertension.
April 2008	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory	Co-Investigator N° A1481244: “A multinational, multicentre, randomized, parallel group, double-blind study to assess the efficacy and safety of 1

	Sponsor: Pfizer Pharmaceutical	mg, 5 mg, 20 mg TID of oral sildenafil in the treatment of subject aged 18 year and over with pulmonary arterial hypertension (PAH)"
October 2006	"Sapienza" University of Rome, Department of Cardiovascular, Respiratory Sponsor: United Therapeutics Pharmaceutical	Co-Investigator TDE-PH-301 ; "A 16-week, international, multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension" A MULTINATIONAL, MULTICENTRE, RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH).
May 2006	"Sapienza" University of Rome, Department of Cardiovascular, Respiratory Sponsor: United Therapeutics Pharmaceutical	Co-Investigator TDE-PH-302 ; "international, multicenter, Open Label study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension" A MULTINATIONAL, MULTICENTRE, Open Label STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH).
June 2009	"Sapienza" University of Rome, Department of Cardiovascular, Respiratory Sponsor: United Therapeutics Pharmaceutical	Co-Investigator FREEDOM-C1 : "A 16-week, international, multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension" A MULTINATIONAL, MULTICENTRE, RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH).
May 2006	"Sapienza" University of Rome, Department of Cardiovascular, Respiratory Sponsor: United Therapeutics Pharmaceutical	Co-Investigator FREEDOM-C2 : "international, multicenter, Open Label study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension" A MULTINATIONAL, MULTICENTRE, Open Label STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH).
May 2008	"Sapienza" University of Rome, Department of Cardiovascular, Respiratory Sponsor: ACTELION Pharmaceutical	Co-Investigator AC-055-302 SERAPHIN : Study with Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve clinical outcome A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension.
July 2008	"Sapienza" University of Rome, Department of Cardiovascular, Respiratory Sponsor: ACTELION Pharmaceutical	Co-Investigator AC-055-303 SERAPHIN : Study with Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve clinical outcome A multicenter, open label, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension.
June 2007	"Sapienza" University of Rome, Department of Cardiovascular, Respiratory	Co-Investigator COMPERA Registry

ATTIVITÀ DI DOCENZA IN CORSI
AVANZATI IN AMBITO REGOLATORIO
E SPERIMENTAZIONE CLINICA

May 2014	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Bayer Pharmaceutical	Co-Investigator Expert Riociguat Registry
Nov 2013	“Sapienza” University of Rome, Department of Cardiovascular, Respiratory Sponsor: Bayer Pharmaceutical	Co-Investigator RESPITE: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)

1. Nuove regole europee sulla Sperimentazione Clinica dei medicinali per uso umano. Policlinico Umberto I: L'attuale iter approvativo, l'esperienza del CTC. Roma 24 giugno 2015
2. Le sperimentazioni cliniche di medicinali alla luce del Regolamento UE 536/2014, L'impatto delle regole comunitarie sui Comitati Etici. Roma, 23 giugno 2015 Studio Professionale Associato a Baker & McKenzie.
3. Farmindustria Il regolamento UE 536/2014. Cosa cambia e cosa fare? L'impatto del nuovo regolamento sui Comitati Etici. Martedì 7 luglio 2015 Sala Convegni di Farmindustria, Largo del Nazareno
4. “La Farmacovigilanza in Sperimentazioni Cliniche” convegno di Farmacovigilanza, organizzato dall'Università di Roma “La Sapienza” e dall'Area Politica del Farmaco, Regione Lazio, Dicembre 2012
5. PHARMACISTS EDUCATION PROGRAM, Hospital pharmacists should be actively involved in clinical trials of medicines.
The management of the experimental drugs, pharmacist in ethics committees. Roma, presso il Nobile Collegio Chimico-farmaceutico Roma, nei giorni 17-18 ottobre 2017
6. Lettura Magistrale presso ISMETT Palermo. Il nuovo Regolamento Europeo, impatto sulle strutture di ricerca. 21 marzo 2016
7. Comitati Etici: Semplificare le procedure autorizzative, innovare gli aspetti organizzativi e accelerare la negoziazione di Contratto di Sperimentazione Clinica. STUDI NO PROFIT: dal Project Management alla Farmacovigilanza. IKN Italy Planet Heath Roma 18-21 settembre 2017.
8. Le sperimentazioni cliniche spontanee in Italia. Esecuzione pratica di una sperimentazione spontanea
TEMAS Forum Milano 16 dicembre 2015. Tempo di Docenza 105 minuti
9. Il Regolamento Europeo sulle Sperimentazioni Cliniche 536/2014 Come cambia il ruolo del Comitato Etico, Pubblicazione dei dati e accesso ai dati , Gli studi no-profit e nuovo Regolamento Europeo
TEMAS Forum Milano 7-06-2017 Tempo di Docenza 195 minuti
10. Aggiornamento delle ICH - GCP E6 (R2) I nuovi requisiti delle Good Clinical Practice:. Inquadramento regolatorio delle sperimentazioni clinichegli obblighi dello sperimentatore nelle sperimentazioni cliniche.
TEMAS Forum Milano 24 maggio 2017. Tempo di Docenza 210 minuti.
11. Uso Compassionevole, Off- Label, Off- License dei farmaci in Italia Il ruolo di garanzia del Comitato Etico, casistiche particolari
TEMAS Forum Milano 20 aprile 2017 Tempo di Docenza 210 minuti
12. Le sperimentazioni cliniche spontanee dei dispositivi medici. Esecuzione pratica di una sperimentazione spontanea. Esempio pratico di uno studio spontaneo . Assicurazione della qualità: esame di un IIT nell'ambito di un audit.
TEMAS Forum Finceramica, Faenza 6 luglio 2015. Tempo di Docenza 195 minuti
13. Gli Studi Osservazionali. La (corretta) pianificazione di uno studio osservazionale . Esecuzione pratica di un studio osservazionale . Valutazione statistica di uno studio osservazionale: cenni
TEMAS Forum Milano 22 febbraio 2017 Tempo di Docenza 150 minuti
14. Regolamento Europeo sulle Sperimentazioni Cliniche
Le principali novità introdotte dal Regolamento
TEMAS Forum Milano 4 luglio 2016 Tempo di Docenza 75 minuti

15. Sperimentazioni spontanee Project & Quality Management, esecuzione pratica e oversight di una sperimentazione spontanea
TEMAS Forum Milano 20 giugno 2017 Tempo di Docenza 150 minuti
16. Corso Aziendale di Farmacovigilanza Az. Policlinico Umberto I, Docenza di farmacovigilanza nelle sperimentazioni cliniche.
6-6-2012; 5-12-2012; 2-10-2013; 24-10-2013; 20-11-2014 Tempo di docenza 45 minuti a sessione.
17. 2020-2021 – Corso di laurea magistrale *Biotechnology* (corso in lingua inglese), insegnamento di *Farmacovigilanza*. Università degli Studi di Roma Tor Vergata.
18. 2020-2021 – Corso di Alta Formazione in *Formazione Manageriale in ambito sanitario*, modulo *Management della ricerca e comitati etici*. "Sapienza" – Università di Roma.
19. 2021-2022 – Master di II Livello in *Monitoraggio, assicurazione e controllo qualità nei clinical trials*. "Sapienza" – Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive.
20. 2021-2022 – Corso di Alta Formazione in *Formazione Manageriale in ambito sanitario*, *Management della ricerca e comitati etici*. "Sapienza" – Università di Roma.
21. 2021-2022 – Master di II Livello in *Ricerca Clinica, metodologia, farmacovigilanza, aspetti legali e regolamentari* – modulo *Aspetti regolatori dei Trial Clinici, pianificazione e sviluppo di un protocollo clinico, dossier autorizzativo, consenso informato, legislazione dei processi autorizzativi, funzionamento del CE, report ICH*. "Sapienza" – Università di Roma.
22. 2021-2022 – Corso di Alta Formazione *Metodologia della Ricerca Clinica: dall'Idea ai Risultati*. Università degli Studi di Roma "UnitelmaSapienza".
23. 2021-2022 – Corso di Laurea delle Professioni Sanitarie – insegnamento di *Diritto sanitario, deontologia e bioetica, management sanitario ed infermieristico*. "Sapienza" – Università di Roma, Facoltà di Medicina e Odontoiatria.
24. 2022-2023 – Corso di Alta Formazione in *Formazione Manageriale in ambito sanitario* – docenza sull'organizzazione dei Comitati Etici. "Sapienza" – Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive.
25. 2022-2023 – Master di II Livello in *Monitoraggio, assicurazione e controllo qualità nei clinical trials*. "Sapienza" – Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive.
26. 2022-2023 – Corso di Laurea di I Livello in Infermieristica D/Aeronautica Militare – insegnamento di *Diritto sanitario, deontologia e bioetica, management sanitario ed infermieristico*. "Sapienza" – Università di Roma, Facoltà di Medicina e Odontoiatria.
27. 2022-2023 – Master di II Livello in *Ricerca Clinica, metodologia, farmacovigilanza, aspetti legali e regolamentari* – modulo *Aspetti regolatori dei Trial Clinici, pianificazione e sviluppo di un protocollo clinico, dossier autorizzativo, consenso informato, legislazione dei processi autorizzativi, funzionamento del CE, report ICH*. "Sapienza" – Università di Roma, Dipartimento di Medicina Traslazionale e di Precisione.
28. 2023-2024 – Master di II Livello in *Oncologia Integrata*, modulo di *Management sanitario ed approccio agli Studi Clinici*. "Sapienza" – Università di Roma.
29. 2023-2024 – Corso di Alta Formazione *Etica per la Ricerca*. "Sapienza" – Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive.
30. 2023-2024 – Master di II Livello in *Monitoraggio, assicurazione e controllo qualità nei clinical trials*. "Sapienza" – Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive.
31. 2023-2024 – Master interfacoltà di II Livello in *Gestione Integrata dei Dispositivi Medici – Medical Technologies Regulatory Affairs* (codice 32678), modulo di base e Corso di Alta Formazione *Ricerca Clinica sui Dispositivi Medici*. "Sapienza" – Università di Roma, Dipartimento di Scienze Odontostomatologiche.
32. 2023-2024 – Corso di laurea magistrale *Biotechnology* (corso in lingua inglese), insegnamento di *Farmacovigilanza*. Università degli Studi di Roma Tor Vergata.
33. 2023-2024 – Corso di Alta Formazione in *Formazione Manageriale in ambito sanitario* – docenza sull'organizzazione dei Comitati Etici. "Sapienza" – Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive.
34. 2023-2024 – Master di II Livello in *Ricerca Clinica, metodologia, farmacovigilanza, aspetti legali e regolamentari* – modulo *Aspetti regolatori dei Trial Clinici, pianificazione e sviluppo di un protocollo clinico, dossier autorizzativo, consenso informato, legislazione dei processi autorizzativi, funzionamento del CE, report ICH*. "Sapienza" – Università di Roma, Dipartimento di Medicina Traslazionale e di Precisione.
35. 2024-2025 – Corso di Alta Formazione in *Formazione Manageriale in ambito sanitario* – docenza sull'organizzazione dei Comitati Etici. "Sapienza" – Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive.
36. 2024-2025 – Master di II Livello in *Ricerca Clinica, metodologia, farmacovigilanza, aspetti legali e regolamentari* – modulo *Aspetti regolatori dei Trial Clinici, pianificazione*

e sviluppo di un protocollo clinico, dossier autorizzativo, consenso informato, legislazione dei processi autorizzativi, funzionamento del CE, report ICH. "Sapienza" – Università di Roma, Dipartimento di Medicina Traslazionale e di Precisione.

37. 2024-2025 – Master interfacoltà di II Livello in *Gestione Integrata dei Dispositivi Medici – Medical Technologies Regulatory Affairs* (codice 32678), modulo di base e Corso di Alta Formazione Ricerca Clinica sui Dispositivi Medici. "Sapienza" – Università di Roma, Dipartimento di Scienze Odontostomatologiche e Maxillo-facciale.

Inoltre è presente nell'elenco dei docenti aziendali del Policlinico Umberto I.

CAPACITÀ E COMPETENZE ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

La mia attività di ricerca sottolinea una buona esperienza clinico-scientifica nel campo delle malattie cardiovascolari rare, con particolare attenzione all'ipertensione polmonare. Attraverso il coinvolgimento in trial internazionali e studi osservazionali di lungo termine, e al trasferimento nella pratica clinica di farmaci che oggi rappresentano lo standard di cura.

L'attività di ricerca si è interrotta quando ho preso servizio presso il Clinical Trial Center e successivamente all'URCCC dell'AOU Policlinico Umberto I circa nel 2013.

Ho sviluppato competenze sulla base di esperienze Nazionali ed Internazionali per attività in ambito regolatorio e quindi in grado di supportare, organizzare, eseguire e coordinare a livello nazionale e internazionale, studi clinici promossi da industrie, società scientifiche, enti di ricerca, singoli ricercatori e Dipartimenti Universitari.

Ottima conoscenza della legislazione europea e nazionale relativa agli studi clinici con principi di metodologia e discipline regolatorie GCP.

Come responsabile dell'URCCC ho maturato la competenza e la conoscenza necessaria per seguire trial clinici in tutte le discipline mediche e chirurgiche e su device e farmaci seguendo ed impostando per quanto di competenza, con il Clinical Trial Center e l'Unità di Ricerca più di 8000 trial clinici nel corso degli anni di attività. Tra i progetti trattati ci sono stati anche H2020, POR, FESR e Ricerca Finalizzata e PNRR e sperimentazioni cliniche su farmaci e dispositivi.

Buona conoscenza e scrittura sistemi di qualità; SOPs sulle sperimentazioni cliniche e sulla gestione del farmaco sperimentale.

Ottima conoscenza di Data Base elettronici e schede raccolta dati elettroniche per protocolli clinici in conformità allo standard FDA CRF 21 Part 11 e certificazione di qualità GAMP5.

In particolare, come responsabile dell'Unità di Ricerca Clinica e Clinical Competence (URCCC) ho:

Predisposto e negoziato i budget di studio con i promotori (industria farmaceutica e no profit), garantendo un equilibrio tra la sostenibilità delle attività cliniche, i fabbisogni del centro e la competitività della struttura.

Analizzato i costi diretti e indiretti (visite, procedure diagnostiche, personale dedicato, farmaco e device, servizi di laboratorio), assicurando la corretta valorizzazione di tutte le prestazioni coinvolte.

Monitorato la spesa e i flussi finanziari durante lo svolgimento dello studio, verificando la corretta erogazione dei fondi, la congruità delle fatture emesse dall'URCCC e la puntualità dei rimborsi da parte dei promotori. L'URCCC si occupa anche dei rimborsi ai pazienti ai sensi della normativa vigente e della procedura aziendale.

Predisposto report periodici per la Direzione e per i Principal Investigator, a supporto della pianificazione delle risorse.

Gestito la fase di chiusura e rendicontazione economica, assicurando la trasparenza e la tracciabilità dei flussi finanziari e favorendo l'ottimizzazione dei ricavi per il centro.

Questa attività ha richiesto un costante confronto con i vari attori coinvolti (promotori, amministrazione, personale clinico e di ricerca),

CAPACITÀ E COMPETENZE TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc.

OTTIME capacità informatiche per il pacchetto Office

Conoscenza del sistema informatico CE-Online di Cineca per Comitati Etici

ALTRE CAPACITÀ E COMPETENZE

Competenze non precedentemente indicate.

Un'ottima esperienza nel trattamento del paziente cardiologico critico,
Un'ottima esperienza nella gestione diagnostico-terapeutica del paziente con cuore polmonare cronico e con ipertensione arteriosa polmonare malattia rara ad alto impatto di mortalità e morbilità.

Un'ottima competenza nella valutazione funzionale cardiopolmonare con est da sforzo, test ergospirometrico, test provocativi di ischemia miocardica circa, prove di funzionalità respiratoria.

Un'ottima esperienza nelle altre metodiche non invasive (holter, ecocardiografia).

Un'ottima competenza riguardo a cateterismi cardiaci destri diagnostici e di valutazione emodinamica, in particolare test di vasodilatazione acuta con ossido nitrico/prostaglandine, valutazione riserva inotropa con dobutamina.

PATENTE O PATENTI

Patente A e B

ULTERIORI INFORMAZIONI

Membro delle seguenti Società e Associazioni e ruoli:

Società Italiana di Cardiologia (S.I.C.) fino al 2018

Consigliere del Gruppo di Studio della S.I.C. sulla Circolazione Polmonare e Funzione Ventricolare Destra, per il biennio 2010-2012.

Segretario del Gruppo di Studio della S.I.C. sulla Circolazione Polmonare e Funzione Ventricolare Destra, per il biennio 2008-2009.

Consigliere Associazione Malati Ipertensione Polmonare (A.M.I.P.) dal 2008 al 2012.

Membro del Pulmonary Vascular Research Institute (PVRI), Istituto di ricerca indipendente con il fine di incrementare lo sviluppo e la ricerca nel campo delle patologie vascolari polmonari.

Nel 2012 Reviewer of the European Journal of Musculoskeletal Diseases (EJMD).

Nel 2017 Reviewer per International Journal of Cardiology

Nel 2017 AICRO Working Group Italiano sui Clinical Trial Center, redazione del White Paper Italiano sui Clinical Trial Center: <https://www.aicro.it/wp-content/uploads/2016/10/AICRO-White-Paper.pdf>

Membro dell'Accademia Lancisiana

Editor in Chief Medical Academy Journal

Il sottoscritto, ai sensi degli artt. 46 e 47 del D.P.R. 28 dicembre 2000 n. 445 e s.m.i., dichiara che quanto riportato nel presente curriculum vitae corrisponde a verità.

Il sottoscritto, consapevole che – ai sensi dell'art. 76 del D.P.R. n. 445/2000 - le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali, dichiara che le informazioni rispondono a verità.

Il sottoscritto autorizza il trattamento dei propri dati personali ai sensi dell'art. 13 del D.lgs. 30 giugno 2003 n. 196 – “Codice in materia di protezione dei dati personali” e dell'art. 13 GDPR 679/16 – “Regolamento europeo sulla protezione dei dati personali”.

Data 27-09-2025.

Firm.to



NICCOLO' STEFANI LOCATION

BUSINESS LEADER POPULATION HEALTH AND CLINICAL AI

Miami, FL, US

WORK

- 2025 - now Business Leader Population Health and Clinical AI @ RadNet DeepHealth
- 2024 - 2025 Vice President Portfolio and Clinical Development @ [DeepHealth](#)
- 2023 - 2024 Chief Medical Officer Precision Diagnosis @ [Philips](#)

EDUCATION

- Medical School Florence
Master's degree

2000 - 2006

SKILLS

- PACS
- Medical Imaging
- Radiology

SUMMARY

Niccolo' Stefani, based in Miami, FL, US, is currently a Business Leader Population Health and Clinical AI at RadNet DeepHealth. Niccolo' Stefani brings experience from previous roles at DeepHealth and Philips. Niccolo' Stefani holds a 2000 - 2006 Master's degree @ Medical School Florence. With a robust skill set that includes PACS, Medical Imaging, Radiology, DICOM, Medical Devices and more. Niccolo' Stefani has 1 emails and 1 mobile phone numbers on RocketReach.

Medical Science Leader – Clinical AI (Remote, US) DeepHealth, RadNet's AI division

INFORMAZIONI PERSONALI



avv. prof. Alberto Gambino

📍 ROMA (Via dei Tre Orologi 14/a - 00197) ☎ +39 06 8088855

☎ +39 348 7062847

✉ alberto.gambino@gspb.it alberto.gambino@studioagambino.it
albertogambino@ordineavvocatiroma.org
 🌐 www.studioagambino.it www.gspb.it

Sesso Maschile | Data di nascita 28/09/1967 | Nazionalità Italiana

POSIZIONE

Avvocato Cassazionista
 Professore Ordinario di Diritto Privato

ESPERIENZA
PROFESSIONALE

Dal 1991

Partner dello Studio Legale Gambino

Dal 2021

Fondatore dello Studio Legale GSPB (Gambino-Scanzano-Pesce-Bavasso)

Attività professionale

Diritto civile, pubblico e societario

- Contratti d'impresa: redazione e revisione di contratti d'impresa, tra cui contratti di vendita, distribuzione, somministrazione, concessione, appalto e locazione; relativa assistenza giudiziale.
- Infrastrutture: attività di consulenza e assistenza legale nel settore delle infrastrutture materiali e immateriali.
- Operazioni straordinarie e finanza straordinaria: assistenza legale nell'ambito di operazioni di fusione, acquisizione e dismissione di società, riorganizzazione di gruppi societari, trasferimenti d'azienda, costituzione di joint-venture, raggruppamenti temporanei di imprese di tipo orizzontale e verticale.
- Responsabilità civile: contenzioso e assistenza stragiudiziale in materia di illecito civile, lesione a diritti patrimoniali, della personalità e reputazione di enti e persone fisiche, con riferimento anche a danni morali e non patrimoniali.
- Contenzioso e responsabilità degli amministratori: assistenza legale in contenziosi giudiziali e arbitrali tra soci, tra soci e società e tra società e amministratori e sindaci con particolare riferimento alle azioni di responsabilità nei confronti di questi ultimi.
- Antitrust e regolazione: assistenza legale giudiziale e stragiudiziale, anche davanti all'AGCM, per vertenze in diritto antitrust, operazioni di concentrazione e concorrenza sleale.
- Privacy, GDPR, proprietà industriale e intellettuale, Information

Technology: assistenza in questioni di *Data protection* anche dinanzi al Garante per la protezione dei dati personali. Contenzioso e assistenza in problematiche relative a privative industriali, diritto d'autore e diritto dell'innovazione tecnologica.

- 2020-2023 Giurista esperto del Dipartimento per la Programmazione Economica (PPP) – Delegato al tavolo di lavoro per la redazione nuove linee guida ANAC
 - Dal 2019 Componente della Commissione ricorsi contro i provvedimenti dell'Ufficio Italiano Brevetti e Marchi
 - 2019-2020 Componente della Commissione per il Concorso notarile, Min. Giustizia
 - 2018-2020 Arbitro presso la Camera Arbitrale dell'Autorità Nazionale Anticorruzione
 - 2015 Presidente della Commissione per l'esame di abilitazione alla professione forense presso la Corte d'Appello di Roma
 - 2014 Giurista esperto del Comitato per lo sviluppo e la tutela dell'offerta legale di opere digitali presso l'Autorità per le Garanzie nelle Comunicazioni.
 - 2011-2014 Direttore della Scuola di Specializzazione per le professioni legali
 - 2009-2012 Arbitro della Camera Arbitrale, Autorità di Vigilanza sui Contratti Pubblici di Lavori, Servizi e Forniture
 - 2007-2010 Presidente del Comitato consultivo permanente per il diritto d'autore
 - 2007-2008 Componente della Commissione Soa presso l'Autorità di vigilanza sui contratti pubblici di lavori, servizi e forniture
 - 1999-2012 Consigliere giuridico presso il Senato
- Componente di Commissioni e Comitati presso i Ministeri: Sviluppo economico (2015), Istruzione (2015), Salute (2009), Politiche familiari (2007), Beni culturali (2006); presso PCM: CNB (2022).

ISTRUZIONE E FORMAZIONE

- Dal 2010 Iscritto all'albo degli Avvocati patrocinanti dinanzi alle Giurisdizioni Superiori
- Dal 2004 Abilitazione a professore di prima fascia di diritto privato
Università degli Studi Insubria di Varese-Como
Professore di ruolo a tempo definito
Università di Napoli "Parthenope" (2005-2008) e Università di Roma Europea (dal 2008)

Società scientifiche: Civilisti italiani (socio effettivo, dal 2008); Associazione Internazionale di Diritto delle Assicurazioni (consiglio direttivo, dal 2014)

Principali pubblicazioni in tema di regolazione, concorrenza, servizi di pubblica utilità e servizi a tariffa e tutela degli utenti

Autore e curatore di circa duecento tra monografie, articoli e saggi su temi di diritto della concorrenza e della regolazione, diritto della protezione dei dati personali, diritto privato e commerciale, societario e industriale, diritto dell'informatica e dell'innovazione tecnologica

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Reg. (UE) 2016/679 e del Decreto Legislativo 30 giugno 2003, n. 196 e successive modifiche e integrazioni.

Roma,

avv. prof. Alberto Gambino